(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/070201 A1

(51) International Patent Classification:
C07D 211/26 (2006.01) *C07D 417/06* (2006.01)
C07D 211/22 (2006.01) *A61K 31/445* (2006.01)
C07D 401/12 (2006.01) *A61K 31/453* (2006.01)
C07D 407/12 (2006.01) *A61P 9/00* (2006.01)
C07D 409/06 (2006.01)

(21) International Application Number:
PCT/US2006/043920

(22) International Filing Date:
13 November 2006 (13.11.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/736,564	14 November 2005 (14.11.2005)	US
60/845,291	18 September 2006 (18.09.2006)	US
60/845,331	18 September 2006 (18.09.2006)	US

(71) Applicant *(for all designated States except US)*: **VITAE PHARMACEUTICALS, INC.** [US/US]; 502 WEST OFFICE CENTER DRIVE, Fort Washington, PA 19034 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BALDWIN, John, J.** [US/US]; 621 GYPSY HILL CIRCLE, Gwynedd, PA 19437 (US). **CLAREMON, David, A.** [US/US]; 1508 AIDENN LAIR ROAD, Maple Glen, PA 19002 (US). **TICE, Colin** [US/US]; 1211 STRATFORD AVENUE, Elkins Park, PA 19027 (US). **CACATIAN, Salvation** [US/US]; 247 S. JUNIPER STREET, APT. 804, Philadelphia, PA 19107 (US). **DILLARD, Lawrence, W.** [US/US]; 496 KINGS ROAD, Yardley, PA 19067 (US). **ISHCHENKO, Alexey, V.** [UA/US]; 1241 BROOKVIEW PLACE, Elkins Park, PA 19027 (US). **YUAN, Jing** [CN/US]; 3855 BLAIR MILL ROAD APT. 219E, Horsham, PA 19044 (US). **XU, Zhenrong** [CN/US]; 3855 BLAIR MILL ROAD APT. 235F, Horsham, PA 19044 (US). **MCGEEHAN, Gerard** [US/US]; 1105 WESTOVER ROAD, Wilimington, DE 19807 (US). **SIMPSON, Robert, D.** [US/US]; 2001 N. VAN BUREN STREET, Wilmington, DE 19802 (US). **SINGH, Suresh, B.** [US/US]; 4 ADAMS ROAD, Kendall Park, NJ 08824 (US). **ZHAO, Wei** [CN/US]; 930 HERITAGE DRIVE, Eagleville, PA 19403 (US). **FLAHERTY, Patrick, T.** [US/US]; 1134 BILTMORE AVENUE, Pittsburgh, PA 15216 (US).

(74) Agents: **ABELLEIRA, Susan, M.** et al.; HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, Concord, MA 01742-9133 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASPARTIC PROTEASE INHIBITORS



(57) Abstract: The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

WO 2007/070201 A1

ASPARTIC PROTEASE INHIBITORS

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/736,564, filed on November 14, 2005, U.S. Provisional Application No. 60/845,291, filed on September 18, 2006 and U.S. Provisional Application No. 60/845,331, filed on September 18, 2006. The entire teachings of the above applications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Aspartic proteases, including renin, β-secretase (BACE), HIV protease, HTLV protease and plasmepsins I and II, are implicated in a number of disease states. In hypertension elevated levels of angiotensin I, the product of renin catalyzed cleavage of angioteninogen are present. Elevated levels of β amyloid, the product of BACE activity on amyloid precursor protein, are widely believed to be responsible for the amyloid plaques present In the brains of Alzheimer's disease patients. The viruses HIV and HTLV depend on their respective aspartic proteases for viral maturation. *Plasmodium falciparum* uses plasmepsins I and II to degrade hemoglobin.

In the renin-angiotensin-aldosterone system (RAAS) the biologically active peptide angiotensin II (Ang II) is generated by a two-step mechanism. The highly specific aspartic protease renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE). Ang II is known to work on at least two receptor subtypes called AT_1 and AT_2. Whereas AT_1 seems to transmit most of the known functions of Ang II, the role of AT_2 is still unknown.

Modulation of the RAAS represents a major advance in the treatment of cardiovascular diseases (Zaman, M. A. et al *Nature Reviews Drug Discovery* **2002**, *1*, 621-636). ACE inhibitors and AT_1 blockers have been accepted as treatments of hypertension (Waeber B. *et al.*, "The renin-angiotensin system: role in experimental and human hypertension", in Berkenhager W. H., Reid J. L. (eds): *Hypertension*, Amsterdam, Elsevier Science Publishing Co, **1996**, 489-519; Weber M. A., *Am. J.*

Hypertens., **1992**, *5*, 247S). In addition, ACE inhibitors are used for renal protection (Rosenberg M. E. *et al., Kidney International,* **1994**, *45*, 403; Breyer J. A. *et al., Kidney International,* **1994**, *45*, S156), in the prevention of congestive heart failure (Vaughan D. E. *et al., Cardiovasc. Res.*, **1994**, *28*, 159; Fouad-Tarazi F. *et al., Am. J. Med.,* **1988**, *84 (Suppl. 3A),* 83) and myocardial infarction (Pfeffer M. A. *et al., N Engl. J. Med.,* **1992**, *327*, 669).

Interest in the development of renin inhibitors stems from the specificity of renin (Kleinert H. D., *Cardiovasc. Drugs,* **1995**, *9*, 645). The only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin. In contrast, ACE can also cleave bradykinin besides Ang I and can be bypassed by chymase, a serine protease (Husain A., *J. Hypertens.*, **1993**, *11*, 1155). In patients, inhibition of ACE thus leads to bradykinin accumulation causing cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%) (Israili Z. H. *et al., Annals of Internal Medicine,* **1992**, *117*, 234). Chymase is not inhibited by ACE inhibitors. Therefore, the formation of Ang II is still possible in patients treated with ACE inhibitors. Blockade of the ATI receptor (e.g., by losartan) on the other hand overexposes other AT-receptor subtypes to Ang II, whose concentration is dramatically increased by the blockade of AT1 receptors. In summary, renin inhibitors are not only expected to be superior to ACE inhibitors and AT_1 blockers with regard to safety, but more importantly also with regard to their efficacy in blocking the RAAS.

Only limited clinical experience (Azizi M. *et al., J. Hypertens.*, **1994**, *12*, 419; Neutel J. M. *et al., Am. Heart,* **1991**, *122*, 1094) has been generated with renin inhibitors because their peptidomimetic character imparts insufficient oral activity (Kleinert H. D., *Cardiovasc. Drugs,* **1995**, *9*, 645). The clinical development of several compounds has been stopped because of this problem together with the high cost of goods. It appears as though only one compound has entered clinical trials (Rahuel J. *et al., Chem. Biol.*, **2000**, *7*, 493; Mealy N. E., *Drugs of the Future,* **2001**, *26*, 1139). Thus, metabolically stable, orally bioavailable and sufficiently soluble renin inhibitors that can be prepared on a large scale are not available. Recently, the first non-peptide renin inhibitors were described which show high *in vitro* activity (Oefner C. *et al., Chem. Biol.*, **1999**, *6*, 127; Patent Application WO 97/09311; Maerki H. P. *et al., Il Farmaco,* **2001**, *56*, 21). The present invention relates to the unexpected identification

of renin inhibitors of a non-peptidic nature and of low molecular weight. Orally active renin inhibitors which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to pathophysiologically altered local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and restenosis, are described.

All documents cited herein are incorporated by reference.

SUMMARY OF THE INVENTION

One embodiment of the invention is an aspartic protease inhibitor represented by Structural Formula (I):



(I);

or a pharmaceutically acceptable salt thereof. The variables in Structural Formula (I) are described in the following paragraphs.

Z is –O- or -CH_2-.

X_1 is a covalent bond, -O-, -S-, -S(O)-, -$S(O)_2$-.

Y_1 is a covalent bond or C_1-C_{10} alkylene, C_1-C_{10} alkenylene or C_1-C_{10} alkynylene, each optionally substituted at one or more substitutable carbon atom with halogen, cyano, hydroxyl, (C_1-C_3)alkyl, (C_1-C_3)alkoxy or halo(C_1-C_3)alkoxy, provided that Y_1 is a covalent bond only when X_1 is a covalent bond.

R^1 is a) (C_3-C_7) cycloalkyl; or b) phenyl, heteroaryl, or bicyclic heteroaryl optionally substituted with 1 to 3 groups independently selected from:

1) fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-

C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl.

R^2 is $-OC(O)(NH_2)$, $-OC(S)(NH_2)$, $-SC(S)(NH_2)$, $-SC(O)(NH_2)$, $-OC(O)(NHR^9)$, $-OC(S)(NHR^9)$, $-SC(S)(NHR^9)$, $-SC(O)(NHR^9)$, $-NHC(O)OR^9$, $-NHC(S)SR^9$, $-NHC(S)OR^9$, $-NHC(O)SR^9$, $-C(O)R^9$, $-C(S)R^9$, $-C(O)(NH_2)$, $-C(S)(NH_2)$, $-C(O)(NHR^9)$, $-C(S)(NHR^9)$ or -NHC(O)H, wherein R^9 is a straight or branched C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl, (C_3-C_4)cycloalkyl or straight or branched C_1-C_5 alkoxyalkyl.

R^3 is –H, -F, C_1-C_5 alkyl, $-NHC(O)R^{10}$, -OH or $-OR^{10}$, wherein R^{10} is C_1-C_3 alkyl, provided that when R^3 is –F or –OH, then X_1 is not -O-, -S-, -S(O)-, $-S(O)_2$- and R^1-Y_1-X_1 is not $-OC(O)(NH_2)$, $-OC(S)(NH_2)$, $-SC(S)(NH_2)$, $-SC(O)(NH_2)$, $-OC(O)(NHR^9)$, $-OC(S)(NHR^9)$, $-SC(S)(NHR^9)$, $-SC(O)(NHR^9)$, $-NHC(O)OR^9$, $-NHC(S)OR^9$, $-NHC(S)SR^9$, $-NHC(O)SR^9$ or -NHC(O)H.

Q is Q1, Q2, Q3, Q4, Q5, or Q6:



Q1 Q2 Q3 Q4 Q5 Q6

R^4 is -H or (C_1-C_3)alkyl.

R^5 is a) H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl; or b) phenyl(C_1-C_2)alkyl, phenoxymethyl, or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy; and

R^6 is a) -H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl; or b) phenyl(C_1-C_2)alkyl, phenoxymethyl or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy, provided that R^5 and R^6 are not both -H.

G is OH, NH_2 or NHR^7.

R^7 is a) (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, (C_4-C_{10})cycloalkylalkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, or aminocarbonyl(C_1-C_6)alkyl or b) phenyl(C_1-C_2)alkyl optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy; or c) R^5 and R^7 together are $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, or $-(CH_2)_4-$, optionally substituted with 1 or 2 groups independently selected from fluorine, (C_1-C_8)alkyl, halo(C_1-C_8)alkyl, (C_3-C_6)cycloalkyl, halo(C_3-C_6)cycloalkyl, hydroxy(C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl(C_1-C_2)alkyl, halo(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, hydroxylated(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, (C_1-C_8)alkoxy, halo(C_1-C_8)alkoxy, (C_3-C_6)cycloalkoxy, halo(C_3-C_6)cycloalkoxy, and heterocyclyl.

Another embodiment of the invention is an aspartic protease inhibitor represented by Structural Formula (I*):



(I*);

or a pharmaceutically acceptable salt thereof. The variables in Structural Formula *(I*)* are described in the following paragraphs.

Z is –O- or $-(CH_2)_q-$, wherein q is 0-3.

X_1 is a covalent bond, -O-, -S-, -S(O)-, $-S(O)_2-$.

Y_1 is a covalent bond or C_1-C_{10} alkylene, C_1-C_{10} alkenylene or C_1-C_{10} alkynylene, each optionally substituted at one or more substitutable carbon atom with halogen, cyano, nitro, hydroxyl, (C_1-C_3)alkyl, (C_1-C_3)alkoxy or halo(C_1-C_3)alkoxy, provided that Y_1 is a covalent bond only when X_1 is a covalent bond.

R^1 is (C_3-C_7) cycloalkyl, phenyl, heteroaryl, or bicyclic heteroaryl each optionally substituted with 1 to 3 groups independently selected from:

fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; and phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl.

R^2 is $-NHC(=NR_{12})(NH_2)$, $-NHC(=NR^{12})(NHR^9)$,  , $-OC(O)(NH_2)$, $-OC(S)(NH_2)$, $-SC(S)(NH_2)$, $-SC(O)(NH_2)$, $-OC(O)(NHR^9)$, $-OC(S)(NHR^9)$, $-SC(S)(NHR^9)$, $-SC(O)(NHR^9)$, $-NHC(O)OR^9$, $-NHC(S)SR^9$, $-NHC(S)OR^9$, $-NHC(O)SR^9$, $-C(O)R^9$, $-C(S)R^9$, $-C(O)(NH_2)$, $-C(S)(NH_2)$, $-C(O)(NHR^9)$, $-C(S)(NHR^9)$ or -NHC(O)H, wherein R^9 is a straight or branched C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl, (C_3-C_4)cycloalkyl or straight or branched C_1-C_5 alkoxyalkyl and R^{12} is H, (C_1-C_6)alkyl, phenyl, heteroaryl, cyano, nitro, $-S(O)R^9$, $-S(O_2)R^9$, $-S(O_2)NHR^9$, $-S(O_2)NR^9R^9$, $-C(O)R^9$, $-C(S)R^9$, $-C(O)OR^9$, $-C(S)OR^9$, $-C(O)(NH_2)$, $-C(O)(NHR^9)$.

R^3 is –H, -F, C_1-C_5 alkyl, -NHC(O)R^{10}, -OH or –OR^{10}, wherein R^{10} is C_1-C_3 alkyl, provided that when R^3 is –F or –OH, then X_1 is not -O-, -S-, -S(O)-, -S(O)$_2$- and R^1-Y_1-X_1 is not –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), -SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)OR^9, -NHC(S)SR^9, -NHC(O)SR^9 or -NHC(O)H.

Q is Q1, Q2, Q3, Q4, Q5, or Q6:



R^4 is -H or (C_1-C_3)alkyl.

R^5 is a) H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl; or b) phenyl(C_1-C_2)alkyl, phenoxymethyl, or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy,

halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl wherein s is 1 or 2.

R^6 is a) -H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl;
or b) phenyl(C_1-C_2)alkyl, phenoxymethyl or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl provided that R^5 and R^6 are not both -H..

G is OH, NH_2 or NHR^7.

R^7 is a) (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, (C_4-C_{10})cycloalkylalkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, or aminocarbonyl(C_1-C_6)alkyl or b) phenyl(C_1-C_2)alkyl optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy; or c) R^5 and R^7 together are $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, or $-(CH_2)_4-$, optionally

substituted with 1 or 2 groups independently selected from fluorine, (C_1-C_8)alkyl, halo(C_1-C_8)alkyl, (C_3-C_6)cycloalkyl, halo(C_3-C_6)cycloalkyl, hydroxy(C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl(C_1-C_2)alkyl, halo(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, hydroxylated(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, (C_1-C_8)alkoxy, halo(C_1-C_8)alkoxy, (C_3-C_6)cycloalkoxy, halo(C_3-C_6)cycloalkoxy, and heterocyclyl.

Another embodiment of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an aspartic protease inhibitor disclosed herein (e.g., a compound represented by Structural Formula (I), Structural Formula (I*) or a pharmaceutically acceptable salt thereof). The pharmaceutical composition is used in therapy, e.g., for inhibiting an aspartic protease mediated disorder in a subject.

Another embodiment of the invention is a method of antagonizing one or more aspartic proteases in a subject in need of such treatment. The method comprises administering to the subject an effective amount of an aspartic protease inhibitor disclosed herein (e.g., a compound represented by Structural Formula (I), Structural Formula (I*) or a pharmaceutically acceptable salt thereof).

Another embodiment of the invention is a method of treating an aspartic protease mediated disorder in a subject. The method comprises administering to the subject an effective amount of an aspartic protease inhibitor disclosed herein (e.g., a compound represented by Structural Formula (I), Structural Formula (I*) or a pharmaceutically acceptable salt thereof).

Another embodiment of the invention is the use of an aspartic protease inhibitor disclosed herein (e.g., a compound represented by Structural Formula (I), Structural Formula (I*) or a pharmaceutically acceptable salt thereof)) for the manufacture of a medicament for antagonizing one or more aspartic proteases in a subject in need of such treatment.

Another embodiment of the invention is the use of an aspartic protease inhibitor disclosed herein (e.g., a compound represented by Structural Formula (I), Structural Formula (I*) or a pharmaceutically acceptable salt thereof)) for the manufacture of a medicament for treating an aspartic protease mediated disorder in a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a plot showing changes in mean arterial blood pressures of transgenic rats treated with 10 mg/kg of compound XL-7.

FIG. 2 is a plot showing mean plasma concentrations of compound L-6a in transgenic rats over time following oral administration of 10 mg/kg of compound L-6a.

FIG. 3 is a plot showing changes in mean arterial blood pressures of transgenic rats treated with 10 mg/kg of compound L-6a.

FIG. 4 is an x-ray powder diffraction pattern obtained from a sample of the tartrate salt of compound L-6a

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to an aspartic protease inhibitor represented by Structural Formula (I), Structural Formula (I*) or a pharmaceutically acceptable salt thereof. Values and particular values for the variables in Structural Formula (I) and Structural Formula (I*) are provided in the following paragraphs. For Structural Formula I:

Z is –O- or -CH_2-. In a particular embodiment, Z is –CH_2-.

X_1 is a covalent bond, -O-, -S-, -S(O)-, -$S(O)_2$-. In a particular embodiment, X_1 is a covalent bond or –O-.

Y_1 is a covalent bond or C_1-C_{10} alkylene, C_1-C_{10} alkenylene or C_1-C_{10} alkynylene, each optionally substituted at one or more substitutable carbon atoms with halogen, cyano, hydroxyl, (C_1-C_3)alkyl, (C_1-C_3)alkoxy or halo(C_1-C_3)alkoxy, provided that Y_1 is a covalent bond only when X_1 is a covalent bond. In a particular embodiment, Y_1 is C_1-C_5 alkylene optionally substituted at a substitutable carbon atom with halogen, cyano, hydroxyl, methyl, methoxy, halo(C_1-C_3)methoxy. More particularly, Y_1 is (C_1-C_2)alkylene when X_1 is O or Y_1 is (C_2-C_3)alkylene when X_1 is a covalent bond.

R^1 is a) (C_3-C_7) cycloalkyl; or b) phenyl, heteroaryl, or bicyclic heteroaryl optionally substituted with 1 to 3 independently selected groups represented by R^{11}. In a particular embodiment, R^1 is phenyl optionally substituted with 1 to 3 independently selected groups represented by R^{11}.

R^2 is –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), –SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)SR^9, -NHC(S)OR^9, -NHC(O)SR^9, -C(O)R^9, -C(S)R^9, -C(O)(NH_2),

-C(S)(NH_2), -C(O)(NHR^9), -C(S)(NHR^9) or -NHC(O)H. In a particular embodiment, R^2 is -OC(O)(NHR^9), -NHC(O)OR^9, -C(O)R^9, -C(O)(NHR^9) or -NHC(O)H.

R^3 is –H, -F, C_1-C_5 alkyl, -NHC(O)R^{10}, -OH or –OR^{10}, wherein R^{10} is C_1-C_3 alkyl, provided that when R^3 is –F or –OH, then X_1 is not -O-, -S-, -S(O)-, -S($O)_2$- and R^1-Y_1-X_1 is not –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), -SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)OR^9, -NHC(S)SR^9, -NHC(O)SR^9 or -NHC(O)H. In a particular embodiment, R^3 is –H, -NHC(O)R^{10} or –OH.

Q is Q1, Q2, Q3, Q4, Q5, or Q6:



Q1 Q2 Q3 Q4 Q5 Q6 ;

In a particular embodiment, Q is Q1 or Q2. More particularly, Q is Q1.

R^4 is -H or (C_1-C_3)alkyl In a particular embodiment, R^4 is -H.

R^5 and R^6 are independently: a) H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl; or b) phenyl(C_1-C_2)alkyl, phenoxymethyl or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy, provided that R^5 and R^6 are not both –H. In a particular embodiment, one of R^5 and R^6 is –H or methyl and the other is as just described. More particularly, R^5 is as just described and R^6 is –H or methyl. Alternatively, R^5 and R^6 are independently (C_1-C_7)alkyl, halo(C_1-C_7)alkyl, hydroxy(C_1-C_7)alkyl, cyclohexylmethyl, 2-(cyclohexyl)lethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, (C_1-C_2)alkyl cyclohexylmethyl, di(C_1-C_2)alkyl cyclohexylmethyl, hydroxylated (C_1-C_2)alkyl cyclohexylmethyl, hydroxylated di(C_1-C_2)alkylcyclohexylmethyl, (3-

noradamantyl)methyl or (tetrahydropyranyl)methyl. In a particular embodiment, one of R^5 and R^6 is –H or methyl and the other is as just described. More particularly, R^5 is as just described and R^6 is –H or methyl. Alternatively , R^5 and R^6 are independently (C_1-C_4)alkyl, halo(C_1-C_4)alkyl, hydroxy(C_1-C_4)alkyl, cyclohexylmethyl, halocyclohexylmethyl or hydroxylated cyclohexylmethyl. In a particular embodiment, one of R^5 and R^6 is –H or methyl and the other is as just described. More particularly, R^5 is as just described and R^6 is –H or methyl.

G is -OH, $-NH_2$ or $-NHR^7$. In a particular embodiment, G is NH_2 or NHR^7.

R^7 is a) (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, (C_4-C_{10})cycloalkylalkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, or aminocarbonyl(C_1-C_6)alkyl or b) phenyl(C_1-C_2)alkyl optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy; or c) R^5 and R^7 together are $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, or $-(CH_2)_4-$, optionally substituted with 1 or 2 groups independently selected from fluorine, (C_1-C_8)alkyl, halo(C_1-C_8)alkyl, (C_3-C_6)cycloalkyl, halo(C_3-C_6)cycloalkyl, hydroxy(C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl(C_1-C_2)alkyl, halo(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, hydroxylated(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, (C_1-C_8)alkoxy, halo(C_1-C_8)alkoxy, (C_3-C_6)cycloalkoxy, halo(C_3-C_6)cycloalkoxy, and heterocyclyl. In a particular embodiment, R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3-$ optionally substituted with C_1-C_4 alkyl or cyclohexyl.

R^9 is a straight or branched C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl, (C_3-C_4)cycloalkyl or straight or branched C_1-C_5 alkoxyalkyl. In a particular embodiment, R^9 is a straight C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl. In another particular embodiment, R^9 is methyl or ethyl.

R^{11} is 1) fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine,

chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl. In a particular embodiment, R^{11} is chloro, fluoro or methyl.

In a particular embodiment, when R^5 and R^7 together with their intervening atoms form a ring or when G is hydroxy, R^2 is –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), –SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)SR^9, -NHC(S)OR^9, -NHC(O)SR^9, or -C(S)(NH_2), wherein R^9 is a straight or branched C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl, (C_3-C_4)cycloalkyl or straight or branched C_1-C_5 alkoxyalkyl.

For Structural Formula (I*):

Z is –O- or –$(CH_2)_q$–, wherein q is 0-3.

X_1 is a covalent bond, -O-, -S-, -S(O)-, -$S(O)_2$-.

Y_1 is a covalent bond or C_1-C_{10} alkylene, C_1-C_{10} alkenylene or C_1-C_{10} alkynylene, each optionally substituted at one or more substitutable carbon atom with halogen, cyano, nitro, hydroxyl, (C_1-C_3)alkyl, (C_1-C_3)alkoxy or halo(C_1-C_3)alkoxy, provided that Y_1 is a covalent bond only when X_1 is a covalent bond.

R^1 is (C_3-C_7) cycloalkyl, phenyl, heteroaryl, or bicyclic heteroaryl each optionally substituted with 1 to 3 groups independently selected from:

fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; and

phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl.

R^2 is –NHC(=NR_{12})(NH_2), –NHC(=NR^{12})(NHR^9),  , –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), –SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9),

-SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)SR^9, -NHC(S)OR^9, -NHC(O)SR^9, -C(O)R^9, -C(S)R^9, -C(O)(NH$_2$), -C(S)(NH$_2$), -C(O)(NHR^9), -C(S)(NHR^9) or -NHC(O)H, wherein R^9 is a straight or branched C$_1$-C$_5$ alkyl, straight or branched C$_1$-C$_5$ haloalkyl, (C$_3$-C$_4$)cycloalkyl or straight or branched C$_1$-C$_5$ alkoxyalkyl and R^{12} is H, (C$_1$-C$_6$)alkyl, phenyl, heteroaryl, cyano, nitro, -S(O)R^9, -S(O$_2$)R^9, -S(O$_2$)NHR^9, -S(O$_2$)NR^{9}R^9, -C(O)R^9, -C(S)R^9, -C(O)OR^9, -C(S)OR^9, -C(O)(NH$_2$), -C(O)(NHR^9).

R^3 is –H, -F, C$_1$-C$_5$ alkyl, -NHC(O)R^{10}, -OH or –OR^{10}, wherein R^{10} is C$_1$-C$_3$ alkyl, provided that when R^3 is –F or –OH, then X$_1$ is not -O-, -S-, -S(O)-, -S(O)$_2$- and R^1-Y$_1$-X$_1$ is not –OC(O)(NH$_2$), –OC(S)(NH$_2$), –SC(S)(NH$_2$), -SC(O)(NH$_2$), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)OR^9, -NHC(S)SR^9, -NHC(O)SR^9 or -NHC(O)H.

Q is Q1, Q2, Q3, Q4, Q5, or Q6:



Q1 Q2 Q3 Q4 Q5 Q6

R^4 is -H or (C$_1$-C$_3$)alkyl.

R^5 is a) H, (C$_1$-C$_{10}$)alkyl, (C$_4$-C$_{10}$)cycloalkylalkyl, halo(C$_1$-C$_{10}$)alkyl, hydroxy(C$_1$-C$_{10}$)alkyl, halo(C$_4$-C$_{10}$)cycloalkylalkyl, hydroxylated (C$_4$-C$_{10}$)cycloalkylalkyl, (C$_1$-C$_2$)alkyl(C$_4$-C$_{10}$)cycloalkylalkyl, halogenated (C$_1$-C$_2$)alkyl(C$_4$-C$_{10}$)cycloalkylalkyl, di(C$_1$-C$_2$)alkyl(C$_4$-C$_{10}$)cycloalkylalkyl, hydroxylated (C$_1$-C$_2$)alkyl(C$_4$-C$_{10}$)cycloalkylalkyl, hydroxylated di(C$_1$-C$_2$)alkyl(C$_4$-C$_{10}$)cycloalkylalkyl, (C$_4$-C$_{10}$)bicycloalkyl(C$_1$-C$_3$)alkyl, (C$_8$-C$_{12}$)tricycloalkyl(C$_1$-C$_3$)alkyl, (C$_1$-C$_5$)alkoxy(C$_1$-C$_5$)alkyl, halo(C$_1$-C$_5$)alkoxy(C$_1$-C$_5$)alkyl, (C$_1$-C$_5$)alkylthio(C$_1$-C$_5$)alkyl, halo(C$_1$-C$_5$)alkylthio(C$_1$-C$_5$)alkyl, or saturated heterocyclyl(C$_1$-C$_3$)alkyl optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C$_1$-C$_6$)alkyl, (C$_3$-C$_6$)cycloalkyl, (C$_4$-C$_7$)cycloalkylalkyl, (C$_2$-C$_6$)alkenyl, (C$_5$-C$_7$)cycloalkylalkenyl, (C$_2$-C$_6$)alkynyl, (C$_3$-C$_6$)cycloalkyl(C$_2$-C$_4$)alkynyl, halo(C$_1$-C$_6$)alkyl, halo(C$_3$-C$_6$)cycloalkyl, halo(C$_4$-C$_7$)cycloalkylalkyl, halo(C$_2$-C$_6$)alkenyl, halo(C$_3$-C$_6$)alkynyl, halo(C$_5$-C$_7$)-cycloalkylalkynyl, (C$_1$-C$_6$)alkoxy, (C$_3$-C$_6$)cycloalkoxy, (C$_4$-C$_7$)cycloalkylalkoxy, halo(C$_1$-C$_6$)alkoxy, halo(C$_3$-C$_6$)cycloalkoxy, halo(C$_4$-C$_7$)cycloalkylalkoxy, (C$_1$-C$_6$)alkanesulfonyl and aminocarbonyl; or b) phenyl(C$_1$-C$_2$)alkyl, phenoxymethyl, or heteroaryl(C$_1$-C$_2$)alkyl each optionally

substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl wherein s is 1 or 2.

R^6 is a) -H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl;
or b) phenyl(C_1-C_2)alkyl, phenoxymethyl or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl provided that R^5 and R^6 are not both -H.

G is OH, NH_2 or NHR^7.

R^7 is a) $(C_1\text{-}C_6)$alkyl, halo$(C_1\text{-}C_6)$alkyl, $(C_4\text{-}C_{10})$cycloalkylalkyl, $(C_1\text{-}C_5)$alkoxy$(C_1\text{-}C_5)$alkyl, or aminocarbonyl$(C_1\text{-}C_6)$alkyl or b) phenyl$(C_1\text{-}C_2)$alkyl optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, $(C_1\text{-}C_3)$alkyl, halo$(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, and halo$(C_1\text{-}C_3)$alkoxy; or c) R^5 and R^7 together are $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, or $-(CH_2)_4-$, optionally substituted with 1 or 2 groups independently selected from fluorine, $(C_1\text{-}C_8)$alkyl, halo$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, halo$(C_3\text{-}C_6)$cycloalkyl, hydroxy$(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_2)$alkyl, halo$(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_2)$alkyl, hydroxylated$(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_2)$alkyl, $(C_1\text{-}C_8)$alkoxy, halo$(C_1\text{-}C_8)$alkoxy, $(C_3\text{-}C_6)$cycloalkoxy, halo$(C_3\text{-}C_6)$cycloalkoxy, and heterocyclyl.

In a particular embodiment, when R^5 and R^7 together with their intervening atoms form a ring or when G is hydroxy, R^2 is $-NHC(=NR_{12})(NH_2)$, $-NHC(=NR^{12})(NHR^9)$,  , $-OC(O)(NH_2)$, $-OC(S)(NH_2)$, $-SC(S)(NH_2)$, $-SC(O)(NH_2)$, $-OC(O)(NHR^9)$, $-OC(S)(NHR^9)$, $-SC(S)(NHR^9)$, $-SC(O)(NHR^9)$, $-NHC(O)OR^9$, $-NHC(S)SR^9$, $-NHC(S)OR^9$, $-NHC(O)SR^9$, or $-C(S)(NH_2)$, wherein R^9 is a straight or branched $C_1\text{-}C_5$ alkyl, straight or branched $C_1\text{-}C_5$ haloalkyl, $(C_3\text{-}C_4)$cycloalkyl or straight or branched $C_1\text{-}C_5$ alkoxyalkyl and R^{12} is H, $(C_1\text{-}C_6)$alkyl, phenyl, heteroaryl, cyano, nitro, $-S(O)R^9$, $-S(O_2)R^9$, $-S(O_2)NHR^9$, $-S(O_2)NR^9R^9$, $-C(O)R^9$, $-C(S)R^9$, $-C(O)OR^9$, $-C(S)OR^9$, $-C(O)(NH_2)$, $-C(O)(NHR^9)$.

In a specific embodiment, the aspartic protease inhibitor of the invention is represented by Structural Formula (II) or Structural Formula (IIa), or a pharmaceutically acceptable salt of the aspartic protease inhibitor represented by Structural Formula (II) or (IIa):



(II);



(IIa).

Values and particular values for the variables in Structural Formula (II) and Structural Formula (IIa) are as provided for Structural Formula (I) and Structural Formula (I*) above. In a particular embodiment, one of R^5 and R^6 is -H or methyl and the other is as described for Structural Formula (I) and Structural Formula (I*); and the remainder of the values and particular values for Strutural Formula (II) and (IIa) are as described for Structural Formula (I) and Structural Formula (I*). More particularly, R^6 is -H or methyl and the remainder of the values and particular values for Structural Formulas (II) and (IIa) are as described for Structural Formula (I) and Structural Formula (I*).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (III)-(VII), or a pharmaceutically acceptable salt thereof:



(III);



(IV);



(V);



(VI);

and



(VII).

Values and particular values for the variables in Structural Formulas (III)-(VII) are as provided for Structural Formula (I) and Structural Formula (I*) above. In a particular embodiment, one of R^5 and R^6 is -H or methyl and the other is as described for Structural Formula (I) and Structural Formula (I*); and the remainder of the values and particular values for Structural Formulas (III)-(VII) are as described for Structural Formula (I) and Structural Formula (I*). More particularly, R^6 is -H or methyl and the remainder of the values and particular values for Structural Formulas (III)-(VII) are as described for Structural Formula (I) and Structural Formula (I*).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (IIIa)-(VIIa), or a pharmaceutically acceptable salt thereof:



(IIIa);



(IVa);



(Va);



(VIa);

and



(VIIa).

Values and particular values for the variables in Structural Formulas (IIIa)-(VIIa) are as provided for Structural Formula (I) and Structural Formula (I*)above. In a particular embodiment, one of R^5 and R^6 is -H or methyl and the other is as described for Structural Formula (I) and Structural Formula (I*); and the remainder of the values and particular values for Strutural Formulas (IIIa)-(VIIa) are as described for Structural Formula (I) and Structural Formula (I*). More particularly, R^6 is -H or methyl and the

remainder of the values and particular values for Structural Formulas (IIIa)-(VIIa) are as described for Structural Formula (I) and Structural Formula (I*).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (VIII)-(XII), or a pharmaceutically acceptable salt thereof:



(VIII);



(IX);



(X);



(XI); and



(XII).

n is 0, 1, 2, or 3; and the values and particular values for the remainder of the variables in Structural Formulas (VIII)-(XII) are as provided for Structural Formula (I) and Structural Formula (I*) above. In a particular embodiment, one of R^5 and R^6 is -H or methyl and the other is as described for Structural Formula (I) and Structural Formula (I*); and the remainder of the values and particular values for Structural Formulas (VIII)-(XII) are as described for Structural Formula (I) and Structural Formula (I*). More particularly, R^6 is -H or methyl and the remainder of the values and particular values for Structural Formulas (VIII)-(XII) are as described for Structural Formula (I) and Structural Formula (I*).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XIII)-(XVII), or a pharmaceutically acceptable salt thereof:



(XIII);



(XIV);



(XV);



(XVI);

and



(XVII).

A first set of values for the aspartic protease inhibitor represented by Structural Formulas (XIII)-(XVII) is provided in the following paragraphs:

R^6 is H or methyl; ;

R^{11} is fluorine, chlorine, bromine, cyano, nitro, $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_4$-$C_7)$cycloalkylalkyl, $(C_2$-$C_6)$alkenyl, $(C_5$-$C_7)$cycloalkylalkenyl, $(C_2$-$C_6)$alkynyl, $(C_3$-$C_6)$cycloalkyl$(C_2$-$C_4)$alkynyl, halo$(C_1$-$C_6)$alkyl, halo$(C_3$-$C_6)$cycloalkyl, halo$(C_4$-$C_7)$cycloalkylalkyl, halo$(C_2$-$C_6)$alkenyl, halo$(C_3$-$C_6)$alkynyl, halo$(C_5$-$C_7)$-cycloalkylalkynyl, $(C_1$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkoxy, $(C_4$-$C_7)$cycloalkylalkoxy, halo$(C_1$-$C_6)$alkoxy, halo$(C_3$-$C_6)$cycloalkoxy, halo$(C_4$-$C_7)$cycloalkylalkoxy and $(C_1$-$C_6)$alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, $(C_1$-$C_3)$alkyl, halo$(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$-alkoxy, and halo$(C_1$-$C_3)$alkoxy, and aminocarbonyl;

n is 0, 1, 2 or 3;

m is 2 or 3; and

values and particular values for the remainder of the variables in Structural Formulas (XIII)-(XVII) are as described for Structural Formula (I) and Structural Formula (I*).

A second set of values for the aspartic protease inhibitor represented by Structural Formulas (XIII)-(XVII) is provided in the following paragraphs:

One of R^5 and R^6 is -H, $(C_1$-$C_7)$alkyl, halo$(C_1$-$C_7)$alkyl, hydroxy$(C_1$-$C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, $(C_1$-$C_2)$alkyl cyclohexylmethyl, di$(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1$-$C_2)$alkylcyclohexylmethyl, (3-

noradamantyl)methyl or (tetrahydropyranyl)methyl; and the other is R^6 is –H or methyl; and

values and particular values for the remainder of the variables are as described for the first set of values for Structural Formulas (XIII)-(XVII).

A third set of values for the aspartic protease inhibitor represented by Structural Formulas (XIII)-(XVII) is provided in the following paragraphs:

R^5 is $(C_1$-$C_7)$alkyl, halo$(C_1$-$C_7)$alkyl, hydroxy$(C_1$-$C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, $(C_1$-$C_2)$alkyl cyclohexylmethyl, di$(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1$-$C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $–(CH_2)_3$- optionally substituted with C_1-C_4 alkyl or cyclohexyl; and

values and particular values for the remainder of the variables are as described for the first set of values for Structural Formulas (XIII)-(XVII).

A fourth set of values for the aspartic protease inhibitor represented by Structural Formulas (XIII)-(XVII) is provided in the following paragraphs:

R^5 is –H or methyl;

R^6 is $(C_1$-$C_7)$alkyl, halo$(C_1$-$C_7)$alkyl, hydroxy$(C_1$-$C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, $(C_1$-$C_2)$alkyl cyclohexylmethyl, di$(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1$-$C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $–(CH_2)_3$- optionally substituted with C_1-C_4 alkyl or cyclohexyl; and

values and particular values for the remainder of the variables are as described for the first set of values for Structural Formulas (XIII)-(XVII).

A fifth set of values for the aspartic protease inhibitor represented by Structural Formula (XIII)-(XVII) is provided in the following paragraphs:

R^9 is methyl or ethyl;

R^{11} is chloro, fluoro or methyl; and

values and particular values for the remainder of the variables are as described for the third set of values for Structural Formulas (XIII)-(XVII).

A sixth set of values for the aspartic protease inhibitor represented by Structural Formula (XIII)-(XVII) is provided in the following paragraphs:

R^9 is methyl or ethyl;

R^{11} is chloro, fluoro or methyl; and

values and particular values for the remainder of the variables are as described for the fourth set of values for Structural Formulas (XIII)-(XVII).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XVIII)-(XXII), or a pharmaceutically acceptable salt thereof:



(XVIII);



(XIX);



(XX);



(XXI);



and (XXII).

Values and particular values for the variables in Structural Formulas (XVIII)-(XXII) are as described for the first set of values for Structural Formulas (XIII)-(XVII). Alternatively, values and particular values for the variables in Structural Formulas (XVIII)-(XXII) are as described for the second set of values for Structural Formulas (XIII)-(XVII). In another alternative, values and particular values for the variables in Structural Formulas (XVIII)-(XXII) are as described for the third set of values for Structural Formulas (XIII)-(XVII). In yet another alternative, values and particular

values for the variables in Structural Formulas (XVIII)-(XXII) are as described for the fourth set of values for Structural Formulas (XIII)-(XVII).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XXIII)-(XXV), or a pharmaceutically acceptable salt thereof:



(XXIII);



(XXIV); and



(XXV).

Values and particular values for the variables in Structural Formulas (XXIII)-(XXV) are as described for Structural Formulas (XIII)-(XVII).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XXVI)-(XXVIII), or a pharmaceutically acceptable salt thereof:



(XXVI);



(XXVII); and



(XXVIII).

Values and particular values for the variables in Structural Formulas (XXVI)-(XXVIII) are as described for Structural Formulas (XIII)-(XVII).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XXIX)-(XXXI), or a pharmaceutically acceptable salt thereof:



(XIX);



(XXX); and



(XXXI).

Values and particular values for the variables in Structural Formulas (XXIX)-(XXXI) are as described for Structural Formulas (XIII)-(XVII).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XXXII)-(XXXIV), or a pharmaceutically acceptable salt thereof:



(XXXII);



(XXXIII); and



(XXXIV).

Values and particular values for the variables in Structural Formulas (XXXII)-(XXXIV) are as described for Structural Formulas (XIII)-(XVII).

In another specific embodiment, the aspartic protease inhibitor of the invention is represented by a structural formula selected from Structural Formulas (XXXV)-(XXXVII), or a pharmaceutically acceptable salt thereof:



(XXXV);



(XXXVI);

and



(XXXVII).

Values and particular values for the variables in Structural Formulas (XXXV)-(XXXVII) are as described for Structural Formulas (XIII)-(XVII).

Another embodiment of the invention is an aspartic protease inhibitor represented by Structural Formula (XXXVIIa-e):



(XXXVIIa)



(XXXVIIb)



(XXXVIIc)



(XXXVIId)



(XXXVIIe).

R^8 isobutyl, cyclohexyl, cyclopentyl, cyclobutylmethyl or isopropoxy and the values and particular values for the remainder of the variables are as described for Structural Formulas (III) – (VII).

Another embodiment of the invention is each of the following compounds or their enantiomers, diastereomers, or pharmaceutically acceptable salts:

Compound Number	Name
I-1	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)-4-(2-fluorophenyl)-4-hydroxybutylcarbamate

I-2	methyl 4-(3-chloro-2-fluorophenyl)-4-(1-(4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-3	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-dimethylphenyl)-4-hydroxybutylcarbamate
I-4	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-5	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-6	methyl 4-(3-chlorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-7	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-7	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-8	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-difluorophenyl)-4-hydroxybutylcarbamate
I-9	methyl 4-(1-(2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-10	methyl 4-(1-(2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-11	ethyl 4-(3-chlorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-12	methyl 4-(1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-13	methyl 4-(3-chloro-2-fluorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-14	methyl 4-(2-chloro-3-fluorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-15	methyl 4-(3-chloro-5-fluorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-16	methyl 4-(1-(3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate

I-17	methyl 4-(2,3-difluorophenyl)-4-(1-(1-(4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-18	methyl 4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-19	methyl 4-(1-(2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxybutylcarbamate
I-20	methyl 4-(3-chloro-2-fluorophenyl)-4-(1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-21	methyl 4-(2-chloro-3-fluorophenyl)-4-(1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-22	methyl 4-(3-chloro-2-fluorophenyl)-4-(1-(1-(4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-23	methyl 4-(3-chloro-2,4-difluorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-24	methyl 4-acetamido-4-(3-chlorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-25	methyl 4-(3-chlorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-25	methyl 4-(3-chlorophenyl)-4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-26	(3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl carbamate
I-27	(3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl methylcarbamate
I-28	(3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate
I-28	(3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate
I-29	(3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate
I-29	(3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate
I-30	methyl 2-((3-chlorophenyl)(1-(4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-31	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I-32	methyl 2-((1-(1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-34	methyl 2-((1-(1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-35	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-36	methyl 2-((1-(3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-37	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I-38	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-38	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-39	methyl 2-((1-(2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)(3-chloro-2-fluorophenyl)methoxy)ethylcarbamate
I-41	ethyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-42	methyl 2-(1-(3-chlorophenyl)-1-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I-43	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-44	methyl 2-((3-chloro-5-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-45	methyl 2-((3-chlorophenyl)(1-(1-(4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-46	methyl 2-((3-chlorophenyl)(1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-46	methyl 2-((3-chlorophenyl)(1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-48	methyl 2-((3-chloro-2-fluorophenyl)(4-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I-49	ethyl 2-((3-chloro-2-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-50	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-51	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-(4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-52	methyl 2-((3-chlorophenyl)(1-(1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-53	2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate
I-54	2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl methylcarbamate
I-55	2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl ethylcarbamate
I-56	3-((3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-56	3-((3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-57	3-((2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-58	3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-58	3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-59	N-(1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((2,3-difluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-60	3-((3-chlorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-61	3-((3-chlorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-62	N-(1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((2,3-difluorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)piperidine-1-carboxamide
I-63	N-(1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((2,3-difluorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-64	3-((3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-64	3-((3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-65	3-((3-chlorophenyl)(2-(2-methoxyethylamino)-2-oxoethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-66	3-((3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-67	3-((3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-67	3-((3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-68	3-((3-chlorophenyl)(3-oxo-3-(propylamino)propoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-69	3-((3-chlorophenyl)(3-(isopropylamino)-3-oxopropoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-70	3-((3-chloro-2-fluorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-71	3-(5-amino-1-(3-chlorophenyl)-1-hydroxy-5-oxopentyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-72	3-(1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-73	3-(1-(3-chlorophenyl)-5-(ethylamino)-1-hydroxy-5-oxopentyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-74	3-(1-(3-chlorophenyl)-4-formamido-1-hydroxybutyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-75	3-((3-chlorophenyl)(4-oxohexyloxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-76	3-(1-(3-chlorophenyl)-1-hydroxy-6-oxoheptyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-77	methyl 2-((3-chlorophenyl)(1-(4-isobutylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-78	methyl 2-((3-chloro-2-fluorophenyl)(1-(4-isobutylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-79	methyl 2-((3-chloro-2-fluorophenyl)(1-(4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-80	methyl 2-((3-chlorophenyl)(1-(4-isopropoxypiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-81	methyl 2-((3-chlorophenyl)(1-(4-cyclopentylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-82	methyl 2-((3-chlorophenyl)(1-(4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-83	methyl 2-((3-chlorophenyl)(1-(4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is each of the compounds listed below or their salts, especially their pharmaceutically acceptable salts:

I-1a		methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluorophenyl)-4-hydroxybutylcarbamate
I-2a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-3a		methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-dimethylphenyl)-4-hydroxybutylcarbamate

I-4a		methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-5a		methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-6a		methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-7a		methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-7b		methyl (R)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-8a		methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-difluorophenyl)-4-hydroxybutylcarbamate
I-9a		methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-10a		methyl (4S)-4-((3R)-1-((2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-11a		ethyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

I-12a		methyl (S)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-13a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-14a		methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-15a		methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-16a		methyl (S)-4-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-17a		methyl (S)-4-(2,3-difluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-18a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-19a		methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxybutylcarbamate

I-20a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-21a		methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-22a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-23a		methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-24a		methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-25a		methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-25b		methyl (R)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-26a		(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl carbamate

I-27a		(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl methylcarbamate
I-28a		(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate
I-28b		(S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate
I-29a		(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate
I-29b		(S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate
I-30a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-31a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I-32a		methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-34a		methyl 2-((1R)-((3R)-1-((2S)-1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

I-35a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-36a		methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-37a		methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I-38a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-38b		methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-39a		methyl 2-((R)-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)(3-chloro-2-fluorophenyl)methoxy)ethylcarbamate
I-41a		ethyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-42a		methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate

I-43a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-44a		methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-45a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-46a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47b		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-48a		methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I-49a		ethyl 2-((R)-(3-chloro-2-fluorophenyl)((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-50a		methyl 2-((1R)-(3-chloro-2-fluorophenyl)((3R)-1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-51a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-52a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-53a		2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate
I-54a		2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl methylcarbamate
I-55a		2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl ethylcarbamate
I-56a		(3R)-3-((R)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-56b		(3R)-3-((S)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-57a		(3R)-3-((S)-(2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-58a		(3R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-58b		(3R)-3-((S)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-59a		(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-60a		(3R)-3-((R)-(3-chlorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-61a		(3R)-3-((R)-(3-chlorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-62a		(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)piperidine-1-carboxamide
I-63a		(3R)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-64a		(3R)-3-((R)-(3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-65a		(3R)-3-((R)-(3-chlorophenyl)(2-(2-methoxyethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-66a		(3R)-3-((R)-(3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-67a		(3R)-3-((R)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-67b		(3R)-3-((S)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-68a		(3R)-3-((R)-(3-chlorophenyl)(3-oxo-3-(propylamino)propoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-69a		(3R)-3-((R)-(3-chlorophenyl)(3-(isopropylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-70a		(3R)-3-((R)-(3-chloro-2-fluorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-71a		(3R)-3-((S)-5-amino-1-(3-chlorophenyl)-1-hydroxy-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-72a		(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-73a		(3R)-3-((S)-1-(3-chlorophenyl)-5-(ethylamino)-1-hydroxy-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-74a		(3R)-3-((S)-1-(3-chlorophenyl)-4-formamido-1-hydroxybutyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-75a		(3R)-3-((R)-(3-chlorophenyl)(4-oxohexyloxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-76a		(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-6-oxoheptyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-77a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4R)-4-isobutylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-78a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((3S,4R)-4-isobutylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-79a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((3S,4S)-4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-80a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4S)-4-cyclopentylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-81a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3R,4R)-4-cyclopentylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-82a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4R)-4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-83a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4S)-4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is each of the compounds listed below or their salts, especially their pharmaceutically acceptable salts:

I-1a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluorophenyl)-4-hydroxybutylcarbamate
I-2a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-3a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-dimethylphenyl)-4-hydroxybutylcarbamate
I-4a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-5a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-6a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-7a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-8a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-difluorophenyl)-4-hydroxybutylcarbamate
I-9a	methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-10a	methyl (4S)-4-((3R)-1-((2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-11a	ethyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

I-12a	methyl (S)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-13a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-14a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-15a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-16a	methyl (S)-4-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-17a	methyl (S)-4-(2,3-difluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-18a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-19a	methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxybutylcarbamate
I-20a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-21a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-22a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-23a	methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-24a	methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-25a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-25b	methyl (R)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate

I-30a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-31a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I-32a	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-34a	methyl 2-((1R)-((3R)-1-((2S)-1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-35a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-36a	methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-37a	methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I-38a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-39a	methyl 2-((R)-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)(3-chloro-2-fluorophenyl)methoxy)ethylcarbamate
I-41a	ethyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-42a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43b	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-44a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-45a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-46a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-48a	methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I-49a	ethyl 2-((R)-(3-chloro-2-fluorophenyl)((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-51a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-52a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-56a	(3R)-3-((R)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-58a	(3R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-59a	(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-64a	(3R)-3-((R)-(3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-64b	(3R)-3-((R)-(3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-65a	(3R)-3-((R)-(3-chlorophenyl)(2-(2-methoxyethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-67a	(3R)-3-((R)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-68a	(3R)-3-((R)-(3-chlorophenyl)(3-oxo-3-(propylamino)propoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-74a	(3R)-3-((S)-1-(3-chlorophenyl)-4-formamido-1-hydroxybutyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-76a	(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-6-oxoheptyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-77a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4R)-4-isobutylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-78a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((3S,4R)-4-isobutylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-79a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((3S,4S)-4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-80a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4S)-4-cyclopentylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-81a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3R,4R)-4-cyclopentylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-82a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4R)-4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-83a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4S)-4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is each of the following compounds or their enantiomers, diastereomers, or pharmaceutically acceptable salts:

I-1a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluorophenyl)-4-hydroxybutylcarbamate
I-3a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-dimethylphenyl)-4-hydroxybutylcarbamate
I-4a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-5a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-6a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-7a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-9a	methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate

I-13a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-14a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-15a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-16a	methyl (S)-4-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-20a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-22a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-23a	methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-24a	methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-25a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-31a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I-32a	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-35a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-36a	methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-37a	methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I-39a	methyl 2-((R)-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)(3-chloro-2-fluorophenyl)methoxy)ethylcarbamate
I-42a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate

I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-44a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-45a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-46a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-48a	methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I-51a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-52a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-58a	(3R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-76a	(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-6-oxoheptyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-83a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S,4S)-4-cyclohexylpiperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

A particular embodiment of the invention is each of the following compounds or their enantiomers, diastereomers, or pharmaceutically acceptable salts:

5

Cpd. No.	Cpd. Name
I-6a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-13a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

I-15a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-22a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-24a	methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-25a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-31a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I-32a	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-35a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-36a	methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-37a	methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I-42a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-44a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-45a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-51a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-52a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is each of the compounds listed below or their enantiomers, diastereomers, or pharmaceutically acceptable salts:

Compound Number	Name
I*-1	methyl 2-((3-fluorophenyl)(1-(5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-2	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-3	methyl 2-((1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-4	methyl 2-((1-(1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-5	methyl 2-((1-(1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-6	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(tetrahydrofuran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-7	methyl 2-((1-(4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-8	methyl 2-((1-(5,5-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-9	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate
I*-10	methyl 2-(cyclohexyl(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-11	methyl 2-((3-chlorophenyl)(1-(4-isobutylpyrrolidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-12	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl)methoxy)ethylcarbamate
I*-13	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl)methoxy)ethylcarbamate
I*-14	methyl 2-((1-(2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

I*-15	methyl 2-((1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate
I*-16	methyl 2-((1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate
I*-17	methyl 2-((3-chlorophenyl)(1-(5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-18	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate
I*-19	methyl 2-((1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-20	methyl 2-((1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate
I*-21	methyl 2-((1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-22	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate
I*-23	methyl 4-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate
I*-24	methyl 2-((1-(1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-25	3-(1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I*-26	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-27	methyl 2-((1-(1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-28	methyl 2-((1-(2-amino-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-29	methyl 2-((3-chlorophenyl)(1-(1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-30	3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-(methylamino)-3-(etrahydro-2H-pyran-3-yl)propan-2-yl)piperidine-1-carboxamide
I*-31	3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-yl)piperidine-1-carboxamide

I*-32	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate
I*-33	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate
I*-34	methyl 2-((3-chlorophenyl)(1-(4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-35	methyl 2-((1-(2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-36	methyl 2-((3,5-dimethylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-37	methyl 2-((2,5-dimethylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-38	methyl 2-((1-(2-amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-39	methyl 2-((1-(1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-40	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-41	methyl 2-((1-(1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-42	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-43	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-44	methyl 2-((3-chlorophenyl)(1-(4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-45	3-((3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I*-46	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-47	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-48	methyl 2-((1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-49	methyl 2-((2-fluoro-5-methylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-50	methyl 2-((5-fluoro-2-methylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-51	methyl 2-((3-fluorophenyl)(1-(1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-52	methyl 2-((3-fluoro-5-methylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-53	methyl 2-((1-(1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-54	methyl 4-(3-fluorophenyl)-4-hydroxy-4-(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I*-55	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-56	methyl 2-((3-fluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-57	methyl 2-((2-fluorophenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-58yl)methoxy)ethylcarbamate
I*-58	methyl 2-((1-(2-amino-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-59	methyl 2-((1-(1-amino-3-cyclohexyl-2-methylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-60	methyl 2-((5-chloro-2-methylphenyl)(1-(1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-61	3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-(1-(methylamino)-3-(oxepan-3-yl)propan-2-yl)piperidine-1-carboxamide
I*-62	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(2-oxopyrrolidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-63	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-64	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-65	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4-difluorophenyl)methoxy)ethylcarbamate
I*-66	methyl 2-((3-chlorophenyl)(4-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I*-67	methyl 2-((3-chlorophenyl)(1-(1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-68	methyl 2-((1-(2-amino-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-69	methyl 2-((2,5-difluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-70	methyl 2-((3,5-difluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-71	methyl 2-((2,3-difluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-72	methyl 2-((1-(1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I*-73	methyl 2-((1-(2-amino-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-74	methyl 2-((1-(1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-75	methyl 2-((3-chlorophenyl)(4-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I*-76	methyl 2-((3-fluorophenyl)(1-(1-(1-methyl-6-oxopiperidin-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-77	methyl 2-((-1-(1-(2,6-dimethyl-tetrahydro-2H-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-78	methyl 2-((3-fluorophenyl)(1-(4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-79	methyl 2-((5-fluoro-2-methylphenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-80	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(4-oxocyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-81	methyl 2-(1-(3-chlorophenyl)-1-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-82	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-83	methyl 2-((1-(3-amino-1-cyclohexylpentan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-84	methyl 2-((3-chlorophenyl)(1-(1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-85	methyl 2-((5-chloro-2-methylphenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-86	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(4-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-87	methyl 1-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)propan-2-ylcarbamate
I*-88	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-89	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-90	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-91	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-92	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-93	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-94	methyl 2-((3,5-difluorophenyl)(1-(1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-95	methyl 2-((3,5-difluorophenyl)(1-(1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-96	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate
I*-97	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate
I*-98	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-99	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((S)-oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-100	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-101	methyl 2-((5-chloro-2-methylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-102	methyl 2-((3-chlorophenyl)(1-(1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-103	methyl 2-(1-(3-chlorophenyl)-1-(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-104	methyl 2-((3-chlorophenyl)(1-(1-(2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-105	methyl 2-((3-chlorophenyl)(1-(1-(2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-106	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-107	methyl 2-((5-chloro-2-methylphenyl)(1-(1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-108	methyl 2-((3-chlorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-109	methyl 2-((1-(2-amino-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)ethylcarbamate

I*-110	methyl 2-((3-chlorophenyl)(1-(2-(methylamino)-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-111	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-112	methyl 2-((1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-113	methyl 2-((3,5-difluorophenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-114	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate
I*-115	methyl 2-((2,3-difluoro-6-methylphenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-116	methyl 2-((5-chloro-2-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-117	methyl 2-((5-chloro-2-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-118	methyl 2-((3-chloro-4-fluorophenyl)(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-119	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4,5-trifluorophenyl)methoxy)ethylcarbamate
I*-120	methyl 2-((1-(1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-121	methyl 2-((3-chloro-5-fluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-122	methyl 2-((1-(2-amino-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)ethylcarbamate
I*-123	methyl 2-((1-(1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-124	methyl 2-((3-chlorophenyl)(1-(1-(3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-125	methyl 2-((3-chlorophenyl)(1-(1-(3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-126	3-((3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I*-127	methyl 2-((3-chlorophenyl)(1-(N'-cyano-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-128	3-((3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)-N-(1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I*-129	methyl 2-((1-(1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-130	methyl 2-((3-chlorophenyl)(1-(1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-131	methyl 2-((3-chlorophenyl)(1-(1-(1-methyl-6-oxopiperidin-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-132	methyl 2-((3-chlorophenyl)(1-(1-(2,6-dimethyl-tetrahydro-2H-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-133	methyl 2-((5-chloro-2-methylphenyl)(1-(2-(methylamino)-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-134	methyl 2-((3,5-difluorophenyl)(1-(4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-135	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-136	methyl 2-((1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate
I*-137	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-138	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-139	methyl 4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I*-140	methyl 2-((3-chloro-2-fluorophenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-141	methyl 2-((3-chloro-5-fluorophenyl)(1-(1-(methylamino)-3-(oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-142	methyl 4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I*-143	methyl 2-((3-chloro-5-fluorophenyl)(1-(2-(methylamino)-3-(oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-144	methyl 2-((1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate
I*-145	methyl 2-((1-(1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-146	methyl 2-((3-chlorophenyl)(1-(1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-147	methyl 2-((1-(1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-148	methyl 2-((3-chloro-2,4-difluorophenyl)(1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-149	methyl 2-((1-(1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-150	methyl 2-(1-(3-chlorophenyl)-1-(1-(1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butoxy)ethylcarbamate
I*-151	methyl 2-(1-(3-chlorophenyl)-1-(1-(1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-152	methyl 2-((1-(1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-153	methyl 2-((3-chloro-5-fluorophenyl)(1-(1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is each of the compounds listed below or their salts, especially their pharmaceutically acceptable salts:

Compound Number		
I*-1a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-2a		methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-3a		methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-4a		methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-5a		methyl 2-((R)-((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

I*-6a		methyl 2-((R)-(3-fluorophenyl)((3R)-1-((S)-1-(methylamino)-3-(tetrahydrofuran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-7a		methyl 2-((R)-((R)-1-((S)-4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl) methoxy)ethylcarbamate
I*-8a		methyl 2-((R)-((R)-1-((S)-5,5-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-9a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl) methoxy)ethylcarbamate
I*-10a		methyl 2-((S)-cyclohexyl ((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy) ethylcarbamate
I*-11a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3R*,4S*)-4-isobutylpyrrolidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-12a		methyl 2-((S)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl) methoxy)ethylcarbamate
I*-13a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl) methoxy)ethylcarbamate
I*-14a		methyl 2-((R)-((R)-1-((S)-2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl) piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-15a		methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl) methoxy)ethylcarbamate
I*-16a		methyl 2-((S)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl) methoxy)ethylcarbamate
I*-17a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-18a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl) methoxy)ethylcarbamate

I*-19a		methyl 2-((R)-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-20a		methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate
I*-21a		methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-22a		methyl (S)-4-((S)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate
I*-23a		methyl (R)-4-((S)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate
I*-24a		methyl 2-((R)-((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-25a		R)-3-((R)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I*-26a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-27a		methyl 2-((R)-((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-28a		methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-29a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-30a		(R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-yl)piperidine-1-carboxamide
I*-31a		(R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-yl)piperidine-1-carboxamide

I*-32a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate
I*-33a		methyl 2-((S)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate
I*-34a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-35a		methyl 2-((R)-((R)-1-((S)-2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl) piperidin-3-yl)(3-chlorophenyl)methoxy)eth ylcarbamate
I*-36a		methyl 2-((R)-(3,5-dimethylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-37a		methyl 2-((R)-(2,5-dimethylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-38a		methyl 2-((R)-((R)-1-((R)-2-amino-3-phenoxypropylcarbamoyl) piperidin-3-yl)(3-chlorophenyl)methoxy)eth ylcarbamate

I*-39a		methyl 2-((R)-((R)-1-((S)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl) methoxy)ethylcarbamate
I*-40a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-41a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-42a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-43a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-44a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S*,4R*)-4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy) ethylcarbamate

I*-45a		R)-3-((3R)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I*-46a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-47a		*methyl* 2-((*R*)-(3-fluorophenyl)((3R)-1-((S)-1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)*piperidin*-3-yl)methoxy)ethylcarbamate
I*-48a		methyl 2-((R)-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-*(methylamino)propan*-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-49a		methyl 2-((R)-(2-fluoro-5-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-50a		methyl 2-((R)-(5-fluoro-2-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-51a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-52a		methyl 2-((R)-(3-fluoro-5-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-53a		methyl 2-((R)-((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-54a		methyl (S)-4-(3-fluorophenyl)-4-hydroxy-4-((3R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I*-55a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-56a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-57a		methyl 2-((R)-(2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-58a		methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-59a		methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexyl-2-methylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-60a		methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-61a		R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-yl)piperidine-1-carboxamide

I*-62a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(2-oxopyrrolidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-63a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-64a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-65a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4-difluorophenyl)methoxy)ethylcarbamate
I*-66a		methyl 2-((S)-(3-chlorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I*-67a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-68a		methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-69a		methyl 2-((R)-(2,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-70a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-71a		methyl 2-((R)-(2,3-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-72a		methyl 2-((R)-((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate

I*-73a		methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-74a		methyl 2-((R)-((3R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate
I*-75a		methyl 2-((S)-(3-chlorophenyl)((R)-4-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I*-76a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-((R)-1-methyl-6-oxopiperidin-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-77a		methyl 2-((R)-((R)-1-((S)-1-((2S,4r,6R)-2,6-dimethyl-tetrahydro-2H-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl) methoxy)ethylcarbamate
I*-78a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-79a		methyl 2-((R)-(5-fluoro-2-methylphenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-80a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(4-oxocyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-81a		methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-82a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((2S,3R)-1-cyclohexyl-3-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-83a		methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylpentan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

I*-84a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-85a		methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-86a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(4-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-87a		methyl 1-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)propan-2-ylcarbamate
I*-88a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-89a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-90a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-91a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-92a		methyl 2-((S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-93a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-94a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((R)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-95a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-96a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate
I*-97a		methyl 2-((R)-((S)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate
I*-98a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-99a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((S)-oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-100a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-101a		methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-102a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-103a		methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-104a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-((1R*,2S*)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-105a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((1R*,2S*)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-106a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-107a		methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-108a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-109a		methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)ethylcarbamate
I*-110a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy) ethylcarbamate
I*-111a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-112a		methyl 2-((R)-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate

I*-113a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-114a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate
I*-115a		methyl 2-((R)-(2,3-difluoro-6-methylphenyl)(1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-116a		methyl 2-((5-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-117a		methyl 2-((R)-(5-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-118a		methyl 2-((R)-(3-chloro-4-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-119a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4,5-trifluorophenyl)methoxy)ethylcarbamate
I*-120a		methyl 2-((R)-((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-121a		methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-122a		methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)ethylcarbamate
I*-123a		methyl 2-((R)-((3R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

I*-124a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((1r,3S,4R)-3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-125a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((1s,3R,4S)-3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-126a		(R)-3-((R)-(3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I*-127a		methyl 2-((R)-(3-chlorophenyl)((R)-1-(N'-cyano-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)carbamimidoyl)piperidin-3-yl) methoxy)ethylcarbamate
I*-128a		(R)-3-((R)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I*-129a		methyl 2-((R)-((3R)-1-(1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-130a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((2S,3R)-1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-131a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((R)-1-methyl-6-oxopiperidin-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-132a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((2S,4r,6R)-2,6-dimethyl-tetrahydro-2H-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-133a		methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-2-(methylamino)-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-134a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-135a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-136a		methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate
I*-137a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((3R)-1-((S)-1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-138a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-139a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((3R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I*-140a		methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-141a		methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-142a		methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-1-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I*-143a		methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-144a		methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate
I*-145a		methyl 2-((R)-((R)-1-((S)-1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

I*-146a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-147a		methyl 2-((R)-((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-148a		methyl 2-((R)-(3-chloro-2,4-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-149a		methyl 2-((R)-((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-150a		methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butoxy)ethylcarbamate

I*-151a		methyl 2-((R)-1-(3-chlorophenyl)-1-((3R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-152a		methyl 2-((R)-((R)-1-((S)-1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-153a		methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-154a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-((R)-6,6-dimethyl-tetrahydro-2H-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-155a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-((R)-6,6-dimethyl-tetrahydro-2H-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*156a		methyl 2-((R)-((R)-1-((S)-1-((R)-6,6-dimethyl-tetrahydro-2H-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

I*-157a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((R)-6,6-dimethyl-tetrahydro-2H-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-158a		methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((R)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-159a		methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-((R)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-160a		methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-((R)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is an aspartic protease inhibitor represented by Structural Formula (XL):



(XL)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is alkyl, cycloalkyl or cycloalkylalkyl;

R^2 is H or alkyl;

R^3 is F, Cl, Br, cyano, nitro, alkyl, haloalkyl, alkoxy, haloalkoxy, or alkanesulfonyl; and

n is 0, 1, 2, or 3.

In another specific embodiment, the aspartic protease inhibitor of the present invention is one of the following compounds or their enantiomers or diastereomers. Also included are pharmaceutically acceptable salts, solvates, or hydrates of all of the following and their enantiomers and diastereomers:

Cpd No.	Structural	Name
XL-1		methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
XL-2		methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl) methoxy)ethylcarbamate
XL-3		methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)-ethylcarbamate
XL-4		methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
XL-5		methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)-ethylcarbamate
XL-6		methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)-ethylcarbamate

XL-7		methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
XL-8		methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is an aspartic protease inhibitor represented by Structural Formula (L):



(L);

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is alkyl, cycloalkyl or cycloalkylalkyl;

R^2 is H or alkyl;

R^3 is F, Cl, Br, cyano, nitro, alkyl, haloalkyl, alkoxy, haloalkoxy or alkanesulfonyl; and

n is 0, 1, 2, or 3.

In a specific embodiment, the aspartic protease inhibitor of the present invention is one of the following compounds or their enantiomers or diastereomers. Also included are pharmaceutically acceptable salts, solvates or hydrates of all of the following and their enantiomers and diastereomers:

Compound Number	Structure	Name
L-1		*methyl* 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(*m*-tolyl)-methoxy)ethylcarbamate
L-2a		methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-2b		methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-3a		methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-3b		methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-3c, 3d		methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((3*R*)-1-((*R*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

L-4a		methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-4b		methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-5a		methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-5b		methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-6a		methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-6b		methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

L-7		methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl) piperidin-3-yl)(phenyl) methoxy)ethylcarbamate
L-8		methyl 2-((*R*)-(3-chloro-4-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-9		ethyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
L-10		methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Another embodiment of the invention is an intermediate represented by Structural Formula (XXXVIII) and salts thereof (preferably pharmaceutically acceptable salts):



(XXXVIII).

E = H or a nitrogen protecting group. Amine protecting groups include carbamate, amide, and sulfonamide protecting groups known in the art (T.W. Greene and P. G. M. Wuts "Protective Groups in Organic Synthesis" John Wiley & Sons, Inc., New York 1999). Specific amine protecting groups include *tert*-butoxycarbon or benzyloxycarbonyl.

The remainder of the variables in Structural Formula (XXXVIII) are as described for Structural Formula (I) and Structural Formula (I*).

Another embodiment of the invention is an intermediate represented by Structural Formula (XXXIX) and salts thereof:



(XXXIX).

E = H or a nitrogen protecting group; n is 0, 1, 2 or 3; and the remainder of the variables in Structural Formula (XXXIX) are as described for Structural Formula (I) and Structural Formula (I*).

Another embodiment of the invention is each of the following compounds or their enantiomers, diastereomers, or pharmaceutically acceptable salts:

Cpd. No.	Cpd. Name
XXXVIII-1	(3-chlorophenyl)(piperidin-3-yl)methyl carbamate
XXXVIII-2	(3-chlorophenyl)(piperidin-3-yl)methyl methylcarbamate
XXXVIII-3	(3-chlorophenyl)(piperidin-3-yl)methyl ethylcarbamate
XXXVIII-4	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-methylacetamide
XXXVIII-5	2-((2,3-difluorophenyl)(piperidin-3-yl)methoxy)-N-propylacetamide
XXXVIII-6	2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)acetamide
XXXVIII-7	methyl 2-((3-fluorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-7	methyl 2-((3-fluorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-8	N-(4-(3-chlorophenyl)-4-hydroxy-4-(piperidin-3-yl)butyl)formamide
XXXVIII-9	3-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-methylpropanamide
XXXVIII-10	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-11	5-(3-chlorophenyl)-5-hydroxy-5-(piperidin-3-yl)pentanamide
XXXVIII-12	2-((2,3-difluorophenyl)(piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-13	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)ethyl carbamate
XXXVIII-14	7-(3-chlorophenyl)-7-hydroxy-7-(piperidin-3-yl)heptan-2-one

XXXVIII-15	6-((3-chlorophenyl)(piperidin-3-yl)methoxy)hexan-3-one
XXXVIII-16	methyl 4-(2-fluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-17	(3-chlorophenyl)(piperidin-3-yl)methyl butylcarbamate
XXXVIII-18	3-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-ethylpropanamide
XXXVIII-19	5-(3-chlorophenyl)-5-hydroxy-N-methyl-5-(piperidin-3-yl)pentanamide
XXXVIII-20	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-propylacetamide
XXXVIII-21	2-((2,3-difluorophenyl)(piperidin-3-yl)methoxy)-N-isopropylacetamide
XXXVIII-22	methyl 2-((3-chlorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-23	2-methoxyethyl (3-chlorophenyl)(piperidin-3-yl)methylcarbamate
XXXVIII-24	2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-25	methyl 4-(3,5-dimethylphenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-26	methyl 4-(3-fluoro-5-methylphenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-27	methyl 4-(2-fluoro-5-methylphenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-28	5-(3-chlorophenyl)-N-ethyl-5-hydroxy-5-(piperidin-3-yl)pentanamide
XXXVIII-29	3-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-propylpropanamide
XXXVIII-30	3-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-isopropylpropanamide
XXXVIII-31	methyl 4-(3-chlorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-32	ethyl 2-((3-chlorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-33	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-(2-methoxyethyl)acetamide
XXXVIII-34	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)ethyl ethylcarbamate
XXXVIII-35	methyl 4-(2,3-difluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-36	methyl 4-(3,5-difluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-37	methyl 2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-38	methyl 2-((3-chloro-5-fluorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-40	ethyl 4-(3-chlorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-41	methyl 4-(3-chlorophenyl)-4-hydroxy-4-(piperidin-3-yl)butyl(methyl)carbamate
XXXVIII-42	methyl 4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-43	methyl 4-(2-chloro-3-fluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate

XXXVIII-44	methyl 4-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-45	ethyl 2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-46	methyl 4-(3-chloro-2,4-difluorophenyl)-4-hydroxy-4-(piperidin-3-yl)butylcarbamate
XXXVIII-47	methyl 4-acetamido-4-(3-chlorophenyl)-4-(piperidin-3-yl)butylcarbamate
XXXVIII-48	methyl 4-(3-chlorophenyl)-4-(piperidin-3-yl)-4-propionamidobutylcarbamate
XXXVIII-49	methyl 2-((2,3-difluorophenyl)(piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-50	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)-N-isopropylacetamide
XXXVIII-51	methyl 2-((3-chloro-2-fluorophenyl)(morpholin-2-yl)methoxy)ethylcarbamate
XXXVIII-52	2-((3-chlorophenyl)(piperidin-3-yl)methoxy)ethanol

A further embodiment of the invention is each of the following compounds or their enantiomers, diastereomers, or pharmaceutically acceptable salts:

Cpd. No.	Cpd. Name
XXXVIII-1a	(R)-(3-chlorophenyl)((R)-piperidin-3-yl)methyl carbamate
XXXVIII-2a	(R)-(3-chlorophenyl)((R)-piperidin-3-yl)methyl methylcarbamate
XXXVIII-3a	(R)-(3-chlorophenyl)((R)-piperidin-3-yl)methyl ethylcarbamate
XXXVIII-3a	(R)-(3-chlorophenyl)((R)-piperidin-3-yl)methyl ethylcarbamate
XXXVIII-4a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-methylacetamide
XXXVIII-5a	2-((R)-(2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)-N-propylacetamide
XXXVIII-6a	2-((S)-(3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)acetamide
XXXVIII-7a	methyl 2-((R)-(3-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-8a	N-((S)-4-(3-chlorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butyl)formamide
XXXVIII-9a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-methylpropanamide
XXXVIII-10a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-11a	(S)-5-(3-chlorophenyl)-5-hydroxy-5-((R)-piperidin-3-yl)pentanamide
XXXVIII-12a	2-((R)-(2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide

XXXVIII-13a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethyl carbamate
XXXVIII-14a	(S)-7-(3-chlorophenyl)-7-hydroxy-7-((R)-piperidin-3-yl)heptan-2-one
XXXVIII-15a	6-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)hexan-3-one
XXXVIII-16a	methyl (S)-4-(2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-17a	(R)-(3-chlorophenyl)((R)-piperidin-3-yl)methyl butylcarbamate
XXXVIII-18a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylpropanamide
XXXVIII-19a	(S)-5-(3-chlorophenyl)-5-hydroxy-N-methyl-5-((R)-piperidin-3-yl)pentanamide
XXXVIII-20a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-propylacetamide
XXXVIII-21a	2-((R)-(2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)-N-isopropylacetamide
XXXVIII-22a	methyl 2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-23a	2-methoxyethyl (R)-(3-chlorophenyl)((R)-piperidin-3-yl)methylcarbamate
XXXVIII-24a	2-((3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-25a	methyl (S)-4-(3,5-dimethylphenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-26a	methyl (S)-4-(3-fluoro-5-methylphenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-27a	methyl (S)-4-(2-fluoro-5-methylphenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-28a	(S)-5-(3-chlorophenyl)-N-ethyl-5-hydroxy-5-((R)-piperidin-3-yl)pentanamide
XXXVIII-29a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-propylpropanamide
XXXVIII-30a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-isopropylpropanamide
XXXVIII-31a	methyl (S)-4-(3-chlorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-32a	ethyl 2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-33a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-(2-methoxyethyl)acetamide
XXXVIII-34a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethyl ethylcarbamate
XXXVIII-35a	methyl (S)-4-(2,3-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-36a	methyl (S)-4-(3,5-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate

XXXVIII-37a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-38a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-40a	ethyl (S)-4-(3-chlorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-41a	methyl (S)-4-(3-chlorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butyl(methyl)carbamate
XXXVIII-42a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-43a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-43a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-44a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-45a	ethyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-46a	methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-47a	methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-48a	methyl (R)-4-(3-chlorophenyl)-4-((R)-piperidin-3-yl)-4-propionamidobutylcarbamate
XXXVIII-49a	methyl 2-((R)-(2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-50a	2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-isopropylacetamide
XXXVIII-51a	methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-morpholin-2-yl)methoxy)ethylcarbamate
XXXVIII-52a	2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethanol

Additional compounds of the invention are listed below. Also included are the enantiomers or diastereomers or pharmaceutically acceptable salts thereof.

Cpd. No.	Cpd. Name
XXXVIII-53a	(*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-54a	(R)-*tert*-butyl 3-((R)-(2,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-55a	(*R*)-*tert*-butyl 3-((*R*)-(3,4-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-56a	(*R*)-*tert*-butyl 3-((*R*)-(3-chloro-2-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-57a	(*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

XXXVIII-58a	(*R*)-*tert*-butyl 3-((*R*)-(2-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-59a	*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(3,4,5-trifluorophenyl)methyl)piperidine-1-carboxylate
XXXVIII-60a	(*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(thiophen-2-yl)methyl)piperidine-1-carboxylate
XXXVIII-61a	(*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(thiazol-2-yl)methyl)piperidine-1-carboxylate
XXXVIII-62a	(3*R*)-*tert*-butyl 3-((2-(methoxycarbonylamino)ethoxy)(4-methylthiazol-2-yl)methyl)piperidine-1-carboxylate
XXXVIII-63a	(R)-*tert*-butyl 3-((R)-(2,3-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-64a	(R)-*tert*-butyl 3-((R)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-65a	(R)-*tert*-butyl 3-((R)-(3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-66a	(R)-*tert*-butyl 3-((R)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-67a	(R)-*tert*-butyl 3-((R)-(2-(methoxycarbonylamino)ethoxy)(m-tolyl)methyl)piperidine-1-carboxylate
XXXVIII-68a	(R)-*tert*-butyl 3-((R)-(2-(methoxycarbonylamino)ethoxy)(3-(trifluoromethyl)phenyl)methyl)piperidine-1-carboxylate
XXXVIII-69a	(R)-*tert*-butyl 3-((R)-(2,5-dimethylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-70a	(R)-*tert*-butyl 3-((R)-(3,5-dimethylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-71a	(R)-*tert*-butyl 3-((R)-(5-fluoro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-72a	(R)-*tert*-butyl 3-((R)-(3-chloro-4-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-73a	(R)-*tert*-butyl 3-((R)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-74a	(*R*)-*tert*-butyl 3-((*R*)-(3-chloro-2,4-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-75a	(R)-*tert*-butyl 3-((R)-(2-(benzyloxy)-3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-76a	(R)-*tert*-butyl 3-((R)-(2-(benzyloxy)-3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-77a	(R)-*tert*-butyl 3-((R)-(3-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-78a	(R)-*tert*-butyl 3-((R)-(3-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-79a	(R)-*tert*-butyl 3-((2,3-difluoro-6-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-80a	(R)-*tert*-butyl 3-((2,3-difluoro-6-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-81a	(R)-*tert*-butyl 2-((S)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)morpholine-4-carboxylate

XXXVIII-82a	(R)-*tert*-butyl 3-((R)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-83a	(R)-*tert*-butyl 3-((R)-(3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-84a	(R)-*tert*-butyl 3-((R)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)piperidine-1-carboxylate
XXXVIII-85a	(R)-*tert*-butyl 3-((R)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)azepane-1-carboxylate
XXXVIII-86a	(R)-*tert*-butyl 3-((R)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)azepane-1-carboxylate
XXXVIII-87a	(3S)-*tert*-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate
XXXVIII-88a	(R)-*tert*-butyl 3-((R)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)ethyl)piperidine-1-carboxylate
XXXVIII-89a	(R)-*tert*-butyl 3-((R)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)butyl)piperidine-1-carboxylate
XXXVIII-90a	(R)-*tert*-butyl 3-((S)-1-(3-fluorophenyl)-1-hydroxy-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate
XXXVIII-91a	(*R*)-*tert*-butyl 3-((*S*)-1-(3-chloro-2-fluorophenyl)-1-hydroxy-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate

When any variable (e.g., aryl, heterocyclyl, R_1, R_2, etc.) occurs more than once in a compound, its definition on each occurrence is independent of any other occurrence.

"Alkyl" means a saturated aliphatic branched or straight-chain mono- or di-valent hydrocarbon radical having the specified number of carbon atoms. Thus, "(C_1-C_8)alkyl" means a radical having from 1-8 carbon atoms in a linear or branched arrangement. "(C_1-C_6)alkyl" includes methyl, ethyl, propyl, butyl, pentyl, and hexyl.

"Alkylene" means $-[CH_2]_x-$, wherein x is a positive integer. x is typically a positive integer from 1-10, more typically from 1-5, even more typically 2-4 and more typically yet from 2-3. Alkylene groups are optionally substituted at any one or more substitutable carbon atom, i.e., a carbon atom that is bonded to a hydrogen, wherein the hydrogen is replaced with a substituent.

"Alkenylene" is an alkylene group in which at least one single bond connecting adjacent methylene groups has been replaced with a double bond. Alkenylene groups are optionally substituted at any one or more substitutable carbon atom, i.e., a carbon atom that is bonded to a hydrogen, wherein the hydrogen is replaced with a substituent.

"Alkynylene" is an alkylene group in which at least one single bond connecting adjacent methylene groups has been replaced with a double bond. Alkynylene groups are optionally substituted at any one or more substitutable carbon atom, i.e., a carbon atom that is bonded to a hydrogen, wherein the hydrogen is replaced with a substituent.

"Cycloalkyl" means a saturated aliphatic cyclic hydrocarbon radical having the specified number of carbon atoms. Thus, (C_3-C_7)cycloalkyl means a radical having from 3-7 carbon atoms arranged in a ring. (C_3-C_7)cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

Haloalkyl and halocycloalkyl include mono, poly, and perhaloalkyl groups where the halogens are independently selected from fluorine, chlorine, and bromine.

Saturated heterocyclic rings are 4-, 5-, 6-, and 7-membered heterocyclic rings containing 1 to 4 heteroatoms independently selected from N, O, and S, and include pyrrolidine, piperidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, isoxazolidine, 1,3-dioxolane, 1,3-dithiolane, 1,3-dioxane, 1,4-dioxane, 1,3-dithiane, 1,4-dithiane, morpholine, thiomorpholine, thiomorpholine 1,1-dioxide, tetrahydro-2H-1,2-thiazine 1,1-dioxide, and isothiazolidine 1,1-dioxide. Oxo substituted saturated heterocyclic rings include tetrahydrothiophene 1-oxide, tetrahydrothiophene 1,1-dioxide, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, tetrahydro-2H-1,2-thiazine 1,1-dioxide, and isothiazolidine 1,1-dioxide, pyrrolidin-2-one, piperidin-2-one, piperazin-2-one, and morpholin-2-one.

"Heteroaryl" means a monovalent heteroaromatic monocyclic and polycylic ring radical containing 1 to 4 heteroatoms independently selected from N, O, and S. Heteroaryl rings include furyl, thienyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridinyl-N-oxide, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, isoindolyl, benzo[b]furyl, benzo[b]thienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,2,5-thiadiazolyl, 1,2,5-thiadiazolyl-1-oxide, 1,2,5-thiadiazolyl-1,1-dioxide, 1,3,4-thiadiazolyl, 1,2,4-triazinyl, 1,3,5-triazinyl, tetrazolyl, and pteridinyl.

Bicyclic heteroaryl rings are bicyclo[4.4.0] and bicyclo[4,3.0] fused ring systems of which at least one ring is aromatic containing 1 to 4 heteroatoms

independently selected from N, O, and S, and include indole, quinoline, isoquinoline, quinazoline, benzothiophene, benzofuran, 2,3-dihydrobenzofuran, benzodioxole, benzimidazole, indazole, benzisoxazole, benzoxazole, and benzothiazole.

Bicycloalkyl rings are fused, bridged and spiro ring systems and include bicyclo[1.1.0]butane, bicyclo[1.2.0]pentane, bicyclo[2.2.0]hexane, bicyclo[3.2.0]heptane, bicyclo[3.3.0]octane, bicyclo[4.2.0]octane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[3.3.2]decane and bicyclo[3.3.3]undecane, spiro[2.2]pentane, spiro[2.3]hexane, spiro[3.3]heptane, spiro[2.4]heptane, spiro[3.4]octane and spiro[2.5]octane.

"Alkoxy" means an alkyl radical attached through an oxygen linking atom. "(C_1-C_4)-alkoxy" includes the methoxy, ethoxy, propoxy, and butoxy.

"Aromatic" means an unsaturated cycloalkyl ring system.

"Aryl" means an aromatic monocyclic or polycyclic ring system. Aryl systems include phenyl, naphthalenyl, fluorenyl, indenyl, azulenyl, and anthracenyl.

"Hetero" refers to the replacement of at least one carbon atom member in a ring system with at least one heteroatom selected from N, S, and O. A hetero ring may have 1, 2, 3, or 4 carbon atom members replaced by a heteroatom.

"Oxo" refers to =O. When an oxo group is a substituent on a carbon atom, they form a carbonyl group (-C(O)-). When one oxo group is a substituent on a sulfur atom, they form a sulfinyl (sulfoxide –S(O)-) group. When two oxo groups are a substituent on a sulfur atom, they form a sulfonyl (sulfone $-S(O)_2-$) group.

Enantiomers, Diastereomers, and Salts

Certain of the disclosed aspartic protease inhibitors may exist in various tautomeric forms. The invention encompasses all such forms, including forms those not depicted structurally.

Certain of the disclosed aspartic protease inhibitors may exist in various stereoisomeric forms. Stereoisomers are compounds which differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted

carbon atom that acts as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms. The symbol "*" in a structural formula represents the presence of a chiral carbon center. "*R*" and "*S*" represent the configuration of substituents around one or more chiral carbon atoms. Thus, "*R**" and "*S**" denote the relative configurations of substituents around one or more chiral carbon atoms. When a chiral center is not defined as R or S and the configuration at the chiral center is not defined by other means, either configuration can be present or a mixture of both configurations is present.

"Racemate" or "racemic mixture" means a compound of equimolar quantities of two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light.

"Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration.

Atoms (other than H) attached to a carbocyclic ring may be in a cis or trans configuration. In the "cis" configuration, the substituents are on the same side in relationship to the plane of the ring; in the "trans" configuration, the substituents are on opposite sides in relationship to the plane of the ring. A mixture of "cis" and "trans" species is designated "cis/trans".

"R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule.

The point at which a group or moiety is attached to the remainder of the compound or another group or moiety can be indicated by "〰" which represents "  ", "  " or "  ".

The disclosed aspartic protease inhibitors may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an

isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods.

When the stereochemistry of a disclosed aspartic protease inhibitor is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enatiomer over the weight of the enantiomer plus the weight of its optical isomer.

When a disclosed aspartic protease inhibitor is named or depicted by structure without indicating the stereochemistry, and the inhibitor has at least one chiral center, it is to be understood that the name or structure encompasses one enantiomer of inhibitor free from the corresponding optical isomer, a racemic mixture of the inhibitor and mixtures enriched in one enantiomer relative to its corresponding optical isomer.

When a disclosed aspartic protease inhibitor is named or depicted by structure without indicating the stereochemistry and has at least two chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a pair of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) and mixtures of diastereomeric pairs in which one diastereomeric pair is enriched relative to the other diastereomeric pair(s).

Pharmaceutically acceptable salts of the compounds of the aspartic protease inhibitors are included in the present invention. For example, an acid salt of an aspartic protease inhibitor containing an amine or other basic group can be obtained by reacting the compound with a suitable organic or inorganic acid, resulting in pharmaceutically

acceptable anionic salt forms. Examples of anionic salts include the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphospate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, and triethiodide salts.

Salts of aspartic protease inhibitors containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base. Such a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'-dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2-hydroxyethyl)amine, procaine, dibenzylpiperidine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.

When a disclosed aspartic protease inhibitor or its pharmaceutically acceptable salt is named or depicted by structure, it is to be understood that solvates or hydrates of the aspartic protease inhibitor or its pharmaceutically acceptable salts are also included. "Solvates" refer to crystalline forms wherein solvent molecules are incorporated into the crystal lattice during crystallization. Solvate may include water or nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and EtOAc. Solvates, wherein water is the solvent molecule incorporated into the crystal lattice, are typically referred to as "hydrates". Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water.

When a disclosed aspartic protease inhibitor or its pharmaceutically acceptable salt is named or depicted by structure, it is to be understood that the compound,

including solvates thereof, may exist in crystalline forms, non-crystalline forms or a mixture thereof. The aspartic protease inhibitor or its pharmaceutically acceptable salts or solvates may also exhibit polymorphism (i.e. the capacity to occur in different crystalline forms). These different crystalline forms are typically known as "polymorphs." It is to be understood that when named or depicted by structure, the disclosed aspartic protease inhibitors and their pharmaceutically acceptable salts, solvates or hydrates also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in solidifying the compound. For example, changes in temperature, pressure, or solvent may result in different polymorphs. In addition, one polymorph may spontaneously convert to another polymorph under certain conditions.

It may be necessary and/or desirable during synthesis to protect sensitive or reactive groups on any of the molecules concerned. Representative conventional protecting groups are described in T.W. Greene and P. G. M. Wuts "Protective Groups in Organic Synthesis" John Wiley & Sons, Inc., New York 1999. Protecting groups may be added and removed using methods well known in the art.

The disclosed aspartic protease inhibitors are useful for ameliorating or treating disorders or diseases in which decreasing the levels of aspartic protease products is effective in treating the disease state or in treating infections in which the infectious agent depends upon the activity of an aspartic protease. In hypertension elevated levels of angiotensin I, the product of renin catalyzed cleavage of angioteninogen are present. Elevated levels of β amyloid, the product of BACE activity on amyloid precursor protein, are believed to be responsible for the amyloid plaques present in the brains of Alzheimer's disease patients. The viruses HIV and HTLV depend on their respective aspartic proteases for viral maturation. *Plasmodium falciparum* uses plasmepsins I and II to degrade hemoglobin.

The disclosed aspartic protease inhibitors are useful for ameliorating or treating disorders or diseases in which decreasing the levels of renin products is effective in treating a disease state. In hypertension elevated levels of angiotensin I, the product of renin catalyzed cleavage of angioteninogen are present. Thus, the disclosed aspartic protease inhibitors can be used in the treatment of hypertension; heart failure such as (acute and chronic) congestive heart failure; left ventricular dysfunction; cardiac hypertrophy; cardiac fibrosis; cardiomyopathy (e.g., diabetic cardiac myopathy and post-infarction cardiac myopathy); supraventricular and ventricular arrhythmias; arial fibrillation; atrial flutter; detrimental vascular remodeling; myocardial infarction and its sequelae; atherosclerosis; angina (whether unstable or stable); renal failure conditions, such as diabetic nephropathy; glomerulonephritis; renal fibrosis; scleroderma; glomerular sclerosis; microvascular complications, for example, diabetic retinopathy; renal vascular hypertension; vasculopathy; neuropathy; diseases of the coronary vessels; proteinuria; albumenuria; post-surgical hypertension; metabolic syndrome; obesity, restenosis following angioplasty; ocular vascular complications, for example, raised intra-ocular pressure, glaucoma, and retinopathy; abnormal vascular growth; angiogenesis-related disorders, such as neovascular age related macular degeneration; hyperaldosteronism; anxiety states; and cognitive disorders (Fisher N.D.; Hollenberg N. K. *Expert Opin. Investig. Drugs*. 2001, *10*, 417-26).

A pharmaceutical composition of the invention may, alternatively or in addition to a disclosed aspartic protease inhibitor, comprise a pharmaceutically acceptable salt of a disclosed aspartic protease inhibitor or a prodrug or pharmaceutically active metabolite of such a compound or salt and one or more pharmaceutically acceptable carriers therefor.

The invention includes a therapeutic method for treating or ameliorating an aspartic protease mediated disorder in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a compound of the aspartic protease inhibitors disclosed herein, or a pharmaceutically acceptable salt thereof.

Administration methods include administering an effective amount (i.e., a therapeutically effective amount) of a compound or composition of the invention at

different times during the course of therapy or concurrently in a combination form. The methods of the invention include all known therapeutic treatment regimens.

"Effective amount" means that amount of active compound agent that elicits the desired biological response in a subject. Such response includes alleviation of the symptoms of the disease or disorder being treated. The effective amount of a disclosed aspartic protease inhibitor in such a therapeutic method is from about .01 mg/kg/day to about 10 mg/kg/day, preferably from about 0.5 mg/kg/day to 5 mg/kg/day.

The invention includes the use of a disclosed aspartic protease inhibitor for the preparation of a composition for treating or ameliorating an aspartic protease mediated chronic disorder or disease or infection in a subject in need thereof, wherein the composition comprises a mixture one or more of the disclosed aspartic protease inhibitors and an optional pharmaceutically acceptable carrier.

"Pharmaceutically acceptable carrier" means compounds and compositions that are of sufficient purity and quality for use in the formulation of a composition of the invention and that, when appropriately administered to an animal or human, do not produce an adverse reaction.

"Aspartic protease mediated disorder or disease" includes disorders or diseases associated with the elevated expression or overexpression of aspartic proteases and conditions that accompany such diseases.

An embodiment of the invention includes administering an aspartic protease inhibitor disclosed herein in a combination therapy (see USP 5821232, USP 6716875, USP 5663188, or Fossa, A. A.; DePasquale, M. J.; Ringer, L. J.; Winslow, R. L. "Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist" *Drug Development Research* 1994, *33*(4), 422-8) with one or more additional agents for the treatment of hypertension including α-blockers, β-blockers, calcium channel blockers, diuretics, natriuretics, saluretics, centrally acting antiphypertensives, angiotensin converting enzyme (ACE) inhibitors, dual ACE and neutral endopeptidase (NEP) inhibitors, angiotensin-receptor blockers (ARBs), aldosterone synthase inhibitors, aldosterone-receptor antagonists, or endothelin receptor antagonists.

α-Blockers include doxazosin, prazosin, tamsulosin, and terazosin.

β-Blockers for combination therapy are selected from atenolol, bisoprol, metoprolol, acetutolol, esmolol, celiprolol, taliprolol, acebutolol, oxprenolol, pindolol, propanolol, bupranolol, penbutolol, mepindolol, carteolol, nadolol, carvedilol, and their pharmaceutically acceptable salts.

Calcium channel blockers include dihydropyridines (DHPs) and non-DHPs. Cetain DHPs are amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, nigulpidine, niludipine, nimodiphine, nisoldipine, nitrendipine, and nivaldipine, and their pharmaceutically acceptable salts. Non-DHPs are flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mibefradil, anipamil, tiapamil, and verampimil, and their pharmaceutically acceptable salts.

A diuretic is, for example, a thiazide derivative selected from amiloride, chlorothiazide, hydrochlorothiazide, methylchlorothiazide, and chlorothalidon.

Centrally acting antiphypertensives include clonidine, guanabenz, guanfacine and methyldopa.

ACE inhibitors include alacepril, benazepril, benazaprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipiril, moveltopril, perindopril, quinapril, quinaprilat, ramipril, ramiprilat, spirapril, temocapril, trandolapril, and zofenopril. Specific ACE inhibitors are benazepril, enalpril, lisinopril, and ramipril.

Dual ACE/NEP inhibitors are, for example, omapatrilat, fasidotril, and fasidotrilat.

Specific ARBs include candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan, and valsartan.

Specific aldosterone synthase inhibitors are anastrozole, fadrozole, and exemestane.

Specific aldosterone-receptor antagonists are spironolactone and eplerenone.

A specific endothelin antagonist is, for example, bosentan, enrasentan, atrasentan, darusentan, sitaxsentan, and tezosentan, and their pharmaceutically acceptable salts.

An embodiment of the invention includes administering an aspartic protease inhibitor disclosed herein or composition thereof in a combination therapy with one or more additional agents for the treatment of AIDS including reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, other HIV protease inhibitors, HIV integrase inhibitors, attachment and fusion inhibitors, antisense drugs, and immune stimulators.

Specific reverse transcriptase inhibitors are zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir, and emtricitabine.

Specific non-nucleoside reverse transcriptase inhibitors are nevirapine, delaviridine, and efavirenz.

Specific HIV protease inhibitors are saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, and fosamprenavir.

Specific HIV integrase inhibitors are L-870,810 and S-1360.

A specific attachment and fusion inhibitor is enfuvirtide.

An embodiment of the invention includes administering an aspartic protease inhibitor disclosed herein or composition thereof in a combination therapy with one or more additional agents for the treatment of Alzheimer's disease including tacrine, donepezil, rivastigmine, galantamine, and memantine.

An embodiment of the invention includes administering an aspartic protease inhibitor disclosed herein or composition thereof in a combination therapy with one or more additional agents for the treatment of malaria including artemisinin, chloroquine, halofantrine, hydroxychloroquine, mefloquine, primaquine, pyrimethamine, quinine, and sulfadoxine

Combination therapy includes co-administration of an aspartic protease inhibitor disclosed herein and said other agent, sequential administration of the disclosed aspartic protease inhibitor and the other agent, administration of a composition containing the aspartic protease inhibitor and the other agent, or simultaneous administration of separate compositions containing the aspartic protease inhibitor and the other agent.

The invention further includes the process for making the composition comprising mixing one or more of the disclosed aspartic protease inhibitors and an

optional pharmaceutically acceptable carrier; and includes those compositions resulting from such a process, which process includes conventional pharmaceutical techniques.

The compositions of the invention include ocular, oral, nasal, transdermal, topical with or without occlusion, intravenous (both bolus and infusion), and injection (intraperitoneally, subcutaneously, intramuscularly, intratumorally, or parenterally). The composition may be in a dosage unit such as a tablet, pill, capsule, powder, granule, liposome, ion exchange resin, sterile ocular solution, or ocular delivery device (such as a contact lens and the like facilitating immediate release, timed release, or sustained release), parenteral solution or suspension, metered aerosol or liquid spray, drop, ampoule, auto-injector device, or suppository; for administration ocularly, orally, intranasally, sublingually, parenterally, or rectally, or by inhalation or insufflation.

Compositions of the invention suitable for oral administration include solid forms such as pills, tablets, caplets, capsules (each including immediate release, timed release, and sustained release formulations), granules and powders; and, liquid forms such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for ocular administration include sterile solutions or ocular delivery devices. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.

The compositions of the invention may be administered in a form suitable for once-weekly or once-monthly administration. For example, an insoluble salt of the active compound may be adapted to provide a depot preparation for intramuscular injection (e.g., a decanoate salt) or to provide a solution for ophthalmic administration.

The dosage form containing the composition of the invention contains an effective amount of the active ingredient necessary to provide a therapeutic and/or prophylactic effect. The composition may contain from about 5,000 mg to about 0.5 mg (preferably, from about 1,000 mg to about 0.5 mg) of a disclosed aspartic protease inhibitor or salt form thereof and may be constituted into any form suitable for the selected mode of administration. The composition may be administered about 1 to about 5 times per day. Daily administration or post-periodic dosing may be employed.

For oral administration, the composition is preferably in the form of a tablet or capsule containing, e.g., 500 to 0.5 milligrams of the active compound. Dosages will vary depending on factors associated with the particular patient being treated (e.g., age,

weight, diet, and time of administration), the severity of the condition being treated, the compound being employed, the mode of administration, and the strength of the preparation.

The oral composition is preferably formulated as a homogeneous composition, wherein the active ingredient is dispersed evenly throughout the mixture, which may be readily subdivided into dosage units containing equal amounts of a disclosed aspartic protease inhibitor. Preferably, the compositions are prepared by mixing a disclosed aspartic protease inhibitor (or pharmaceutically acceptable salt thereof) with one or more optionally present pharmaceutical carriers (such as a starch, sugar, diluent, granulating agent, lubricant, glidant, binding agent, and disintegrating agent), one or more optionally present inert pharmaceutical excipients (such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and syrup), one or more optionally present conventional tableting ingredients (such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, and any of a variety of gums), and an optional diluent (such as water).

Binder agents include starch, gelatin, natural sugars (e.g., glucose and beta-lactose), corn sweeteners and natural and synthetic gums (e.g., acacia and tragacanth). Disintegrating agents include starch, methyl cellulose, agar, and bentonite.

Tablets and capsules represent an advantageous oral dosage unit form. Tablets may be sugarcoated or filmcoated using standard techniques. Tablets may also be coated or otherwise compounded to provide a prolonged, control-release therapeutic effect. The dosage form may comprise an inner dosage and an outer dosage component, wherein the outer component is in the form of an envelope over the inner component. The two components may further be separated by a layer which resists disintegration in the stomach (such as an enteric layer) and permits the inner component to pass intact into the duodenum or a layer which delays or sustains release. A variety of enteric and non-enteric layer or coating materials (such as polymeric acids, shellacs, acetyl alcohol, and cellulose acetate or combinations thereof) may be used.

The disclosed aspartic protease inhibitors may also be administered *via* a slow release composition; wherein the composition includes a disclosed aspartic protease inhibitor and a biodegradable slow release carrier (e.g., a polymeric carrier) or a

pharmaceutically acceptable non-biodegradable slow release carrier (e.g., an ion exchange carrier).

Biodegradable and non-biodegradable slow release carriers are well known in the art. Biodegradable carriers are used to form particles or matrices which retain an active agent(s) and which slowly degrade/dissolve in a suitable environment (e.g., aqueous, acidic, basic and the like) to release the agent. Such particles degrade/dissolve in body fluids to release the active compound(s) therein. The particles are preferably nanoparticles (e.g., in the range of about 1 to 500 nm in diameter, preferably about 50-200 nm in diameter, and most preferably about 100 nm in diameter). In a process for preparing a slow release composition, a slow release carrier and a disclosed aspartic protease inhibitor are first dissolved or dispersed in an organic solvent. The resulting mixture is added into an aqueous solution containing an optional surface-active agent(s) to produce an emulsion. The organic solvent is then evaporated from the emulsion to provide a colloidal suspension of particles containing the slow release carrier and the disclosed aspartic protease inhibitor.

The disclosed aspartic protease inhibitors may be incorporated for administration orally or by injection in a liquid form such as aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil and the like, or in elixirs or similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone, and gelatin. The liquid forms in suitably flavored suspending or dispersing agents may also include synthetic and natural gums. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations, which generally contain suitable preservatives, are employed when intravenous administration is desired.

The disclosed aspartic protease inhibitors may be administered parenterally *via* injection. A parenteral formulation may consist of the active ingredient dissolved in or mixed with an appropriate inert liquid carrier. Acceptable liquid carriers usually comprise aqueous solvents and other optional ingredients for aiding solubility or preservation. Such aqueous solvents include sterile water, Ringer's solution, or an isotonic aqueous saline solution. Other optional ingredients include vegetable oils

(such as peanut oil, cottonseed oil, and sesame oil), and organic solvents (such as solketal, glycerol, and formyl). A sterile, non-volatile oil may be employed as a solvent or suspending agent. The parenteral formulation is prepared by dissolving or suspending the active ingredient in the liquid carrier whereby the final dosage unit contains from 0.005 to 10% by weight of the active ingredient. Other additives include preservatives, isotonizers, solubilizers, stabilizers, and pain-soothing agents. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.

The disclosed aspartic protease inhibitors may be administered intranasally using a suitable intranasal vehicle.

The disclosed aspartic protease inhibitors may also be administered topically using a suitable topical transdermal vehicle or a transdermal patch.

For ocular administration, the composition is preferably in the form of an ophthalmic composition. The ophthalmic compositions are preferably formulated as eye-drop formulations and filled in appropriate containers to facilitate administration to the eye, for example a dropper fitted with a suitable pipette. Preferably, the compositions are sterile and aqueous based, using purified water. In addition to the disclosed aspartic protease inhibitor, an ophthalmic composition may contain one or more of: a) a surfactant such as a polyoxyethylene fatty acid ester; b) a thickening agents such as cellulose, cellulose derivatives, carboxyvinyl polymers, polyvinyl polymers, and polyvinylpyrrolidones, typically at a concentration n the range of about 0.05 to about 5.0% (wt/vol); c) (as an alternative to or in addition to storing the composition in a container containing nitrogen and optionally including a free oxygen absorber such as Fe), an anti-oxidant such as butylated hydroxyanisol, ascorbic acid, sodium thiosulfate, or butylated hydroxytoluene at a concentration of about 0.00005 to about 0.1% (wt/vol); d) ethanol at a concentration of about 0.01 to 0.5% (wt/vol); and e) other excipients such as an isotonic agent, buffer, preservative, and/or pH-controlling agent. The pH of the ophthalmic composition is desirably within the range of 4 to 8.

The invention is further defined by reference to the examples, which are intended to be illustrative and not limiting.

Representative compounds of the invention can be synthesized in accordance with the general synthetic schemes described above and are illustrated in the examples

that follow. The methods for preparing the various starting materials used in the schemes and examples are well within the knowledge of persons skilled in the art.

The following abbreviations have the indicated meanings:

Abbreviation	Meaning
Aq	aqueous
Boc	*tert*-butoxy carbonyl or *t*-butoxy carbonyl
$(Boc)_2O$	di-*tert*-butyl dicarbonate
Brine	saturated aqueous NaCl
Cbz	Benzyloxycarbonyl
CbzCl	Benzyl chloroformate
CDI	carbonyl diimidazole
CH_2Cl_2	methylene chloride
CH_3CN or MeCN	acetonitrile
Cpd	compound
d	day
DAST	diethylaminosulfur trifluoride
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DCC	N,N'-dicyclohexylcarbodiimide
DCU	N,N'-dicyclohexylurea
DIAD	diisopropyl azodicarboxylate
DIEA	N,N-diisopropylethylamine
DMAP	4-(dimethylamino)pyridine
DMF	N,N-dimethylformamide
DMPU	1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
2,4-DNP	2,4-dinitrophenylhydrazine
EDC.HCl	1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
Equiv	equivalents
Et	ethyl
Et_2O	ethyl ether
EtOAc	ethyl acetate
EtOH	ethanol
Fmoc	1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-
Fmoc-OSu	1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-2,5-pyrrolidinedione

h, hr	hour
HOBt	1-hydroxybenzotriazole
HATU	2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HBTU	2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
IPA	isopropyl alcohol
KHMDS	potassium hexamethyldisilazane
LAH or $LiAlH_4$	lithium aluminum hydride
LC-MS	liquid chromatography-mass spectroscopy
LHMDS	lithium hexamethyldisilazane
Me	methyl
MeCN	acetonitrile
MeOH	methanol
MsCl	methanesulfonyl chloride
min	minute
MS	mass spectrum
NaH	sodium hydride
$NaHCO_3$	sodium bicarbonate
NaN_3	sodium azide
NaOH	sodium hydroxide
Na_2SO_4	sodium sulfate
NH_4Cl	ammonium chloride
NMM	N-methylmorpholine
NMP	N-methylpyrrolidinone
$Pd_2(dba)_3$	tris(dibenzylideneacetone)dipalladium(0)
PE	petroleum ether
Ph	phenyl
Quant	quantitative yield
Rt	room temperature
Satd	saturated
$SOCl_2$	thionyl chloride
SPE	solid phase extraction
TBS	t-butyldimethylsilyl
TBSCl	t-butyldimethylsilyl chloride

TEA	triethylamine or Et_3N
TEMPO	2,2,6,6-tetramethyl-1-piperidinyloxy free radical
Teoc	1-[2-(trimethylsilyl)ethoxycarbonyloxy]-
Teoc-OSu	1-[2-(trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione
TFA	trifluoroacetic acid
THF	tetrahydrofuran
tlc	thin layer chromatography
TMS	trimethylsilyl
TMSCl	chlorotrimethylsilane or trimethylsilyl chloride
t_R	retention time
TsOH/tosic acid	p-toluenesulfonic acid

Purification Methods

Prep HPLC refers to preparative reverse phase HPLC on a C-18 column eluted with a water/acetonitrile gradient containing 0.01% TFA run on a Gilson 215 system.

Analytical Methods

LC-MS (3 min)

Column: Chromolith SpeedRod, RP-18e, 50 x 4.6 mm; Mobil phase: A: 0.01%TFA/water, B: 0.01%TFA/CH_3CN; Flow rate: 1 mL/min; Gradient:

Time (min)	A%	B%
0.0	90	10
2.0	10	90
2.4	10	90
2.5	90	10
3.0	90	10

PREPARATIONS OF INTERMEDIATES

PREPARATION 1

Methyl (S)-4-(3-chlorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate (**31**)



Step 1. (R)-tert-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate

To a stirred solution of (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (233 g, 1.2 mol) in THF (1.2 L) was added carbonyldiimidazole (230 g, 1.42 mol). The mixture was stirred for 1 h in an ice-water bath. A suspension of triethylamine (207 mL, 1.41 mol) and *N,O*-dimethylhydroxylamine hydrochloride (138 g, 1.42 mol) in THF (900 mL) was added. The reaction mixture was allowed to warm to rt and stirred overnight. After tlc showed the reaction was complete, the solvent was evaporated. The residue was dissolved in CH_2Cl_2 (1.2 L) and washed successively with 0.5 N aq HCl, satd aq Na_2CO_3 and brine, dried over anhydrous sodium sulfate and evaporated to give (R)-tert-butyl 3-(methoxy(methyl)-carbamoyl)piperidine-1-carboxylate (250 g, 91%), which was used in the next step directly without purification. ^{1}H NMR (400 MHz, $CDCl_3$): 1.44 (s, 9H), 1.60-1.78 (m, 2H), 1.90 (m, 1H), 2.65 (m, 1H), 2.75-2.85 (m, 2H), 3.16 (s, 3H), 3.71 (s, 3H), 4.05-4.19 (m, 2H). MS (E/Z): 273 ($M+H^+$).

Step 2. (R)-tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate

To a solution of 1-bromo-3-chlorobenzene (15 g, 78.3 mmol) in anhydrous THF (150 mL) cooled to –78 °C was added dropwise a solution of 2.5 M n-BuLi in hexanes (31.3 mL, 78.34 mmol). The reaction mixture was stirred at –78 °C for 1 h and a solution of (R)-tert-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (17.8 g, 65.3 mmol) in anhydrous THF (50 mL) was added dropwise. After addition, the mixture was allowed to warm to rt and stirred for 2 h. The mixture was quenched with satd aq NH_4Cl (250 mL) and extracted with EtOAc (3 x 150 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash column chromatography (petroleum ether/EtOAc 5:95) to give (R)-tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (12.9 g, 51%). ^1H NMR (400 MHz, $CDCl_3$): 1.45 (s, 9H), 1.54-1.73 (m, 2H), 1.75 (m, 1H), 2.00 (m, 1H), 2.71-2.78 (m, 1H), 2.93 (m, 2H), 3.30-3.35 (m, 1H), 4.22 (m, 1H), 7.39-7.42 (t, 1H), 7.52 (d, 1H), 7.89 (d, 1H), 7.90 (m, 1H). MS m/z 324 ($M+H^+$).

Step 3. (*R*)-*tert*-butyl 3-((*S*)-4-amino-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate

A 250 mL, round bottom flask was charged with magnesium turnings (0.528 g, 21.7 mmol, 1.16 equiv) and THF (10 mL). The flask was flushed with N_2 and heated to 100 °C. A small crystal of iodine was added. A solution of 1-(3-bromopropyl)-2,2,5,5-tetramethyl-1-aza-2,5-disilacyclopentane (5.239 g, 18.7 mmol, 1.0 equiv) in THF (15 mL) was added dropwise to the boiling THF mixture over 10 min. The reaction mixture was stirred and heated under reflux until most of the Mg was consumed (2.5 h) to afford a solution of [3-(2,2,5,5-tetramethyl-1-aza-2,5-disilacyclopent-1-yl)propyl]magnesium bromide.

To a 250-mL, round bottom flask were added (3-chlorophenyl)((*R*)-*N*-Boc-piperidin-3-yl)methanone (0.800 g, 2.47 mmol) and THF (10 mL). The flask was evacuated and refilled with N_2. The mixture was cooled with a dry ice-acetone bath and the [3-(2,2,5,5-tetramethyl-1-aza-2,5-disilacyclopent-1-yl)propyl]magnesium bromide solution was added *via* a cannula. The reaction mixture was allowed to slowly warm to -8 °C while stirring overnight. The mixture was quenched with 10% aq Na_2CO_3 (10 mL), stirred at rt for 3 h and extracted with CH_2Cl_2 (3 x). The combined organic extracts were dried over Na_2SO_4 and concentrated. The crude product was purified by

reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 10% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 13 min and then 90% CH_3CN/H_2O, 0.1% CF_3COOH over 3.5 min, flow rate 25 mL/min) to give (*R*)-*tert*-butyl 3-((*S*)-4-amino-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate as its TFA salt (0.883 g, 72%). LC-MS (3 min) t_R = 1.30 min, *m/z* 383, 385 (MH^+), 327, 329; ^1H NMR (400 MHz, CD_3OD) δ 7.36 (m, 1H), 7.27-7.13 (m, 3H), 4.26 (br s, 1H), 3.89 (d, *J* = 12.9 Hz, 1H), 2.82-2.68 (m, 2H), 2.44 (br s, 1H), 2.36 (t, *J* = 12.2 Hz, 1H), 1.97-1.79 (m, 2H), 1.64-1.08 (m, 16H), 1.34 (s); ^{13}C NMR (100 MHz, CD_3OD) δ 156.69, 148.15, 135.39, 130.69, 127.74, 127.36, 125.41, 81.04, 78.10, 40.95, 28.69, 26.64, 26.51, 23.30.

Step 4. (*R*)-*tert*-butyl 3-((*S*)-4-(methoxycarbonylamino)-1-(3-chlorophenyl)-1-hydroxybutyl)-piperidine-1-carboxylate

To a 100-mL round bottom flask were added the TFA salt of (*R*)-*tert*-butyl 3-((*S*)-4-amino-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate (0.8164 g, 1.64 mmol, 1.0 equiv), DMAP (0.542 g), CH_2Cl_2 (40 mL) and triethylamine (6 mL). The mixture was cooled in an ice bath and a solution of methyl chloroformate (0.550 g, 5.82 mmol, 3.5 equiv) in CH_2Cl_2 (10 mL) was added. The reaction mixture was allowed to slowly warm to rt and stirred overnight. After the solvents were removed *in vacuo*, the residue was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 70% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 8 min and then 90% CH_3CN/H_2O, 0.1% CF_3COOH over 1.5 min, flow rate 25 mL/min) to give (*R*)-*tert*-butyl 3-((*S*)-4-(methoxycarbonylamino)-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate (0.5020 g, 69%). LC-MS (3 min) t_R = 1.91 min, *m/z* 463 (MNa^+), 441 (MH^+), 343 341; ^1H NMR (400 MHz, $CDCl_3$) δ 7.37-7.36 (m, 1H), 7.28-7.17 (m, 3H), 4.90 (br s, 2H), 4.37 (d, *J* = 12.0 Hz, 1H), 3.97 (d, *J* = 12.3 Hz, 1H), 3.64 (s, 3H), 3.16-3.04 (m, 2H), 2.58-2.49 (m, 2H), 1.98-1.86 (m, 2H), 1.76-1.70 (m, 1H), 1.61-1.56 (m, 1H), 1.45 (s, 9H), 1.48-1.13 (m, 5H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 157.60, 155.31, 146.51, 134.31, 129.36, 126.72, 125.96, 123.76, 80.08, 77.65, 52.21, 46.45, 44.91, 44.56, 40.91, 35.97, 28.42, 25.33, 25.25, 24.34.

Step 5. Methyl (*S*)-4-(3-chlorophenyl)-4-hydroxy-4-((*R*)-piperidin-3-yl)butylcarbamate

A mixture of (*R*)-*tert*-butyl 3-((*S*)-4-(methoxycarbonylamino)-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate (0.0322 g, 0.073 mmol), CH_3CN (30 mL) and 2 *N* aq HCl (25 mL) was vigorously stirred at rt for 24 h. The solvents were removed *in vacuo* to give the HCl salt of methyl (*S*)-4-(3-chlorophenyl)-4-hydroxy-4-((*R*)-piperidin-3-yl)butylcarbamate, which was used without further purification. LC-MS (3 min) t_R = 0.98 min, *m/z* 343, 341 ($M+H^+$), 323.

The following compounds were prepared following procedures analogous to those described above:

XXXVIII-16a	methyl (S)-4-(2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 2-fluorophenyllithium in Step 2
XXXVIII-25a	methyl (S)-4-(3,5-dimethylphenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 3,5-dimethylphenyllithium in Step 2
XXXVIII-26a	methyl (S)-4-(3-fluoro-5-methylphenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 3-fluoro-5-methylphenyllithium in Step 2.
XXXVIII-27a	methyl (S)-4-(2-fluoro-5-methylphenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 2-fluoro-5-methylphenyllithium in Step 2.
XXXVIII-35a	methyl (S)-4-(2,3-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 2,3-difluorophenyllithium in Step 2.
XXXVIII-36a	methyl (S)-4-(3,5-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 3,5-difluorophenyllithium in Step 2.
XXXVIII-40a	ethyl (S)-4-(3-chlorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using ethyl chloroformate in Step 4.
XXXVIII-42a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate.
XXXVIII-43a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate
XXXVIII-44a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 3-chloro-5-fluorophenyllithium in Step 2/

XXXVIII-46a	methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate using 3-chloro-2,4-difluorophenyllithium in Step 2.

PREPARATION 2

(R)-2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)acetamide



Step 1. (R)-tert-butyl 3-(3-chloro-2-fluorobenzoyl)piperidine-1-carboxylate

To a stirred solution of 1-chloro-2-fluoro-benzene (13.0 g, 0.1 mol) in THF (250 mL) at -75°C was added dropwise 2.5 M BuLi in hexane (40 mL, 0.1 mol) during 45 min. After additional stirring for 30 min at –75°C, a solution of (R)-tert-butyl 3-(methoxy(methyl)-carbamoyl)piperidine-1-carboxylate (21.76 g, 0.08 mol) in THF (100 mL) was added dropwise over 30 min. The mixture was allowed to warm from -70°C to 0°C. The mixture was quenched with sat'd aq NH_4Cl, extracted with EtOAc (3 x) and the combined organic layers were dried over Na_2SO_4. Solvent removal and flash column chromatography, eluting with 5% EtOAc in petroleum ether, afforded (R)-tert-butyl 3-(3-chloro-2-fluorobenzoyl)piperidine-1-carboxylate (19.2 g, 70%). ^1H NMR (400MHz, $CDCl_3$): 1.45 (s, 9H), 1.63 (m, 2H), 1.76 (m, 1 H), 2.06 (m, 1H), 2.87(m, 1H), 3.15(m, 1H), 3.25 (m, 1H), 3.9 (m, 1H), 4.2 (m, 1H), 7.18 (m, 1H), 7.60 (m, 2H). MS (E/Z): 342 ($M+H^+$).

Step 2. (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-(3-chloro-2-fluorobenzoyl)piperidine-1-carboxylate (7.75 g, 22.7 mmol) in MeOH (160 mL) was added $NaBH_4$ (6.9 g, 182 mmol) in portions such that the temperature remained below 40°C. After addition, the mixture was stirred at rt for 3 h. Tlc showed the starting material had disappeared. The solvent was removed *in vacuo* and the residue was partitioned between water and EtOAc. The organic layer was washed with H_2O and brine, dried over Na_2SO_4 and evaporated to give (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (4.35 g, 56%) which was used in the next step without purification. MS (E/Z): 344 ($M+H^+$).

Step 3. (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a stirred suspension of NaH (0.608 g, 15.2 mmol) in THF (100 mL) at 0-5°C was added dropwise a solution of (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(hydroxy)methyl)-piperidine-1-carboxylate (4.35 g, 12.68 mmol) in THF (30 mL). The reaction mixture was stirred for an additional 1 h at rt. A solution of ethyl bromoacetate (2.52 g, 15.2 mmol) in THF (30 mL) was added dropwise and the mixture was refluxed for 5 h. Tlc showed the starting material had disappeared. The reaction mixture was poured into satd aq NH_4Cl, extracted with EtOAc (3 x 100 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by chromatography on silica gel to afford (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (4.368 g, 80%). ^1H NMR (400MHz, $CDCl_3$): 0.861 (m, 2H), 1.25 (m, 6H), 1.38&1.43 (s, 9H), 1.59-2.10 (m, 3H), 2.75 (m, 1H), 3.80 (s, 1H), 3.96 (m, 2H), 4.18 (m, 2H), 4.62 (m, 1H), 7.12 (m, 1H), 7.33 (m, 2H); MS (E/Z): 430 (M+1)

Step 4. (R)-tert-butyl 3-((2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-((R)-(3-chloro-2-fluorophenyl)(2-ethoxy-2-oxoethoxy)-methyl)piperidine-1-carboxylate (500 mg, 1.16 mmol) in MeOH (10 mL)

was added NH_3 (*aq*) (28%, 15 mL) at rt. The resulting clear solution was stirred at rt overnight. Solvent and excess ammonia was removed *in vacuo* to afford (R)-tert-butyl 3-((2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate (350 mg, 0.87 mmol, 75%). ^{1}H NMR (400MHz, CD_3OD): 1.45 (s, 9H), 1.56 (m, 1H), 1.90 (m, 1H), 2.95 (m, 2H), 3.55-3.85 (m, 3H), 4.15 (m, 1H), 4.56 (m, 1H), 7.22 (m, 1H), 7.42 (m, 2H); MS (E/Z): 401 ($M+H^+$). The diastereomers can be separated by preparative HPLC if desired.

Step 5. (R)-2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)acetamide

A solution of (R)-tert-butyl 3-((2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate (100 mg, 0.25 mmol) in 20 % TFA/CH_2Cl_2 (5 mL) was stirred at 0°C for 30 min. The solvent was neutralized by adding saturated $NaHCO_3$, extracted three times with CH_2Cl_2 and dried over Na_2SO_4. Evaporation of the solvent gave (R)-2-((3-chloro-2-fluorophenyl)(piperidin-3-yl)methoxy)acetamide (72 mg, 0.24 mmol, 98%). MS (E/Z): 301 ($M+H^+$)

PREPARATION 3

2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide



Step 1. (3R)-tert-butyl 3-((3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (10 g, 0.031 mol) in ethanol was added $NaBH_4$ (4.71g, 0.124 mol) portionwise. When the reaction was complete, the ethanol was distilled off, and water (100 mL) and EtOAc (100 mL) were added to the mixture. The organic phase was separated and the aqueous

layer was extracted with EtOAc (3 x 50 mL). The combined organic phases ware washed with water, dried over Na_2SO_4 and concentrated to give (3R)-tert-butyl 3-((3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (9.1g, 90 %), which used without purification. ^{1}H NMR (400MHz, $CDCl_3$): 1.24-1.45 (m, 4H), 1.46 (m, 9H), 1.61-1.68 (m, 1H), 1.73-1.84 (m, 1H), 3.05-3.26 (m, 2H), 3.55-3.66 (m, 1H), 3.82-3.96 (m, 1H), 4.42 (m, 1H), 7.20 (m, 1H), 7.27-7.30 (m, 2H), 7.32 (s, 1H). MS (E/Z): 326 ($M+H^+$)

Step 2. (3R)-tert-butyl 3-((3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a suspension of NaH (0.608 g, 15.2 mmol) in DMF (60 mL) at 0-5 °C was added dropwise with a solution of (3R)-tert-butyl 3-((3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (4.35 g, 12.68 mmol) in DMF (30 mL). The mixture was stirred for 1h at rt. A solution of ethyl bromoacetate (2.52g, 15.2 mmol) in DMF (30 mL) was added dropwise and the mixture was heated to reflux for 3 h. When the reaction was complete, the mixture was poured into satd aqNH_4Cl, and extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over Na_2SO_4 and concentrated in vacuo to give (3R)-tert-butyl 3-((3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (2.09 g, 40 %). ^{1}H NMR (400MHz, $CDCl_3$): 1.23-1.27 (m, 3H), 1.43-1.45 (m, 9H), 3.95-3.99 (m, 3H), 4.12-4.17 (m, 4H), 4.32-4.38 (d, 1H), 7.14-7.17 (m, 1H), 7.26-7.28 (m, 3H). MS (E/Z): 412 ($M+H^+$).

Step 3. (3R)-tert-butyl 3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a solution of $EtNH_2$ in alcohol (30% by weight, 10 mL) was added (3R)-tert-butyl 3-((3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (100 mg, 0.243 mmol). The mixture was stirred at rt overnight. The mixture was concentrated under vacuum to give crude product, which was purified by preparative tlc (elution solvent: 5:1 petroleum ether/EtOAc) to give (3R)-tert-butyl 3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxylate (57.9 mg. 58%) as a colorless oil. MS (E/Z): 411 ($M+H^+$).

Step 4. 2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide

To a stirred solution of TFA in CH_2Cl_2 (20%v/v, 5 mL) was added (3R)-tert-butyl 3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxylate (57.9 mg, 0.0141 mmol). The reaction was monitored by tlc (elution solvent: 5:1 petroleum ether/EtOAc). When the reaction was complete, the mixture was washed with satd aq $NaHCO_3$ and water, dried over Na_2SO_4 and concentrated to give 2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide (40 mg, 91%). MS (E/Z): 311 ($M+H^+$).

The following compounds were prepared using procedures analogous to those described above:

XXXVIII-4a	2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-methylacetamide
XXXVIII-5a	2-((2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)-N-propylacetamide
XXXVIII-12a	2-((2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-20a	2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-propylacetamide
XXXVIII-21a	2-((2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)-N-isopropylacetamide
XXXVIII-24a	2-((3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide
XXXVIII-33a	2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-(2-methoxyethyl)acetamide
XXXVIII-50a	2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-isopropylacetamide

PREPARATION 4

Methyl 2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate



Step 1: (*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (5.60 g, 17.29 mmol) and (*R*)-2-methyl-CBS-oxazaborolidine (1 M in toluene, 9 mL, 9.00 mmol) cooled to -78 °C was added catecholborane (5.6 mL, 54.0 mmol) dropwise. After 20 min, the reaction temperature was allowed to warm to -15 °C and stirred overnight. The reaction was quenched at 0 °C by careful addition of water and diluted with ether. The resulting suspension was filtered through Celite and washed with ether. The filtrate was washed successively with 1 M aq NaOH (3 x 50 mL), 1 M aq HCl (3 x 50 mL), satd aq $NaHCO_3$ and brine, and dried over Na_2SO_4. The solution was filtered, the filtrate was evaporated under vacuum, and the residue was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (2.44 g) and (*R*)-*tert*-butyl 3-((*S*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (1.21 g). MS: 348 $(M+Na)^+$.

Step 2: (*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a suspension of 60% NaH in oil (960 mg, 24.0 mmol) in anhydrous THF at 0 °C was added a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (1.429 g, 4.40 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at rt for 30 min and a solution of ethyl bromoacetate (2.204g, 13.2 mmol) in anhydrous THF (10 mL) was added dropwise. The resulting suspension was heated at reflux for 3 h and cooled to 0°C again. The same amount of NaH as before was added and stirred for 30 min at rt, followed by addition the same amount of ethyl bromoacetate, and the mixture was heated at reflux overnight. The reaction mixture was cooled to 0 °C and quenched by careful addition of aq NH_4Cl. The mixture was extracted with EtOAc (3 x). The combined organic phases were washed with brine, dried over Na_2SO_4, and filtered. The filtrate was evaporated and the residue was purified by flash chromatography on silica gel to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (1.62 g). MS: 412 $(M+H)^+$.

Step 3: (*R*)-*tert*-Butyl 3-((*R*)-(2-amino-2-oxoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (1.50 g, 3.65 mmol) was dissolved in 7 M NH_3 in MeOH, and stirred at rt for 6 h. The mixture was evaporated under reduced pressure to afford the (*R*)-*tert*-butyl 3-((*R*)-(2-amino-2-oxoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate in quantitative yield. MS: 383 $(M+H)^+$.

Step 4: (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(2-amino-2-oxoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (1.10 g, 2.60 mmol) was dissolved in anhydrous toluene (30 mL) and cooled to 0 °C. Red-Al (65% in toluene, 2.6 mL, 8.64 mmol) was added dropwise. After the addition, the reaction was stirred at rt for 12 h and quenched by adding water slowly. The resulting mixture was filtered through Celite and washing with THF. The

filtrate was evaporated under reduced pressure to give crude product 1.05 g. It was used for next step without further purification.

Step 5: (*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl) piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (1.05 g, ca. 2.6 mmol), Et_3N (3.96 mL, 2.85 mmol), and DMAP (174 mg, 1.43 mmol) in anhydrous CH_2Cl_2 (20 mL) cooled to 0 °C was added a solution of methyl chloroformate (1.35 g, 14.25 mmol) in dichloromethane (20 mL) within 30 min. The reaction was stirred overnight, and evaporated under vacuum. The residue was purified by flash chromatrography on silica gel to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (0.65 g). MS: 427 $(M+H)^+$.

Step 6: Methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate

To a stirred solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (91 mg, 0.21 mmol) in CH_2Cl_2 (3 mL) at rt was added TFA (0.5 mL). The mixture was stirred until complete removal of the Boc group had occurred. The solvent was removed under vacuum to give methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate as its TFA salt. MS: 327 $(M+H)^+$.

The following compounds were prepared using procedures analogous to those described above:

XXXVIII-7a	methyl 2-((R)-(3-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-32a	ethyl 2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-37a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-38a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate

XXXVIII-45a	ethyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate
XXXVIII-49a	methyl 2-((R)-(2,3-difluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate

PREPARATION 5

3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-methylpropanamide



Step 1. (3R)-tert-butyl 3-((3-chlorophenyl)(3-ethoxy-3-oxopropoxy)methyl)piperidine-1-carboxylate

To a slurry of NaH (0.835 g, 0.0348 mol) in DMF (50 mL) was added a solution of (R)-tert-butyl 3-((3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (3.8 g, 0.0116 mol) in DMF (30 mL) dropwise at –15~-5 °C and the reaction mixture was stirred for about 1h at rt. A solution of 3-bromopropionic acid ethyl ester (4.2 g, 0.0232 mol) in DMF (30 mL) was added to the reaction mixture dropwise while the temperature was maintained at –15~-5 °C and the mixture was warmed slowly to rt and stirred overnight. The reaction was cooled in an ice bath and quenched with satd aq NH_4Cl (80 mL). The product was extracted with EtOAc, washed with brine, dried over $NaSO_4$ and purified by flash chromatography to afford (3R)-tert-butyl 3-((3-chlorophenyl)(3-ethoxy-3-oxopropoxy)methyl)piperidine-1-carboxylate (2.0 g, 4.71 mmol, 41%). ^1H NMR (400MHz, $CDCl_3$): 1.12-1.37 (m, 4H), 1.45 (s, 9H), 1.47-1.75 (m, 3H), 1.82-1.93 (m, 1H), 2.50-2.58 (m, 4H), 3.43-3.52 (m, 2H), 3.80-4.01 (m, 2H), 4.07-4.17 (m, 3H), 7.13-7.23 (m, 1H), 7.25-7.27 (m, 3H). MS (E/Z): 426 ($M+H^+$).

Step 2. (R)-tert-butyl 3-((R)-(3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)piperidine-1-carboxylate

(3R)-tert-butyl 3-((3-chlorophenyl)(3-ethoxy-3-oxopropoxy)methyl)piperidine-1-carboxylate (2.0 g, 4.71 mmol) was dissolved in a solution CH_3NH_2 in CH_3OH ((180 mL) and stirred overnight at rt. After the reaction was complete by HPLC analysis, the solvent was removed in vacuo. The residue was purified by preparative HPLC and afforded the desired isomerically pure product (R)-tert-butyl 3-((R)-(3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)piperidine-1-carboxylate (0.80 g, 1.95 mmol, 41% yield). MS (E/Z): 411 ($M+H^+$).

Step 3. Preparation of 3-[S-(3-chloro-phenyl)-(piperidin-3R-yl)-methoxy]-N-methyl-propionamide

(R)-tert-butyl 3-((R)-(3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)piperidine-1-carboxylate (0.80 g, 1.95 mmol) was dissolved in a 20% solution of TFA in CH_2Cl_2 (20.6 mL) and stirred for about 1h at rt until the reaction was complete. The solvent was removed by evaporation and the crude product was purified with preparative HPLC to afford 3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-methylpropanamide (542 mg, 1.75 mmol, 90% yield). MS (E/Z): 311 ($M+H^+$).

The following compounds were prepared using procedures analogous to those described above:

XXXVIII-18a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylpropanamide
XXXVIII-29a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-propylpropanamide
XXXVIII-30a	3-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-isopropylpropanamide

PREPARATION 6

(S)-5-(3-chlorophenyl)-5-hydroxy-N-methyl-5-((R)-piperidin-3-yl)pentanamide



Step 1. (R)-tert-butyl 3-((S)-5-(tert-butyldimethylsilyloxy)-1-(3-chlorophenyl)-1-hydroxypentyl)piperidine-1-carboxylate

A stirred mixture of magnesium turnings (1.32 g, 55 mmol) and anhydrous THF (10 mL) under N_2 was treated with a crystal of iodine and 5 percent of a solution of tert-butyl(4-chlorobutoxy)dimethylsilane (11.15 g, 50 mmol) in THF (40 mL). When the reaction started, the remainder of the chloride solution was added dropwise at a rate sufficient to maintain a gentle reflux. After addition, the reaction mixture was heated under reflux for 1 h and most of magnesium was consumed. The reaction mixture cooled to rt.

A solution of (R)-tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (1.62 g, 5 mmol) in anhydrous THF (20 mL) under N_2 was cooled in a dry ice-acetone bath. The Grignard reagent derived from tert-butyl-(4-chloro-butoxy)-dimethyl-silane (50 mL) prepared above was added dropwise. After addition, the mixture was allowed to warm to rt and stirred for 2 h (monitored by tlc). The reaction was quenched with satd aq NH_4Cl (70 mL) and extracted with EtOAc (3 x 40 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by chromatography on silica gel eluting with 10:90 EtOAc/hexane to afford (R)-tert-butyl 3-((S)-5-(tert-butyldimethylsilyloxy)-1-(3-chlorophenyl)-1-hydroxypentyl)piperidine-1-carboxylate (1.65 g, 65%). ^1H NMR (400MHz, $CDCl_3$): 0.02 (s, 6H), 7.30 (d, 2H), 0.85 (s, 9H), 1.47 (s, 9H), 1.92 (m, 3H), 2.52 (m, 3H), 3.56

(m, 2H), 3.63 (m, 2H), 3.97-4.21 (m, 2H), 4.36 (m, 1H), 7.16-7.25 (m, 3H), 7.36 (m, 1H). MS (E/Z): 512 ($M+H^+$)

Step 2. (R)-tert-butyl 3-((S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-((S)-5-(tert-butyldimethylsilyloxy)-1-(3-chlorophenyl)-1-hydroxypentyl)piperidine-1-carboxylate (511 mg, 1 mmol) in CH_3CN (10 mL) was added tetrabutylammonium fluoride (550 mg, 2 mmol) in one portion. The reaction mixture was stirred at 60 °C for 2 h. The solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel with EtOAc/hexane to give (R)-tert-butyl 3-((S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl)piperidine-1-carboxylate (350 mg, 80%). ^1H NMR (400MHz, $CDCl_3$): 1.05-1.42 (m, 6H), 1.46 (s, 9H), 1.52-1.79 (m, 4H), 1.94-2.03 (m, 2H), 2.55 (m, 2H), 3.56 (m, 2H), 3.97 (m, 1H), 4.36 (m, 1H), 7.20-7.25 (m, 3H), 7.37 (s, 1H). MS (E/Z): 398 ($M+H^+$)

Step 3. (R)-tert-butyl 3-((S)-2-(3-chlorophenyl)-6-oxotetrahydro-2H-pyran-2-yl)piperidine-1-carboxylate

To a stirred solution of (R)-tert-butyl 3-((S)-1-(3-chlorophenyl)-1,5-dihydroxypentyl)piperidine-1-carboxylate (200 mg, 0.5 mmol) in acetone (3 mL) maintained at 0 °C was added an 15% aq $NaHCO_3$ (2 mL), followed by solid NaBr (10.3 mg, 0.1 mmol) and TEMPO (1.56 mg, 0.01 mmol). Trichloroisocyanuric acid (231 mg, 1 mmol) was then slowly added at 0°C. The mixture was warmed to rt, stirred for 3 h and treated with 2-propanol (0.5 mL). The mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was partitioned between water and EtOAc and the aqueous phase was extracted with EtOAc (3 x 20 mL). The organic layers were combined, washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure to provide (R)-tert-butyl 3-((S)-2-(3-chlorophenyl)-6-oxotetrahydro-2H-pyran-2-yl)piperidine-1-carboxylate (160 mg, 81%). ^1H NMR (400MHz, $CDCl_3$): 1.12-1.45 (m, 3H), 1.46 (s, 9H), 1.58-1.81 (m, 6H), 2.22 (m, 2H), 2.42 (m, 2H), 2.56 (m, 2H), 4.05 (m, 1H), 4.36 (m, 1H), 7.16 (m, 1H), 7.27-7.32 (s, 1H). MS (E/Z): 394 ($M+H^+$).

Step 4. (R)-tert-butyl 3-((S)-1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)piperidine-1-carboxylate

(R)-tert-butyl 3-((S)-2-(3-chlorophenyl)-6-oxotetrahydro-2H-pyran-2-yl)piperidine-1-carboxylate (60 mg, 0.153 mmol) was dissolved in a ca 30% solution of methylamine in methanol (3 mL). The mixture was stirred at rt for 2 h then concentrated under reduced pressure to give (R)-tert-butyl 3-((S)-1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)piperidine-1-carboxylate (60 mg, 93%), which was used directly without purification. ^{1}H NMR (400MHz, $CDCl_3$): 1.12-1.45 (m, 3H), 1.46 (s, 9H), 1.58-1.81 (m, 6H), 2.05-2.17 (m, 2H), 2.50-2.58 (m, 2H), 2.69 (m, 3H), 4.06 (m, 1H), 4.12-4.28 (m, 2H), 7.22-7.32 (m, 3H), 7.43 (s, 1H). MS (E/Z): 425 ($M+H^+$).

Step 5. (S)-5-(3-chlorophenyl)-5-hydroxy-N-methyl-5-((R)-piperidin-3-yl)pentanamide

(R)-tert-butyl 3-((S)-1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)piperidine-1-carboxylate (60 mg, 0.14 mmol) was dissolved in a solution of 20%(V/V) TFA/CH_2Cl_2 (3 mL). The reaction mixture was stirred at rt for 1 h, and a solution of saturated sodium bicarbonate was added dropwise to adjust the pH to ~7-8. The resulting mixture was extracted with CH_2Cl_2 (3×10 mL), washed with brine, dried over Na_2SO_4 and concentrated in vacuo to afford 5*S*-(3-chloro-phenyl)-5-hydroxy-5-(piperidin-3*R*-yl)-pentanoic acid methylamide (42 mg, 91%), which was used directly in the next step without purification. MS (E/Z): 325 ($M+H^+$)

The following compounds were made by procedures analogous to thos described above:

XXXVIII-11a	(S)-5-(3-chlorophenyl)-5-hydroxy-5-((R)-piperidin-3-yl)pentanamide
XXXVIII-28a	(S)-5-(3-chlorophenyl)-N-ethyl-5-hydroxy-5-((R)-piperidin-3-yl)pentanamide

PREPARATION 7

2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethanol



Step 1. (R)-tert-butyl 3-((R)-(2-(tert-butyldimethylsilyloxy)ethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

To a mixture of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (0.1964 g, 0.60 mmol, 1.0 equiv) and 60% NaH in oil (0.753 g, 18.8 mmol, 31 equiv) in THF (15 mL) was added (2-bromoethoxy)-*tert*-butyldimethylsilane (2.042 g, 8.5 mmol, 14 equiv). The resulting mixture was heated at 80 °C for 19 h and then quenched with water, extracted with EtOAc and dried over Na_2SO_4. After the solvent was removed, the crude product was used in the next step without further purification.

Step 2. 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethanol

A solution of crude (*R*)-*tert*-butyl 3-((*R*)-(2-(*tert*-butyldimethylsilyloxy)ethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate in CH_3CN (100 mL) and 2 *N* aq HCl (100 mL) was vigorously stirred at rt for 2 d. The solvents were removed in vacuo to give the HCl salt of 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethanol, which was used in the next step without further purification. LC-MS (3 min) t_R = 1.05 min *m/z* 272, 270 $(M + H)^+$.

PREPARATION 8

(R)-tert-butyl 3-((R)-(2-aminoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate



Step 1. (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-ethoxy-2-oxoethoxy)-methyl)piperidine-1-carboxylate (4.368 g, 10.2 mmol) in MeOH (85 mL) was added $NaBH_4$ (3.18 g, 81.5 mmol) in portions such that the temperature remained below 40°C. After addition, the mixture was stirred at rt for 2~3 h. TLC showed the starting material had disappeared. The solvent was removed *in vacuo* and the residue was partitioned between water and EtOAc. The organic layer was washed with H_2O and brine, dried over Na_2SO_4 and evaporated to give (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (3.5 g, 89%). ^1H NMR (400MHz, $CDCl_3$): 1.18 (m, 1H), 1.38-1.46 (s, 9H), 1.65 (m, 1H), 1.85 (m, 2H), 2.66 (m, 1H), 3.25 (m, 1H), 3.38 (m, 2H), 3.69 (m, 3H), 3.93 (m, 1H), 4.52 (m, 6H); MS (E/Z): 388 (M+1)

Step 2. (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)-piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-((3-chloro-2-fluorophenyl)(2-hydroxyethoxy)methyl)-piperidine-1-carboxylate (3.5 g, 9 mmol) in dry CH_2Cl_2 (50 mL) was added Et_3N (3.2 g, 4.2 mL, 27 mmol, 4 eq) at 0 ~ -5°C. Then a solution of MsCl (1.23 g, 10.8 mmol, 1.2 eq) in dry CH_2Cl_2 (20 mL) was added dropwise at the same temperature. After addition, the mixture was allowed to warm to rt gradually. TLC showed the starting material had disappeared. Water (30 mL) was added and the mixture was extracted with CH_2Cl_2 (3 x 20 mL). The combined organic layers were washed with 10% aq citric acid, sat'd aq $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give 3*R*-3-[(3-chloro-2-fluoro- phenyl)-(2-methanesulfonyloxy-ethoxy)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (4.13 g, 99%), which was used in the next step without purification. ^{1}H NMR (400MHz, $CDCl_3$): 1.35 (m, 4H), 1.46 (s, 9H), 1.62 (m, 3H), 1.83 (m, 1H), 2.52-2.81 (m, 2H), 3.05 (m, 3H), 3.56 (m, 2H), 3.92 (m, 1H), 4.30 (m, 2H), 4.48 (m, 1H), 7.13(m, 1H), 7.28 (m, 1H), 7.35 (m, 1H); MS (E/Z): 466 (M+)

Step 3. (R)-tert-butyl 3-((2-azidoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate

3*R*-3[(3-chloro-2-fluoro-phenyl)-(2-methanesulfonyloxy-ethoxy)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (4 g, 8.6 mmol) was dissolved in anhydrous DMF (30 mL), solid NaN_3 (0.84 g, 12.9 mmol) was added and the reaction mixture was heated at 80°C overnight. The reaction mixture was cooled to rt and EtOAc (100 mL) was added. The mixture was washed with water (3 x 30 mL), dried over Na_2SO_4 and evaporated. The residue was separated on a silica column to give (R)-tert-butyl 3-((2-azidoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate (2.6 g, 73%). ^{1}H NMR: (400MHz, $CDCl_3$): 1.24 (m, 1H), 1.38&1.46 (s, 9H), 1.67 (m, 3H), 1.83 (m, 1H), 2.58-2.81 (m, 2H), 3.32 (m, 2H), 3.45 (m, 2H), 3.92 (m, 1H), 4.20 (m, 1H), 4.50 (m, 1H), 7.13(t, 1H), 7.34 (m, 2H), 8.02 (s, 1H);

Step 4. (R)-tert-butyl 3-((R)-(2-aminoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate

To a solution of (R)-tert-butyl 3-((2-azidoethoxy)(3-chloro-2-fluorophenyl)methyl)-piperidine-1-carboxylate (2.6 g, 6.31 mmol) in EtOAc (50 mL) was added wetted Pd/C (0.1 g) and the mixture was stirred overnight under a hydrogen atmosphere maintained by a balloon. The reaction mixture was filtered through a pad of Celite and the solvent was removed to give (R)-tert-butyl 3-((2-aminoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate which was submitted to reverse phase the preparative HPLC to give (R)-tert-butyl 3-((S)-(2-aminoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate (990 mg, 81%) and (R)-tert-butyl 3-((R)-(2-aminoethoxy)(3-chloro-2-fluorophenyl)methyl)piperidine-1-carboxylate (792 mg, 65%). MS (E/Z): 387 ($M+H^+$).

PREPARATION 9

(*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2(methoxycarbonylamino)ethoxy)-methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-fluorobenzoyl)piperidine-1-carboxylate

A solution of 1-bromo-3-fluoro-benzene (57.7 g, 0.33 mol) in anhydrous THF (480 mL) was added dropwise to Mg (10.6 g, 0.44 mol) at rt under nitrogen. The mixture was stirred at 50-60 °C for 1 hr. The resulting Grignard reagent was used for the next step. The Grignard reagent was added dropwise to a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (60g, 0.22 mol) in anhydrous

THF (600 mL) at -78 °C under nitrogen. After addition, the mixture was allowed to stir at rt for 1.5 hr. The mixture was quenched with saturated NH_4Cl solution (300 mL) and extracted with ethyl acetate (3×200 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to give crude (*R*)-*tert*-butyl 3-(3-fluorobenzoyl)piperidine-1-carboxylate (67.5 g, 100%), which was used immediately in the next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of 1 M *R*-CBS-oxazaborolidine in toluene (33 mL, 33 mmol, 0.15 eq) and 10 M BH_3 in THF (22 mL, 0.22 mol, 1.0 eq) at –15 °C under nitrogen was added dropwise a solution of (*R*)-*tert*-butyl 3-(3-fluorobenzoyl)piperidine-1-carboxylate (67.5 g, 0.22 mol) in anhydrous THF (300 mL). After addition, the reaction mixture was stirred for 1 hr at rt. Methanol (200 mL) was added dropwise carefully at 0 °C. The solvent was removed under reduced pressure to provide the crude product. The crude product was dissolved in ethyl acetate until the alcohol was just dissolved (about 5mL/1g), the solvent was removed on the rotary evaporator until a few crystals appeared. To the above solution was added petroleum ether (about 300 mL) under stirring, which was allowed to stir at rt for 2 hr and then filtered, the crystals were washed with petroleum ether and re-crystallized to afford the pure *R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (26 g, 39%).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate

To a suspension of NaH (4.8 g, 120 mmol) in THF (400 mL) at 0-5 °C was added dropwise a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (30.9 g, 100 mmol) in anhydrous THF (100 mL), the reaction mixture was stirred for 1 hr at rt. A solution of ethyl bromoacetate (20.04 g, 13.40 mL, 120 mmol) in anhydrous THF (100 mL) was added dropwise to the above mixture, and the reaction was heated to reflux for 3-5 hr. The reaction mixture was poured into saturated aqueous NH_4Cl, then extracted with ethyl acetate (3×100 mL). The organic layer was washed with water (3×100 mL) and brine, dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford crude (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (29.88g 76 %), which was used for next step without purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (29.88 g, 75.9 mmol) in MeOH (300 mL) was added $NaBH_4$ (23 g, 605.2 mmol) in portions while the temperature was lower than 40 °C. After addition, the mixture was stirred at rt for 2-3 hr. The solvent was removed *in vacuo* to give a residue which was partitioned between water and ethyl acetate. The organic layer was washed with H_2O and brine, dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified on silica gel chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (11 g, 41%).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (11 g, 31.16 mmol) in dry CH_2Cl_2 (140 mL) was added Et_3N (12.60 g, 16.68 mL, 124.65 mmol, 4 eq) at -5-0 °C. Then a solution of MsCl (7.1 g, 4.72 mL, 62.32 mmol, 2 eq) in dry CH_2Cl_2 (40 mL) was added

dropwise at the same temperature. After addition, it was allowed to warm to rt gradually. Water (100 mL) was added. The aqueous layer was extracted with CH_2Cl_2 (3×80 mL), the combined organic layers was washed with 10% citric acid, sat. $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (13.8 g), which was used in the next step without purification.

Step 6. (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (13.8 g, 32 mmol) was dissolved into anhydrous DMF (150 mL), solid NaN_3 (6.1 g, 96 mmol, 3 eq) was added and the reaction mixture was heated to 80 ° for overnight. The reaction mixture was cooled to rt and then was added with ethyl acetate (500 mL), the organic phase was washed with water (3×100 mL) and brine (2×80 mL), dried over Na_2SO_4 and concentrated *in vacuo* to give crude (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (12 g), which was used in the next step without further purification.

Step 7. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate

A suspension of (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (12 g, 31.75 mmol) and $Pd(OH)_2/C$ (1.2 g) in MeOH (240 ml) was stirred under H_2 for 1 hr. The mixture was filtered and evaporated under reduced pressure to give desired (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (10 g).

Step 8. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (10 g, 28.41 mmol) and DMAP (1.8 g, 14.21 mmol, 0.5 eq) in dry CH_2Cl_2 (150 mL), Et_3N (8.62 g, 11.42 mL, 85.23 mmol)

was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate (10.95 mL, 142.05 mmol, 5 eq) in dry CH_2Cl_2 (60 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. Water (80 mL) was added to quench the reaction. The aqueous layer was extracted with CH_2Cl_2 (3×50 mL), the combined organic layers were washed with 10% citric acid (2×80 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by silica gel to afford (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (11.3 g, 97%).

The following compounds were prepared following procedures analogous to those described above:

1) (*R*)-*tert*-butyl 3-((*R*)-(2,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (2,5-difluorophenyl)magnesium bromide in Step 1.
2) (*R*)-*tert*-butyl 3-((*R*)-(3,4-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3,4-difluorophenyl)magnesium bromide in Step 1.
3) (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-2-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3-chloro-2-fluorophenyl)lithium in Step 1.
4) (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (5-chloro-2-fluorophenyl)lithium in Step 1.
5) (*R*)-*tert*-butyl 3-((*R*)-(2-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (2-fluoro-5-methylphenyl)magnesium bromide in Step 1.
6) (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(3,4,5-trifluorophenyl)methyl)piperidine-1-carboxylate using (3,4,5-trifluorophenyl)magnesium bromide in Step 1.

7) (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(thiophen-2-yl)methyl)piperidine-1-carboxylate using thiophen-2-ylmagnesium bromide in Step 1.

8) (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(thiazol-2-yl)methyl)piperidine-1-carboxylate using thiazol-2-yllithium in Step 1.

9) (3*R*)-*tert*-butyl 3-((2-(methoxycarbonylamino)ethoxy)(4-methylthiazol-2-yl)methyl)piperidine-1-carboxylate using (4-methylthiazol-2-yl)lithium in Step 1.

PREPARATION 10

(*R*)-*tert*-butyl 3-((*R*)-(2,3-difluorophenyl)(2-(methoxycarbonylamino)ethoxy) methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(2,3-difluorobenzoyl)piperidine-1-carboxylate

Under protection of N_2, 1,2-difluorobenzene (22 g, 0.19 mol) in anhydrous THF (300 mL) was cooled to -78 °C and 2.5 M n-BuLi solution in hexanes (76 mL, 0.19 mol) was added dropwise slowly. The reaction mixture was stirred at -78 °C for 1 hr, the solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate

(47.7 g, 0.175 mol) in anhydrous THF (200 mL) was slowly added dropwise. The reaction mixture warmed to rt and stirred for 2 hrs. The mixture was quenched with saturated NH_4Cl (300 mL), extracted three times with ethyl acetate, and dried over Na_2SO_4. Solvent removal and flash column chromatography afforded crude (*R*)-*tert*-butyl 3-(2,3-difluorobenzoyl)piperidine-1-carboxylate (*R*)-*tert*-butyl 3-(2,3-difluorobenzoyl)piperidine-1-carboxylate (40 g, 70%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.51 (m, 1 H), 7.34 (m, 1 H), 7.19 (m, 1H), 4.19 (d, 1 H), 3.96 (m, 1 H), 3.23 (m, 1 H), 3.04 (t, 1H), 2.85 (m, 1 H), 2.06 (m, 1 H), 1.75 (m, 1 H), 1.62 (m, 4 H), 1.44 (s, 9 H).

Step 2. (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(2,3-difluorobenzoyl)piperidine-1-carboxylate (10 g, 30.8 mmol) in MeOH (200 mL) was added $NaBH_4$ (9.3 g, 246 mmol) in portions while the temperature was lower than 40 °C. After addition, the mixture was stirred at rt for 2-3 hrs. The solvent was removed *in vacuo* to afford a residue which was partitioned between water and ethyl acetate. The organic layer was washed with water and brine, dried over Na_2SO_4 and evaporated to give the crude product (*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(hydroxy)methyl)piperidine-1- carboxylate (10 g, 99%), which was used in the next step without purification. ^1H NMR ($CDCl_3$, 400 MHz) δ 7.22 (m, 1 H), 7.08 (m, 2 H), 4.85 (t, 1H), 3.94 (d, 0.5 H), 3.78 (d, 1 H), 3.55 (m, 0.5 H), 3.28 (d, 1H), 2.65 (m, 1 H), 1.90 (m, 2 H), 1.68 (m, 3 H), 1.44 (d, 9 H).

Step 3. (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a suspension of NaH (3.5 g, 88.4 mmol) in THF (100 mL) at 0-5 °C was added dropwise a solution of (*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(hydroxy) methyl)piperidine-1-carboxylate (9.6 g, 29.5 mmol) in THF (50 mL), the reaction mixture was stirred for 1 h at rt. A solution of ethyl bromoacetate (14.7 g, 88.4 mmol) in THF (50 mL) was added dropwise to the above mixture, and then refluxed for 3-5 h. The reaction mixture was poured into saturated aqueous NH_4Cl, then extracted with ethyl acetate, dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified on silica gel chromatography to afford (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (9.5 g, 79%).

^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.22 (m, 1 H), 7.08 (m, 2 H), 4.62 (d, 2H), 4.33 (d, 2 H), 4.18 (q, 3 H), 3.95 (m, 4 H), 3.82 (d, 2H), 2.77 (m, 4 H), 1.88 (m, 3 H), 1.44 (s, 9 H), 1.26 (t, 3 H).

Step 4. (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate

To a solution of (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (4 g, 9.7 mmol) in MeOH (80 mL) was added $NaBH_4$ (2.9 g, 77.4 mmol) in portions while the temperature was lower than 40 °C. After addition, the mixture was stirred at rt for 2-3 hrs. The solvent was removed *in vacuo* to give a residue, which was partitioned between water and ethyl acetate. The organic layer was washed with water and brine, dried over Na_2SO_4 and evaporated to give (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (3.5 g, 97%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.12 (m, 3 H), 4.52 (q, 1 H), 4.11 (m, 1H), 3.69 (m, 3 H), 3.41 (m, 3 H), 2.65 (m, 1 H), 2.02 (m, 1H), 1.65 (m, 1 H), 1.42 (d, 9 H).

Step 5. (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate in dry CH_2Cl_2 (50 mL) was added Et_3N (5.2 mL, 37.6 mmol) at -5-0 °C. Then a solution of MsCl (1.3 g, 11.3 mmol) in dry CH_2Cl_2 (20 mL) was added dropwise at the same temperature. After addition, the reaction was allowed to gradually warm to rt. Upon completion of the reaction, 50 mL of water was added, the aqueous layer was extracted with CH_2Cl_2, the combined organic layers were washed with 10% citric acid, sat. $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (4.2 g, 99%), which was used in the next step without purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.12 (m, 3 H), 4.52 (q, 1 H), 4.31 (m, 3 H), 4.09 (t, 1 H), 3.57 (m, 2 H), 3.06 (d, 3 H), 2.70 (m, 2H), 1.93 (m, 2 H), 1.44 (d, 9 H).

Step 6. (3*R*)-*tert*-butyl 3-((2-azidoethoxy)(2,3-difluorophenyl)methyl)piperidine-1-carboxylate

A solution of (3*R*)-*tert*-butyl 3-((2,3-difluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (4.2 g, 9.4 mmol) and solid NaN_3 (0.92 g, 14.1 mmol) in anhydrous DMF (30 mL) was heated to 80 °C overnight. The reaction mixture was cooled to rt and diluted with ethyl acetate (80 mL), the organic phase was washed with water (30 mL×3), dried over Na_2SO_4 and evaporated. The residue was separated on a silica column to give (3*R*)-*tert*-butyl 3-((2-azidoethoxy)(2,3-difluorophenyl)methyl)piperidine-1-carboxylate (3.4 g, 92%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.14 (m, 3 H), 4.50 (q, 1 H), 4.10 (m, 1 H), 3.40 (m, 4 H), 2.70 (m, 2 H), 1.90 (m, 2 H), 1.65 (m, 1 H), 1.41 (d, 9 H).

Step 7. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(2,3-difluorophenyl)methyl)piperidine-1-carboxylate

To a solution of (3*R*)-*tert*-butyl 3-((2-azidoethoxy)(2,3-difluorophenyl)methyl)piperidine-1-carboxylate (3.4 g, 8.58 mmol) in ethyl acetate (50 mL) was added wet Pd/C (0.1 g). Under a hydrogen filled balloon the reaction was allowed to stir overnight. The reaction mixture was filtered through a pad of Celite and the solvent was removed. The residue was isolated by the preparative HPLC to give (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(2,3-difluorophenyl)methyl)piperidine-1-carboxylate (3 g, 94%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.22 (m, 3 H), 4.48 (d, 1 H), 4.01 (d, 1 H), 3.65 (m, 1 H), 3.42 (m, 2 H), 3.08 (m, 4 H), 1.88 (m, 1 H), 1.55 (m, 1 H), 1.43 (s, 9 H).

Step 8. (*R*)-*tert*-butyl 3-((*R*)-(2,3-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(2,3-difluorophenyl)methyl)piperidine-1-carboxylate (195 mg, 0.402 mmol), DMAP (25.8 mg, 0.201 mmol) and Et_3N (0.18 mL) in dry CH_2Cl_2 at 0 °C was added methyl chloroformate (189 mg, 2.013 mmol), the mixture was allowed to warm to rt and stirred overnight. The mixture was concentrated *in vacuo* to give the crude product (*R*)-*tert*-butyl 3-((*R*)-(2,3-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (168 mg, 98%), which was used in the next step without further

purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.21 (m, 3 H), 4.57 (m, 1 H), 4.44 (d, 1 H), 4.08 (m, 1 H), 3.82 (m, 1 H), 3.53 (s, 3 H), 3.29 (d, 2 H), 2.93 (m, 2 H), 1.79 (m, 1 H), 1.63 (m, 1 H), 1.43 (s, 9 H), 1.34 (m, 3 H).

PREPARATION 11

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)-piperidine-1-carboxylate



Step 1-6. (*R*)-*tert*-Butyl 3-((*R*)-(2-azidoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(2-azidoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate was obtained following Preparation 9, Steps 1-6, using (3-chlorophenyl)lithium in Step 1.

Step 7. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-Butyl 3-((*R*)-(2-azidoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (13.3 g, 33.8 mmol) in THF/H_2O (20:1, 180 mL / 9 mL), triphenylphosphane (36.0 g, 135 mmol) was added in portions. The reaction mixture was stirred overnight at rt. The solvent was removed under reduced pressure to afford a residue, which was purified on silica gel chromatography to provide (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (10.4 g, purity: HPLC=75%).

Step 8. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate was converted to (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate following Preparation 9, Step 8.

The following compounds were prepared following procedures analogous to those described above:

1) (*R*)-*tert*-butyl 3-((*R*)-(3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3,5-difluorophenyl)lithium in Preparation 9, Step 1.

PREPARATION 12

(*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. 5-chloro-2-methylbenzenamine

A 2 L flask was charged the solution of 4-chloro-1-methyl-2-nitrobenzene (60 g, 0.35 mol) in MeOH (1 L), Raney Ni was added, the air in flask was replaced three times with H_2, the mixture was stirred for 3 h at rt. The solution was filtered and concentrated. The residue was dissolved in CH_2Cl_2 (500 mL), and the solution was washed with brine, dried over Na_2SO_4. Solvent removal gave 5-chloro-2-methylbenzenamine (50 g, 0.35 mol). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.02-6.93 (d, 2H), 6.70-6.60 (d, 2H), 3.67 (s, 2H), 2.14 (s, 3H).

Step 2. 2-bromo-4-chloro-1-methylbenzene

5-Chloro-2-methylbenzenamine (50 g, 0.355 mol) was dissolved in HBr solution (1.5 M, 100 mL) and cooled to 0 °C, a solution of $NaNO_2$ (27.6 g, 0.4 mol) in water (200 mL) was added dropwise. After addition, the mixture was stirred for 1 hr. In another flask CuBr (30 g, 0.21 mol) was added to HBr solution (1.5 M, 30 mL) and heated to 60 °C, then the mixture was added to the above solution. The mixture was

heated to reflux for 1 hr then cooled to rt. The reaction was quenched with water (500 mL), the aqueous layer was extracted 3 times with CH_2Cl_2, dried over Na_2SO_4, solvent removal and purification by column chromatography afforded 2-bromo-4-chloro-1-methylbenzene (53 g, 0.26 mol). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.53 (s, 1H), 7.20-7.10 (m, 2H), 2.36 (s, 3H).

Step 3. (*R*)-*tert*-butyl 3-(5-chloro-2-methylbenzoyl)piperidine-1-carboxylate

To a solution of 2-bromo-4-chloro-1-methylbenzene (53 g, 0.26mol) in anhydrous THF (600 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in hexane (103 mL, 0.26 mol). After stirring for 1 hr at –78 °C, a solution of the (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (67 g, 0.246 mol) in anhydrous THF (300 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with ethyl acetate (3×400 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to give crude (*R*)-*tert*-butyl 3-(5-chloro-2-methylbenzoyl)piperidine-1-carboxylate (86 g), which was used immediately in the next step without purification.

Step 4-10. (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-(5-chloro-2-methylbenzoyl)piperidine-1-carboxylate was carried thru Preparation 9, Steps 2-8, to afford (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate.

PREPARATION 13



Step 1. (*R*)-*tert*-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate

To a solution of 1-bromo-3-methylbenzene (88.4 g, 0.52 mol) in anhydrous THF (550 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in hexane (210 mL, 0.52 mol). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(m-tolyl)methyl)piperidine-1-carboxylate (120 g, 0.44 mol) in anhydrous THF (500 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with ethyl acetate (3×400 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to give crude (*R*)-*tert*-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate (168 g), which was used immediately for next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*S*)-hydroxy(m-tolyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate (168 g, 0.55 mol) in anhydrous THF (600 mL) at –15 °C under nitrogen was added dropwise a solution of 1 M *R*-CBS-oxazaborolidine in toluene (82 mL, 82 mmol, 0.15 eq). After stirring for 1 hr at –15 °C, a solution of 10 M BH_3 in THF (60 mL, 0.60 mol, 1.1 eq) was added dropwise. After addition, the reaction mixture was stirred for 2 hr at –15 °C. TLC indicated the starting material was disappeared. Methanol (400 mL) was added dropwise carefully at –15 °C. The solvent was removed under reduced pressure, the residue was purified by column chromatography on silica gel eluting with AcOEt/hexane (1:30→1:15) to provide the light yellow oil (95 g, HPLC≥70%, ratio≥3:1). The mixture was dissolved in ethyl acetate until the alcohol was just dissolved (about 5 mL/1 g), the solvent was removed on the rotary evaporator until a few crystals appeared. The solution was cooled to rt slowly and stood for 1-2 hr. To the above solution was added hexane (about 300 mL) and then filtered , the crystals were washed with cool hexane and re-crystallized two more times to afford the pure isomer (*R*)-*tert*-butyl 3-((*S*)-hydroxy(m-tolyl)methyl)piperidine-1-carboxylate (20 g, ee≥99%).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(m-tolyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*S*)-hydroxy(*m*-tolyl)methyl)piperidine-1-carboxylate (30.5 g, 0.1 mol) in MeCN (300 mL), NaH (12 g, 0.3 mol) was added at 0 °C. The mixture was stirred for 1 hr at rt. The mixture was cooled to –40 °C, then bromoacetonitrile (35.7 g, 0.3 mol) was added in portions. The mixture was stirred for 0.5 hr at –20 °C continually. The reaction was quenched with sat. NH_4Cl. The mixture was extracted with CH_2Cl_2. The organic layer was dried over Na_2SO_4, concentrated. Crude (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate was used for the next step without purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(m-tolyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(cyanomethoxy)(m-tolyl)methyl)piperidine-1-carboxylate (20 g, 0.04 mol) was dissolved in anhydrous THF (300 mL), and the solution was heated to reflux under nitrogen. A solution of $BH_3.Me_2S$ (12 mL, 0.12 mol) in THF was added dropwise, and stirring was continued under reflux overnight. The resulting solution was cooled to rt and MeOH was added dropwise to quench the excess borane. After evaporation of the solution, the crude (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate was obtained and used without further purification.

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(m-tolyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate and DMAP in anhydrous CH_2Cl_2, Et_3N was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate in anhydrous CH_2Cl_2 was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. Water was added to quench the reaction. The aqueous layer was extracted with CH_2Cl_2, the combined organic layers were washed with 10% citric acid and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by preparative TLC to afford (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate.

The following compounds were prepared following procedures analogous to those described above:

1) (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(3-(trifluoromethyl)phenyl)methyl)piperidine-1-carboxylate using (3-(trifluoromethyl)phenyl)magnesium bromide in Step 1.

2) (*R*)-*tert*-butyl 3-((*R*)-(2,5-dimethylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (2,5-dimethylphenyl)magnesium bromide in Step 1.

3) (*R*)-*tert*-butyl 3-((*R*)-(3,5-dimethylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3,5-dimethylphenyl)magnesium bromide in Step 1.

4) (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (5-fluoro-2-methylphenyl)lithium in Step 1.

5) (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3-chloro-4-fluorophenyl)magnesium bromide in Step 1.

6) (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3-chloro-5-fluorophenyl)magnesium bromide in Step 1.

7) (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-2,4-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3-chloro-2,4-difluorophenyl)lithium in Step 1.

PREPARATION 14

(*R*)-*tert*-butyl 3-((*R*)-(2-(benzyloxy)-3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. 2-(benzyloxy)-1-bromo-3,5-difluorobenzene

2-Bromo-4,6-difluoro-phenol (10 g, 48 mmol), Bu_4NBr (0.24 g, 0.72 mol) and BnBr (8.22 g, 48 mmol) was mixed in THF (100 mL). 50% KOH (13.46 g, 240 mmol) was added to the mixture, heated to 64 °C and stirred for 2 h. Water was added to the mixture, the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to give the crude product 2-(benzyloxy)-1-bromo-3,5-difluorobenzene (13.7 g, 96%), which was used immediately without purification.

Step 2. (*R*)-*tert*-butyl 3-(2-(benzyloxy)-3,5-difluorobenzoyl)piperidine-1-carboxylate

To a solution of 2-(benzyloxy)-1-bromo-3,5-difluorobenzene (13.7 g, 46 mmol) in anhydrous THF (100 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M n-BuLi in hexane (18.4 mL, 46 mmol). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (10.43 g, 38.3 mmol) in anhydrous THF (40 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 h. The mixture was quenched with saturated NH_4Cl solution (100 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with AcOEt/hexane (1:20→1:10) to provide (*R*)-*tert*-butyl 3-(2-(benzyloxy)-3,5-difluorobenzoyl)piperidine-1-carboxylate (6.4 g, 32%) as a light yellow oil.

Step 3-6. (*R*)-*tert*-butyl 3-((*R*)-(2-(benzyloxy)-3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(2-(benzyloxy)-3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate was obtained analogously to Preparation 13, Steps 2-5.

PREPARATION 15

(*R*)-*tert*-butyl 3-((*R*)-(3-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-fluoro-5-methylbenzoyl)piperidine-1-carboxylate

A 100 mL three-neck flask was charged with Mg (638 mg, 26.6 mmol), a small crystal of iodine. The flask was degassed and refilled into N_2. A solution of 1-bromo-3-fluoro-5- methyl-benzene (5 g, 26.6 mmol) in anhydrous THF was added. The reaction mixture was stirred and heated to reflux for 2 h. Once most of the Mg disappeared the reaction was cooled to –78 °C. Then (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (1.45 g, 5.32 mmol) in anhydrous THF was added dropwise slowly, and the mixture was stirred overnight. The mixture was quenched with saturated NH_4Cl solution (30 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to give the crude product (*R*)-*tert*-butyl 3-(3-fluoro-5-methylbenzoyl)piperidine-1-carboxylate (1.7 g, 99%), which was used immediately without further purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-fluoro-5-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(3-fluoro-5-methylbenzoyl)piperidine-1-carboxylate (1.7 g, 5.3 mmol) in MeOH (30 mL), $NaBH_4$ (1.61 g, 42.3 mmol) was

added in portions and stirred overnight. The reaction was quenched with the addition of water (50mL) and evaporated *in vacuo* until MeOH was removed. The aqueous layer was extracted with EA, washed with brine and dried over Na_2SO_4. The crude product was purified by chromatography to give (*R*)-*tert*-butyl 3-((*R*)-(3-fluoro-5-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate (730 mg, 42.9%).

Step 3-5. (*R*)-*tert*-butyl 3-((*R*)-(3-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(3-fluoro-5-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate analogously to Preparation 13, Steps 3-5.

PREPARATION 16

(*R*)-*tert*-butyl 3-((2,3-difluoro-6-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (2,3-difluoro-5-methylphenyl)trimethylsilane

To a solution of diisopropylamine (20.2 g, 0.2 mol) in THF (500 mL) cooled with an ice-water bath was added a solution of n-BuLi in hexane (2.5 M, 80mL) dropwise for over 30 min. The mixture was stirred in the ice bath for 30 min then cooled to -78 °C. A solution of 1,2-difluoro-4-methylbenzene (12.8 g, 0.1 mol) in THF (80 mL) was added dropwise, after 20-30 min, a solution of TMSCl (21.6 g, 0.2 mol) in THF (20 mL) was added dropwise. The mixture was stirred at -78 °C for 2-3 h. Sat. NH_4Cl (300 mL) was added to the mixture, diluted with water (200 mL) and extracted with ether. The ether layer was washed with brine and dried over Na_2SO_4, the solvent

was removed to give (2,3-difluoro-5-methylphenyl) trimethylsilane (26 g, 100%), which was used for the next step without purification. ^{1}H NMR ($CDCl_3$) δ 6.90 (m, 2H), 2.40 (s, 3H), 0.33 (s, 9H).

Step 2. (*R*)-*tert*-butyl 3-(2,3-difluoro-6-methyl-4-(trimethylsilyl)benzoyl)piperidine-1-carboxylate

To a solution of (2,3-difluoro-5-methylphenyl)trimethylsilane (10 g, 0.05 mol) in anhydrous THF (100 mL) at –78 °C, under nitrogen, was added dropwise a solution of 2.5 M n-BuLi in hexane (20 mL). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (13.6 g, 0.05 mol) in anhydrous THF (60 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 h. The mixture was quenched with saturated NH_4Cl solution (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to give (*R*)-*tert*-butyl 3-(2,3-difluoro-6-methyl-4-(trimethylsilyl)benzoyl)piperidine-1-carboxylate, which was purified by column chromatography on silica gel elating with hexane (2 g, 10%). ^{1}H NMR δ 6.90 (m, 2H), 4.00 (m, 4H), 2.20 (s, 3H), 1.47 (s, 9H), 1.30 (m, 4H),
0.35 (s, 9H).

Step 3. (*R*)-*tert*-butyl 3-(2,3-difluoro-6-methylbenzoyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(2,3-difluoro-6-methyl-4-(trimethylsilyl)benzoyl)piperidine-1-carboxylate (2 g, 4.9 mmol) in THF (20 mL) was added TEAF (0.22 g, 1.5 mmol) in THF (5 mL) at 0 °C. The mixture was stirred for 4 h, after which brine was added, and the mixture was extracted with Et_2O. The organic layer was washed with brine and dried over Na_2SO_4, concentrated. The residue was purified by column chromatography on silica gel to afford (*R*)-*tert*-butyl 3-(2,3-difluoro-6-methylbenzoyl)piperidine-1-carboxylate (1 g, 61%). ^{1}H- NMR δ 7.07 (m, 1H), 6.90 (m, 1H), 4.10 (m, 2H), 3.92 (m, 2H), 2.21 (s, 3H), 1.97 (m, 2H), 1.60 (m, 4H), 1.49 (s, 9H), 1.30 (m, 3H).

Step 4-7. (*R*)-*tert*-butyl 3-((2,3-difluoro-6-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((2,3-difluoro-6-methylphenyl)-(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate analogously to Preparation 15, Steps 2-5.

PREPARATION 17

(*R*)-*tert*-butyl 2-((*S*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)-morpholine-4-carboxylate was prepared according to Preparation 13, Step 1-5, using (*R*)-*tert*-butyl 2-(methoxy(methyl)carbamoyl)morpholine-4-carboxylate and (3-chlorophenyl)lithium in Step 1.

PREPARATION 18

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)-piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-((*R*)-(phenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (3 g, 7.04 mmol) in MeOH (60 mL) was added wet $Pd(OH)_2/C$ (300 mg). The reaction mixture was stirred under 50 psi of hydrogen at 50 °C for 3 h. The suspension was filtered and the filtrate was concentrated *in vacuo*. The crude product was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(phenyl)(2-(methoxycarbonylamino)ethoxy)methyl)-piperidine-1-carboxylate (1.4 g, 51%). ^{1}H NMR (CD_3OD) δ 7.40-7.22 (m, 5H), 4.20 (m, 1H), 4.01 (m, 1H), 3.81 (m, 1H), 3.6 (s, 3H), 3.27 (m, 3H), 2.84 (m, 2H), 1.8-1.5 (m, 2H), 1.45 (s, 9H). MS ESI +ve m/z 393 (M+1).

PREPARATION 19

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-((cyanoimino)(methylthio)methylamino)ethoxy)methyl)piperidine-1-carboxylate

A 25 mL flask was charged with (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (3 g, 8.15 mmol) and dimethyl cyanocarbonimidodithioate (1.2 g, 8.15 mmol) dissolved in 50 mL of MeCN, and 1mL Et_3N was added and the mixture was stirred for overnight. The mixture was evaporated *in vacuo* and the residue was purified by chromatography to give desired (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-((cyanoimino)(methylthio)methylamino)ethoxy)methyl)-piperidine-1-carboxylate (2.2 g, 58%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.28 (m, 2H), 7.23 (m, 1H), 7.16 (m, 1H), 4.10 (m, 2H), 3.86 (m, 1H), 3.68(m, 2H), 3.22 (m, 2H), 2.72 (m, 2H), 1.62 (m, 2H), 1.46 (s, 9H), 1.40-1.10 (m, 4H).

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)piperidine-1-carboxylate

A 100 mL flask was charged with (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-((cyanoimino)(methylthio)methylamino)ethoxy)methyl)piperidine-1-carboxylate (2.2 g, 4.72 mmol) dissolved in 50 mL $MeNH_2$/EtOH solution and stirred overnight. The mixture was concentrated *in vacuo* and used without any further purification.

PREPARATION 20

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)piperidine-1-carboxylate

A 25 mL flask was charged with (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (100 mg, 0.27 mmol) and 2-bromo-thiazole (22 mg, 0.135 mmol) dissolved in propan-2-ol (5 mL) and stirred for 96 hr under reflux. The solvent and excess reagent was removed *in vacuo* to afford a residue purified by chromatography to give the pure (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)piperidine-1-carboxylate (30 mg, 25%)

PREPARATION 21

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)-azepane-1-carboxylate



(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)azepane-1-carboxylate was obtained analogously to Preparation 13, using *tert*-butyl 3-(methoxy(methyl)carbamoyl)azepane-1-carboxylate in Step 1.

The following compounds were prepared following procedures analogous to those described above:

1) (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)azepane-1-carboxylate

PREPARATION 22

(3*S*)-*tert*-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate



Step 1. (3*R*)-*tert*-butyl 3-(bromo(3-fluorophenyl)methyl)piperidine-1-carboxylate

A 250 mL round bottom flask was charged with 0.4845 g (1.56 mmol, 1.0 equiv) of (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate, 0.7920 g (2.39 mmol, 1.52 equiv) of carbon tetrabromide, and 15 mL of CH_2Cl_2. The flask was cooled with an ice bath and then 0.6258 g (2.38 mmol, 1.52 equiv) of triphenylphosphine was added in portions over 5 min. The reaction mixture was allowed to slowly warm to rt while stirring overnight. Analysis of the mixture by LC-MS showed two peaks with the same mass 236 $[M - C_4H_8 - Br]^+$, consistent with a ca 62 : 38 mixture of two isomers: t_R = 10.48 min and 10.93 min in 16 min chromatography, respectively. After the solvent was removed *in vacuo*, the residue was purified by ISCO (40 g silica gel column, 0% →30% ethyl acetate/hexanes over 40 min, flow rate 40 mL/min) to afford 0.2470 g (42%) of (3*R*)-*tert*-butyl 3-(bromo(3-fluorophenyl)methyl)piperidine-1-carboxylate. MS ESI +ve m/z 236 ($M - C_4H_8 - Br$).

Isomer 1 and 2, MS ESI +ve m/z 236 ($M - C_4H_8 - Br$), t_R = 2.13, 2.17 min in 3 min chromatography.

Step 2. (3*S*)-*tert*-butyl 3-(4-amino-1-(3-fluorophenyl)butyl)piperidine-1-carboxylate

An 100 mL round bottom flask was charged with 0.2470 g (0.66 mmol, 1.0 equiv) of (3*R*)-*tert*-butyl 3-(bromo(3-fluorophenyl)methyl)piperidine-1-carboxylate, 10 mL of THF, and 7 mL (0.70 mmol, 1.05 equiv) of 0.1 *M* Li_2CuCl_4 in THF. The mixture was cooled with an ice bath and then a (3-(2,2,5,5-tetramethyl-1,2,5-azadisilolidin-1-yl)propyl)magnesium bromide solution in THF, freshly prepared from 5.2900 g of 1-(3-bromopropyl)-2,2,5,5-tetramethyl-1,2,5-azadisilolidine and 0.5366 g of magnesium turnings in THF, was added via cannula. The resulting deep purple solution was stirred at 0 °C for 3 h. The reaction mixture was quenched with 10 mL of 10% Na_2CO_3, filtered through filter agent, Celite ® 545, washed with CH_2Cl_2, and dried over K_2CO_3. After solvents were evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 10% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 13 min and then 90% CH_3CN/H_2O, 0.1% CF_3COOH over 6 min, flow rate 25 mL/min) to afford 0.092g (30%) of TFA salt of (3*S*)-*tert*-butyl 3-(4-amino-1-(3-fluorophenyl)butyl)piperidine-1-carboxylate. Isomer 1 and 2, MS ESI +ve m/z 351 (M+H), t_R = 1.41, 1.49 min in 3 min chromatography.

Step 3. (3*S*)-*tert*-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate

A 100 mL round bottom flask was charged with 0.092 g of TFA salt of (3*S*)-*tert*-butyl 3-(4-amino-1-(3-fluorophenyl)butyl)piperidine-1-carboxylate, 0.152 g of DMAP, 10 mL of CH_2Cl_2, and 2 mL of DIPEA. The mixture was cooled with an ice bath and then a solution of methyl chloroformate (0.280 g) in CH_2Cl_2 (3 mL) was added. The reaction mixture was allowed to slowly warm to rt while stirring overnight. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 70% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 8 min and then 90% CH_3CN/H_2O, 0.1% CF_3COOH over 2 min, flow rate 25 mL/min) to afford 0.0306

g (38%) of (3*S*)-*tert*-butyl 3-(1-(3-fluorophenyl)-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate. Isomer 1 and 2, MS ESI +ve m/z 431 (MNa^+), 409 (MH^+), t_R = 1.91, 1.98 min in 3 min chromatography.

PREPARATION 23

(*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)ethyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-acetylpiperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (3.320 g, 12.2 mmol) in THF (30 mL) was added 15 mL of 3.0 *M* MeMgCl in THF at -15 °C under N_2. After 0.5 h, the mixture was allowed to warm to rt for 4 h. The reaction mixture was then quenched with 40 mL of 1 *N* HCl and extracted with ethyl acetate (3×), dried over Na_2SO_4. After the solvent was evaporated under reduced pressure, the crude (*R*)-*tert*-butyl 3-acetylpiperidine-1-carboxylate was directly used in the next step without further purification. MS ESI +ve m/z 250 (M+Na).

Step 2. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxyethyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-acetylpiperidine-1-carboxylate, obtained as described above, in THF (20 mL) was added 70 mL of 0.5 *M* (3-chlorophenyl)magnesium bromide in THF at -78 °C under N_2. The mixture was allowed to slowly warm to 12 °C for 18 h. The reaction mixture was then quenched with 10 mL of 10% Na_2CO_3 and extracted with ethyl acetate (3×), dried over Na_2SO_4. After the solvent was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 2.5463 g (62% in two steps) of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxyethyl)piperidine-1-carboxylate. MS ESI +ve m/z 362 (M+Na).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-1-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-1-(3-chlorophenyl)ethyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxyethyl)piperidine-1-carboxylate (2.5463 g, 7.49 mmol), 60% NaH (2.120 g, 53 mmol), and (2-bromoethoxy)(*tert*-butyl)dimethylsilane (7.820 g, 32.7 mmol) in THF was heated at 80 °C for 25 h and then cooled to rt. The reaction mixture was then quenched with water and extracted with ethyl acetate (3×), dried over Na_2SO_4. After the solvent was evaporated under reduced pressure, crude (*R*)-*tert*-butyl 3-((*R*)-1-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-1-(3-chlorophenyl)ethyl)piperidine-1-carboxylate was used directly in the next step without further purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-hydroxyethoxy)ethyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-1-(3-chlorophenyl)ethyl)piperidine-1-carboxylate, tetraethylammonium fluoride (7.600 g, 50.9 mmol) in CH_3CN was heated at 45 °C for 1 h and then was allowed to stir at rt overnight. The reaction mixture was evaporated under reduced pressure, the residue was dissolved into water and extracted with Et_2O (3×), dried over Na_2SO_4. After the solvent was removed *in vacuo*, the crude product was purified by reversed-phase HPLC to give

1.000 g (35% in two steps) of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-hydroxyethoxy)ethyl)piperidine-1-carboxylate. MS ESI +ve m/z 406 (M+Na).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-hydroxyethoxy)ethyl)piperidine-1-carboxylate (1.000 g, 2.6 mmol), phthalimide (1.490 g, 10.1 mmol), triphenylphosphine (4.130 g, 15.7 mmol), and DIAD (3.430 g, 17.0 mmol) in THF was stirred at rt for 40 h. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 0.6792 g (51%) of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethyl)piperidine-1-carboxylate. MS ESI +ve m/z 537 (M+Na).

Step 6. (*R*)-*tert*-butyl 3-((*R*)-1-(2-aminoethoxy)-1-(3-chlorophenyl)ethyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethyl)piperidine-1-carboxylate (0.6792 g, 1.32 mmol) and hydrazine monohydrate (2.350 g) in ethanol (20 mL) was heated at 100 °C for 19 h and then cooled to rt. The precipitates were filtered off and washed with CH_2Cl_2. After the filtrate was evaporated under reduced pressure, the crude (*R*)-*tert*-butyl 3-((*R*)-1-(2-aminoethoxy)-1-(3-chlorophenyl)ethyl)piperidine-1-carboxylate (0.410 g, 81%) was used in the next step without further purification. MS ESI +ve m/z 385 (M+H).

Step 7. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)ethyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(2-aminoethoxy)-1-(3-chlorophenyl)ethyl)piperidine-1-carboxylate (0.410 g, 1.07 mmol), DMAP (0.380 g), DIPEA (4 mL), and methyl chloroformate (0.960 g) in CH_2Cl_2 was stirred at rt for 20 h. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-1-(3-

chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)ethyl)piperidine-1-carboxylate. MS ESI +ve m/z 465 (M+Na).

PREPARATION 24

(*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)butyl)piperidine-1-carboxylate



Step 1-2. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate was obtained using procedures analogous to Preparation 20, Steps 1-2, using propylmagnesium bromide in Step 1.

Step 3. (*R*)-*tert*-butyl 3-((*R*)-1-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate

To a suspension of NaH (2.4 g, 60 mmol) in dry THF (20 mL) was added a solution of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxybutyl)piperidine-1-carboxylate (7.34 g, 20 mmol) in dry THF (80 mL) at 0 °C. The reaction mixture was stirred at rt for 2 h. Then a solution of (2-bromoethoxy)(*tert*-butyl)dimethylsilane (14.3 g, 60 mmol) in THF (100 mL) was added dropwise. After addition, the resulting mixture was stirred under reflux overnight. To the reaction mixture was added

dropwise saturated NH_4Cl solution, extracted by EtOAc (2×100 mL), washed with brine, dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product. The crude product was purified by column chromatography on silica gel to afford (*R*)-*tert*-butyl 3-((*R*)-1-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate (1.1 g, 10%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.35 (s, 1H), 7.22 (m, 3H), 4.05 (m, 2H), 3.81 (m, 2H), 3.31 (m, 2H), 2.42 (t, 3H), 2.06 (m, 3H), 1.85 (m, 2H), 1.58 (m, 2H), 1.44 (s, 9H), 1.41-1.01 (m, 7H), 0.92 (s, 9H), 0.095 (s, 6H).

Step 4. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-hydroxyethoxy)butyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-1-(2-(*tert*-butyldimethylsilyloxy)ethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate (1.1 g, 2.1 mmol) in MeCN (5 mL), TBAF (1.1 g, 4.2 mmol) was added in portions at rt. The reaction mixture was stirred for 2-3 h at 50-60 °C. The solvent was removed *in vacuo* to the crude product, which was purified by column chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-hydroxyethoxy)butyl)piperidine-1-carboxylate (750 mg, 87%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.31 (s, 1H), 7.24 (m, 2H), 7.17(m, 1H), 4.21-3.90 (m, 2H), 3.80 (m, 2H), 3.37 (m, 2H), 2.31 (m, 1H), 2.05 (m, 3H), 1.88 (m, 4H), 1.56 (m, 1H), 1.44 (s, 9H), 1.38-1.10 (m, 2 H), 0.95 (t, 3H).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylsulfonyloxy)ethoxy)butyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-hydroxyethoxy)butyl)piperidine-1-carboxylate (750 mg, 1.82 mmol) in dry CH_2Cl_2 (10 mL) was added Et_3N (550 mg, 5.46 mmol) at -5-0 °C. Then a solution of MsCl (270 mg, 2.37 mmol) in dry CH_2Cl_2 (5 mL) was added dropwise at the same temperature. After addition, it was allowed to warm to rt gradually. Upon completion of the reaction, water (20 mL) was added. The aqueous layer was extracted with CH_2Cl_2 (3×30 mL). The combined organic layers was washed with 10% citric acid, sat. $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give (*R*)-*tert*-

butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylsulfonyloxy)ethoxy)butyl)piperidine-1-carboxylate (900 mg, 99%), which was used in the next step without purification.

Step 6. (*R*)-*tert*-butyl 3-((*R*)-1-(2-azidoethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylsulfonyloxy)ethoxy)butyl)piperidine-1-carboxylate (900 mg, 1.82 mmol) was dissolved into anhydrous DMF (15 mL), solid NaN_3 (230 mg, 3.51 mmol) was added and the reaction mixture was heated to 70 °C overnight. The reaction mixture was cooled to rt and then was diluted with ethyl acetate (110 mL), and water (30 mL), the organic phase was washed with water (3×20 mL), dried over Na_2SO_4 and evaporated to give (*R*)-*tert*-butyl 3-((*R*)-1-(2-azidoethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate (790 mg, 99%).

Step 7. (*R*)-*tert*-butyl 3-((*R*)-1-(2-aminoethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-1-(2-azidoethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate (790 mg, 1.81 mmol) in the mixture of THF/H_2O (20:1, 10.5 mL) was added PPh_3 (1.9 g, 7.25 mmol). The reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure to the residue, which was purified by column chromatography on silica gel to afford (*R*)-*tert*-butyl 3-((*R*)-1-(2-aminoethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate (410 mg, 55%). ^{1}HNMR ($CDCl_3$, 400 MHz) δ 7.31 (s, 1H), 7.24 (m, 2H), 7.15 (m, 1H), 4.31-3.52 (m, 3H), 3.27 (m, 2H), 2.93 (m, 1H), 2.41-2.22 (m, 3H), 2.15-1.95 (m, 3H), 1.85 (m, 4H), 1.57 (m, 1H), 1.44 (s, 9H), 1.38-1.10 (m, 2 H), 0.95 (t, 3H).

Step 8. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)butyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-1-(2-aminoethoxy)-1-(3-chlorophenyl)butyl)piperidine-1-carboxylate (410 mg, 1 mmol) and DMAP (61 mg, 0.5 mmol) in dry CH_2Cl_2 (3 mL), Et_3N (303 mg, 3 mmol) was added. The resulting mixture was cooled to 0-5 °C using a ice-water bath, a solution of methyl chloroformate

(472 mg, 5 mmol) in dry CH_2Cl_2 (2 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 h at 0-5 °C. Upon completion of the reaction water (5 mL) was added and the aqueous layer was extracted with CH_2Cl_2 (3×15 mL). The combined organic layers were washed with 10% citric acid (2×10 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to afford (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-(methoxycarbonylamino)ethoxy)butyl)piperidine-1-carboxylate (460 mg, 98%), which was used in the next step without further purification.

PREPARATION 25

1) (*R*)-*tert*-butyl 3-((*S*)-1-(3-fluorophenyl)-1-hydroxy-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate was obtained analogous to PREPARATION 1 above.

2) (*R*)-*tert*-butyl 3-((*S*)-1-(3-chloro-2-fluorophenyl)-1-hydroxy-4-(methoxycarbonylamino)butyl)piperidine-1-carboxylate was obtained analogously to PREPARATION 1 above.

PREPARATION 26

(R)-4-(*tert*-Butoxycarbonyl)morpholine-2-carboxylic acid



Step 1. (R)-2-(Benzyloxymethyl)morpholine

To a stirred mixture of (R)-2-(benzyloxymethyl)oxirane (10.0 g, 60.9 mmol) and NaOH (19.49 g, 487.2 mmol) in H_2O (46 mL) and MeOH (18 mL), there was added 2-aminoethyl hydrogen sulfate (36.8 g, 255.8 mmol) in portions. After addition the

reaction mixture was stirred at 40°C for 2 h. After cooling, the mixture was treated with NaOH (15.0 g, 375.0 mmol) then toluene (70 mL) and stirred at 65°C overnight. The mixture was cooled, diluted with toluene (27 mL) and H_2O (92 mL). The toluene layer was separated and the aqueous layer was extracted with CH_2Cl_2 (2 x 50 mL). The combined organic layers were concentrated to give crude (R)-2-(benzyloxymethyl)morpholine (~14 g), which was used without purification. MS m/z 208 ($M+H^+$).

Step 2. (R)-*tert*-Butyl 2-(benzyloxymethyl)morpholine-4-carboxylate

To a solution of crude (R)-2-(benzyloxymethyl)morpholine (~14 g) in acetone (100 mL) and H_2O (30 mL) at 0°C, there was added K_2CO_3 (25.2 g, 182.7 mmol), followed by $(Boc)_2O$ (14.6 g, 67.0 mmol). The resulting solution was warmed to rt, and stirred until no starting material remained (~30 min), acetone was removed under vacuum, and the aqueous solution was extracted with CH_2Cl_2 (4 x 10 mL). The combined organic layers were washed with H_2O (10 mL) and the solvent was removed. The residue was purified by flash column chromatography to give (R)-*tert*-butyl 2-(benzyloxymethyl)morpholine-4-carboxylate (8.33 g, 44% over 2 steps). ^1H NMR (400MHz, $CDCl_3$): 7.34 (m, 5 H), 4.56 (s, 2 H), 3.88 (d, 2 H), 3.82 (br, 1 H), 3.40 (m, 1 H), 3.48 (m, 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.44 (s, 9 H); MS m/z 330 ($M+Na^+$).

Step 3. (R)-*tert*-Butyl 2-(hydroxymethyl)morpholine-4-carboxylate

To a solution of (R)-*tert*-butyl 2-(benzyloxymethyl)morpholine-4-carboxylate (8.33 g, 27.1 mmol) in EtOH was added Pd-C (wet, 3.6 g), and the resulting mixture was stirred at rt under a H_2 balloon overnight. After filtration, the solvent was removed under vacuum, and the residue was purified by flash column chromatography to give (R)-*tert*-butyl 2-(hydroxymethyl)morpholine-4-carboxylate (5.84 g, 99 %) as a clear oil. ^1H NMR (400MHz, $CDCl_3$): 3.88 (d, 2 H), 3.82 (br, 1 H), 3.64 (d, 1 H), 3.56 (m, 3 H), 2.94 (m, 1 H), 2.76 (m, 1 H), 1.90 (br, 1 H), 1.44 (s, 9 H); MS m/z 218 ($M+H^+$).

Step 4. (R)-4-(*tert*-Butoxycarbonyl)morpholine-2-carboxylic acid

Sat'd aq $NaHCO_3$ (15 mL) was added to a solution of (R)-*tert*-butyl 2-(hydroxymethyl)-morpholine-4-carboxylate (1.09 g, 5.0 mmol) in acetone (50 mL),

stirred and maintained at 0°C. Solid NaBr (0.1 g, 1 mmol) and TEMPO (0.015 g, 0.1 mmol) were added. Trichloroisocyanuric acid (2.32 g, 10.0 mmol) was then added slowly within 20 min at 0°C. After addition the mixture was warmed to rt and stirred overnight. 2-Propanol (3 mL) was added, and the resulting solution was stirred at rt for 30 min, filtered through a pad of Celite, concentrated under vacuum, and treated with sat'd aq Na_2CO_3 (15 mL). The aqueous solution was washed with EtOAc (5 mL), acidified with 6 N HCl, and extracted with EtOAc (5 x 10 mL). The combined organic layers were dried over Na_2SO_4 and the solvent was removed to give (R)-4-(*tert*-butoxycarbonyl)morpholine-2-carboxylic acid (1.07 g, 92 %) as a white solid. ^{1}H NMR (400MHz, $CDCl_3$): 4.20 (br, 1 H), 4.12 (d, 1 H), 4.02 (d, 1 H), 3.84 (m, 1 H), 3.62 (m, 1 H), 3.04 (m, 2 H), 1.44 (s, 9 H); MS m/z 232 ($M+H^+$).

PREPARATION 27

Methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-morpholin-2-yl)methoxy)ethylcarbamate was prepared from (R)-4-(*tert*-butoxycarbonyl)morpholine-2-carboxylic acid using procedures analogous to those described in Preparation 1 Steps 1 and 2 and Preparation 4.

PREPARATION A

(S)-2-(Trimethylsilyl)ethyl 2-amino-3-cyclohexylpropylcarbamate



Step 1. (S)-2-(*tert*-Butoxycarbonylamino)-3-cyclohexylpropyl methanesulfonate

A solution of (S)-*N*-Boc-2-amino-3-cyclohexylpropanol (20 g, 0.078 mol) in CH_2Cl_2 (400 mL) and triethylamine (19.6 g, 0.195 mol) was cooled to –20°C. Methanesulfonyl chloride (19.5 g, 0.171 mol) was added with fast dropwise addition maintaining the internal temperature at -20°C. The reaction mixture was stirred at –

20°C for an additional 30 min then for 1 h at 0°C and then quenched with ice-cold water (200 mL). The mixture was extracted with CH_2Cl_2 (3×100 mL), washed with water (3×50 mL), dried over Na_2SO_4, concentrated to give the crude (S)-2-(*tert*-butoxycarbonylamino)-3-cyclohexylpropyl methanesulfonate (23.3 g, 90%), which was used for the next reaction without further purification. ^{1}H NMR (400MHz, $CDCl_3$): 4.93 (m, 1H), 4.60 (d, *J*=7.6Hz, 1H), 3.67 (m, 2H), 3.12 (s, 3H), 1.87-1.50 (m, 5H), 1.45 (s, 9H), 1.40-0.72 (m, 8H), MS (E/Z): 336 ($M+H^+$).

Step 2. (S)-*tert*-butyl 1-azido-3-cyclohexylpropan-2-ylcarbamate

To a solution of (S)-2-(*tert*-butoxycarbonylamino)-3-cyclohexylpropyl methanesulfonate (23.3 g, 0.070 mol) in anhydrous DMF (300 mL) was added solid NaN_3 (13.5 g, 0.21 mol). The reaction mixture was heated at 80°C overnight. After cooling to rt, the reaction solution was diluted with EtOAc (1200 mL) and water (400 mL). The organic phase was separated and washed with brine (3 x 300 mL), dried over Na_2SO_4 and evaporated. The residue was purified by column chromatography on silica gel to give (S)-*tert*-butyl 1-azido-3-cyclohexylpropan-2-ylcarbamate as a clear oil (13.6 g, 69%). ^{1}H NMR (400MHz, $CDCl_3$): 4.45 (d, *J*=8.0Hz, 1H), 3.84 (m, 1H), 3.45 (m, 1H), 3.31 (m, 1H), 1.81-1.60 (m, 5H), 1.45 (s, 9H), 1.40-0.78 (m, 8H). MS (E/Z): 383 ($M+H^+$).

Step 3. (S)-*tert*-butyl 1-amino-3-cyclohexylpropan-2-ylcarbamate

A mixture of (S)-tert-butyl 1-azido-3-cyclohexylpropan-2-ylcarbamate (13.6 g, 0.048 mol) and Pd/C (1.4 g) in methanol (200 mL) was hydrogenated with a balloon overnight. The mixture was filtered through a pad of Celite and the solvent was removed to give (S)-tert-butyl 1-amino-3-cyclohexylpropan-2-ylcarbamate (10.5 g, 86%), which was used in the next step without purification. ^{1}H NMR (400MHz, $CDCl_3$): 4.52 (d, *J*=8.4Hz, 1H), 3.68 (m, 2H), 2.73 (dd, *J*=13.6&4.4Hz, 1H), 2.58 (dd, *J*=13.6&6.0Hz, 1H), 1.81 (m, 1H), 1.65 (m, 4H), 1.42 (s, 9H), 1.40-1.00 (m, 6H), 1.00-0.70 (m, 2H). MS (E/Z): 257 ($M+H^+$).

Step 4. (S)-tert-Butyl 1-(2-(trimethylsilyl)ethoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate

To a vigorously stirred biphasic solution of (S)-tert-butyl 1-amino-3-cyclohexylpropan-2-ylcarbamate (10.5 g, 0.041 mol), K_2CO_3 (10.2 g, 73.8 mol), H_2O (60 mL), and CH_2Cl_2 (120 mL) was added 1-[2-trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione (TeocOSu) (11.14 g, 0.043 mol). The mixture was stirred for 2 h at rt, and then the reaction was washed with brine (3×20 mL), dried over Na_2SO_4, decanted, stripped, and separated on 50 g of SiO_2 to give (S)-tert-butyl 1-(2-(trimethylsilyl)ethoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate (8.5 g, 52%) as a clear oil. ^{1}H NMR (400MHz, $CDCl_3$): 5.52 (brs, 1H), 4.42 (brs, 1H), 4.11 (m, 2H), 3.73 (brs, 1H), 3.30-3.03 (m,2H), 1.81-1.50 (m, 5H), 1.43 (s, 9H), 1.42-1.02 (m, 6H), 1.02-0.76 (m, 4H), 0.03 (s, 9H); MS (E/Z): 401 ($M+H^+$).

Step 5. (S)-2-(Trimethylsilyl)ethyl 2-amino-3-cyclohexylpropylcarbamate

(S)-tert-butyl 1-(2-(trimethylsilyl)ethoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate (8.5 g, 0.0213 mol) was dissolved into a minimal volume of ethyl ether (120 mL) and added to a solution of tosic acid (4.46 g, 0.023 mol) in 25 mL of absolute EtOH. This solution was placed on a rotary evaporator and ethyl ether was removed at ambient temp. The flask was then lowered into the water bath (temperature: 60°C) and the selective de-protection of the Boc group proceeded concurrently with removal of the remainder of solvent. The reaction was completed by 2 h and gave an off-white solid. This material was cooled to rt and dissolved in 100 mL of a mixture EtOH:H_2O (1:1, v/v). This was washed with hexanes:EtOAc (5:1, v/v, 3×12 mL), basified with 1N NaOH (pH>10), and extracted with EtOAc (3×50 mL). The combined organic extracts were washed (3×5mL 1N NaOH, 3×5mL brine), dried, decanted and stripped to give the free base of (S)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropylcarbamate (5.24 g, 82%). ^{1}H NMR (400MHz, $CDCl_3$): 5.09 (brs, 1H), 4.14 (t, J=8.4Hz, 2H), 3.23 (m, 1H) 2.88 (m, 2H), 1.75-1.48 (m, 5H), 1.5-0.75 (m, 10H), 0.05 (s, 9H). MS (E/Z): 301 ($M+H^+$).

PREPARATION B

(S)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropyl(methyl)carbamate



Step 1. (S)-*tert*-Butyl 1-cyclohexyl-3-(methylamino)propan-2-ylcarbamate

(S)-2-(tert-butoxycarbonylamino)-3-cyclohexylpropyl methanesulfonate (28 g, 83.6 mmol) was dissolved into a solution of methylamine in ethanol (about 30% by weight, 300 mL). The reaction was heated at 50-60°C overnight and concentrated in *vacuo*. The residue was dissolved in EtOAc, washed with brine (2x100 mL), dried over $MgSO_4$, and concentrated to give the crude product. This crude product was purified by flash chromatography (AcOEt:Hex.=2:1 first, then EtOAc: MeOH=1:1) to afford pure (S)-tert-butyl 1-cyclohexyl-3-(methylamino)propan-2-ylcarbamate (10.6 g, 47%). ^1H NMR (400MHz, $CDCl_3$): 4.81 (brs, 1H), 3.89 (m, 1H), 2.77 (m, 2H), 2.54 (s, 3H), 2.44 (m, 2H), 1.78 (m, 1H), 1.67 (m, 4H), 1.44 (s, 9H), 1.50-1.10 (m, 6H), 1.00-0.77 (m, 2H), 0.05 (s, 9H). MS (E/Z): 271 ($M+H^+$).

Step 2. (S)-tert-butyl 1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate

To a vigorously stirred 2-phase solution of (S)-tert-butyl 1-cyclohexyl-3-(methylamino)propan-2-ylcarbamate (7.25 g, 0.027 mol), K_2CO_3 (6.66 g, 0.048 mol), H_2O (40 mL) and CH_2Cl_2 (80 mL) was added 1-[2-trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione (TeocOSu) solid (7.3 g, 0.028 mol). After stirring for 2 h at rt, the reaction was added to CH_2Cl_2 (200mL), washed with satd aq $NaHCO_3$ (3 x 15 mL) then brine (3 x 15 mL), dried over Na_2SO_4 and concentrated. The residue was purified by column chromatography on 40 g of silica gel to give (S)-tert-butyl 1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate as a clear oil (5.78 g,

50%). ^{1}H NMR (400MHz, $CDCl_3$) δ 4.50 (d, J=7.6Hz, 1H), 4.15 (t, J=7.6Hz, 2H), 3.89 (m, 1H), 3.56-2.95 (m, 2H), 2.92&2.90 (s, 3H), 1.82 (m, 1H), 1.66 (m, 4H), 1.41 (s, 9H), 1.50-1.10 (m, 6H), 1.00-0.70 (m, 4H), 0.01 (s, 9H). MS (E/Z): 415 ($M+H^+$).

Step 3. (S)-2-(Trimethylsilyl)ethyl 2-amino-3-cyclohexylpropyl(methyl)carbamate

(S)-tert-butyl 1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate (5.78 g, 0.014 mol) was dissolved into a minimal volume of ethyl ether (100 mL) and added to a solution of TsOH (2.92 g, 0.0154 mol) in 20.0 mL of absolute EtOH. This solution was placed on a rotary evaporator and the Et_2O was removed at ambient temp. The flask was then lowered into the water bath (temperature: 60°C) and the selective de-protection of the BOC group proceeded concurrently with removal of the remainder of the solvent. The reaction was completed by 2 h and gave an off-white solid, which was washed with hexanes:EtOAc (5:1, v/v, 3×10mL), basified with 1N NaOH (pH>10), and extracted with ethyl ether (3×50 mL). The combined organic extracts were washed with 1N NaOH (3×5mL) and brine (3 x 5 mL),dried, decanted and stripped to give the free base of (S)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropyl(methyl)carbamate (3.5 g, 80%). ^{1}H NMR (400MHz, $CDCl_3$): 4.15 (t, *J*=8.4Hz, 2H), 3.10 (m, 3H), 2.91 (s, 3H), 1.78-1.56 (m, 5H), 1.50-1.00 (M, 6H), 1.00-0.70 (m, 4H), 0.01 (s, 9H). MS (E/Z): 315 ($M+H^+$).

PREPARATION C

Benzyl (2S,3S)-3-amino-4-cyclohexylbutan-2-ylcarbamate



Step 1. Tert-butyl (2S,3R)-1-cyclohexyl-3-hydroxybutan-2-ylcarbamate

To a solution of tert-butyl (S)-2-cyclohexyl-1-((S)-oxiran-2-yl)ethylcarbamate (0.63 g, 2.5 mmol) and triethylamine (0.65 mL, 5 mmol) in methanol (15 mL) was added Pd/C (0.1 g), and the mixture was hydrogenated under 30 psi pressure at rt overnight. The mixture was filtered and the filtrate was concentrated to give tert-butyl (2S,3R)-1-cyclohexyl-3-hydroxybutan-2-ylcarbamate (0.44 g, 70%). ^{1}H NMR (400MHz, $CDCl_3$): 4.48 (brs, 1H), 3.78 (m, 2H), 2.30 (brs, 1H), 1.82 (m, 1H), 1.66 (m, 4h), 1.45 (s, 9H), 1.40 -1.00 (m, 6H), 1.10 (d, J=6.4 Hz, 3H), 1.00-0.70 (m, 2H); MS (E/Z): 272 ($M+H^+$).

Step 2. Tert-butyl (2S,3R)-1-cyclohexyl-3-(methanesulfonyloxy)butan-2-ylcarbamate

To a solution of tert-butyl (2S,3R)-1-cyclohexyl-3-hydroxybutan-2-ylcarbamate (0.44 g, 1.62 mmol) in dry CH_2Cl_2 (10 mL) was added Et_3N (0.71 g, 7 mmol, 4 eq) at 0 to -5°C. A solution of methanesulfonyl chloride (0.8 g, 7 mmol, 2 eq) in dry CH_2Cl_2 (5 mL) was added dropwise at the same temperature. The mixture was allowed to warm to rt gradually. TLC showed that the starting material had disappeared. Water (30 mL) was added. The aqueous layer was extracted with CH_2Cl_2 (3 x 20 mL). The combined organic layers was washed with 10% aq citric acid, satd aq $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give tert-butyl (2S,3R)-1-cyclohexyl-3-(methanesulfonyloxy)butan-2-yl-carbamate (0.46 g, 81%), which was used in the next step without purification.

Step 3. Tert-butyl (2S,3S)-3-azido-1-cyclohexylbutan-2-ylcarbamate

tert-Butyl (2S,3R)-1-cyclohexyl-3-(methanesulfonyloxy)butan-2-ylcarbamate (0.46 g, 1.32 mmol) was dissolved into anhydrous DMF (10 mL), solid NaN_3 (0.26 g, 4 mmol) was added and the reaction mixture was heated to 80°C overnight. The reaction mixture was cooled to rt and diluted with EtOAc (100 mL) and water (30 mL). The organic phase was washed with water (3 x 30 mL), dried over Na_2SO_4 and evaporated. The residue was separated by chromatography on a silica gel column to give tert-butyl (2S,3S)-3-azido-1-cyclohexylbutan-2-ylcarbamate (0.215 g, 55%). ^{1}H NMR (400MHz, $CDCl_3$): 4.38 (d, J=9.2Hz, 1H), 3.72 (m, 1H), 3.60 (m, 1H), 1.82 (m, 1H), 1.67 (m, 4h),

1.44 (s, 9H), 1.40 -1.00 (m, 6H), 1.28 (d, J=6.4 Hz, 3H), 1.00-0.75 (m, 2H); MS (E/Z): 297 ($M+H^+$).

Step 4. Tert-butyl (2S,3S)-3-amino-1-cyclohexylbutan-2-ylcarbamate

A solution of tert-butyl (2S,3S)-3-azido-1-cyclohexylbutan-2-ylcarbamate (0.215 g, 0.73 mmol) in methanol (10 mL) was added to wetted Pd/C (0.1 g) and was hydrogenated with a balloon overnight. The reaction mixture was filtered through a pad of Celite and the solvent was removed to give tert-butyl (2S,3S)-3-amino-1-cyclohexylbutan-2-ylcarbamate (0.153 g, 78%), which was used in the next step without purification.

Step 5. Benzyl (2S,3S)-3-(tert-butoxycarbonyl)amino-4-cyclohexylbutan-2-ylcarbamate

To a mixture of tert-butyl (2S,3S)-3-amino-1-cyclohexylbutan-2-ylcarbamate (0.153 g, 0.57 mmol) and Et_3N (0.19 mL, 1.42 mmol) in methanol (5 mL) at 0°C was added dropwise a solution of CBZCl (0.116 g, 0.68 mmol) in methanol (3 mL). The mixture was warmed to rt, stirred 2 h, evaporated to remove methanol, diluted with water (15 mL) and extracted with EtOAc (3 ×10 mL). The combined organic layers were washed with brine (15 mL), dried and evaporated to give benzyl (2S,3S)-3-(tert-butoxycarbonyl)amino-4-cyclohexylbutan-2-ylcarbamate (0.117 g, 51%) that was used in the next step without further purification. ^1H NMR (400MHz, $CDCl_3$): 7.32 (m, 5H), 5.37 (brs, 1H), 5.09 (s, 2H), 4.36 (brs (1H), 3.76 (m, 2H), 1.82 (m, 1H), 1.66 (m, 4H), 1.44 (s, 9H), 1.35 -1.10 (m, 6H), 1.07 (d, J=6.4 Hz, 3H), 1.00-0.78 (m, 2H); MS (E/Z): 405 ($M+H^+$).

Step 6. Benzyl (2S,3S)-3-amino-4-cyclohexylbutan-2-ylcarbamate

Benzyl (2S,3S)-3-(tert-butoxycarbonyl)amino-4-cyclohexylbutan-2-ylcarbamate (0.117 g, 0.29 mmol) was dissolved in 2 N HCl in methanol (10 mL, 20 mmol). The mixture was allowed to stir at 40–50°C for 2 h. The mixture was concentrated *in vacuo* to give the HCl salt of benzyl (2S,3S)-3-amino-4-cyclohexylbutan-2-ylcarbamate (0.077 g, 78%).

Benzyl (2R,3S)-3-amino-4-cyclohexylbutan-2-ylcarbamate was prepared following the procedure described above starting with (1*S*,R)-(2-cyclohexyl-1-oxiranyl-ethyl)-carbamic acid *tert*-butyl ester.

PREPARATION D

(S)-2-(trimethylsilyl)ethyl 3-amino-5,5-dimethylhexyl(methyl)carbamate



Step 1. tert-Butyl (S)-1-(methylcarbamoyl)-3,3-dimethylbutylcarbamate

To a solution of (S)-2-(t-butoxyaminocarbonylamino)-4,4-dimethylpentanoic acid (1.0 g, 4.08 mmol) and methylamine hydrochloride in DMF (10 mL) was added DIEA (2.1 mL, 12.2 mmol), followed by HBTU (1.55 g, 4.08 mmol). The resulting solution was stirred at rt until no starting material remained (~2 h). The solution was diluted with EtOAc (10 mL), washed with 1 N aq HCl (2 x 5 mL), sat'd aq $NaHCO_3$ (10 mL) and brine, and dried over Na_2SO_4. After removal of the solvent, the crude product was purified by flash column chromatography to give tert-butyl (S)-1-(methylcarbamoyl)-3,3-dimethylbutyl carbamate (1.05 g, quant.) as a clear oil. MS m/z 281 ($M+Na^+$).

Step 2. tert-Butyl (S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamate

To a solution of tert-butyl (S)-1-(methylcarbamoyl)-3,3-dimethylbutyl carbamate (1.05 g, 4.08 mmol) in toluene (10 mL) at 0°C, there was added Red-Al (65 wt% in toluene, 3.73 mL, 12.2 mmol) dropwise. The solution was warmed to rt slowly and stirred overnight. The reaction was quenched with ice water, filtered through

Celite, and solvent was removed to give tert-butyl (S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamate (0.79 g, 79%) as a clear oil. MS m/z 245 ($M+H^+$).

Step 3. 2-(Trimethylsilyl)ethyl (S)-2-tert-butylcarboxylamino-4,4-dimethylpentylmethyl carbamate

To a solution of tert-butyl (S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamate (0.79 g, 3.24 mmol) in acetone (10 mL) and water (3 mL) was added K_2CO_3 (1.34 g, 9.72 mmol), followed by Teoc-OSu (0.84 g, 3.24 mmol). The resulting mixture was stirred at rt until no starting material remained (~1 h). Acetone was removed *in vacuo*, and the aqueous residue was extracted with CH_2Cl_2 (4 x 5 mL), the combined organic layers were concentrated, and the crude residue was purified by flash column chromatography to give 2-(trimethylsilyl)ethyl (S)-2-tert-butylcarboxylamino-4,4-dimethylpentylmethyl carbamate (0.74 g, 59%) as a clear oil. MS m/z 389 ($M+H^+$).

Step 4. (S)-2-(trimethylsilyl)ethyl 3-amino-5,5-dimethylhexyl(methyl)carbamate

To a solution of 2-(trimethylsilyl)ethyl (S)-2-tert-butylcarboxylamino-4,4-dimethylpentylmethyl carbamate (0.74 g, 1.90 mmol) in ether (7 mL) was added a solution of p-toluenesulfonic acid (0.37 g, 1.92 mmol) in 1.5 mL of ethanol (1.5 mL). Transfer of the p-toluenesulfonic acid was completed with the aid of ether (1 mL). The solution was placed on a rotary evaporator and the ether removed under reduced pressure at rt. Then, with continuing evacuation, the bath temperature was raised to 60-65°C for 20 min, during which gas evolution was evident. The solid residue of the toluensulfonate salt of (S)-2-(trimethylsilyl)ethyl 3-amino-5,5-dimethylhexyl(methyl)carbamate was used without purification in the next step. MS m/z 289 ($M+H^+$).

PREPARATION E

Benzyl (S)-2-amino-3-(cis-4-fluorocyclohexyl)propylmethylcarbamate



Step 1. tert-butyl (S)-1-(methoxycarbonyl)-2-(4-(t-butyldimethylsilyloxy)cyclohexyl)-ethylcarbamate

To a solution of TBSCl (12.7 g, 85 mmol) in dichloromethane (20 mL) was added dropwise a mixture of 2-tert-butoxycarbonylamino-3-(4-hydroxy-cyclohexyl)-propionic acid methyl ester (17 g , 56 mmol) and imidazole (7.68 g, 113 mmol) in dichloromethane (200 mL) at 0°C. After stirring at rt for 5 h, the reaction mixture was washed with water and brine. The organic layer was dried over Na_2SO_4 and concentrated to give tert-butyl (S)-1-(methoxycarbonyl)-2-(4-(t-butyldimethylsilyloxy)cyclohexyl)ethylcarbamate (21 g, 91%) that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.08(d, 6 H), 0.89(d, 9 H), 1.45 (s, 9 H), 1.51(m, 4 H), 1.58 (m, 1 H), 1.68 (t, 4 H), 1.85 (d, 1 H) 3.71 (d, 3 H), 3.91 (m, 1 H), 4.34 (m, 1 H), 4.86 (m,1 H).

Step 2. (2S)-2-(t-butoxycarbonylamino)-3-(4-(t-butyldimethylsilyloxy)cyclohexyl)propan-1-ol

To a solution of tert-butyl (S)-1-(methoxycarbonyl)-2-(4-(t-butyldimethylsilyloxy)-cyclohexyl)ethylcarbamate (25 g, 60 mmol) in EtOH (500 mL) at 0°C was added $NaBH_4$ (18 g, 480 mmol) in portions. The mixture was stirred for 6 h

at rt and then evaporated. The residue was partitioned between water (200 mL) and EtOAc (2 x 200 mL). The combined organic layers were washed with brine, dried over $MgSO_4$, and evaporated to give (2S)-2-(t-butoxycarbonylamino)-3-(4-(t-butyldimethylsilyloxy)cyclohexyl)propan-1-ol (23 g, yield 98%). ^1H NMR ($CDCl_3$, 400 MH_Z) δ 0.08(d, 6 H), 0.89(d, 9 H), 1.30(m, 4 H), 1.40 (t, 2 H), 1.45 (s, 9 H), 1.61(m, 1 H), 1.58 (m, 1 H), 1.68 (t, 4 H), 1.85 (d, 1 H) 3.50 (m, 1 H), 3.65 (m, 1 H), 3.73 (m, 1 H), 3.91 (s, 1 H), 4.53(s, 1 H).

Step 3. (2S)-2-(t-butoxycarbonylamino)-3-(4-(t-butyldimethylsilyloxy)cyclohexyl)-1-methanesulfonyloxypropane

To a solution of (2S)-2-(t-butoxycarbonylamino)-3-(4-(t-butyldimethylsilyloxy)-cyclohexyl)propan-1-ol (23 g, 59 mmol) in CH_2Cl_2 (250 mL) was added Et_3N (15 g, 148 mmol). The reaction mixture was cooled to -20°C and a solution of MsCl (14.9 g, 131 mmol) in CH_2Cl_2 (40 mL) added dropwise. After returning to rt then stirring for an additional 1 h, at which point TLC showed no starting material, water (100 mL) was added and the mixture was extracted with CH_2Cl_2 (2 x 150 mL). The combined organic layers were washed with brine, dried over $MgSO_4$ and evaporated to give crude (2S)-2-(t-butoxycarbonylamino)-3-(4-(t-butyldimethyl-silyloxy)cyclohexyl)-1-methanesulfonyloxypropane (30 g) that was used in the next step without further purification.

Step 4. tert-Butyl (S)-1-(4-(t-butyldimethylsilyloxy)cyclohexyl)-3-(methylamino)propan-2-ylcarbamate

A solution of crude (2S)-2-(t-butoxycarbonylamino)-3-(4-(t-butyldimethylsilyloxy) cyclohexyl)-1-methanesulfonyloxypropane (30 g) in methylamine alcohol solution (300 mL) was heated under reflux overnight. The solvent was removed *in vacuo* and the residue was purified by silica chromatography to obtain tert-butyl (S)-1-(4-(t-butyldimethylsilyloxy)cyclohexyl)-3-(methylamino)propan-2-ylcarbamate as a solid (15 g, 63% for 2 steps). ^1H NMR ($CDCl_3$, 400 MHz) δ 0.08(d, 6 H), 0.89(d, 9 H), 1.25(t, 3 H), 1.45 (s, 9 H), 1.61(m, 2 H), 1.82 (t, 2 H), 2.01 (d, 1 H),

2.56(d, 2 H), 2.80(d, 2 H), 2.95(t, 2 H), 3.49(m, 1 H), 3.61(m, 1 H), 3.90 (s, 1 H), 5.35 (d, 1 H), 7.15(m, 1 H) .

Step 5. tert-Butyl (S)-1-(4-(t-butyldimethylsilyloxy)cyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate

To a mixture solution of tert-butyl (S)-1-(4-(t-butyldimethylsilyloxy)cyclohexyl)-3-(methylamino)propan-2-ylcarbamate (112 g, 209 mmol) and Et_3N (52.8 g, 522 mmol) in CH_2Cl_2 (1200 mL) was added dropwise a solution of benzyl chloroformate (39 g, 230 mmol) in CH_2Cl_2 (40 mL) at -20°C. After stirring for an additional 2 h, water (400 mL) was added and the mixture was extracted with CH_2Cl_2 (2 x 200 mL). The organic layers were washed with brine, dried over $MgSO_4$, and evaporated. The residue was purified by silica chromatography to afford crude tert-butyl (S)-1-(4-(t-butyldimethylsilyloxy)cyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate (90 g) as an oil which was a mixture of two isomers. The isomers were separated by preparative HPLC. ^1H NMR(CDCl3, 400 MH_Z): δ=0.08(s, 6 H), 0.89(s, 9 H), 1.28(m, 4 H), 1.40(d, 9 H), 1.59(m, 4 H), 2.96(d, 3 H), 3.05(d, 1 H), 3.15(d, 1 H), 3.45(t, 3 H), 3.90(s, 1 H), 5.12(d, 2 H), 7.33(m, 5 H).

Step 6. tert-Butyl (S)-1-(trans-4-hydroxycyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate

tert-Butyl (S)-1-(trans-4-(t-butyldimethylsilyloxy)cyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate (18 g, 34 mmol) was treated with 4 M nBu_4NF/THF (50 mL) at 50°C for 6 h. Water (30 mL) was added and the mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over $MgSO_4$ and evaporated to give crude tert-butyl (S)-1-(trans-4-hydroxycyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate (9 g, 64%) that was purified by silica chromatography. ^1H NMR ($CDCl_3$, 400 MHz) δ 1.41(d, 9 H), 1.65(m, 6 H), 1.95(m, 3 H), 2.98(d, 3 H), 3.10(m, 1 H), 3.52(m, 1 H), 3.90(m, 1 H), 5.13(d, 2 H), 7.33(m, 5 H).

Step 7. tert-Butyl (S)-1-(cis-4-fluorocyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate

A mixture of tert-butyl (S)-1-(trans-4-hydroxycyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate (3 g, 7mmol), Et_3N (12 mL, 88mmol), $NEt_3(HF)_3$ (4.71 mL, 29mmol) and perfluorobutanesulfonyl fluoride (5.21 mL, 29mmol) was stirred in THF (70 mL, 1 mmol/10 mL) at 50°C until HPLC revealed complete conversion. The reaction mixture was quenched with water and extracted with EtOAc (2 x 100 mL), dried over $MgSO_4$ and evaporated. The residue was then purified by prep HPLC to give tert-butyl (S)-1-(trans-4-fluorocyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate (1.16 g, 40%) as a white solid. ^1H NMR ($CDCl_3$, 400 MHz) δ 1.41(d, 9 H), 1.68(m, 6 H), 1.96(m, 3 H), 2.98(d, 3 H), 3.20(m, 1 H), 3.52(m, 1 H), 3.90(m, 1 H), 5.13(d, 2 H), 7.33(m, 5 H).

Step 8. Benzyl (S)-2-amino-3-(cis-4-fluorocyclohexyl)propylmethylcarbamate

A solution of tert-butyl (S)-1-(trans-4-fluorocyclohexyl)-3-(N-(benzyloxycarbonyl)-N-methylamino)propan-2-ylcarbamate (550 mg, 1.3 mmol) in TFA/CH_2Cl_2 (20 mL, v/v 20%) was stirred for 1 h at rt, quenched with satd aq $NaHCO_3$ until no further gas evolution was visible and extracted with CH_2Cl_2 (2 x 50mL). The combined organic layers were washed with brine, dried over $MgSO_4$, filtered and condensed under reduced pressure to obtain benzyl (S)-2-amino-3-(cis-4-fluorocyclohexyl)propylmethylcarbamate (400 mg, yield 95%). ^1H NMR($CDCl_3$, 400 MHz) δ 1.42(m, 4 H), 1.64(m, 4 H), 2.98(d, 3 H), 3.21(m, 1 H), 3.50(m, 1 H), 3.90(m, 1 H), 5.13(d, 2 H), 7.33(m, 5 H).

PREPARATION F

Benzyl (S)-2-amino-3-(trans-4-fluorocyclohexyl)propylmethylcarbamate



Step 1. Benzyl (S)-2-(t-butoxycarbonylamino)-3-(trans-4-fluorocyclohexyl)propyl-(methyl)carbamate

A mixture of benzyl (S)-2-(t-butoxycarbonylamino)-3-(cis-4-hydroxycyclohexyl)-propyl(methyl)carbamate (1 g, 2.38 mmol), base Et_3N (5 mL, 28 mmol), a fluoride source $NEt_3(HF)_3$ (1.9 mL, 9.52 mmol) and perfluorobutanesulfonyl fluoride (2.1 mL, 9.52 mmol) were stirred in THF (24 mL, 1 mmol/10 mL) in a capped vial or flask at 50°C until LC revealed complete conversion. The reaction mixture was quenched with water and extracted with EtOAc (2 x100 mL), dried over $MgSO_4$, and evaporated. The residue was then purified by preparative HPLC to give benzyl (S)-2-(t-butoxycarbonylamino)-3-(trans-4-fluorocyclohexyl)propyl-(methyl)carbamate (200.mg, 20%) as a white solid.

Step 2. (2-Amino-3-(4-fluoro-cyclohexyl)-propyl)-methyl-carbamic acid benzyl ester

A solution of benzyl (S)-2-(t-butoxycarbonylamino)-3-(trans-4-fluorocyclohexyl)-propyl(methyl)carbamate (200 mg, 0.47 mmol) in TFA/CH_2Cl_2 (15 mL, v/v 20%) was stirred for 1 h at rt, then quenched by addition of sat'd aq $NaHCO_3$ solution until gas evolution ceased. The mixture was extracted with CH_2Cl_2 (2 x 50 mL). The combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure to obtain benzyl (S)-2-amino-3-(trans-4-fluorocyclohexyl)propyl(methyl)carbamate (140 mg, yield 93%). ^{1}HNMR ($CDCl_3$, 400 MH_Z): δ 1.42(m, 4 H), 1.64(m, 4 H), 2.98(d, 3 H), 3.21(m, 1 H), 3.50(m, 1 H), 3.90(m, 1 H), 5.13(d, 2 H), 7.33(m, 5 H).

PREPARATION G

(S)-2-(trimethylsilyl)ethyl 2-amino-3-(3-noradamantyl)propyl(methyl)carbamate



Step 1a-c. 3-(3-noradamantyl)propanoic acid

A 250-mL flask was charged with 3-noradamantylcarboxaldehyde (3.3g, 22 mol), Ph_3PCHCO_2Me (9.2 g, 27.5 mmol, 1.25 equiv) and $CHCl_3$ (100 mL). The mixture was heated to reflux for 18 h. The clear solution was allowed to cool to ambient and evaporated. The sticky residue was taken up in 4:1 hexanes/EtOAc (200 mL) and filtered through a pad of silica gel. The pad was washed with additional 4:1 hexanes/EtOAc (200 mL) and the filtrate was evaporated. The product was isolated by flash chromatography on 120 g of silica, eluting with 0-17% EtOAc in hexanes. This afforded (E)-methyl 3-(3-noradamantyl)acrylate (4.13 g, 0.2 mmol, 90%).

A 500-mL pressure bottle was charged with (E)-methyl 3-(3-noradamantyl)acrylate (7.8 g, 37.8 mmol), 10% Pd/C (1.8 g), and (MeOH) 100 mL. The bottle was fitted to a Parr hydrogenation shaker, pressurized to 50 psi with H_2, and evacuated. The fill/evacuation procedure was repeated 3 x, and the apparatus pressurized with 50 psi H_2 and shaken for 3h. After this time tlc analysis showed no remaining enoate. The mixture was filtered through a pad of celite. The spent catalyst was washed with additional methanol and the combined filtrates were evaporated to yield methyl 3-(3-noradamantyl)propanoate (7.8 g, 37.8 mmol) in quantitative yield.

Methyl 3-(3-noradamantyl)propanoate (7.8 g, 37.8 mmol) was dissolved in THF (150 mL) and the solution was cooled to 0 °C. To this was added 1.0 M aqueous LiOH (148 mL). The biphasic reaction mixture was vigorously stirred at 0 °C. After 3 h, a homogeneous solution was produced and LC-MS analysis showed no ester remained. The pH of the solution was lowered to ~4 by the dropwise addition of concentrated HCl. The mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with EtOAc (4 x 30 mL). The combined organic layers were dried over Na_2SO_4, filtered, and evaporated to afford 3-(3-noradamantyl)propanoic acid (7.15 g, 36.8 mmol) as a tacky solid.

Step 2 . (S)-4-benzyl-3-(3-(3-noradamantyl)propanoyl)oxazolidin-2-one

3-(3-Noradamantyl)propanoic acid (7.15 g, 36.8 mmol, 1.0 equiv) was dissolved in THF (70 mL) and the solution was cooled to 0 °C. To the stirred solution were added N-methylmorpholine (4.25 mL, 38.7 mmol, 1.05 equiv) and isobutyl chloroformate (4.52 mL, 38.7 mmol, 1.05 equiv). A white precipitate rapidly formed and the mixture containing the 3-(noradamantyl)propanoic(isobutylcarbonic) anhydride was allowed to stir for 0.5 h at 0 °C. A separate 500-mL 3-neck flask was charged with S-(-)-4-benzyloxazolidinone (8.5 g, 47.8 mmol, 1.35 equiv) and THF (100 mL). The mixture was cooled to -78 °C and ^{n}BuLi (19.1 mL of a 2.5 M solution) was added over a 10 min period. This was allowed to stir for 0.5 h at -78 °C. The first solution was rapidly filtered through a pad of Celite and the resulting clear filtrate transferred via cannula to the solution of the deprotonated oxazolidinone. After stirring for 0.5 h at -78 °C. LC-MS analysis showed consumption of the mixed anhydride. The mixture was quenched with brine and allowed to warm to rt. The mixture was transferred to a separatory funnel. The organic layer was separated and evaporated. Flash chromatography (120 g SiO_2, 0-27% EtOAc in hexanes) afforded (S)-4-benzyl-3-(3-(3-noradamantyl)propanoyl)oxazolidin-2-one.

Step 3a-d. tert-butyl (S)-1-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(3-noradamantyl)-1-oxopropan-2-ylcarbamate

A solution of LDA was generated by charging an oven-dried 50-mL flask with dry THF (10 mL) and diisopropylamine (152 mg, 1.5 mmol, 1.5 equiv). The mixture

was cooled to -0 °C and ^{n}BuLi (2.5 M, 0.6 mL, 1.5 mmol, 1.5 equiv) added dropwise over 5 min. The mixture was stirred for 0.5 h and cooled to -78 °C. A solution of (S)-4-benzyl-3-(3-(3-noradamantyl)propanoyl)oxazolidin-2-one (335 mg, 1.0 mmol, 1.0 equiv) in THF (9 mL) was cooled to -78 °C and added to the solution of LDA via cannula. The mixture was allowed to stir for 0.5 h. A separate flask was charged with $^{t}BuCO_2N{=}NCO_2{}^{t}Bu$ (345 mg, 1.5 mmol, 1.5 equiv) and THF (9 mL) and cooled to –78 °C. This solution was transferred to the enolate solution with the aid of a cannula. The resulting mixture was allowed to stir at -78 °C for 0.5 h. Tlc analysis showed consumption of the starting material. The mixture was quenched with HOAc (0.5 mL), and allowed to warm to rt. The solution was transferred to a separatory funnel and the organic layer was washed with water and brine, dried over Na_2SO_4 and filtered. The product was purified by flash chromatography on SiO_2, eluting with 0-37% EtOAc in hexanes. This yielded di-tert-butyl 1-((S)-1-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(3-noradamantyl)-1-oxopropan-2-yl)hydrazine-1,2-dicarboxylate (477 mg, 0.82 mmol, 82%).

The Boc protected hydrazine was dissolved in 3:1 CH_2Cl_2/TFA (20 mL) and stirred for 4 h. LC-MS analysis showed only the presence of the desired product. The mixture was evaporated to afford (S)-4-benzyl-3-((S)-3-(3-noradamantyl)-2-hydrazinylpropanoyl)oxazolidin-2-one as its TFA salt which was used directly in the next step.

The hydrazine TFA salt was dissolved in EtOH (10 mL) of and transferred to a Parr hydrogenation shaker. PtO_2 (56 mg, 0.25 mmol, 0.3 equiv) was added and the vessel pressurized to 60 psi with H_2, and evacuated. The fill/evacuation procedure was repeated 3 times, and then the apparatus pressurized with 60 psi H_2 and shaken for 4 h. After this time the hydrazine was no longer observed in the LC/MS. The mixture was filtered and evaporated to give crude (S)-3-((S)-2-amino-3-cyclopentylpropanoyl)-4-benzyloxazolidin-2-one which was used without purification.

Crude (S)-3-((S)-2-amino-3-cyclopentylpropanoyl)-4-benzyloxazolidin-2-one from the previous step was dissolved in 1:1 acetonitrile/10% aqueous K_2CO_3 (20 mL). Boc_2O (327 mg, 1.5 mmol, 1.8 equiv) was added and mixture was stirred for 4h. LC-MS showed consumption of the free amine. The acetonitrile was removed *in vacuo* and the product was extracted with EtOAc (2 x 20 mL). The combined organic extracts

were dried over Na_2SO_4, filtered, and evaporated. Flash chromatography afforded tert-butyl (S)-1-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(3-noradamantyl)-1-oxopropan-2-ylcarbamate (148 mg, 0.32 mmol).

Step 4a-e. (S)-2-(trimethylsilyl)ethyl 2-amino-3-(3-noradamantyl)propyl(methyl)carbamate

tert-butyl (S)-1-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(3-noradamantyl)-1-oxopropan-2-ylcarbamate (2.0 g, 4.23 mmol) was dissolved in THF and the solution was cooled to 0 °C. Methanol (250 μL) was added, followed by a solution of $LiBH_4$ (2.0 M in THF, 8.6 mL, 4.0 equiv). The mixture was allowed to stir at 0 °C until LC-MS analysis indicated that the starting material had been consumed. Excess $LiBH_4$ was quenched by addition of satd aq NH_4Cl and the contents were transferred to a separatory funnel. The layers were separated, the aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na_2SO_4, filtered and evaporated. The protected residue was purified by flash chromatography on silica, eluting with 0-29% EtOAc in hexanes. This afforded (S)-tert-butyl 1-(3-noradamantyl)-3-hydroxypropan-2-ylcarbamate (1.24 g, >98%).

(S)-tert-butyl 1-(3-noradamantyl)-3-hydroxypropan-2-ylcarbamate (75 mg, 0.25 mmol, 1.0 equiv) was dissolved in CH_2Cl_2 and cooled to 0 °C. Triethylamine (101 mg, 1.0 mmol, 4.0 equiv) was added, followed by methanesulfonyl chloride (58 mg, 0.50 mmol, 2.0 equiv). The mixture was allowed to stir till the starting material was consumed by LC.MS analysis. The mixture was quenched by addition of satd aq NH_4Cl and the contents were transferred to a separatory funnel. The layers were separated and the organic layer was washed with brine, dried over Na_2SO_4, filtered, and evaporated to afford (S)-2-(tert-butoxycarbonylamino)-3-(3-noradamantyl) methanesulfonate which was used directly in the next step.

The crude mesylate was dissolved in of 33 wt % methylamine in ethanol (20 mL). The mixture was heated to reflux overnight. The solution was evaporated and the residue was taken up in EtOAc. The solution was washed with saturated $NaHCO_3$ and brine, and evaporated to afford crude (S)-tert-butyl 1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamate which was used directly in the next step.

The crude amine was dissolved in 1:1 acetonitrile/10% aqueous K_2CO_3 (20 mL). TeocOSu (97 mg, 0.375 mmol, 1.5 equiv) was added and mixture was stirred for 4h. LC-MS showed consumption of the free amine. The acetonitrile was removed *in vacuo* and the aqueous residue was extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over Na_2SO_4, filtered, and evaporated. The product was isolated by flash chromatography on silica eluting with 0-27% EtOAc. (S)-2-(trimethylsilyl)ethyl 2-(t-butoxycarbonylamino)-3-(3-noradamantyl)propyl(methyl)carbamate (36 mg, 0.080 mmol, 32 % yield for Steps 4b-d) was isolated.

(S)-2-(trimethylsilyl)ethyl 2-(t-butoxycarbonylamino)-3-(3-noradamantyl)propyl(methyl)carbamate (36 mg, 0.080 mmol, 1.0 equiv) was dissolved in MeOH (5 mL). Toluenesulfonic acid hydrate (16 mg, 0.088 mmol, 1.1 equiv) was added and the solvent was removed at 65 °C under vacuum to afford (S)-2-(trimethylsilyl)ethyl 2-amino-3-(3-noradamantyl)propyl(methyl)carbamate. This material was used without purification.

PREPARATION H

2-(trimethylsilyl)ethyl (2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamate



Step 1. 2-(iodomethyl)tetrahydro-2H-pyran

A CH_2Cl_2 solution of (tetrahydro-2H-pyran-2-yl)methanol (7.91 g, 68.1 mmol), Et_3N (14 mL, 102 mmol), and catalytic DMAP was treated with 4-bromobenzenesulfonyl chloride (14.3 g, 74.9 mmol). After 2 h, the reaction was quenched with water. The organic layer was washed with 1M HCl and brine, dried over Na_2SO_4, filtered, and concentrated. The crude material was purified by

chromatography on silica gel (EtOAc/Hex) to afford ((tetrahydro-2H-pyran-2-yl)methyl 4-bromobenzenesulfonate as an oil (16 g).

A solution of ((tetrahydro-2H-pyran-2-yl)methyl 4-bromobenzenesulfonate (16 g, 48 mmol) in acetone (250 mL) was treated with sodium iodide (73 g, 48 mmol). The solution was heated at 40 °C for 24 h. The reaction was cooled to rt and the acetone was removed under reduced pressure. The residue was dissolved in hexane and water. The aqueous layer was extracted with hexane three times. The combined organic extracts were dried over Na_2SO_4, filtered and concentrated. The residue was passed through a plug of silica gel, eluting with hexanes several times. After solvent removal, 2-(iodomethyl)tetrahydro-2H-pyran was isolated as an oil (10 g). ^{13}C NMR (400MHz, $CDCl_3$): 77.2, 68.8, 31.7, 25.6, 23.2, 10.0.

Step 2. (2S)-methyl 2-(*tert*-butoxycarbonylamino)-3-(tetrahydro-2H-pyran-2-yl)propanoate

To a solution of (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine in THF at -78 °C, *n*-BuLi (16 mL, 2.5 M in Hexanes) was added dropwise. The mixture was stirred for 1 h and a solution of 2-(iodomethyl)tetrahydro-2H-pyran in THF (6 mL) was added. The reaction flask was transferred to a -20 °C freezer and allowed to stir for 72 h. The reaction was quenched with satd aq NH_4Cl and the aqueous solution was extracted with ether. The combined organic layers were dried over Na_2SO_4. The solvent was removed under reduced pressure and the crude product was purified by chromatography on silica gel (EtOAc/Hex). The product was dissolved in acetonitrile (50 mL) and 2 M aq HCl (50 mL) and stirred at rt for 4 h. The solvent was evaporated and the crude material redissolved in water (100 mL) and THF (100mL). The solution was chilled to 0 °C and K_2CO_3 (23 g, 166 mmol) was added in portions, followed by addition of di-*tert*-butyl dicarbonate (22.6 g, 104 mmol). The mixture was allowed to warm rt and stirred for several hours. The aqueous layer was extracted with EtOAc (3 x). The combined organic layers were washed with brine, dried over $MgSO_4$, filtered, and concentrated. The crude product was purified by chromatography on silica gel (EtOAc/Hex) to afford (2S)-methyl 2-(*tert*-butoxycarbonylamino)-3-(tetrahydro-2H-pyran-2-yl)propanoate (6.61 g). MS m/z 310 (M+Na).

Step 3. *tert*-butyl (2S)-1-hydroxy-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamate

(2S)-methyl 2-(*tert*-butoxycarbonylamino)-3-(tetrahydro-2H-pyran-2-yl)propanoate (3.88 g, 13.52 mmol) was dissolved in 4 N HCl in dioxane (4 mL). After deprotection was complete the solvent was evaporated. The crude material was redissolved in CH_2Cl_2 and neutralized with aq $NaHCO_3$. The aqueous layer was extracted with CH_2Cl_2 (3 x). The combined organic layers were dried over Na_2SO_4, and filtered. After solvent removal, the crude (2S)-methyl 2-amino-3-(tetrahydro-2H-pyran-2-yl)propanoate was used without any further purification. MS m/z 188 (M+1).

At -78 °C, (2S)-methyl 2-amino-3-(tetrahydro-2H-pyran-2-yl)propanoate (1.84 g, 7.74 mmol) in THF (16 mL) was treated with lithium aluminum hydride (8 mL, 1 M in THF) at a rate such that the temperature remained below -65 °C. The reaction was allowed to warm to rt. Upon completion, the reaction was cooled to 0 °C and quenched by dropwise addition of water, avoiding a rise in temperature above 2 °C, the slurry was then stirred for an additional 1 h. The emulsion was dispersed by stirring with 1 M aq NaOH for 30 min, allowing warming to rt. Celite was added and stirred. The slurry was filtered through celite and washed several times with diethyl ether. The filtrate was concentrated to provide (2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propan-1-ol as an oil and used without any further purification. A solution of (2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propan-1-ol in THF (20 mL) and water (20 mL) was cooled to 0 °C. Potassium carbonate (3.2 g, 23.2 mmol) was added, followed by di-*tert*-butyl dicarbonate (2.2 g, 10.06 mmol). The reaction was subsequently warmed to rt and stirred for 2 h. The aqueous layer was extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried over $MgSO_4$, and filtered. After solvent removal the crude material was purified by chromatography on silica gel (EtOAc/Hex) to afford *tert*-butyl (2S)-1-hydroxy-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamate (1.41 g) as an oil. MS m/z 282 (M+Na).

Step 4. 2-(trimethylsilyl)ethyl (2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamate

At 0 °C, *tert*-butyl (2S)-1-hydroxy-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamate (1.41 g, 5.44 mmol) in CH_2Cl_2 (50 mL) was treated with Et_3N (2.3 mL, 16.3 mmol) followed by methanesulfonyl chloride (1.1 mL, 13.6 mmol). The reaction was allowed to stir for 1 h and quenched with water. The organic layer was washed with satd aq $NaHCO_3$ and brine, dried over Na_2SO_4, and filtered. After removal of solvent, the crude material was purified using chromatography on silica gel (EtOAc/Hex) to afford (2S)-2-(*tert*-butoxycarbonylamino)-3-(tetrahydro-2H-pyran-2-yl)propyl methanesulfonate (0.90 g) as a solid. MS m/z 360 (M+Na).

The mesylate (0.90 g, 2.66 mmol) and sodium azide (0.89 g, 13.3 mmol) were dissolved in DMF (30 mL). The mixture was heated at 60 °C for 4 h. The reaction was treated with ice water (100 mL) and extracted with EtOAc (3 x). The organic layer was dried over $MgSO_4$ and filtered. The solvent was removed under reduced pressure and the product was used without any further purification. At -78 °C, a solution of the azide (~2.66 mmol) in THF (20 mL) was treated with $LiAlH_4$ (3.1 mL, 1M in THF). The reaction was allowed to warm to 0 °C over several hours. The reaction was quenched by the addition of brine at 0 °C. Celite was added to the emulsion and stirred for several hours before filtering through a bed of celite. Evaporation of solvent afforded *tert*-butyl (2S)-1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamate which was used without further purification. MS m/z 259 (M+1).

A solution of the amine was dissolved in CH_2Cl_2 (13 mL) and water (5 mL). The solution was treated with K_2CO_3 (2.20 g, 15.9 mmol) and 1-[2-trimethylsilyl)ethoxycarbonyloxy] pyrrolidin-2,5-dione (1.24 g, 4.79 mmol). The reaction was stirred for 1 h. The layers were separated and the organic layer was washed with water. After removal of solvent the crude material was redissolved in diethyl ether (2 mL) and ethanol (30 mL). The solution was treated with *p*-toluenesulfonic acid (0.53 g, 2.71 mmol) and placed on a rotary evaporator with a 60 °C water bath. The solvent was removed. Additional solvent was added and removed as above until complete removal of the Boc group had occurred. The crude material was redissolved in CH_2Cl_2 and washed with satd aq $NaHCO_3$. The aqueous layer was extracted with CH_2Cl_2 (3 x). The combined organic layers were washed with brine,

dried over Na_2SO_4, and concentrated. The crude product was purified by chromatography on silica gel (10% MeOH/ CH_2Cl_2) to afford 2-(trimethylsilyl)ethyl (2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamate (0.62g) as an oil. MS m/z 303 (M+1).

The following compounds were prepared following procedures analogous to those described above:

2-(trimethylsilyl)ethyl (2S)-2-amino-3-(tetrahydro-2H-pyran-4-yl)propylcarbamate using (tetrahydro-2H-pyran-4-yl)methanol in the first step.

PREPARATION I

tert-Butyl (2R,3S)-2-amino-3-cyclohexyl-3-(trimethylsilyloxy)propyl(methyl)carbamate



Step 1. Potassium phthalimide

A three-neck round-bottomed flask fitted with a reflux condenser was charged with phthalimide (80 g, 0.54 mole) and absolute ethanol (1600 mL). The mixture was gently boiled for about 15 min or until no more of the phthalimide dissolved. The hot

solution was decanted from any solid into a specially prepared solution of 30.5 g (0.54 mol) of potassium hydroxide. A precipitate of potassium phthalimide separated at once. The mixture was stirred and cooled quickly to rt, and the precipitate was filtered with suction. To the alcoholic mother liquors a second portion of phthalimide (80 g) was added, and the entire process was repeated. The two crops of crystals were combined and washed with acetone (200 mL) to remove any unchanged phthalimide. Air-dried potassium phthalimide was obtained (170 g, 92%).

Step 2. 2-(2,2-diethoxyethyl)isoindoline-1,3-dione

A three-necked round-bottomed flask fitted with an efficient stirrer and a reflux condenser was charged with potassium phthalimide (150 g, 0.81 mol) and 2-bromo-1,1-diethoxy-ethane (196 g, 1.0 mol) and DMF (500 mL). The stirrer was started and the mixture was heated for about 3-4 h in an oil bath maintained at 150 °C. The solvent DMF was removed under reduced pressure. The residue was purified by column chromatography to afford pure 2-(2,2-diethoxyethyl)isoindoline-1,3-dione (185 g, yield 87%). ^{1}H NMR (400MHz, MeOD): 1.16 (t, 6H), 3.48-3.60 (m, 2H), 3.68-3.75 (m, 2H), 3.76-3.89 (d, 2H), 4.89 (t, 1H), 7.68-7.75 (m, 2H), 7.85-7.96 (m, 2H). MS (E/Z): 264 ($M+H^+$).

Step 3. 2-(1,3-dioxoisoindolin-2-yl)acetaldehyde

2-(2,2-diethoxyethyl)isoindoline-1,3-dione (40.00 g, 0.15 mol) was dissolved in 85 % formic acid (150 mL) and the mixture was stirred for 2 h at rt. After tlc analysis indicated full conversion to the aldehyde (2,4-DNP stain used for visualization), the solvent was removed and the resultant solid was dried at 150 mm torr vacuum to give 2-(1,3-dioxoisoindolin-2-yl)acetaldehyde (27 g, 95%).

Step 4. (2S,3S)-3-cyclohexyl-2-(1,3-dioxoisoindolin-2-yl)-3-hydroxypropanal

2-(1,3-dioxoisoindolin-2-yl)acetaldehyde (2.04 g, 10.7 mmol) was dissolved into a minimal amount of anhydrous N-methylpyrrolidinone (5. 0 mL). Heating was required for full dissolution. The solution was cooled to rt and cyclohexanecarboxaldehyde (5.60 g, 50 mmol) was added. The solution was cooled to 0 °C and solid L-proline (0.40 g, 3.4 mmol) was added in one portion. The reaction

was stirred for 1 h at 0 °C and the orange mixture was stored in the refrigerator (6 °C) for 36 h. The crude reaction was taken up in 5:1 Et_2O/Hexanes (100 mL) and water (20 mL). The layers were separated and the aqueous phase mixture was extracted with 5:1 Et_2O/Hexanes (3 x 10 mL). The combined organic layers were washed with water (5 x10 mL) and brine (3 x 10 mL), dried over Na_2SO_4, decanted and stripped to give crude (2S,3S)-3-cyclohexyl-2-(1,3-dioxoisoindolin-2-yl)-3-hydroxypropanal (4.55 g), which was used in the next step without purification.

Step 5. 2-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-yl)isoindoline-1,3-dione

Crude (2S,3S)-3-cyclohexyl-2-(1,3-dioxoisoindolin-2-yl)-3-hydroxypropanal (3.22 g, 10.7 mmol, calculated according to theoretical yield) was dissolved in anhydrous THF (20 mL). The solution was cooled to 0 °C. Acetic acid (5.5 mL, 90mmol), methylamine solution (33% in EtOH, 5.0 mL, 40.0 mmol) and $NaHB(OAc)_3$ (8.80 g, 40.0 mmol) were added sequentially and in single portions. The ice bath was removed and the mixture was stirred for 2 h at rt. The solvent was stripped and the crude 2-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-yl)isoindoline-1,3-dione (6.45 g) was used directly in the next step.

Step 6. *tert*-Butyl (2R,3S)-3-cyclohexyl-2-(1,3-dioxoisoindolin-2-yl)-3-hydroxypropyl(methyl)carbamate

Crude 2-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-yl)isoindoline-1,3-dione (3.38 g, 10.7 mmol) was dissolved in THF (20 mL). A solution of K_2CO_3 (13.8 g, 100 mmol) in water (40 mL) was added followed by Boc_2O (10.9 g, 50 mmol). The two phase system was stirred for 1 h at rt. The reaction was extracted with Et_2O (2 x 30 mL). The combined organic extracts were washed with satd aq $NaHCO_3$ (40 mL) and brine, dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography to give pure *tert*-butyl (2R,3S)-3-cyclohexyl-2-(1,3-dioxoisoindolin-2-yl)-3-hydroxypropyl(methyl)carbamate (1.02 g, 22.9%). ^1H NMR (400MHz, MeOD): 7.70-7.95 (m, 4H), 4.05-4.50 (m, 3H), 3.20-3.45 (m, 1H), 2.80-2.86 (s, 3H), 1.10-1.80 (m, 11H), 1.00-1.10 (s, 9H). MS (E/Z): 417.3 ($M+H^+$).

Step 7. *tert*-Butyl (2R,3S)-2-amino-3-cyclohexyl-3-hydroxypropyl(methyl)carbamate

tert-butyl (2R,3S)-3-cyclohexyl-2-(1,3-dioxoisoindolin-2-yl)-3-hydroxypropyl(methyl)carbamate (500 mg, 1.20 mmol) was dissolved into a minimal volume of EtOH (12 mL) and hydrazine monohydrate (85% in EtOH, 0.35 mL, 6.00 mmol) was added. The solution was heated at 55 °C for 45 min and then the reaction temperature was raised to reflux for 2 h. A white solid formed. The reaction was cooled to rt, Et_2O (50 mL) was added and the reaction was filtered. The filtrate was stripped and the residue was stirred in Et_2O (15 mL) for 1 h and filtered. The filtrate was stripped to afford *tert*-butyl (2R,3S)-2-amino-3-cyclohexyl-3-hydroxypropyl(methyl)carbamate (300 mg, yield 87%), which was pure enough to use directly in the next step. MS (E/Z): 287 ($M+H^+$).

Step 8. *tert*-Butyl (2R,3S)-2-amino-3-cyclohexyl-3-(trimethylsilyloxy)propyl(methyl)carbamate

To a solution of crude *tert*-butyl (2R,3S)-2-amino-3-cyclohexyl-3-hydroxypropyl(methyl)carbamate (300 mg, 1.05 mmol) in anhydrous THF was added pyridine (846 μL, 10.50 mmol) and TMSCl (663 μL , 5.25 mmol). The mixture was heated to 60 °C and maintained for 20 min, then quenched with satd aq $NaHCO_3$ (5 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over $NaSO_4$, and concentrated to afford *tert*-butyl (2R,3S)-2-amino-3-cyclohexyl-3-(trimethylsilyloxy)propyl(methyl)carbamate (350 mg, yield 93.1%). ^1H NMR (400MHz, MeOD): 0.13 (s, 9H), 0.80-1.40 (m, 6H), 1.40 (s, 9H), 1.50-2.10 (m, 5H), 2.90 (s, 3H), 3.15-3.50 (m, 4H). MS (E/Z): 359.0 ($M+H^+$).

PREPARATION J

(S)-2-(trimethylsilyl)ethyl 2-(t-butoxycarbonylamino)-3-(1-fluorocyclohexyl)propyl(methyl)carbamate



Step 1. (S)-tert-butyl 4-((1-hydroxycyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate

A 250-mL, round-bottom flask was charged with (S)-tert-butyl 4-(2-methoxy-2-oxoethyl)-2,2-dimethyloxazolidine-3-carboxylate (7.0 g, 25.6 mmol) and THF (150 mL). The solution was cooled to 0°C and a solution of 1,5-bis(brmomagnesio)pentane (0.5 M in THF, 64 mL, 32.6 mmol, 1.25 equiv) was added over a 30 min period with the aid of a syringe pump. After 3h, LC-MS analysis showed consumption of the starting ester and indicated formation of a ca 4:1 mixture of the desired (S)-tert-butyl 4-((1-hydroxycyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate and (4S)-*tert*-butyl 4(2-hydroxyheptyl)-2,2-dimethyloxazolidinone-3-carboxylate. The excess Grignard reagent was quenched with water and the layers were separated. The organic layer was washed with brine, dried over Na_2SO_4, filtered and evaporated. Flash chromatography on silica, eluting with 0-29% EtOAc, afforded (S)-tert-butyl 4-((1-hydroxycyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate.

Step 2. (S)-tert-butyl 4-((1-fluorocyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate

(S)-tert-Butyl 4-((1-hydroxycyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate (2.70 g, 8.63 mmol) was dissolved in CH_2Cl_2 and the solution was cooled to -78 °C. DAST (2.78 g, 17.2 mmol, 2.0 equiv) was added via syringe and the solution

was stirred overnight with concomitant warming to rt. LC-MS showed consumption of the starting alcohol. Satd aq $NaHCO_3$ was added and the mixture was stirred for 1 h. The layers were separated and the organic layer was washed with brine, dried over Na_2SO_4, and filtered. The resulting solution was treated with m-CPBA (1.5 g, 8.6 mmol) and stirred for 3 h. After this time the olefinic by-products from the fluorination were consumed. The excess m-CPBA was quenched by addition of 10% aq $Na_2S_2O_3$ (50 mL). The layers were separated and the organic layer was washed with satd aq $NaHCO_3$ and brine, dried over Na_2SO_4, filtered and evaporated. Flash chromatography on silica, eluting with 0-29% EtOAc in hexanes, afforded (S)-tert-butyl 4-((1-fluorocyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate (725 mg).

Step 3. (S)-tert-butyl 1-(1-fluorocyclohexyl)-3-hydroxypropan-2-ylcarbamate

(S)-tert-butyl 4-((1-fluorocyclohexyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate (1.1 g, 3.50 mmol, 1.0 equiv) was dissolved in methanol (30 mL). To this mixture was added camphorsulfonic acid (202 mg, 0.875 mmol, 0.5 equiv) and the solution was stirred at rt for 3 h. After this time the starting material was consumed. Satd aq $NaHCO_3$ was added and the methanol was removed *in vacuo*. The aqueous residue was extracted with EtOAc (3 x 10 mL) and the combined organic extracts were washed with brine, dried over Na_2SO_4, filtered and evaporated. Flash chromatography on silica, eluting with 0-47% EtOAc in hexanes, afforded (S)-tert-butyl 1-(1-fluorocyclohexyl)-3-hydroxypropan-2-ylcarbamate (275 mg).

Step 4. (S)-2-(tert-butoxycarbonylamino)-3-(1-fluorocyclohexyl)propyl methanesulfonate

(S)-tert-butyl 1-(1-fluorocyclohexyl)-3-hydroxypropan-2-ylcarbamate (275 mg, 1.0 mmol, 1.0 equiv) was dissolved in CH_2Cl_2 and the mixture was cooled to 0 °C. To this solution was added methanesulfonyl chloride (230 mg, 2.0 mmol, 2.0 equiv) and triethylamine (304 mg, 3.0 mmol, 3.0 equiv). The mixture was stirred at 0 °C for 0.5 h. After this time LC/MS showed consumption of the starting material. The mixture was transferred to a separatory funnel and 1.0 M aq HCl added. The layers were separated and the organic layer was washed with brine, dried over Na_2SO_4, filtered and evaporated. The crude (S)-2-(tert-butoxycarbonylamino)-3-(1-fluorocyclohexyl)propyl methanesulfonate was used directly in the next step.

Step 5. (S)-tert-Butyl 1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamate

Crude (S)-2-(tert-butoxycarbonylamino)-3-(1-fluorocyclohexyl)propyl methanesulfonate and $(n\text{-}Bu)_4N^+I^-$ (249 mg, 1.0 mmol) were dissolved in 33% methylamine in ethanol (50 mL). The mixture was heated to 50 °C for 17 h. The solution was cooled to rt and the volatile materials were removed *in vacuo*. The residue was dissolved in ether, washed with brine, dried over Na_2SO_4, filtered and evaporated. To afford crude (S)-tert-butyl 1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamate.

Step 6. (S)-2-(trimethylsilyl)ethyl 2-(t-butoxycarbonylamino)-3-(1-fluorocyclohexyl)propyl(methyl)carbamate

Crude (S)-tert-butyl 1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamate and TeocOSu (137 mg, 0.5 mmol) were dissolved in 1:1 CH_3CN/10% aqueous K_2CO_3 (20 mL). The mixture was stirred for 2 h. After this time all of the free amine was consumed. The CH_3CN was removed *in vacuo* and the aqueous residue extracted with EtOAc (3x10 mL). The combine organic extracts washed with brine, dried over Na_2SO_4, filtered and evaporated. Flash chromatography on silica, eluting with 0-27% EtOAc in hexanes, afforded (S)-2-(trimethylsilyl)ethyl 2-(t-butoxycarbonylamino)-3-(1-fluorocyclohexyl)propyl(methyl)carbamate (70 mg).

PREPARATION K

(S)-tert-butyl 1-(p-nitrophenoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate



Step 1. (S)-tert-butyl 1-(2-(trimethylsilyl)ethoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate

To a stirred mixture of (S)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropylcarbamate (4.61 g, 15.4 mmol), dioxane (50 mL) and 10% aq K_2CO_3 (50 mL) was added solid Boc_2O (3.50 g, 15.4 mmol). The mixture was stirred at rt for 18 h. Dioxane was removed on the rotary evaporator and the aqueous residue was extracted with ether (175 mL). The ether layer was washed with 5% aq HCl (50 mL), satd aq $NaHCO_3$ (50 mL) and brine (50 mL) and dried over $MgSO_4$. Removal of the solvent afforded (S)-tert-butyl 1-(2-(trimethylsilyl)ethoxycarbonyl-amino)-3-cyclohexylpropan-2-ylcarbamate (6.55 g, quant) as a yellow oil.

Step 2. (S)-tert-butyl 1-amino-3-cyclohexylpropan-2-ylcarbamate

To a stirred solution of (S)-tert-butyl 1-(2-(trimethylsilyl)ethoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate (6.55 g, 15.4 mmol) in MeCN (100 mL) was added Et_4NF (7.5 g, 50 mmol). The mixture was stirred overnight at rt and at 60°C for 7 h. The mixture was concentrated and the oily residue was taken up in EtOAc (175 mL). The mixture was washed with water (2 x 50 mL) and brine (50 mL) and dried over Na_2SO_4. Removal of the solvent afforded (S)-tert-butyl 1-amino-3-cyclohexylpropan-2-ylcarbamate (3.39 g, 80%) as a syrup.

Step 3. (S)-tert-butyl 1-(p-nitrophenoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate

To a stirred solution of (S)-tert-butyl 1-amino-3-cyclohexylpropan-2-ylcarbamate (0.65 g, 2.54 mmol) in MeCN (20 mL) and THF (5 mL) was added

powdered $NaHCO_3$ (0.43 g, 5.08 mmol) followed by a solution of p-nitrophenyl chloroformate (0.51 g, 5.08 mmol) in MeCN (20 mL) dropwise over 10 min. The mixture was stirred at rt for 2 h, filtered through a pad of Celite and concentrated to leave a white solid. This material was purified by chromatography on a 40-g silica cartridge eluted with a gradient from 0-100% EtOAc in hexanes to afford (S)-tert-butyl 1-(p-nitrophenoxycarbonylamino)-3-cyclohexylpropan-2-ylcarbamate (0.67 g, 67%) as an off-white solid.

The following compounds were prepared using procedures analogous to those described above:
tert-butyl (2S)-1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamate using 2-(trimethylsilyl)ethyl (2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamate in Step 1.

PREPARATION L

4-Nitrophenyl (S)-3-cyclohexyl-1-((2-(trimethylsilyl)ethylcarbamate)methylamino)propan-2-yl)carbamate



A 100-mL round bottom-flask was charged with diisopropylethylamine (820 mg, 6.34 mmol, 2.0 equiv), 2-(trimethylsilyl)ethyl (S)-2-amino-3-cyclohexylpropylmethylcarbamate (996 mg, 3.17 mmol, 1.0 equiv) and CH_2Cl_2 (30 mL) The resulting solution was cooled to 0 °C and a solution of 4-nitrophenylchloroformate (733 mg, 3.64 mmol, 1.15 equiv) in CH_2Cl_2 (20 mL) was added at a rate such that the internal temperature did not rise above 5°C. After 1h an aliquot was examined by LC-MS which showed no unreacted starting material. The reaction was quenched with water and the layers were separated. The organic layer was washed with of 5% aq K_2CO_3 (2 x 40 mL), 0.25 M aq HCl, and brine, dried over Na_2SO_4 and evaporated. Excess 4-nitrophenyl-chloroformate was removed by flash chromatography on silica, eluting with 0 to 10% methanol in CH_2Cl_2. This afforded 4-

nitrophenyl (S)-3-cyclohexyl-1-((2-(trimethylsilyl)ethylcarbamate)-methylamino)propan-2-yl)carbamate (990 mg, 65%). MS ESI +ve m/z 503 ($M+Na^+$).

PREPARATION M

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropyl(ethyl)-carbamate



Step 1. (*S*)-*tert*-butyl 3-cyclohexyl-1-(ethylamino)-1-oxopropan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 3-cyclohexyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (1.17 g, 4.3 mmol) and TEA (2.4 mL, 17.2 mmol) in anhydrous DMF was added 2.0 M $EtNH_2$ solution in EtOH (6.5 mL, 13 mmol), followed by HBTU (1.96 g, 5.2 mmol). The resulting solution was stirred at rt for 3 h. The reaction was concentrated under reduced pressure and the residue dissolved in EtOAc (50 mL). The mixture was then washed with 1 M NaOH (4 times), 1 M HCl (3 times), sat. aq. $NaHCO_3$, brine, dried over Na_2SO_4 and filtered. The concentrated residue gave (*S*)-*tert*-butyl 3-cyclohexyl-1-(ethylamino)-1-oxopropan-2-ylcarbamate (444 mg, 34%). MS ESI +ve m/z 299 (M+H).

Step 2. (*S*)-*tert*-butyl 1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 3-cyclohexyl-1-(ethylamino)-1-oxopropan-2-ylcarbamate (444 mg, 1.49 mmol) in anhydrous toluene at 0 °C was added Red-Al (65%, 1.39 g, 1.36 mL, 4.47 mmol) over 20 min. After the addition, the reaction was allowed to stir at rt overnight. The reaction was cooled to 0 °C and quenched with $Na_2SO_4 \cdot 10\ H_2O$. The resulting mixture was stirred for 2-3 h, filtered through Celite, and washed with THF (200 mL). The filtrate was dried and concentrated to give crude

product (*S*)-*tert*-butyl 1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamate (338mg, 45% over 2 steps). MS ESI +ve m/z 285 (M+H).

Step 3. (*S*)-2-(trimethylsilyl)ethyl 2-(*N*-*tert*-butoxycarbonyl)amino-3-cyclohexylpropyl(ethyl)carbamate

To a solution of (*S*)-*tert*-butyl 1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamate (338 mg) and TeocOSu (386 mg, 1.49 mmol) in THF was added TEA (0.6 mL). The resulting solution was stirred at rt for 30 min and evaporated. The residue was purified through chromatography on silica gel to give (*S*)-2-(trimethylsilyl)ethyl 2-(*N*-*tert*-butoxycarbonyl)amino)-3-cyclohexylpropyl-(ethyl)carbamate (287 mg , 45% over 2 steps).

Step 4. (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropyl(ethyl)carbamate

To a solution of (*S*)-2-(trimethylsilyl)ethyl 2-(*N*-*tert*-butoxycarbonyl)amino)-3-cyclohexylpropyl(ethyl)carbamate (116 mg, 0.27 mmol) in Et_2O (10 mL) was added TSA (51 mg, 0.30 mmol) in EtOH (1 mL). The solvent was removed at rt and heated to 60 °C under vacuum for 30 min to give (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexylpropyl(ethyl)carbamate as a TsOH salt. MS ESI +ve m/z 329 (M+H).

PREPARATION N

2-(trimethylsilyl)ethyl (2*S*,3*R*)-2-amino-1-cyclohexylpentan-3-yl(methyl)carbamate



Step 1. (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclohexylpropanoic acid

To a solution of (*S*)-2-amino-3-cyclohexylpropanoic acid HCl salt (5.00 g, 24.07 mmol) and TEA (15 mL) in THF (150 mL) was added Boc_2O (5.51 g, 25.28 mmol). The resulting mixture was stirred at rt overnight. The organic solvent was removed under reduced pressure. The residue was dissolved in EtOAc and washed with 1 M HCl, sat. aq. $NaHCO_3$, 10% citric acid, and brine. The organic layer was dried over Na_2SO_4, filtered, and concentrated to give (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclohexylpropanoic acid (6.30g, 96%). MS ESI +ve m/z 272 (M+H).

Step 2. (*S*)-*tert*-butyl 3-cyclohexyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate

To a solution of (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclohexylpropanoic acid (12.1 g, 44.53 mmol) and N,O-dimethylhydroxylamine hydrochloride (5.62 g, 57.89 mmol) in anhydrous DMF (200 mL) was added TEA (20 mL, 145 mmol), HOBt (6.62 g, 48.98 mmol), HBTU (18.58 g, 48.99 mmol. The suspension was stirred at rt for 2 h and concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL), washed with 1 M NaOH (3 × 100 mL), H_2O, 1 M HCl (3 × 100 mL), sat. aq. $NaHCO_3$, brine, and dried over Na_2SO_4, and filtered. The filtrate was concentrated to

give amide (*S*)-*tert*-butyl 3-cyclohexyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (13.04 g, 93%). MS ESI +ve m/z 337 (M+Na).

Step 3. (*S*)-*tert*-butyl 1-cyclohexyl-3-oxopentan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 3-cyclohexyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (5.23 g, 16.66 mmol) in anhydrous toluene (80 mL) at -20 °C was added EtMgBr (3 M in Et_2O, 16.7 mL, 49.97 mmol) slowly. The reaction was allowed to warm to 0 °C, and stirred at this temperature for 2 h. The reaction was quenched with 1 M HCl at 0 °C and extracted with EtOAc. The organic phase was washed with sat. aq. $NaHCO_3$, brine, concentrated to give (*S*)-*tert*-butyl 1-cyclohexyl-3-oxopentan-2-ylcarbamate. The product was used in the next step without further purification. MS ESI +ve m/z 306 (M+Na).

Step 4. (*S*)-*tert*-butyl 1-cyclohexyl-3-hydroxypentan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 1-cyclohexyl-3-oxopentan-2-ylcarbamate in THF/MeOH (60/15 mL) at 0 °C was carefully added $NaBH_4$ (630 mg, 16.66 mmol). After 20 min, sat. aq. NH_4Cl was added to quench the reaction, and extracted with EtOAc, washed with brine, dried over Na_2SO_4, filtered, and concentrated to give (*S*)-*tert*-butyl 1-cyclohexyl-3-hydroxypentan-2-ylcarbamate (4.77 g, 96%, in a ratio of 40:60) as a white solid. MS ESI +ve m/z 286 (M+H).

Step 5. (*S*)-2-(*tert*-butoxycarbonylamino)-1-cyclohexylpentan-3-yl 4-methylbenzenesulfonate

To a mixture of (*S*)-*tert*-butyl 1-cyclohexyl-3-hydroxypentan-2-ylcarbamate (1.067 g, 3.74 mmol), catalytic amount of DMAP, and pyridine (0.651 g, 8.24 mmol) at 0 °C was added TsCl (0.856 g, 4.49 mmol) in CH_2Cl_2 (4 mL) over 2 min. The resulting solution was stirred at rt overnight. The reaction mixture was diluted with EtoAc, washed with 1 M HCl, sat. aq. $NaHCO_3$, brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated and purified by on silica gel chromatography to give (*S*)-2-(*tert*-butoxycarbonylamino)-1-cyclohexylpentan-3-yl 4-methylbenzenesulfonate as a white solid. MS ESI +ve m/z 462 (M+Na).

Step 6. (*S*)-*tert*-butyl 1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamate

A solution of (*S*)-2-(*tert*-butoxycarbonylamino)-1-cyclohexylpentan-3-yl 4-methylbenzenesulfonate (640 mg, 1.46 mmol) in 33% $MeNH_2$ (in EtOH) (0.02 M) was heated to 60 °C for 1 h in a pressure sealed vessel. The solvent was removed under reduced pressure to give (*S*)-*tert*-butyl 1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamate. MS ESI +ve m/z 299 (M+H).

Step 7. (2*S*)-*tert*-butyl 1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)pentan-2-ylcarbamate

To the solution of (*S*)-*tert*-butyl 1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamate in THF (20 mL) was added TeocOSu(398 mg, 1.53 mmol), followed by TEA (0.5 mL). The reaction mixture was stirred for 30 min at rt, and concentrated. The residue was partially purified through chromatography on silica gel to give (2*S*)-*tert*-butyl 1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)pentan-2-ylcarbamate. MS ESI +ve m/z 465 (M+Na).

Step 8. (*S*)-2-(trimethylsilyl)ethyl 2-amino-1-cyclohexylpentan-3-yl(methyl)carbamate

The (2*S*)-*tert*-butyl 1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)pentan-2-ylcarbamate (137 mg, 0.14 mmol) was dissolved in Et_2O (5 mL), anhydrous TSA (24 mg, 0.14 mmol) dissolved in EtOH was added. The solvent was removed *in vacuo* using a hot bath at 60 °C for 30 min to give (S)-2-(trimethylsilyl)ethyl 2-amino-1-cyclohexylpentan-3-yl(methyl)carbamate. MS ESI +ve m/z 343 (M+H).

PREPARATION O

2-(trimethylsilyl)ethyl (2*S*,3*R*)-2-amino-1-cyclohexylpentan-3-ylcarbamate



Step 1. *tert*-butyl (2*S*,3*R*)-3-azido-1-cyclohexylpentan-2-ylcarbamate

To a solution of mixture of *S*-2-(*tert*-butoxycarbonylamino)-1-cyclohexylpentan-3-yl 4-methylbenzenesulfonate (544 mg, 1.24 mmol) in anhydrous DMF was added NaN_3 (241 mg, 3.71 mmol). The resulting solution was heated to 80 °C for 2 h. The reaction was cooled to rt and diluted with EtOAc. The mixture was washed with H_2O, brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated and purified via chromatography on silica gel to give *tert*-butyl (2*S*,3*R*)-3-azido-1-cyclohexylpentan-2-ylcarbamate (second fraction) and (*S*)-*tert*-butyl 3-azido-1-cyclohexylpentan-2-ylcarbamate (first fraction) (in a ratio of 40:60 by LC-MS). The mixed fraction was continuously subjected to silica gel chromatography isolate pure *tert*-butyl (2*S*,3*R*)-3-azido-1-cyclohexylpentan-2-ylcarbamate. MS ESI +ve m/z 311 (M+H).

Step 2. *tert*-butyl (2*S*,3*R*)-3-amino-1-cyclohexylpentan-2-ylcarbamate

A solution of *tert*-butyl (2*S*,3*R*)-3-azido-1-cyclohexylpentan-2-ylcarbamate (64 mg, 0.21 mmol) and 10% Pd/C in methanol (20 mL) was hydrogenated at 40 psi for 1 h. The catalyst was filtered off, and the filtrate concentrated to give *tert*-butyl (2*S*,3*R*)-3-amino-1-cyclohexylpentan-2-ylcarbamate (55 mg, 93%). MS ESI +ve m/z 285 (M+H).

Step 3-4. 2-(trimethylsilyl)ethyl (2*S*,3*R*)-2-amino-1-cyclohexylpentan-3-ylcarbamate

2-(trimethylsilyl)ethyl (2*S*,3*R*)-2-amino-1-cyclohexylpentan-3-ylcarbamate was prepared following procedures analogous to Preparation N, Steps 7-8, using *tert*-butyl

(2*S*,3*R*)-3-amino-1-cyclohexylpentan-2-ylcarbamate in Step 7. MS ESI +ve m/z 329 (M+H).

PREPARATION P

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexyl-2-methylpropylcarbamate



Step 1. (*S*)-2-amino-3-cyclohexyl-2-methylpropanoic acid

(*S*)-2-(*Tert*-butoxycarbonylamino)-2-methyl-3-phenylpropanoic acid (1.95 g, 6.98 mmol) was hydrogenated under H_2 (50 psi), catalyzed by PtO_2 (200 mg), in TFA/H_2O (30/30 mL) overnight. The catalyst was filtered off and concentrated to give (*S*)-2-amino-3-cyclohexyl-2-methylpropanoic acid in quantitative yield. MS ESI +ve m/z 186 (M+H).

Step 2. (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclohexyl-2-methylpropanoic acid

The (*S*)-2-amino-3-cyclohexyl-2-methylpropanoic acid was dissolved in 1 M NaOH (50 mL) and THF (30 mL), to this stirred solution was added Boc_2O (1.60 g, 7.33 mmol), 2 h later another portion of Boc_2O (3.20 g, 14.66 mmol) was added. The reaction was stirred for another 12 h and extracted with hexane to remove excess Boc_2O, the separated aqueous phase was acidified with citric acid and extracted with EtOAc two times. The combined organic phases was washed with brine, and dried over Na_2SO_4, filtered, and evaporated to give (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclohexyl-2-methylpropanoic acid (1.99 g, 100%). MS ESI +ve m/z 186 (M+H).

Step 3. (*S*)-*tert*-butyl 1-amino-3-cyclohexyl-2-methyl-1-oxopropan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 1-amino-3-cyclohexyl-2-methyl-1-oxopropan-2-ylcarbamate (0.814 g, 2.85 mmol) and TEA (1.2 mL, 8.55 mmol) in anhydrous DMF (30 mL) was added 0.8 M NH_3 solution in THF (14 mL), followed by HBTU (1.297 g,

3.42 mmol). The resulting solution was stirred at room temperature for 48 h. Concentrated under reduced pressure to remove most of DMF, the residue was dissolved in EtOAc (50 mL), and washed with 1 M NaOH (3 times), 1 M HCl (3 times), sat. aq. $NaHCO_3$, brine, dried over Na_2SO_4 and filtered, and concentrated to give (*S*)-*tert*-butyl 1-amino-3-cyclohexyl-2-methyl-1-oxopropan-2-ylcarbamate (811 mg, 100%). The product was used in the next step without further purification. MS ESI +ve m/z 285 (M+H).

Step 4. (*S*)-*tert*-butyl 1-amino-3-cyclohexyl-2-methylpropan-2-ylcarbamate

(*S*)-*tert*-butyl 1-amino-3-cyclohexyl-2-methyl-1-oxopropan-2-ylcarbamate To a solution of (*S*)-*tert*-butyl 1-amino-3-cyclohexyl-2-methyl-1-oxopropan-2-ylcarbamate (811 mg, 2.85 mmol) in anhydrous toluene (15 mL) at 0 °C was added Red-Al (65%, 2.66 g, 2.6 mL, 8.55 mmol) within 20 min. After the addition, the reaction was allowed to be stirred at room temperature overnight. The reaction was cooled to 0 °C and quenched with $Na_2SO_4 \cdot 10\ H_2O$. The resulting mixture was stirred for 2-3 h, filtered through Celite, and washed with THF (200 mL). The filtrate was dried and concentrated to give crude product (*S*)-tert-butyl 1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamate (860 mg). MS ESI +ve m/z 271 (M+H).

Step 5-6. (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexyl-2-methylpropylcarbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclohexyl-2-methylpropylcarbamate was obtained using procedures analogous to Preparation M, Steps 3-4, using (*S*)-tert-butyl 1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamate in Step 3. MS ESI +ve m/z 315 (M+H).

PREPARATION Q

(*S*)-*tert*-butyl 2-((*tert*-butyldimethylsilyloxy)methyl)aziridine-1-carboxylate



Step 1. (*R*)-methyl 2-amino-3-hydroxypropanoate hydrochloride salt

To a solution of (*R*)-2-amino-3-hydroxypropanoic acid (105 g, 1 mol) in methanol (1200 mL) was added thionyl chloride (87.6 mL, 142.8 g, 1.2 mol) dropwise at 0 °C. After addition, the reaction mixture was heated at reflux for 12 h. Volatiles were evaporated to give the (*R*)-methyl 2-amino-3-hydroxypropanoate hydrochloride salt (155 g, yield 100%) as a solid that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 8.51 (brs, 2 H), 4.08 (s, 1H), 3.79 (m, 2 H), 3.71 (s, 3 H).

Step 2. (*R*)-methyl 2-(*tert*-butoxycarbonylamino)-3-hydroxypropanoate

To a stirred suspension of (*R*)-methyl 2-amino-3-hydroxypropanoate hydrochloride (155 g, 1 mol) in CH_2Cl_2 (1200 mL) was added DIEA (194 g, 1.5 mol). A solution of Boc_2O (218 g, 1 mol) in CH_2Cl_2 (800 mL) was added dropwise to the above mixture, the reaction mixture was allowed to stir overnight. The solution was washed with 1N aqueous HCl (600 mL), saturated $NaHCO_3$ (500 mL), and brine (500 mL). The solution was then dried, filtered, and evaporated to give (*R*)-methyl 2-(*tert*-butoxycarbonylamino)-3-hydroxypropanoate (245 g, yield 96%) as an oil that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 5.29 (brs, 1 H), 4.35 (s, 1H), 3.91 (dd, *J*=18, 3.2 Hz, 2 H), 3.77 (s, 3 H), 2.37 (brs, 1 H), 1.44 (s, 9 H).

Step 3. (*R*)-methyl 2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-6-carboxylate

To a solution of (*R*)-methyl 2-(*tert*-butoxycarbonylamino)-3-hydroxypropanoate (27.5 g, 0.126 mol) in DMF (250 mL) was added imidazole (25.7 g, 0.378 mol), followed by TBSCl (20.9 g, 0.139 mol) and the reaction mixture stirred for 4 h. The solvents were removed *in vacuo* and dissolved in EtOAc (300 mL). The solution was washed with saturated NH_4Cl (2×100 mL), then with saturated $NaHCO_3$ (100 mL), and brine (100 mL). The organic layer was then dried, filtered, and solvent removed *in vacuo* to give (*R*)-methyl 2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-6-carboxylate (40 g, yield 95%) as an oil that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 5.34 (brs, 1 H), 4.35 (m, 1 H), 4.05 (dd, *J*=13.2, 3.6 Hz, 1 H), 3.82 (dd, *J*=14, 4.4 Hz, 1 H), 1.45 (s, 9 H), 3.73 (s, 3 H), 0.86 (s, 9 H), 0.02 (s, 6 H).

Step 4. (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-hydroxypropan-2-ylcarbamate

To a solution of (*R*)-methyl 2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-6-carboxylate (40 g, 0.12 mol) in MeOH (500 mL) at 0 °C was added $NaBH_4$ (38 g, 1 mol) in portions. The mixture was stirred for 2 h at rt followed by removal of solvent *in vacuo*. The residue was partitioned between water (200 mL) and EtOAc (2×200 mL). The organic layers were washed with saturated aqueous $NaHCO_3$ solution, then brine, dried with $MgSO_4$, and evaporated to obtain the alcohol (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-hydroxypropan-2-ylcarbamate (36 g, yield 98%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 5.15 (brs, 1 H), 3.78 (m, 2 H), 3.68 (m, 2 H), 2.25 (brs, 1 H), 1.45 (s, 9 H), 0.89 (s, 9 H), 0.07 (s, 6 H).

Step 5. (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-hydroxypropan-2-ylcarbamate

To a solution of Ph_3P (19.65 g, 75 mmol) dissolved in 9:1 THF/CH_3CN (600 mL), cooled to 0 °C, DIAD (14.7 mL, 75 mmol) was added dropwise over 15 min. After stirring for 30 min, a solution of (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-hydroxypropan-2-ylcarbamate (15.25 g, 50 mmol) in THF (100 mL) was added dropwise over 15 min. The reaction mixture was allowed to warm to rt and stirred for 24 h. After adding water (100 mL) evaporating volatiles, the residue was further diluted with water (100 mL) and extracted with EtOAc (2×100 mL). The organic layers were washed with saturated aqueous brine, dried with $MgSO_4$, and evaporated, then purified by silica chromatography to provide (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-hydroxypropan-2-ylcarbamate as an oil (7.8 g, yield 54%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 3.82 (dd, *J*=16.4, 4.4 Hz, 1 H), 3.64 (dd, *J*=16.4, 4.8 Hz, 1 H), 2.55 (m, 1 H), 2.26 (d, *J*=6 Hz 1 H), 2.06 (d, *J*=3.6 Hz 1 H), 1.45 (s, 9 H), 0.89 (s, 9 H), 0.07 (s, 6 H).

PREPARATION R

(*S*)-benzyl 2-amino-3-cyclopentylpropyl(methyl)carbamate



Step 1. (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-cyclopentylpropan-2-ylcarbamate

A 100 mL, three-neck round bottom flask was charged with Mg powder (720 mg, 30 mmol), then a solution of cyclopentylbromide (3.73 g, 25 mmol) in THF (25 mL) was added dropwise while a heat gun heated the flask. After stirring for 2 h, most of the Mg was consumed. The cyclopentylmagnesium bromide was added to a suspension of CuBr-SMe_2 (307.5 mg, 1.5 mmol) in THF (80 mL) at -78 °C, the cuprate was stirred for 30 min and a solution of (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-hydroxypropan-2-ylcarbamate (2.87 g, 10 mmol) in Et_2O (30 mL) was added. After stirring for 2 h, the reaction mixture was washed with saturated $NaHCO_3$ (2×20 mL) and brine (30 mL). The organic layer was dried with $MgSO_4$, the solvent evaporated, and the residue purified by silica gel chromatography to obtain (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-cyclopentylpropan-2-ylcarbamate as an oil (2.9 g, yield 81%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 4.60 (brs, 1 H), 3.58 (m, 3 H), 1.81 (m, 3 H), 1.60 (m, 3 H), 1.50 (m, 3 H), 1.44 (s, 9 H), 1.10 (m, 2 H), 0.89 (s, 9 H), 0.04 (s, 6 H).

Step 2. (*S*)-*tert*-butyl 1-cyclopentyl-3-hydroxypropan-2-ylcarbamate

(*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-cyclopentylpropan-2-ylcarbamate (2.9 g, 8.1 mmol) was treated with 1 M Bu_4NF/THF (24.3 mL) at 0 °C for 1 h. The reaction was diluted with water (30 mL) and extracted with EtOAc (3×40 mL). The organic layers were washed with saturated aqueous brine, dried over $MgSO_4$, and evaporated to give crude (*S*)-*tert*-butyl 1-cyclopentyl-3-hydroxypropan-2-ylcarbamate that was used without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 4.60 (brs, 1 H), 3.68 (m, 2 H), 3.52 (m, 1 H), 1.81 (m, 3 H), 1.60 (m, 3 H), 1.50 (m, 3 H), 1.44 (s, 9 H), 1.09 (m, 2 H).

Step 3. (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclopentylpropyl methanesulfonate

To a solution of (*S*)-*tert*-butyl 1-cyclopentyl-3-hydroxypropan-2-ylcarbamate in CH_2Cl_2 (30 mL) Et_3N (3.2 mL, 24.3 mmol) was added. The reaction mixture was cooled to 0 °C followed by dropwise addition of MsCl (1.1 g, 9.7 mmol) in CH_2Cl_2 (10 mL). After stirring for an additional 2 h, water (30 mL) was added and the mixture was extracted with CH_2Cl_2 (2×30 mL). The organic layers were washed with saturated

aqueous brine, dried over $MgSO_4$, and evaporated to give crude (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclopentylpropyl methanesulfonate that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 4.59 (brs, 1 H), 4.27 (dd, *J*=10, 3.2 Hz, 1 H), 4.17 (dd, *J*=10, 4 Hz, 1 H), 3.86 (m, 1 H), 3.02 (s, 3 H), 1.81 (m, 3 H), 1.60 (m, 3 H), 1.50 (m, 3 H), 1.46 (s, 9 H), 1.09 (m, 2 H).

Step 4. (*S*)-*tert*-butyl 1-cyclopentyl-3-(methylamino)propan-2-ylcarbamate

A solution of (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclopentylpropyl methanesulfonate in methylamine alcohol solution (30 mL) was heated at reflux overnight. The solvent was removed *in vacuo*, the residue was purified by silica chromatography to obtain (*S*)-*tert*-butyl 1-cyclopentyl-3-(methylamino)propan-2-ylcarbamate as a solid (900 mg, yield 43% for 3 steps). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 5.66 (brs, 1 H), 3.92 (brs, 1 H), 3.17 (m, 1 H), 2.90 (m, 1 H), 2.69 (s, 3 H), 1.81 (m, 3 H), 1.60 (m, 3 H), 1.49 (m, 3 H), 1.44 (s, 9 H), 1.10 (m, 2 H).

Step 5. (*S*)-*tert*-butyl 1-cyclopentyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate

To a mixture of (*S*)-*tert*-butyl 1-cyclopentyl-3-(methylamino)propan-2-ylcarbamate and Et_3N (1.5 mL, 10.6 mmol) in CH_2Cl_2 (10 mL) was added dropwise a solution of CbzCl (720 mg, 4.22 mmol) in CH_2Cl_2 (5 mL) at 0 °C. After stirring for an additional 2 h, water (30 mL) was added and reaction extracted with CH_2Cl_2 (2×10 mL), the organic layers were washed with saturated aqueous brine, dried over $MgSO_4$, and evaporated, then purified by silica gel chromatography to obtain (*S*)-*tert*-butyl 1-cyclopentyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate as an oil (550 mg, yield 40%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.33 (m, 5 H), 5.16 (s, 2 H), 4.57 (brs, 1 H), 3.83 (brs, 1 H), 3.40 (m, 1 H), 3.15 (m, 1 H), 2.96 (s, 3 H), 1.81 (m, 3 H), 1.60 (m, 3 H), 1.49 (m, 3 H), 1.43 (s, 9 H), 1.10 (m, 2 H).

Step 6. (*S*)-benzyl 2-amino-3-cyclopentylpropyl(methyl)carbamate

A solution of (*S*)-*tert*-butyl 1-cyclopentyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate (550 mg) in TFA/CH_2Cl_2 (10 mL, 20% v/v) was stirred for 2 hrs at 5 °C. The reaction was neutralized with

saturated aqueous $NaHCO_3$ and extracted with CH_2Cl_2 (3×30 mL). The combined extracts were washed with saturated brine (30 mL), dried over Na_2SO_4, and evaporated to give (*S*)-benzyl 2-amino-3-cyclopentylpropyl(methyl)carbamate (420 mg) that was used without further purification.

PREPARATION S

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cycloheptylpropyl(methyl)carbamate

Step 1-4. (*S*)-*tert*-butyl 1-cycloheptyl-3-(methylamino)propan-2-ylcarbamate

(*S*)-*tert*-butyl 1-cycloheptyl-3-(methylamino)propan-2-ylcarbamate was obtained following procedures analogous to Preparation R, Steps 1-4, using cyclopentylmagnesium bromide in Step 1. MS ESI +ve m/z 285 (M+H).

Step 5-6. (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cycloheptylpropyl(methyl)carbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cycloheptylpropyl(methyl)carbamate was prepared from (*S*)-*tert*-butyl 1-cycloheptyl-3-(methylamino)propan-2-ylcarbamate using procedures analogous to those described in Preparation M, Steps 3-4. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.0 (s, 9 H), 0.95 (t, 2 H), 1.12 (m, 2 H), 1.41 (m, 6 H), 1.53 (m, 5 H), 1.62 (m, 3 H), 2.94 (s, 3 H), 3.39 (m, 2 H), 4.11 (t, 2 H). MS ESI +ve m/z 329 (M+H).

The following compounds were prepared following procedures analogous to those described above:

1) (*S*)-2-(trimethylsilyl)ethyl 2-amino-5,5-dimethylhexyl(methyl)carbamate using neopentylmagnesium chloride in Step 1.
2) (*S*)-2-(trimethylsilyl)ethyl 2-amino-4,4-dimethylhexyl(methyl)carbamate using (2,2-dimethylbutyl)magnesium bromide in Step 1.
3) (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-cyclopentylpropyl(methyl)carbamate using cyclopentylmagnesium bromide in Step 1.

PREPARATION T

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(4-methylcyclohexyl)propyl(methyl)carbamate



Step 1. (*S*)-2-amino-3-(4-methylcyclohexyl)propanoic acid

A 250 mL Parr shaker vessel was charged with 1.0 g (5.6 mmol) of (*S*)-2-amino-3-p-tolylpropanoic acid, 63 mg (0.28 mmol, 5 mol%) of PtO_2, and 10 mL of 1:1 TFA:water. The vessel was placed in a Parr hydrogenation shaker, pressurized to 50 psi, and shaken for 2 d. Analysis of the mixture by LC/MS indicated a ca 1:1 mixture of *cis*:*trans* isomers. The contents were filtered through a pad of Celite and the spent catalyst washed with additional water. The clear filtrate was evaporated to afford crude TFA salt of (*S*)-2-amino-3-(4-methylcyclohexyl)propanoic acid which was used directly in the next step.

Step 2. (*S*)-2-(*tert*-butoxycarbonylamino)-3-(4-methylcyclohexyl)propanoic acid

The crude TFA salt (*S*)-2-amino-3-(4-methylcyclohexyl)propanoic acid was dissolved in 20 mL of dioxane and 30 mL of 0.67 M NaOH. The pH of the solution was raised to >14 by addition of solid KOH followed by addition di-*tert*-butyl dicarbonate (3.03 g, 13.9 mmol, 1.05 equiv). An additional 600 mg of di-*tert*-butyl dicarbonate was added and the mixture stirred overnight. After this time all the free amine had been consumed. The mixture was cooled to 0 °C and solution pH lowered to <4 by addition of saturated citric acid. The solvent was removed using a rotary evaporator and the product extracted with 5x25 mL of EtOAc. The combined organic extracts were dried over Na_2SO_4, filtered and evaporated to yield crude (*S*)-2-(*tert*-

butoxycarbonylamino)-3-(4-methylcyclohexyl)propanoic acid as a sticky solid which was used without further purification.

Step 3. (*S*)-*tert*-butyl 1-(methylamino)-3-(4-methylcyclohexyl)-1-oxopropan-2-ylcarbamate

A mixture of (*S*)-2-(*tert*-butoxycarbonylamino)-3-(4-methylcyclohexyl)propanoic acid (2.080 g, 7.29 mmol, 1.0 equiv), EDC (3.308 g, 2.37 equiv), HOBT (1.752 g, 1.78 equiv), DIEA (7.6 mL, 6 equiv) and 33% wt. methylamine in EtOH (2.771 g, 4 equiv) in CH_2Cl_2 (80 mL) was stirred at rt for 21 h. The solvents were removed *in vacuo* and 200 mL of 1 *N* HCl was added. The mixture was extracted three times with EtOAc, washed with brine, and dried over Na_2SO_4. After the solvents were removed *in vacuo*, the residue was purified by reversed-phase HPLC to give 1.0167 g (47%) of (*S*)-*tert*-butyl 1-(methylamino)-3-(4-methylcyclohexyl)-1-oxopropan-2-ylcarbamate. MS ESI +ve m/z 321 (M+Na). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 6.27 (br s, 1H), 4.91 (br s, 1H), 4.11-4.07 (m, 1H), 2.80, 2.79 (d, J = 4.8 Hz, 3H), 1.85-1.20 (m, 21H), 0.88, 0.85 (d, J = 6.4 Hz, 3H).

Step 4. (*S*)-*tert*-butyl 1-(methylamino)-3-(4-methylcyclohexyl)propan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 1-(methylamino)-3-(4-methylcyclohexyl)-1-oxopropan-2-ylcarbamate (1.0075 g, 3.38 mmol, 1.0 equiv) in THF (40 mL) was added 7 mL (7 mmol, 2.1 equiv) of 1.0 *M* $LiAlH_4$ in THF at 0 °C under N_2. The mixture was stirred at rt for 19 h and then sodium sulfate decahydrate (6.45 g, 20 mmol) was added carefully to quench excess $LiAlH_4$. The mixture was filtered and the solid was washed with ether. After the solvents were removed *in vacuo*, the crude (*S*)-*tert*-butyl 1-(methylamino)-3-(4-methylcyclohexyl)propan-2-ylcarbamate (1.04 g) was used in the next step without further purification. MS ESI +ve m/z 285 (M+H).

Step 5-6. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(4-methylcyclohexyl)-propylmethylcarbamate

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(4-methylcyclohexyl)-propylmethylcarbamate was prepared from (*S*)-*tert*-butyl 1-(methylamino)-3-(4-

methylcyclohexyl)propan-2-ylcarbamate using procedures analogous to those described in Preparation M, Steps 3-4. MS ESI +ve m/z 329 (M+1).

PREPARATION U

2-(trimethylsilyl)ethyl 2-amino-3-(1-methylcyclohexyl)propyl(methyl)carbamate



Step 1. 1-bromo-1-methylcyclohexane

A mixture of 16.73 g of 1-methylcyclohexanol and 50 mL of 48 wt. % hydrobromic acid in water was stirred at rt for 3 d. The reaction mixture was extracted with hexanes, washed with brine, and dried over Na_2SO_4. The extracts were evaporated under reduced pressure to afford 24.365 g (94%) of 1-bromo-1-methylcyclohexane, which was used in the next step without further purification. ^{13}C NMR ($CDCl_3$, 100 MHz) δ 71.78, 43.01, 35.28, 25.18, 23.48.

Step 2. methyl 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propanoate

A mixture of 1-bromo-1-methylcyclohexane (7.200 g, 3.0 equiv), tributyltin hydride (8 mL, 2.2 equiv), methyl 2-(benzyloxycarbonylamino)acrylate (3.120 g, 13.26 mmol, 1.0 equiv), and 2,2'-azobisisobutyronitrile (0.370 g, 0.17 equiv) in benzene (30 mL) was heated at 100 °C for 6 h. After the reaction mixture was evaporated under reduced pressure, the crude methyl 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propanoate was used directly in the next step without further purification. MS ESI +ve m/z 356 (M+Na).

Step 3. 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propanoic acid

A mixture of methyl 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propanoate, 10.00 g of KOH, 100 mL of MeOH, and 20 mL of water was vigorously stirred at rt for 17 h. After methanol was evaporated under reduced pressure, the residue was diluted with water and extracted with Et_2O (2×). The aqueous phase was treated with 100 mL of 2 *N* HCl, extracted with EtOAc (3×), and dried over Na_2SO_4. The extracts were evaporated under reduced pressure to afford 1.5150 g (36% in two steps) of 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propanoic acid. MS ESI +ve m/z 320 (M+H).

Step 4. benzyl 1-hydroxy-3-(1-methylcyclohexyl)propan-2-ylcarbamate

A mixture of 0.510 g (1.60 mmol) of 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propanoic acid, 5 mL of THF, and 10 mL of 1.0 *M* BH_3·THF in THF was stirred at 0 °C for 2 h. The mixture was allowed to warm to rt for 16 h. The reaction mixture was then cooled with an ice bath and quenched with 20 mL of MeOH and 2 mL of HOAc. After the solvents were removed *in vacuo*, the residue was purified by reversed-phase HPLC to afford 0.3655 g (75%) of benzyl 1-hydroxy-3-(1-methylcyclohexyl)propan-2-ylcarbamate. MS ESI +ve m/z 328 (M+Na).

Step 5. 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propyl methanesulfonate

A mixture of 0.3607 g (1.18 mmol) of benzyl 1-hydroxy-3-(1-methylcyclohexyl)propan-2-ylcarbamate, 0.4 mL (2.87 mmol, 2.43 equiv) of triethylamine, 0.1 mL (1.29 mmol, 1.09 equiv) of methanesulfonyl chloride in CH_2Cl_2 (10 mL) was stirred at 0 °C for 1.5 h. The reaction mixture was quenched with ice water, extracted with CH_2Cl_2, washed with aqueous $NaHCO_3$, and dried over Na_2SO_4. After the solvent was removed *in vacuo*, the crude 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propyl methanesulfonate was used directly in the next step without further purification. MS ESI +ve m/z 406 (M+Na).

Step 6. benzyl 1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamate

A mixture of 2-(benzyloxycarbonylamino)-3-(1-methylcyclohexyl)propyl methanesulfonate in 16 mL of THF, and 10 mL of 33% wt. methylamine in EtOH was

heated at 70 °C for 3 h. After cooling to rt, the reaction mixture was evaporated under reduced pressure. The crude benzyl 1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamate was used directly in the next step without further purification. MS ESI +ve m/z 319 (M+H).

Step 7. (*S*)-*tert*-butyl 1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(4-methylcyclohexyl)propan-2-ylcarbamate

A mixture of benzyl 1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamate, obtained as described above, K_2CO_3 (5.06 g), TeocOSu (0.80 g, 3.08 mmol, 2.6 equiv), H_2O (20 mL) and CH_2Cl_2 (100 mL) was stirred vigorously at rt for 3 h. The reaction mixture was extracted with CH_2Cl_2 (2×), and dried over Na_2SO_4. After the solvent was removed *in vacuo*, the residue was purified by reversed-phase HPLC to afford 0.2479 g (45% in three steps) of (*S*)-*tert*-butyl 1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(4-methylcyclohexyl)propan-2-ylcarbamate. MS ESI +ve m/z 485 (M+Na).

Step 8. 2-(trimethylsilyl)ethyl 2-amino-3-(1-ethylcyclohexyl)propyl(methyl)carbamate

A 250 mL round bottom flask was charged with 0.2479 g (0.54 mmol) of (*S*)-*tert*-butyl 1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(4-methylcyclohexyl)propan-2-ylcarbamate, 0.2784 g of 10% Pd/C, and 20 mL of MeOH. The reaction mixture was stirred at rt under a balloon of hydrogen for 5 h. The mixture was then filtered through filter agent, Celite ® 545, washed with MeOH. The filtrate was evaporated under reduced pressure to afford 0.1799 g (100%) of 2-(trimethylsilyl)ethyl 2-amino-3-(1-methylcyclohexyl)propyl(methyl)carbamate, which was used in the next step without further purification. MS ESI +ve m/z 329 (M+H).

PREPARATION V

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(1-adamantyl)propyl(methyl)carbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(1-adamantyl)propyl(methyl)carbamate was prepared from tricyclo[3.3.1.13,7]decane-1-propanoic acid using procedures analogous to those described in Preparation G, Steps 2-4 above.

PREPARATION W

tert-butyl 2-amino-3-(bicyclo[2.2.2]octan-1-yl)propyl(methyl)carbamate



Step 1. 2-chloro-1-methoxybicyclo[2.2.2]oct-5-ene-2-carbonitrile

A solution of 1-methoxy-1,4-cyclohexadiene (15.0 g, 0.14 mol) and 2-chloroacylonitrile (17.5 g, 0.20 mol) in benzene was heated at reflux for 15 h. The solvent was removed, and the residue was purified by column chromatography to afford 2-chloro-1-methoxybicyclo[2.2.2]oct-5-ene-2-carbonitrile (14.0 g, 52%). ^{1}H NMR ($CDCl_3$, 400MHz) δ 6.44-6.23 (m, 2H), 3.51 (s, 3H), 2.69-2.50 (m, 2H), 2.27-1.41 (m, 5H).

Step 2. 1-methoxybicyclo[2.2.2]oct-5-en-2-one

A solution of 2-chloro-1-methoxybicyclo[2.2.2]oct-5-ene-2-carbonitrile (14.0 g, 71mmol) and $Na_2S.\ 9H_2O$ (34.0 g, 142 mmol) in ethanol (175 mL) was heated under reflux for 14 h. The solution was poured into H_2O and extracted three times with ether. The combined extracts were washed with saturated aqueous NH_4Cl solution, H_2O, and brine. The organic layer was dried over Na_2SO_4, concentrated to the residue. The

crude product was purified by column chromatography to afford 1-methoxybicyclo[2.2.2]oct-5-en-2-one (5.7 g, 57%). ^{1}H NMR ($CDCl_3$, 400MHz) δ 6.46 (dd, 1H), 6.22 (d, 1H), 3.50 (s, 3H), 2.94 (m, 1H), 2.11 (m, 2H), 1.53-1.92 (m, 4H).

Step 3. 1-methoxybicyclo[2.2.2]octan-2-one

To a solution of 1-methoxybicyclo[2.2.2]oct-5-en-2-one (16.5 g, 0.11 mol) in MeOH (250 mL) was added Raney-Ni (3.3 g). The reaction mixture was stirred at 40 ℃ and 45 psi under H_2 atmosphere for 2-3 h (8.0 g, 40%). The resulting mixture was filtered, the filtrate was concentrated *in vacuo* to produce 1-methoxybicycol[2.2.2]octan-2-one (15.0 g, 90%). ^{1}H NMR ($CDCl_3$, 400MHz) δ 3.33 (s, 3H), 2.32 (d, 2H), 2.09 (m, 1H), 1.49-1.95 (m, 8H).

Step 4. 1-methoxybicyclo[2.2.2]octane

To a solution of potassium hydroxide (17 g, 250 mmol) and 85% hydrazine hydrate (11.5 g, 186 mmol) in ethylene glycol (220 mL) was added 1-methoxybicycol[2.2.2]octan-2-one (11.0 g, 71.4 mmol). The mixture was heated to 195 ℃ over 1 h and heated for an additional hour. The flask was then fitted for distillation, and approximate 20 mL (two layers) of liquid was collected over a period of 1 h at 195 °C. Subsequent dropwise addition of water (215 mL) to the reaction over a period of 3 h afforded a second fraction of distillates (approximately 180 mL). The combined distillates were extracted with ether (3×80 mL), the organic phase was dried over Na_2SO_4, and the volatiles were removed to produce 1-methoxybicycol[2.2.2]octane (4.5 g, 45%) which was used in the next step directly without purification. ^{1}H NMR ($CDCl_3$, 400MHz) δ 3.14 (s, 3H), 1.63-1.59 (m, 6H), 1.58-1.51 (m, 6H), 1.47 (m, 1H).

Step 5. 1-bromobicyclo[2.2.2]octane

To a stirred mixture of 1-methoxybicycol[2.2.2]octane (4.0 g, 28 mmol) and acetyl bromide (6.2 g, 50.4 mmol) was added 10 drops of stannic chloride at 0 °C. After stirring for 0.5 h, the temperature was allowed to rise to 20-25 ℃ and stirring was continued at the same temperature for 3 h. After cooling to 0 °C, water (30 mL) was added and the mixture was stirred for 10 min. Then the mixture was poured into water (150 mL) and extracted with ether (100 mL×3). The ether layers were combined,

washed with aqueous sodium bicarbonate and water, and dried over sodium sulfate. The solvent was removed under reduced pressure to produce 1-bromobicyclo[2.2.2]octane (4.0 g, 75%), which was used for next step without purification. ^{1}H NMR ($CDCl_3$) δ 2.23 (m, 6H), 1.95 (m, 1H), 1.81-1.63 (m, 6H), 1.52 (m, 1H).

Step 6. methyl 2-(benzyloxycarbonylamino)-3-(bicyclo[2.2.2]octan-1-yl)propanoate

methyl 2-(benzyloxycarbonylamino)acrylate (2.05 g, 0.0095 mol, 1 eq.), 1-bromobicyclo[2.2.2]octane (1.8 g, 0.0095 mol, 1 eq.) and AIBN (0.312 g, 0.0019 mol, 0.2 eq.) were dissolved in benzene (30 mL) and heated to reflux. Bu_3SnH (5.53 g, 0.019 mol, 2 eq.) was then added. The resulting mixture was stirred at reflux for 14 hrs. The solvent was removed and the residue was purified via preparative TLC (EtOAc/Petroleum ether = 1:9) to give methyl 2-(benzyloxycarbonylamino)-3-(bicyclo[2.2.2]octan-1-yl)propanoate (480 mg, 15%) as a foam. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.35 (m, 5H), 5.13 (m, 2H), 4.42 (m, 1H), 3.73 (s, 3H), 1.8- 1.1 (m, 15H), 1.28 (m, 1H).

Step 7. benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-hydroxypropan-2-ylcarbamate

methyl 2-(benzyloxycarbonylamino)-3-(bicyclo[2.2.2]octan-1-yl)propanoate (720 mg, 2.087 mmol, 1 eq.) was dissolved in 15 mL of MeOH. $NaBH_4$ (631 mg, 16.7 mmol, 8 eq.) was added in portions. The mixture was stirred for 1.5 h. Saturated aq. $NaHSO_3$ (20 mL) was added and the pH of the mixture was adjusted to 7-8 with $NaHSO_3$ (s). The mixture was evaporated and extracted with EtOAc (20 mL×5). The organic phase was combined and evaporated to give benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-hydroxypropan-2-ylcarbamate as oil, which was used in the next step without further purification. MS ESI +ve m/z 318 (M+H).

Step 8. 2-(benzyloxycarbonylamino)-3-(bicyclo[2.2.2]octan-1-yl)propyl methanesulfonate

To a solution of benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-hydroxypropan-2-ylcarbamate (668 mg, 2.1 mmol, 1 eq.), TEA (638 mg, 6.3 mmol, 3 eq.) in CH_2Cl_2 (100 mL) was added dropwise MsCl (289 mg, 2.52 mmol, 1.2 eq.) at 0-5 ℃. The resulting mixture was stirred for 2 hrs. Then the mixture was poured into water (20 mL) and extracted with CH_2Cl_2 (20 mL×4). The organic phase was combined and evaporated to give 2-(benzyloxycarbonylamino)-3-(bicyclo[2.2.2]octan-1-yl)propyl methanesulfonate (1.1 g, crude) as oil, which was used in the next step without further purification.

Step 9. benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamate

2-(benzyloxycarbonylamino)-3-(bicyclo[2.2.2]octan-1-yl)propyl methanesulfonate (830 mg, 2.1 mmol) was dissolved in 15 mL of NH_2Me in MeOH and stirred at 30-40 ℃ overnight. The mixture was concentrated to give benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamate (1.0g, crude) as an oil, which was used in the next step without further purification. MS ESI +ve m/z 331 (M+H).

Step 10. benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-(N-methyl-N-*tert*-butoxycarbonylamino)propan-2-ylcarbamate

To a solution of benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamate (695 mg, 2.1 mmol, 1 eq.) and TEA (636 mg, 6.3 mmol, 3 eq.) in CH_2Cl_2 (50 mL) was added dropwise Boc_2O (681 mg, 3.15 mmol, 1.5 eq.). The resulting mixture was stirred overnight. Water (20 mL) was added into the mixture. The mixture was extracted with CH_2Cl_2 (20 mL×4) and the organic phase was combined and concentrated. The residue was purified via preparative TLC (EtOAc/Petroleum ether = 1:4) to afford benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-(N-methyl-N-*tert*-butoxycarbonylamino)propan-2-ylcarbamate (250 mg, 28%) as a white foam. ^1H NMR ($CDCl_3$, 400 MHz) δ 7.32 (m, 5 H), 5.09 (m, 2 H), 3.85 (m, 1 H), 2.85 (s, 3 H), 2.76 (d, 2 H), 1.44 (s, 9H), 1.52-1.13 (m, 15 H).

Step 11. *tert*-butyl 2-amino-3-(bicyclo[2.2.2]octan-1-yl)propyl(methyl)carbamate

A mixture of benzyl 1-(bicyclo[2.2.2]octan-1-yl)-3-(N-methyl-N-*tert*-butoxycarbonylamino)propan-2-ylcarbamate (250 mg, 0.58 mmol)and $Pd(OH)_2$ (20%, 60 mg) in 12 Ml of absolute of MeOH was hydrogenated under 20 psi H_2 for 2 h. TLC (EtOAc/Petroleum ether = 1:2) indicated the completion of reaction. The mixture was then filtered and evaporated to afford *tert*-butyl 2-amino-3-(bicyclo[2.2.2]octan-1-yl)propyl(methyl)carbamate (150 mg, 87%) as oil, which was used in the next step without further purification.

PREPARATION X

(±) 3-benzyl 7-*tert*-butyl 3,7-diazabicyclo[4.1.0]heptane-3,7-dicarboxylate



Step 1. Benzyl 5,6-dihydropyridine-1(2*H*)-carboxylate

A solution of 1,2,3,6-tetrahydropyridine (5.0 g, 60.15 mmol) and triethylamine (16.77 mL, 2 equiv) in CH_2Cl_2 (50 mL) was cooled to 0°C (ice-water bath) followed by slow addtion of benzyl chloroformate (9.7 mL, 1.1 equiv). After 30 min, the reaction mixture was allowed to warm slowly to rt and stirred for 4 h. The mixture was diluted with ether (300 mL), washed with 5% aq HCl (2 x 50 mL), satd aq $NaHCO_3$ (40 mL) and brine (40 mL), and dried over Na_2SO_4. After concentration, benzyl 5,6-dihydropyridine-1(2*H*)-carboxylate (9.93 g, 78% yield) was left.

MS ESI +ve m/z 218 (M+1).

Step 2. Benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate

A solution of benzyl 5,6-dihydropyridine-1(2*H*)-carboxylate (9.93 g, 45.76 mmol) in CH_2Cl_2 (75 mL) was cooled to 0 °C. Solid *m*-chloroperoxybenzoic acid (77%, 15.38 g, 1.5 equiv) was added. After 10 min, the reaction mixture was warmed slowly to rt. A white precipitate formed after 1 h. The reaction was complete after an additional hour of stirring. The mixture was diluted with ether (300 mL), washed by with 5% aq NaOH (2 x 40 mL), 25% aq $Na_2S_2O_3$ solution (3 x 20 mL) and brine (30 mL), and dried over Na_2SO_4. After concentration, the residue was purified by flash chromatography to afford benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (7.87 g, 74% yield). MS ESI +ve m/z 234 (M+1).

Step 3. trans-benzyl 4-azido-3-hydroxypiperidine-1-carboxylate and trans-benzyl 3-azido-4-hydroxypiperidine-1-carboxylate

Benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (6.78 g, 29.1 mmol), sodium azide (3.78 g, 2 equiv), and ammonium chloride (1.56 g, 1 equiv) were dissolved in methanol (100 mL) and water (20 mL). The mixture was heated at 65 °C for 18 h. The mixture was cooled to rt and methanol was removed under vacuum. The aqueous residue was extracted with ether (3 x 120 mL). The combined ether layers were washed with brine (30 mL) and dried over Na_2SO_4. Concentration afforded a mixture of regioisomers, trans-benzyl 4-azido-3-hydroxypiperidine-1-carboxylate and trans-benzyl 3-azido-4-hydroxypiperidine-1-carboxylate (8.07 g, quant.) which was used without further purification. MS ESI +ve m/z 277 (M+1).

Step 4. trans-benzyl 4-azido-3-(tosyloxy)piperidine-1-carboxylate and trans-benzyl 3-azido-4-(tosyloxy)piperidine-1-carboxylate

trans-benzyl 4-azido-3-hydroxypiperidine-1-carboxylate and trans-benzyl 3-azido-4-hydroxypiperidine-1-carboxylate (8.07 g, 29.1 mmol) and pyridine (6 mL, 2.55 equiv) were dissolved in CH_2Cl_2 (20 mL) and cooled to 0 °C. Solid *p*-TsCl (11.1 g, 2.1 equiv) was added. After 5 min, the reaction mixture was allowed to warm to rt slowly and stirred overnight. The mixture was diluted with ether (300 mL), washed with 5% HCl (3 x 35 mL), satd aq $NaHCO_3$ (40 mL), brine (30 mL), and dried over Na_2SO_4.

After concentration, the residue was purified by flash chromatography (120 g silica gel column, 0 - 50% EtOAc in hexanes gradient) to afford a mixture of trans-benzyl 4-azido-3-(tosyloxy)piperidine-1-carboxylate and trans-benzyl 3-azido-4-(tosyloxy)piperidine-1-carboxylate (12.18 g, 97%). MS ESI +ve m/z 431 (M+1).

Step 5. trans-benzyl 4-amino-3-(tosyloxy)piperidine-1-carboxylate and trans-benzyl 3-amino-4-(tosyloxy)piperidine-1-carboxylate

To a 0 °C solution of $CuSO_4$•5 H_2O (642 mg, 0.5 equiv) in methanol (30 mL), $NaBH_4$ (200 mg, 1.05 equiv) was added. To the stirred black suspension was added a solution of trans-benzyl 4-azido-3-(tosyloxy)piperidine-1-carboxylate and trans-benzyl 3-azido-4-(tosyloxy)piperidine-1-carboxylate (2.21 g, 5.14 mmol) in methanol (20 mL). Additional $NaBH_4$ (578 mg, 3 equiv) was added in four portions over the course of 1 h. The reaction mixture was filtered through a pad of Celite and concentrated. The residue was diluted with CH_2Cl_2 (70 mL), washed with water (15 mL), satd aq NH_4Cl solution (2 x 10 mL), brine (15 mL), and dried over Na_2SO_4. Concentration afforded trans-benzyl 4-amino-3-(tosyloxy)piperidine-1-carboxylate and trans-benzyl 3-amino-4-(tosyloxy)piperidine-1-carboxylate (1.34 g, 64%). The product was used for the next step without further purification. MS ESI +ve m/z 405 (M+1).

Step 6. (±) 3-benzyl 7-*tert*-butyl 3,7-diaza-bicyclo[4.1.0]heptane-3,7-dicarboxylate

The regioisomers, trans-benzyl 4-amino-3-(tosyloxy)piperidine-1-carboxylate and trans-benzyl 3-amino-4-(tosyloxy)piperidine-1-carboxylate, (274 mg, 0.678 mmol) and DIEA (177 µL, 1.5 equiv) were dissolved in methanol (8 mL) and heated to 80 °C for 20 min in a CEM Microwave reactor. The reaction mixture was concentrated and redissolved in CH_2Cl_2 (10 mL). $(Boc)_2O$ (150 mg, 1 equiv) was added and the mixture was stirred overnight at rt. The reaction mixture was concentrated and purified by flash chromatography (40 g silica gel column, 0-45 % EtOAc in hexanes gradient) to afford (±) 3-benzyl 7-*tert*-butyl 3,7-diazabicyclo[4.1.0]heptane-3,7-dicarboxylate (227 mg, quant). MS ESI +ve m/z 355 (M+Na).

The following compounds were prepared following procedures analogous to those described above:

1) 3-benzyl 6-tert-butyl 3,6-diaza-bicyclo[3.1.0]hexane-3,6-dicarboxylate using 2,5-dihydro-1H-pyrrole in Step 1.

PREPARATION Y

(±)-(3*S*,4*R*)-benzyl 3-amino-4-(cyclobutylmethyl)piperidine-1-carboxylate



Step 1. (±)-trans-benzyl 3-(*tert*-butoxycarbonylamino)-4-(cyclobutylmethyl)piperidine-1-carboxylate

(±)-3-benzyl 7-*tert*-butyl 3,7-diaza-bicyclo[4.1.0]heptane-3,7-dicarboxylate (62 mg, 0.187 mmol), CuI (8 mg, 0.2 equiv), and a stirring bar were put in a 100-mL flask. The flask was evacuated and backfilled with N_2 gas (3 x). Dry THF (5 mL) was added and the mixture was cooled to -40 °C. (Cyclobutylmethyl)magnesium bromide in THF (620 μL, 3 equiv., ~0.89 M) was added slowly. After 8 min, the reaction mixture was allowed to warm slowly to rt. After 20 min, the reaction mixture turned black. After stirring a further 2 h the reaction was complete. Satd aq NH_4Cl solution (5 mL) was added to quench the reaction. The reaction mixture was partitioned between EtOAc (50 mL) and satd aq NH_4Cl solution (20 mL). The aqueous layer was extracted with EtOAc (20 mL). The combined EtOAc layers were washed with water (15 mL), brine (15 mL), and dried over Na_2SO_4. After concentration, the residue was purified by Gilson to afford (±)-trans-benzyl 3-(*tert*-butoxycarbonylamino)-4-(cyclobutylmethyl)piperidine-1-carboxylate (14 mg, 19% yield). MS ESI +ve m/z 425 (M+Na).

Step 2. (±)-trans-benzyl 3-amino-4-(cyclobutylmethyl)piperidine-1-carboxylate

(±)-trans-benzyl 3-(*tert*-butoxycarbonylamino)-4-(cyclobutylmethyl)piperidine-1-carboxylate (14 mg, 0.035 mmol)) was dissolved in 1:1 2N aq HCl/acetonitrile (8 mL) and stirred overnight at rt. The reaction mixture was basified with 5% aq NaOH solution to about pH = 9. The acetonitrile was removed under vacuum. The aqueous

residue was extracted with CH_2Cl_2 (3 x 20 mL). The combined organic layers were washed with brine (10 mL) and dried over Na_2SO_4. Concentration afforded (±)-trans-benzyl 3-amino-4-(cyclobutylmethyl)piperidine-1-carboxylate (8.9 mg, 85% yield). The crude product was used in the next step without further purification. MS ESI +ve m/z 303 (M+Na).

The following compounds were prepared following procedures analogous to those described above:

1) (±)-trans-benzyl 3-amino-4-isobutylpyrrolidine-1-carboxylate using (±)-3-benzyl 6-*tert*-butyl 3,6-diaza-bicyclo[3.1.0]hexane-3,6-dicarboxylate and isobutylmagnesium bromide in Step 1.

PREPARATION Z

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl-(methyl)carbamate



Step 1a-e. (±)-*tert*-butyl((1*r*,2*R*,4*S*)-2-fluoro-4-(iodomethyl)cyclopentyloxy)dimethylsilane

The (1*S*,3*r*,5*R*)-6-oxa-bicyclo[3.1.0]hexan-3-ylmethanol (2.73 g, 24.0 mmol, 1.0 equiv)), NEt^iPr_2 (6.8 g, 48.0 mmol, 2.0 equiv) and DMAP (2.9 g, 24 mmol, 1.0 equiv) were dissolved in CH_2Cl_2 and the solution cooled to 0 °C. Pivaloyl chloride (5.80 g, 48.0 mmol, 2.0 equiv) was added and the mixture stirred for 2h. The mixture was transferred to a separatory funnel and solution washed with saturated NH_4Cl, brine,

dried over Na_2SO_4, filtered, and evaporated. The crude epoxyester was purified by flash chromatography on silica, eluting with 0-27% EtOAc in hexanes. This affords 4.1 g (86% yield) of the epoxy ester.

The above epoxide (4.1 g, 20.7 mmol) was dissolved in 10 mL of $NEt_3(HF)_3$ and the mixture heated to 117 °C for 17 h. After this time, the mixture was cooled to ambient temperature and the excess HF quenched by addition of 10% K_2CO_3. The mixture was diluted with EtOAc, and the layers separated. The organic layer was washed with 0.5 M HCl, brine, dried over Na_2SO_4, filtered, and evaporated. The crude fluorohydrin (4.53 g) was used in the next step with no further purification.

The crude fluorohydrin, (4.53g, > 20 mmol), TBSCl (6.23 g, 42 mmol, 2.0 equiv) and imidazole (5.72 g, 84.0 mmol, 4.0 equiv) were dissolved in 10 mL of DMF. The mixture was stirred at ambient temperature for 16 h. After this time the solvent was removed *in vacuo*. The residue was portioned between Et_2O and water. The layers were separated and the organic layer washed with 0.5 M HCl, brine dried over $MgSO_4$, filtered, and evaporated. This solution cooled to 0 °C and a solution of $LiAlH_4$ in THF (1.0 M, 21 mL, 1.0 equiv) added. After 1h, the excess $LiAlH_4$ was quenched by drop wise addition of brine and the resulting slurry dispersed by addition of ca 10 g of Celite. The mixture was filtered through a pad of Celite and evaporated to yield 1.20 g (5.2 mmol, 25 % yield) of the desired alcohol.

The above alcohol (1.10 g, 4.4 mmol, 1.0 equiv), PPh_3 (1.45 g, 5.5 mmol, 1.25 equiv), and imidazole (1.0 g, 14.7 mmol, 3.3 equiv) were dissolved in THF. Iodine (1.4 g, 5.5 mmol, 1.25 equiv) was added in portions over a 20 min period. The solvent was removed and the mixture filtered through a pad of silica, eluting with Et_2O. The filtrate was evaporated and the iodide purified by flash chromatography on silica, eluting with 0-7% EtOAc in hexanes. This afforded 1.31 g (83% yield) of (±)-*tert*-butyl((1*r*,2*R*,4*S*)-2-fluoro-4-(iodomethyl)cyclopentyloxy)dimethylsilane.

Step 2a-c. (*S*)-methyl 2-(*tert*-butoxycarbonylamino)- 3-((1*r**,3*S**,4*S**)-3-fluoro-4-hydroxycyclopentyl)propanoate

(*R*)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (134 g, 7.24 mmol, 1.5 equiv) was dissolved in 9 mL of THF and the solution cooled to -78 °C. A 2.5 M solution of ^{n}BuLi (2.9 mL, 7.24 mmol, 1.5 equiv) was added over a 15 min period and

the resulting solution stirred for 0.5 h. A solution of (±)-*tert*-butyl((1*r*,2*R*,4*S*)-2-fluoro-4-(iodomethyl)cyclopentyloxy)dimethylsilane (1.73 g, 4.83 mmol, 1.0 equiv) in THF (9 mL) was added. The mixture was stirred at -78 °C for 2h, then warmed to -20 and allowed to stir overnight at that temperature. The mixture was quenched with water and the organic layer washed with brine, dried over Na_2SO_4, filtered, and evaporated. The resulting mixture was dissolved in 60 mL of 1:1 CH_3CN:2.0 M HCl. After stirring for 5 h at ambient temperature the mixture was evaporated and re-dissolved in 30 mL of CH_3CN. To this was added 30 mL of 10% K_2CO_3, followed by 3.3 g (15 mmol, 3.0 equiv) of di-*tert*-butyl dicarbonate and the mixture rapidly stirred for 1h. After the time the solution was evaporated. The yellow residue was dissolved in EtOAc and washed with 10% K_2CO_3, 0.5 M HCl, brine, then dried over Na_2SO_4, filtered, and evaporated. The desired protected amino acid was purified by flash chromatography on silica, eluting with 0-41% EtOAc. This afforded 1114 mg (3.63 mmol, 75% yield) of (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-((1*r**,3*S**,4*S**)-3-fluoro-4-hydroxycyclopentyl)propanoate.

Step 3. (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate

(*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-((1*r**,3*S**,4*S**)-3-fluoro-4-hydroxycyclopentyl)propanoate (798 mg, 2.35 mmol, 1.0 equiv), $C_4F_9SO_2F$ (1425 mg, 4.7 mmol, 2.0 equiv), $NEt_3(HF)_3$ (1138 mg, 7.1 mmol, 3.0 equiv) and NEt_3 (1427 mg, 14.1 mmol, 6.0 equiv) were dissolved in THF and the mixture allowed to stir at ambient temperature for 19h. The excess HF was quenched by quenched by addition of 10% K_2CO_3. The mixture was diluted with EtOAc, and the layers separated. The organic layer was washed with 0.5 M HCl, brine, dried over Na_2SO_4, filtered, and evaporated. The difluoride was purified by flash chromatography on silica, eluting with 0-29% EtOAc in hexanes. This afforded 423 mg (1.24 mmol, 53% yield) of pure (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate.

Step 4a-f. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl(methyl)carbamate

Lithium hydroxide hydrate (48 mg, 1.14 mmol, 3.0 equiv) was dissolved in 1.0 mL of water. This was added to a solution of (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate (116 mg, 0.379 mmol, 1.0 equiv) in 10 mL of THF. The solution was stirred for 2 h. The mixture was quenched by addition of 10% citric acid (~2 mL) and the mixture diluted with water and EtOAc. The layers were separated and the organic layer dried over Na_2SO_4, filtered, and evaporated. The resulting acid was dissolved in THF (10 mL), cooled to 0 °C, and borane (1.0 M in THF, 3.0 mL, 8.0 equiv) added. The mixture was stirred at 0 °C for 3h. The mixture was diluted with EtOAc and 0.25 M HCl added. The layers were separated and the organic layer washed with brine, dried over $MgSO_4$, filtered through a pad of silica gel, and evaporated. This afforded 88 mg of the desired amino alcohol.

The amino alcohol (88 mg, 0.28 mmol, 1.0 equiv), tosyl chloride (420 mg, 2.21 mmol, 7.9 equiv) and DABCO (50 mg, 0.445 mmol, 1.6 equiv) were dissolved in pyridine and the mixture stirred for 48 h at ambient. The mixture was evaporated and the residue taken up in EtOAc/0.5 M HCl. The layers were separated and the organic layer washed with 0.5 M HCl, brine, dried over Na_2SO_4, filtered, and evaporated. The crude tosylate was purified by flash chromatography on silica, eluting with 0-29% EtOAc in hexanes. The resulting tosylate was used directly in the next step.

The above tosylate and was dissolved in 20 mL of 33% NH_2Me in EtOH. The mixture was heated to 45 °C for 3h. The mixture was evaporated and the residue dissolved in Et_2O, washed with K_2CO_3, brine, then dried over Na_2SO_4, filtered, and evaporated. The crude amine was used in the next step with no further purification.

The above amine was dissolved in 10 mL of 1:1 acetonitrile/10% aqueous K_2CO_3. TeocOSu (64 mg, 0.275 mmol) was added and mixture stirred for 4h. The acetonitrile was removed *in vacuo* and the product extracted with 2 x 20 mL of EtOAc. The combined organic extracts were dried over Na_2SO_4, filtered, and evaporated. The product was isolated by flash chromatography on silica eluting with 0-29% EtOAc. The protected amine (35 mg, 0.075 mmol, 27% yield for the four steps) was isolated.

(*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate was obtained by following procedures analogous to procedures in Preparation M, Step 4 using *tert*-butyl (*S*)-1-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamate in Step 4.

PREPARATION A1

tert-butyl (*S*)-2-amino-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl(methyl)carbamate



Step 1-5. (±)-*tert*-butyl((1*r*,2*R*,4*R*)-2-fluoro-4-(iodomethyl)cyclopentyloxy)dimethylsilane

(±)-*tert*-butyl((1*r*,2*R*,4*R*)-2-fluoro-4-(iodomethyl)cyclopentyloxy)dimethylsilane was obtained using procedures analogous to Preparation Z, Steps 1-5, using (1*S*,3*s*,5*R*)-6-oxa-bicyclo[3.1.0]hexan-3-ylmethanol in Step 1.

Step 6. (2*S*,5*R*)-2-(((1*r**,3*R**,4*R**)-3-(*tert*-butyldimethylsilyloxy)-4-fluorocyclopentyl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine

A solution of (*R*)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (1.2 g, 1.5 equiv.) in dry THF (30 mL) was cooled to -78 °C. *n*-BuLi (1.6 M in Hexane, 4.08 mL, 1.5 equiv.) was added dropwise. After stirring 1 h at -78 °C, a solution of (±)-*tert*-

butyl((1*r*,2*R*,4*R*)-2-fluoro-4-(iodomethyl)cyclopentyloxy)dimethylsilane (1.56 g, 4.36 mmol) in dry THF (8 mL) was added dropwise. The mixture was stirred another 2 h at -78 °C. The mixture was warmed up to rt slowly, quenched by sat. NH_4Cl solution (30 mL), extracted by diethyl ether (2 × 150 mL). The combined organic layers were washed by brine (30 mL), dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (40 g column, 0~25% EtOAc in Hexanes) to afford (2*S*,5*R*)-2-(((1*r**,3*R**,4*R**)-3-(*tert*-butyldimethylsilyloxy)-4-fluorocyclopentyl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (1.81 g, quant. yield) as a clear oil. MS ESI +ve m/z 415 (M+1).

Step 7. (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((1*r**,3*R**,4*R**)-3-fluoro-4-hydroxycyclopentyl)propanoate

(2*S*,5*R*)-2-(((1*r**,3*R**,4*R**)-3-(*tert*-butyldimethylsilyloxy)-4-fluorocyclopentyl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (500 mg, 1.21 mmol) was dissolved in 1:1 mixture of 1 N HCl solution and acetonitrile (50 mL). The mixture was stirred 3 h at rt, then concentrated. K_2CO_3 (840 mg, 5 equiv.) and CbzOSu (903 mg, 3 equiv.) were added to the residue. The mixture was dissolved in 1:1 water and acetonitrile (50 mL), stirred overnight at rt. The acetonitrile was removed by evaporation under reduced pressure. The aqueous residue was extracted by EtOAc (3 × 20 mL). The combined organic layers were washed by brine (20 mL), dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (40 g column) to afford 274 mg (67 % yield) of (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((1*r**,3*R**,4*R**)-3-fluoro-4-hydroxycyclopentyl)propanoate. MS ESI +ve m/z 362 (M+Na). ^{1}H NMR ($CDCl_3$) δ 7.35(m, 5H), 5.34(s, 1H), 5.10(s, 2H), 4.82(d, 1H), 4.39-4.19(m, 2H), 3.73(s, 3H), 2.43-2.24(m, 2H), 2.09-1.38(m, 6H). ^{19}F NMR ($CDCl_3$) δ -175.92.

Step 8. (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate

A solution of (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((1*r**,3*R**,4*R**)-3-fluoro-4-hydroxycyclopentyl)propanoate (135 mg, 0.398 mmol) in CH_2Cl_2 (6 mL) was cooled to -78 °C followed by the slow addition of DAST (100 μL, 2 equiv.). After 1 h,

the reaction mixture was warmed up to rt slowly and stirred overnight. Sat. $NaHCO_3$ solution (10 mL) was added to quench the reaction. The mixture was separated. The aqueous phase was extracted by CH_2Cl_2 (25 mL). The combined organic layers were concentrated and purified by prep HPLC to afford 55 mg (41% yield) (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate. MS ESI +ve m/z 364 (M+Na). ^1H NMR ($CDCl_3$) δ 7.35(m, 5H), 5.33(d, 1H), 5.10(s, 2H), 4.89(m, 1H), 4.76(m, 1H), 4.37(td, 1H), 3.74(s, 3H), 2.30-2.07(m, 2H), 1.99(m, 1H), 1.80-1.60(m, 3H). ^{19}F NMR ($CDCl_3$) δ -199.81.

Step 9. (*S*)-2-(benzyloxycarbonylamino)-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl methanesulfonate

A solution of (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propanoate (218 mg, 0.64 mmol) in dry THF (8 mL) was cooled to 0 °C. A 2.0 M $LiBH_4$ solution in THF (640 μL, 2 eq.) was added slowly. After 20 min, the reaction mixture was warmed up to rt slowly. After stirring for 2 hrs, the mixture was cooled to 0 °C, quenched by 5% HCl (10 mL), diluted by EtOAc (20 mL). After separation, the aqueous phase was extracted by EtOAc (2 × 10 mL). The combined organic layers were washed by brine (10 mL), dried over Na_2SO_4. After filtration and concentration, the crude product was redissolved in CH_2Cl_2 (6 mL) and pyridine (1.5 mL). DMAP (40 mg, 0.5 equiv.) and methylsulfonyl chloride (174μL, 13.5 equiv.) was added sequentially. After stirring overnight at rt, the mixture was diluted by EtOAc (35 mL), washed by 5% HCl (2 ×12 mL), sat. $NaHCO_3$ solution (12 mL), brine (10 mL), dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (12 g column, 5%-80% EtOAc in Hexanes) to afford 187 mg (75% yield) of (*S*)-2-(benzyloxycarbonylamino)-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl methanesulfonate as a clear oil. MS ESI +ve m/z 393 (M+1). ^1H NMR ($CDCl_3$) δ 7.34(m, 5H), 5.09(s, 2H), 5.01(m, 1H), 4.83(d, 2H), 4.20(m, 2H), 3.94(m, 1H), 2.96(s, 3H), 2.46-1.92(m, 3H), 1.67(m, 4H).
^{19}F NMR ($CDCl_3$) δ -196.74.

Step 10. benzyl (*S*)-1-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)-3-(N-Methyl-N-*tert*-butoxycarbonylamino)propan-2-ylcarbamate

(*S*)-2-(benzyloxycarbonylamino)-3-((1*r*,3R,4*S*)-3,4-difluorocyclopentyl)propyl methanesulfonate (187 mg, 0.478 mmol), 33% methylamine in ethanol (2 mL) and ethanol (2 mL) were mixed and heated in CEM microwave oven for 20 min at 90 °C. The mixture was then concentrated, redissolved in CH_2Cl_2 (6 mL). $(Boc)_2O$ (200 mg, 2 equiv.) and Et_3N (164 μL, 1 equiv.) were added. The mixture was stirred 3 h at rt. The mixture was then concentrated and the residue was purified by prep HPLC to afford 72 mg (35% yield for 2 steps) of benzyl (*S*)-1-((1r,3R,4*S*)-3,4-difluorocyclopentyl)-3-(N-Methyl-N-*tert*-butoxycarbonylamino)propan-2-ylcarbamate as a clear oil. MS ESI +ve m/z 449 (M+Na).

Step 11. *tert*-butyl (*S*)-2-amino-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl(methyl)carbamate

benzyl (*S*)-1-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)-3-(N-Methyl-N-*tert*-butoxycarbonylamino)propan-2-ylcarbamate (72 mg, 0.169 mmol), $PdCl_2$ (catalytic amount, ca 15 mg) were mixed with methanol (20 mL). The mixture was put on Parr hydrogenation shaker for 30 min at 30 psi H_2 atmosphere. The mixture was filtered, concentrated to afford 51 mg (quant. yield) crude *tert*-butyl (*S*)-2-amino-3-((1*r*,3*R*,4*S*)-3,4-difluorocyclopentyl)propyl(methyl)carbamate.

PREPARATION B1

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(4,4-difluorocyclohexyl)propyl(methyl)carbamate



Step 1. L-tyrosine methyl ester

To a solution of L-tyrosine (45.3 g, 0.25 mol) in CH_3OH (680 mL), $SOCl_2$ (44.6 g, 0.375 mol) was added dropwise at 0 °C. After addition, the mixture was allowed to warm to rt and then refluxed for overnight. The reaction mixture was concentrated to give L-tyrosine methyl ester (49.2 g, 100 %), which was used in the next step without purification.

Step 2. L-N-Boc-tyrosine methyl ester

To a solution of Boc_2O (60 g, 0.275 mol) in CH_2Cl_2 (700 mL) was added dropwise to a solution of L-tyrosine methyl ester (49.2 g, 0.25 mol) and Et_3N (63.1 g, 0.625 mol) in CH_2Cl_2 (200 mL) at 0 °C. After stirring at rt for 3 h, the mixture was concentrated to give the crude ester, which was purified by column to give pure L-N-Boc-tyrosine methyl ester (68.1 g, 92%). ^1H NMR ($CDCl_3$, 400MHz) δ 6.96 (d, 2H), 6.73 (d, 2H), 5.88 (s, 1H), 5.00 (d, 1H), 4.53 (m, 1H), 3.71 (s, 3H), 3.00 (m, 2H), 1.42 (s, 9H). MS ESI +ve m/z 296 (M+1).

Step 3. (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-hydroxycyclohexyl)propanoate

A solution of -N-Boc-tyrosine methyl ester (68.1 g, 0.231 mol) in methanol (1200 mL) was added Rh/C (13.6 g, 5% on wetted carbon) and hydrogenated for overnight at 55-60 °C and under 55 psi. The catalyst was filtered off with Celite and the filtrate was concentrated to give (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-hydroxycyclohexyl)propanoate (59.5 g, 85.6%) as an oil. ^1H NMR ($CDCl_3$, 400MHz) δ 4.90 (m, 1H), 4.34 (m, 1H), 3.97 (m, 1H), 3.72 (s, 3H), 3.52 (m, 1H), 2.00-0.80 (m, 11H), 1.43 (s, 9H). MS ESI +ve m/z 303 (M+1).

Step 4. (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-oxocyclohexyl)propanoate

To a solution of oxalyl dichloride (49.5 g, 0.39 mol) in dry CH_2Cl_2 (480 mL) was added dropwise a solution of dry DMSO (60.8 g, 0.78 mol) in dry CH_2Cl_2 (200 mL) at -65 °C for about 0.5-1 hr. Then a solution of (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-hydroxycyclohexyl)propanoate (59.5 g, 0.197 mol) in dry CH_2Cl_2 (600 mL) was added dropwise to the above mixture for about 0.5-1 hr. It was allowed to stir for 4-6 hr at -50- -30 °C. Upon completion of the reaction, 158 mL of

Et_3N was added dropwise and the mixture was warmed to rt. The solution was added *sat.* $NaHCO_3$, extracted by EtOAc, washed with H_2O, brine, dried over Na_2SO_4, filtered and concentrated. The residue was purified by flash chromatograph to give (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-oxocyclohexyl)propanoate (39.5 g, 67 %). ^1H NMR ($CDCl_3$, 400MHz) δ 5.00 (d, J=8.0H, 1H), 4.39 (m, 1H), 3.74 (s, 3H), 2.40-1.30 (m, 11H), 1.44 (s, 9H). MS ESI +ve m/z 301 (M+1).

Step 5. (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4,4-difluorocyclohexyl)propanoate

To a solution of (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-oxocyclohexyl)propanoate (29.9 g, 0.1 mol) in dry benzene (600 mL) was added dropwise the solution of DAST (32.5 g, 0.2 mol) at 0 °C. After addition, the mixture was heated to reflux under N_2 atmosphere for 2-3 hrs. The mixture was treated with sat. $NaHCO_3$ (400 mL) and EtOAc (300 mL). The aqueous phase was extracted with EtOAc and the combined organic layer was washed with brine (300 mL), dried over Na_2SO_4, filtered, concentrated *in vacuo* to give the crude (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4,4-difluorocyclohexyl)propanoate (28.6 g, 89%), which was used in the next step without purification. ^1H NMR ($CDCl_3$, 400MHz) δ 4.93 (brs, 1H), 4.35 (m, 1H), 3.74 (s, 3H), 2.30-1.10 (m, 11H), 1.44 (s, 9H). MS ESI +ve m/z 322 (M+1).

Step 6. (*S*)-*tert*-butyl 1-(4,4-difluorocyclohexyl)-3-hydroxypropan-2-ylcarbamate

To a solution of (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4,4-difluorocyclohexyl)propanoate (28.6 g, 0.089 mol) in EtOH (600 mL) at 0 °C was added $NaBH_4$ (27.1 g, 0.713 mol) in portions while the temperature was maintained at 0-5 °C. The mixture was stirred for 2-3 hr at rt and then evaporated. The residue was partitioned between water and EtOAc. The organic layer was washed with H_2O and brine, dried over Na_2SO_4 and evaporated to give (*S*)-*tert*-butyl 1-(4,4-difluorocyclohexyl)-3-hydroxypropan-2-ylcarbamate (25.7 g, 99%), which was used in the next step without purification. ^1H NMR ($CDCl_3$, 400MHz) δ 4.61 (d, J=7.6Hz, 1H), 3.70 (m, 1H), 3.50 (m, 1H), 2.45-1.10 (m, 11H), 1.44 (s, 9H). MS ESI +ve m/z 295 (M+1).

Step 7-10. (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(4,4-difluorocyclohexyl)propyl(methyl)carbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(4,4-difluorocyclohexyl)propyl(methyl)carbamate was obtained using procedures analogous to Preparation S, Steps 3-6, using (*S*)-*tert*-butyl 1-(4,4-difluorocyclohexyl)-3-hydroxypropan-2-ylcarbamate in Step 3. ^{1}H NMR (CD_3OD, 400M Hz) δ 4.17 (t, 2H), 3.15 (m, 1H), 2.93 (s, 3H), 2.61 (dd, 1H), 2.36 (dd, 1H), 2.12-1.16 (m, 11H), 1.00 (t, 2H), 0.04 (s, 9H). MS ESI +ve m/z 351 (M+1).

PREPARATION C1

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*S*)-1-methyl-6-oxopiperidin-3-yl)propyl(methyl)carbamate



Step 1. (*S*)-*tert*-butyl 4-((R)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl) pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (244 mg, 0.63 mmol) in anhydrous DCM (6 mL) was added pyridine (2 mL) and catalytic amount of DMAP, the solution was chilled to 0 °C. TsCl (360 mg, 1.88 mmol) was added and stirred at rt overnight. The reaction mixture was diluted with EtOAc (40 mL) and washed with 1 N HCl (two times, 50 ml + 20 ml), followed by H_2O, aq. $NaHCO_3$, brine, dried over Na_2SO_4, and filtered. After evaporation, the residue was purified on silica gel column, eluted with 0-20% EtOAc in hexane to afford (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (317 mg, yield 93%). MS ESI +ve m/z 564 (M+Na).

Step 2. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((methylamino)methyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (300 mg, 0.55 mmol) was dissolved in 30% $MeNH_2$ in EtOH (60 mL), the solution was heated to 70 °C for 2 h in a pressure sealed vessel. After cooling to rt, the solvent was removed under reduced pressure to give (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((methylamino)methyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (212 mg, 95%). MS ESI +ve m/z 401 (M+H).

Step 3. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-1-methyl-6-oxopiperidin-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((methylamino)methyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (212 mg, 0.53 mmol) in absolute MeOH was added a NaOMe solution in MeOH (33%, 0.4 mL). The resulting solution was stirred for 24 h. The solvent was removed under reduced pressure, the residue was dissolved in EtOAc (50 mL), washed with 1 M HCl, sat. aq. $NaHCO_3$, brine, and dried over Na_2SO_4, filtered and evaporated to give (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-1-methyl-6-oxopiperidin-3-yl)methyl)oxazolidine-3-carboxylate (160 mg, 92%). MS ESI +ve m/z 564 (M+Na).

Step 4. *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-1-methyl-6-oxopiperidin-3-yl)propan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-1-methyl-6-oxopiperidin-3-yl)methyl)oxazolidine-3-carboxylate (230 mg, 0.70 mmol) in MeOH (10 mL) was added p-TSA (30 mg, 0.17 mmol) and stirred at rt overnight. TEA (1 mL) was added, followed by Boc_2O (30 mg). The reaction mixture was stirred for another 30 min. The solvent was removed under vacuum to give crude product *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-1-methyl-6-oxopiperidin-3-yl)propan-2-ylcarbamate, which was used for next step without further purification. MS ESI +ve m/z 287 (M+H).

Step 5-8. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-1-methyl-6-oxopiperidin-3-yl)propyl(methyl)carbamate

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-1-methyl-6-oxopiperidin-3-yl)propyl(methyl)carbamate was obtained using procedures analogous to Preparation Z, Steps 4c-4f, using *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-1-methyl-6-oxopiperidin-3-yl)propan-2-ylcarbamate in Step 4c. MS ESI +ve m/z 344 (M+H).

PREPARATION D1

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(2-oxopiperidin-1-yl)propyl(methyl)carbamate



Step 1. (*S*)-*tert*-butyl 1-amino-3-(*tert*-butyldimethylsilyloxy)propan-2-ylcarbamate

A solution of (*S*)-*tert*-butyl 2-((*tert*-butyldimethylsilyloxy)methyl)aziridine-1-carboxylate (5 g, 17.42 mmol) in NH_3/MeOH (50 mL) was stirred at 50-60 °C for 48 h. After the reaction was complete, the mixture was concentrated *in vacuo*. The residue was purified on silica gel chromatography to afford (*S*)-*tert*-butyl 1-amino-3-(*tert*-butyldimethylsilyloxy)propan-2-ylcarbamate (2.5 g, 47%). ^{1}H NMR ($CDCl_3$, 300 MHz) δ 3.67 (m, 3 H), 2.88 (d, 2H), 2.71 (s, 3 H), 1.44 (s, 9 H), 0.88 (s, 9 H), 0.0 (s, 6 H).

Step 2. (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-(5-chloropentanamido)propan-2-ylcarbamate

(*S*)-*tert*-butyl 1-amino-3-(*tert*-butyldimethylsilyloxy)propan-2-ylcarbamate (1 g, 3.29 mmol) was taken up in 10 mL of CH_2Cl_2 and cooled to 0 °C. To this was added Et_3N (0.731 g, 7.24 mmol), followed by 5-chloro-pentanoyl chloride (0.557 g, 3.62 mmol). The reaction mixture was allowed to warm to rt and stirred for 4 h. Upon completion of the reaction, satd NaCl solution was added. The organic layer was extracted with EA, dried over Na_2SO_4, and concentrated under reduced pressure. The residue was purified by column to give (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-

(5-chloropentanamido)propan-2-ylcarbamate (1.2 g, 86%). ^{1}H NMR ($CDCl_3$, 300 MHz) δ 6.31 (s, 1 H), 5.04 (d, 1 H), 3.65 (m, 3H), 3.53 (m, 2 H), 3.40 (m, 2H), 2.18 (t, 2 H), 1.78 (m, 4 H), 1.43 (s, 9 H), 0.88 (s, 9 H), 0.0 (s, 6 H).

Step 3. (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamate

Upon cooling a solution of (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-(5-chloropentanamido)propan-2-ylcarbamate (500 mg, 1.18 mmol) in DMF (10 mL) to 0 °C, NaH (52 mg, 1.30 mmol) was added. The reaction mixture was stirred for 4 h. The mixture was taken up in EtOAc, washed with saturated NaCl solution, dried over Na_2SO_4, concentrated under reduced pressure and the crude (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamate was used in next step without purification (370 mg, 81%). ^{1}H NMR ($CDCl_3$, 300 MHz) δ 5.25 (d, 1H), 4.04-3.81 (m, 2 H), 3.67-3.20 (m, 4H), 2.36 (m, 2 H), 1.78 (m, 4 H), 1.41 (s, 9 H), 0.88 (s, 9 H), 0.0 (s, 6 H).

Step 4. (*S*)-*tert*-butyl 1-hydroxy-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamate

To a suspension of (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamate (370 mg, 0.96 mmol) in CH_3CN (3 mL) was added TBAF (750 mg, 2.88 mmol). The reaction mixture was stirred for 1 h at 50-60 °C. The reaction mixture was concentrated *in vacuo* and then EA was added. This solution was washed with brine, water and concentrated again to afford crude (*S*)-*tert*-butyl 1-hydroxy-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamate (260 mg 100 %), which was used in the next step without further purification.

Step 5-8. (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(2-oxopiperidin-1-yl)propyl(methyl)carbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(2-oxopiperidin-1-yl)propyl(methyl)carbamate was obtained following procedures analogous to Preparation S, Steps 3-6, using (*S*)-*tert*-butyl 1-hydroxy-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamate in Step 3. ^{1}H NMR ($CDCl_3$, 300 MHz) δ 4.15 (t, 2 H), 3.21-3.37 (m, 7H), 2.94 (s, 3 H), 2.39 (m, 2 H), 1.80 (m, 4 H), 0.99 (t, 2 H), 0.0 (s, 9 H).

PREPARATION E1

(*R*)-*tert*-butyl 2-amino-3-(2-oxopyrrolidin-1-yl)propyl(methyl)carbamate



Step 1. (*R*)-methyl 2-(benzyloxycarbonylamino)-3-(4-chlorobutanamido)propanoate

A solution of (*R*)-methyl 3-amino-2-(benzyloxycarbonylamino)propanoate hydrochloride (4.0 g, 0.014 mol) in methanol (80 mL) was cooled to 0 °C. To this mixture was added Et_3N (3.3 g, 31 mmol), followed by 4-chlorobutanoyl chloride (2.3 g, 15.0 mmol). The reaction mixture was allowed to warm to rt and stirred for 4 h. The reaction was quenched with saturated brine (200 mL), the organic layer extracted with CH_2Cl_2, washed with 1N HCl, saturated brine, dried over $MgSO_4$ and concentrated to give crude (*R*)-methyl 2-(benzyloxycarbonylamino)-3-(4-chlorobutanamido)propanoate (5.0 g) that was used in the next step without further purification. ^1H NMR ($CDCl_3$, 400 MHz) δ 7.45-7.35 (m, 5H) 6.01 (s, 1H), 5.84 (d, 1H), 5.11 (d, 2H), 4.42 (t, 5H), 3.68-3.50 (m, 6H), 2.32 (t, 2H), 2.08 (t, 2H).

Step 2. (*R*)-benzyl 1-(4-chlorobutanamido)-3-hydroxypropan-2-ylcarbamate

To a solution of (*R*)-methyl 2-(benzyloxycarbonylamino)-3-(4-chlorobutanamido)propanoate (5.0 g, 14 mmol) in 100 mL of anhydrous MeOH was added $NaBH_4$ (12.9 g, 0.33 mol) and the mixture was stirred at rt overnight. The pH of the reaction mixture was adjusted to 8-9 using $NaHCO_3$, the mixture was evaporated to near dryness, followed by extraction with EtOAc. The organic layer was washed with water, dried over Na_2SO_4, filtered and concentrated to give (*R*)-benzyl 1-(4-chlorobutanamido)-3-hydroxypropan-2-ylcarbamate (3.9 g, yield 85%) that was used in

the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.37-7.30 (m, 5H) 5.13 (d, 2H), 3.77 (m, 1H), 3.57 (m, 4H), 2.32 (t, 2H), 2.08 (t, 2H).

Step 3. (*R*)-benzyl 1-hydroxy-3-(2-oxopyrrolidin-1-yl)propan-2-ylcarbamate

A solution of (*R*)-benzyl 1-(4-chlorobutanamido)-3-hydroxypropan-2-ylcarbamate (3.9 g, 11.9 mmol) in DMF was cooled to 0 °C, followed by the addition of NaH (0.72 g, 17.9 mmol). The mixture was stirred at rt for 4 h. DMF was removed under high vacuum, and the residue was taken up in EtOAc, washed with 1 N HCl, saturated $NaHCO_3$, NaCl, dried over Na_2SO_4, and concentrated to give the crude product, which was purified by column chromatography to give (*R*)-benzyl 1-hydroxy-3-(2-oxopyrrolidin-1-yl)propan-2-ylcarbamate (1.1 g, yield 33%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.39-7.27 (m, 5H), 5.45 (d, 1H), 5.10 (d, 1H), 4.70 (s, 2H), 3.72 (m, 1H), 3.54-3.40 (m, 4H), 3.20-3.17 (m, 1H), 2.40 (t, 2H), 2.07 (t, 2H).

Step 4-7. (*R*)-*tert*-butyl 2-amino-3-(2-oxopyrrolidin-1-yl)propyl(methyl)carbamate

(*R*)-*tert*-butyl 2-amino-3-(2-oxopyrrolidin-1-yl)propyl(methyl)carbamate was obtained following procedures analogous to Preparation W, Steps 8-11, using (*R*)-benzyl 1-hydroxy-3-(2-oxopyrrolidin-1-yl)propan-2-ylcarbamate in Step 8. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.32 (s, 1H) 3.48 (s, 2H), 3.35 (m, 1H), 3.23 (s, 3H), 2.91 (s, 2H), 2.79 (d, 1H), 2.42 (m, 1H,), 2.07 (m, 4H), 1.45 (s, 9H).

PREPARATION F1

(*S*)-*tert*-butyl 2,2-dimethyl-4-(((*S*)-tetrahydrofuran-3-yl)methyl)oxazolidine-3-carboxylate



Step 1. (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate

To a solution of HMDS in anhydrous THF (200 mL) was added dropwise 2.5 M *n*BuLi in hexane (130 mL) and the mixture was stirred at -78 °C for 1 h. To a solution

of N-Boc pyroglutamic ester (80 g, 0.311 mol) in anhydrous THF (1600 mL) stirred at -78 ℃ was added to the above solution of lithium hexamethyldisilazide in THF. After the reaction mixture was stirred at -78 ℃ for 1 hour, 3-bromopropene (38.47 g, 0.318 mol) in THF (200 mL) was added and stirring was continued for 2 h. The reaction mixture was quenched with saturated ammonium chloride solution (600 mL) at -78 ℃ and extracted with EtOAc (3×500 mL). The combined organic layers were dried over Na_2SO_4, filtered and evaporated to dryness. The crude product was separated by column chromatography to afford (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate (15 g, 16%). ^{1}H NMR (CD_3OD) δ 5.4-5.3 (m, 1H), 5.1-5.0 (m, 2H), 4.6-4.5 (m, 1H), 4.3-4.2 (m, 2H), 2.8-2.6 (m, 2H), 2.2-2.1 (m, 2 H), 1.5-1.4 (s, 9 H), 1.3-1.2 (t, 3 H).

Step 2. *tert*-butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate

To a solution of (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate (30 g, 0.1 mol) in MeOH/H_2O (700/70 mL) was added $NaBH_4$ (25 g, 0.66 mol), the resulting mixture was stirred 1 h at rt and quenched with sat. aq. NH_4Cl (300 mL). The organic solvent was removed under vacuum and extracted with EA (3×250 mL). The combined organic phases were washed with brine (250 mL), dried over anhydrous Na_2SO_4, filtered and evaporated to afford the crude *tert*-butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate (22 g, 85%). It was used for the next step without further purification. ^{1}H NMR (CD_3OD) δ 5.8-5.7 (m, 1H), 5.1-5.0 (m, 2 H), 4.9-4.8 (d, 1 H), 3.7-3.5 (m, 4 H), 2.2-2.0 (m, 2 H), 1.7-1.5 (m, 2 H), 1.5-1.4 (s, 9 H).

Step 3. (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

tert-butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate (6.8 g, 26.2 mmol) was dissolved in acetone (150 mL) followed by the addition of BF_3•Et_2O (2.62 mmol). The reaction mixture was cooled to 0 °C and 2, 2-dimethoxypropane (4.1 g, 39.4 mmol) was added. The resulting mixture was stirred at rt for 1 h, TEA (0.5 mL) was added and stirred for another 5 min before evaporating under reduced pressure. The residue was dissolved in Et_2O (300 mL), washed with 1 N HCl (80 mL), sat. aq.

$NaHCO_3$ (80 mL), brine (80 mL) successively, and dried, filtered, and concentrated under vacuum to give crude (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (7.5 g, 96%). It was used for the next step without further purification. ^1H NMR (CD_3OD) δ 1.4-1.5 (m, 13 H), 1.5-1.6 (d, 6 H), 1.6-1.9 (m, 2 H), 2.0-2.1 (m, 1H), 3.3-3.5 (m, 2H), 3.6-3.8 (m, 2H), 3.8-3.9 (m, 2H), 4.1-4.2 (m, 1H), 5.0-5.1 (m, 2 H), 5.7-5.8 (m, 1H).

Step 4. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (11.5 g, 38.4 mmol), imidazole (7.84 g, 115.2 mmol) and DMAP (234 mg, 1.92 mmol) in CH_2Cl_2 (200 mL) was added a solution of TBSCl (8.68 g, 57.6 mmol) in CH_2Cl_2 (100 mL) dropwise. The reaction mixture was stirred at rt for overnight. Water (100 mL) was added and the aqueous layer was extracted with CH_2Cl_2 (3×100 mL). The combined organic layers was washed with brine (70 mL), then dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (9 g, 57%).

Step 5. (*S*)-*tert*-butyl 4-((*S*)-2-((*tert*-butyldimethylsilyloxy)methyl)-4-hydroxybutyl)-2,2-dimethyloxazolidine-3-carboxylate

A solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (15g) in dry CH_2Cl_2 (250 mL) was treated with a stream of O_3 until the reaction mixture turned blue at -78 °C. The system was then flushed with O_2 to remove excess ozone. Me_2S was added and the mixture was allowed to warm to rt. Solvents were removed *in vacuo* to give the crude product (12 g). The crude product was dissolved in 250 mL of dry THF. The resulting mixture was cooled to 0 °C before $LiAlH_4$ was added. After being stirred for 30 min, the reaction was quenched with 40 mL of H_2O followed by 120 mL of 1 N NaOH. The resulting white slurry was filtered through celite, and the clear, colorless filtrate was dried over anhydrous Na_2SO_4. Filtration followed by concentration *in vacuo* gave the crude

product, which was purified by flash column to give the pure product (*S*)-*tert*-butyl 4-((*S*)-2-((*tert*-butyldimethylsilyloxy)methyl)-4-hydroxybutyl)-2,2-dimethyloxazolidine-3-carboxylate (5.2 g, 34%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.06 (s, 6H), 0.89 (s, 9H), 1.46 (s, 12H), 1.50 (m, 3H), 1.53 (m, 3H), 3.09 (m, 1H), 3.49 (m, 2H), 3.50 (m, 2H), 3.7 (m, 2H), 3.90 (m, 1H).

Step 6. (*S*)-*tert*-butyl 4-((*S*)-2-((*tert*-butyldimethylsilyloxy)methyl)-4-(methylsulfonyloxy)butyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*S*)-2-((*tert*-butyldimethylsilyloxy)methyl)-4-hydroxybutyl)-2,2-dimethyloxazolidine-3-carboxylate and TEA in CH_2Cl_2 at 0 °C was added dropwise a solution of MsCl. The mixture was stirred for 2 h. The mixture was washed with water and dried over Na_2SO_4. The organic phase was distilled off to give the crude product (*S*)-*tert*-butyl 4-((*S*)-2-((*tert*-butyldimethylsilyloxy)methyl)-4-(methylsulfonyloxy)butyl)-2,2-dimethyloxazolidine-3-carboxylate (6.2g). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.06 (s, 6H, 0.89 (s, 9H), 1.46 (s, 12H), 1.50 (s, 3H), 1.53 (m, 3H), 2.94 (s, 3H), 3.49 (m, 2H), 3.50 (m, 2H), 3.7 (m, 2H), 3.9 (m, 1H).

Step 7. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*S*)-tetrahydrofuran-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*S*)-2-((*tert*-butyldimethylsilyloxy)methyl)-4-(methylsulfonyloxy)butyl)-2,2-dimethyloxazolidine-3-carboxylate (6.2 g) in 200 mL of THF was added TEAF. The reaction mixture was stirred for 12 h under reflux. The mixture was diluted with EA, washed with water back extracted EA. The combined organic layer was washed with brine, filtered, and concentrated. The crude product was purified by flash column to give the pure product (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*S*)-tetrahydrofuran-3-yl)methyl)oxazolidine-3-carboxylate (2.4 g, 67 %).

PREPARATION G1

tert-butyl (*S*)-1-hydroxy-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamate



Step 1. (*S*)-*tert*-butyl 4-((*R*)-2-(allyloxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (30 g, 100 mmol, 1eq) in anhydrous THF (600 mL) was added NaH (60%, 16 g, 400 mmol, 4 eq) in portions at 0 °C. The mixture was stirred for 10 min at 0 °C, followed by the dropwise addition of allyl bromide (48 g, 400 mmol, 4 eq) over 15 min . After stirring for 30 min at 0 °C, the mixture was allowed to warm to rt and stirred for 16 h. The reaction was quenched with aq. NH_4Cl and the mixture was extracted with EA (3x). The combined organic layers were washed with brine, dried over Na_2SO_4, concentrated under reduced pressure to afford the crude product. It was purified by column chromatography on silica gel (PE:EA=100:1→60:1) to give (*S*)-*tert*-butyl 4-((*R*)-2-(allyloxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (26.15g, 77.0%).

Step 2. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*,Z)-2,3,4,7-tetrahydrooxepin-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-(allyloxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (700 mg, 2.06 mmol, 1 eq) in anhydrous CH_2Cl_2 was added Grubbs catalyst 2nd generation ((1,3-Bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium) (173 mg, 0.21 mol, 0.1eq). The resulting mixture was stirred and heated to reflux for 4 h. The solvent was removed under reduced pressure to afford the crude product. It was purified by column chromatography on silica gel (PE:EA=100:1) to give (*S*)-*tert*-butyl

2,2-dimethyl-4-(((*R*,Z)-2,3,4,7-tetrahydrooxepin-3-yl)methyl)oxazolidine-3-carboxylate (563 mg, 88%).

Step 3. (*S*)-*tert*-butyl 2,2-dimethyl-4-((*R*)-oxepan-3-ylmethyl)oxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*,Z)-2,3,4,7-tetrahydrooxepin-3-yl)methyl)oxazolidine-3-carboxylate was dissolved in EtOH, followed by the addition of Raney Ni. The mixture was hydrogenated at rt for 3h. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to afford (*S*)-*tert*-butyl 2,2-dimethyl-4-((*R*)-oxepan-3-ylmethyl)oxazolidine-3-carboxylate (408 mg, 72%).

Step 4. *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 2,2-dimethyl-4-((*R*)-oxepan-3-ylmethyl)oxazolidine-3-carboxylate (160 mg, 0.51 mmol) in MeOH (10 mL) was added p-TSA (30 mg, 0.17 mmol) and stirred at rt for 2 h. TEA (1 mL) was added, followed by 1 drop of Boc_2O. The reaction mixture was stirred for another 30 min. The solvent was removed under vacuum to give crude product *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamate, which was used for next step without further purification. MS ESI +ve m/z 296 (M+Na).

PREPARATION H1

tert-butyl (*S*)-1-amino-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate



Step 1. (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-oxepan-3-yl)propyl 4-methylbenzenesulfonate

Above crude alcohol was dissolved in pyridine (3 mL), to this stirred solution was added catalytic amount of DMAP and TsCl (117 mg, 0.61 mmol). One hour later another portion of TsCl (30 mg) was added and stirred for another 1.5 h. The reaction was diluted with EtOAc, and washed with 1 M HCl, sat. aq. $NaHCO_3$, brine, and dried, and filtered, and concentrated to give (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-oxepan-3-yl)propyl 4-methylbenzenesulfonate. MS ESI +ve m/z 450 (M+Na).

Step 2. *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate

The solution of NaN_3 (47 mg, 0.72 mmol) and (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-oxepan-3-yl)propyl 4-methylbenzenesulfonate (103 mmol, 0.24 mmol) in anhydrous DMF was heated to 80 °C for 2 h. After cooling to rt, the reaction was diluted with EtOAc and washed with H_2O, brine, dried over Na_2SO_4, filtered, and concentrated. The residue was purified by chromatography on silica gel to give *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate. MS ESI +ve m/z 321 (M+Na).

Step 3. *tert*-butyl (*S*)-1-amino-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate

Above *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate was hydrogenated under H_2 (40 psi), catalyzed by 10% Pd/C, in MeOH for 1 h. The catalyst was filtered off and concentrated to give *tert*-butyl (*S*)-1-amino-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate (55 mg, 83% over 2 steps). MS ESI +ve m/z 273 (M+H).

PREPARATION I1

tert-butyl (*S*)-1-amino-3-((*S*)-oxepan-3-yl)propan-2-yl(methyl)carbamate



Step 1. *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-yl(methyl)carbamate

To a solution of *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate (83 mg, 0.28 mmol) in anhydrous THF (5 mL) at -78 °C was added 1.0 M LHMDS solution in THF (1.1 mL, 1.12 mmol), then stirred at this temperature for 30 min. To this mixture was added MeI (237 mg, 104 μL, 1.67 mmol), then the temperature was allowed to warm to 0 °C, and stand for 12 h and -20 °C. The reaction mixture was quenched with saturated aq. NH_4Cl, extracted with EtOAc (30 mL), the separated organic phase was washed with H_2O (2 × 10 mL), brine, and dried over Na_2SO_4, and filtered. The filtrate was concentrated, the resulting slurry was purified through flash chromatography on silica gel (eluted with gradient system, 0-30% EtOAc in hexane) to

afford *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-yl(methyl)carbamate. MS ESI +ve m/z 321 (M+Na).

Step 2. *tert*-butyl (*S*)-1-amino-3-((*S*)-oxepan-3-yl)propan-2-yl(methyl)carbamate

Above *tert*-butyl (*S*)-1-azido-3-((*S*)-oxepan-3-yl)propan-2-yl(methyl)carbamate was hydrogenated under H_2 (40 psi), catalyzed by 10% Pd/C, in MeOH for 1 h. The catalyst was filtered off and concentrated to give *tert*-butyl (*S*)-1-amino-3-((*S*)-oxepan-3-yl)propan-2-ylcarbamate (76.8 mg, 96% over 2 steps). MS ESI +ve m/z 287 (M+H).

PREPARATION J1

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(oxepan-4-yl)propyl(methyl)carbamate



Step 1. oxepan-4-one

A 500 mL 2-neck round-bottomed flask was charged with an addition funnel and distillation apparatus cooled with dry ice-acetone bath. A mixture of KOH (30 g, 0.54 mol), water (50 mL) and carbitol (150 mL) was heated to 70 °C, then a solution of N-methyl-N-nitroso- p-toluenesulfonamide (107 g, 0.5 mol) in ether (500 mL) was added dropwise and the ethereal diazomethane solution was collected. To a solution of tetrahydro-pyran-4-one (25 g, 0.25 mol) in ether (150 mL) was added dropwise a solution of 1 M CH_2N_2 in ether (500 mL) at 0 °C. After addition, methanol (125 mL) was added dropwise. Immediately, a brisk evolution of nitrogen ensued. The reaction mixture was allowed to warm to rt and stir for 2 h. The remaining diazomethane was destroyed with a few drops of acetic acid. The solvent was removed under reduced pressure to give the oxepan-4-one (20 g, 70%), which was used for the next step directly without further purification. ^{1}H NMR ($CDCl_3$) δ 1.82 (m, 2H), 2.66 (m, 4H), 3.82 (m, 4H).

Step 2. oxepan-4-ol

To a solution of oxepan-4-one (20 g, 0.175 mol) in MeOH (350 mL) was added $NaBH_4$ (13 g, 0.35 mol) while the temperature was lower than 40 °C. After addition, the reaction mixture was stirred at rt for 2-3 h. The solvent was removed *in vacuo* to the residue, which was partitioned between water and EtOAc. The aqueous layer was

extracted EtOAc (3×100 mL). The combined organic layers was washed with brine, dried over anhydrous Na_2SO_4, concentrated *in vacuo* to afford oxepan-4-ol (13 g, 64%), which was used for the next step directly without further purification. ^{1}H NMR ($CDCl_3$) δ 1.45-2.01 (m, 6H), 2.33 (brs, 1H), 3.51-4.03 (m, 5H).

Step 3. 4-bromooxepane

To a solution of oxepan-4-ol (13 g, 0.112 mol) and PPh_3 (35 g, 0.134 mol) in CH_2Cl_2 (250 mL) was added a solution of CBr_4 (52 g, 0.157 mol) in CH_2Cl_2 (200 mL) at 0-5 °C. After addition, the reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure to provide a residue. Ether (300 mL) was added, a white precipitate formed. The solid was filtered off, the filtrate was concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel to give 4-bromo-oxepane (8.0 g, 40%). ^{1}H NMR ($CDCl_3$) δ 1.65 (m, 1H), 1.96 (m, 1H), 2.06-2.33 (m, 4H), 3.55 (m, 1H), 3.72 (m, 3H), 4.41 (m, 1H).

Step 4-9. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(oxepan-4-yl)propyl(methyl)carbamate

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(oxepan-4-yl)propyl(methyl)carbamate was obtained following procedures analogous to Preparation S, Steps 1-6, using *tert* oxepan-4-ylmagnesium bromide in Step 1. ^{1}H NMR ($CDCl_3$) δ 0.04 (s, 9H), 1.02 (t, 3H), 1.13-1.53 (m, 8H), 1.61-1.87 (m, 5 H), 2.93 (s, 3H), 3.03-3.18 (m, 3H), 3.53-3.81 (m, 4H), 4.16 (m, 2H).

PREPARATION K1

2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine



Step 1. (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid

To a round bottom flask, Et_3N (303g, 3mol) was added dropwise to a stirred solution of Boc_2O (261.6 g, 1.2 mol) and 2-amino-pentanedioic acid 5-methyl ester (161 g, 1 mol) in water (800 ml) and dioxane (800 ml). After 18 hr the solution was extracted with petroleum ether (2 ×1000ml) and the aqueous phase was cooled on ice and carefully acidified to pH 3 by slow addition of 10% citric acid solution. The urethane was then extracted into EtOAc (3 ×1000ml) and the combined extracts were washed with brine, then dried (Na_2SO_4), filtered and concentrated under reduced pressure to give (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid (238g, 91.2%), which was used without further purification.

Step 2. (*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate

To a stirred solution of (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid (35.2 g,0.135 mol) in THF (500 mL) at -10 °C was added N-methylmorpholine (15 mL, 0.135 mol) followed by ethyl chloroformate (14.72 g, 0.135 mol). After 10 min, $NaBH_4$ (15.37 g, 0.405 mol) was added in one portion. MeOH

(1200 mL) was then added dropwise to the mixture over a period of 20 min at 0 °C. The solution was stirred for an additional 20 min and then neutralized with 1M $KHSO_4$. The organic solvent was removed and the aqueous layer was extracted with EtOAc (3 ×500 ml). The combined organic phases were washed consecutively with 1M $KHSO_4$ (300 mL), H_2O (300 mL), 5% aqueous $NaHCO_3$ (300 mL), and dried (Na_2SO_4). The solvent was evaporated to give a residue, which was purified by column chromatography to give the desired (*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate (24 g, 72%)

Step 3. (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-Methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate (24 g, 97.2 mmol) and isopropenyl methyl ether (88.8 g, 854.6 mmol) was dissolved in acetone (2000 mL) and BF_3•Et_2O (0.82 mL, 5.84 mmol) was added at rt. The mixture was stirred for 1 hr at rt. The reaction was quenched by addition of Et_3N (11.6 mL). The reaction solution was washed with aqueous saturated $NaHCO_3$ (200 mL) and evaporated, and (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (25.1 g, 90 %) was obtained as an oil , which was used in the next step without further purification.

Step 4. (*S*)-3-(3-(*tert*-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)propanoic acid

An aqueous solution of sodium hydroxide (195 mL, 4.0 M in H_2O, 0.261mol, 3.0 eq) was added to a solution of (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (25.1 g, 0.087 mol), and the resulting cloudy reaction mixture was stirred at 23 °C for 3.5 hr. The mixture was concentrated under reduced pressure to ~50 mL volume and then was partitioned between 0.5 M HCl (360 ml) and EtOAc (2 × 360ml). The combined organic layers were dried over Na_2SO_4 and were filtered. The filtrate was concentrated under reduced pressure to give (*S*)-3-(3-(*tert*-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)propanoic acid (21.6 g, 91%), which was used without further purification.

Step 5. (*S*)-*tert*-butyl 2,2-dimethyl-4-(3-((*R*)-4-methyl-2-oxooxazolidin-3-yl)-3-oxopropyl)oxazolidine-3-carboxylate

A 2000 mL flask was charged with (*S*)-3-(3-(*tert*-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)propanoic acid (21.6 g, 79 mmol) and 750 mL of dry THF. The solution was cooled to 0 °C, then triethylamine (23.94 g, 237 mmol, 3.0 equiv) and pivaloyl chloride (9.76 mL, 79 mmol, 1.0 equiv) were sequentially added. The solution was stirred for 4 hr at 0 °C. After this time (*R*)-4-benzyl-2-oxalozolidinone (13.26g, 75.2 mmol, 0.95 equiv) and dried LiCl (3.68 g, 86.4 mmol, 1.1 equiv) were added and the reaction was allowed to stir for 13 hr with concomitant warming to ambient temperature. After this time 560 mL of 0.5 M HCl was added, the mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with EtOAc (3×370 mL), and the combined organic layers washed with 10% K_2CO_3 (2×370 mL), and brine (2×370 mL), then dried over Na_2SO_4, and evaporated. The crude material was purified by flash chromatography, eluting with 0-29% EtOAc in hexanes. This afforded 26.3g (81%) of (*S*)-*tert*-butyl 2,2-dimethyl-4-(3-((*R*)-4-methyl-2-oxooxazolidin-3-yl)-3-oxopropyl)oxazolidine-3-carboxylate as a clear syrup.

Step 6. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((*R*)-4-methyl-2-oxooxazolidine-3-carbonyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate

At 0 °C, 1.0M $TiCl_4$ in CH_2Cl_2 solution (8.55 mL, 0.7 eq) was added to CH_2Cl_2 (100 mL) followed by the addition of 1.0M $TiCl(O\textit{i}\text{-}Pr)_3$ in hexanes solution (4.28 mL, 0.35 eq) and stirred 5 min DIPEA (2.87 mL, 1.35 eq) was added and stirred 15 min. A solution of (*S*)-*tert*-butyl 2,2-dimethyl-4-(3-((*R*)-4-methyl-2-oxooxazolidin-3-yl)-3-oxopropyl)oxazolidine-3-carboxylate (5.28 g, 12.22 mmol) in CH_2Cl_2 (50 mL) was added. The reaction mixture was stirred 1 hr at 0 °C. To the solution, t-butylacrylate (2.22 mL, 1.25 eq) was added and the mixture was left stirred over 48 hr with concomitant warming to rt. The mixture was concentrated, partitioned between EtOAc (300 mL) and 1% HCl solution (100 mL). The organic layer was washed with sat. $NaHCO_3$ solution (60 mL), brine (60 mL), dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (120 g column, 0~35% EtOAc in Hexanes gradient) to afford 4.12 g (60%) (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((*R*)-4-

methyl-2-oxooxazolidine-3-carbonyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate as a yellowish solid. MS ESI +ve m/z 583 (M+Na).

Step 7. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-*tert*-Butyl 4-((*R*)-5-*tert*-butoxy-2-((*R*)-4-methyl-2-oxooxazolidine-3-carbonyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (4.12 g, 7.36 mmol) was dissolved in 4:1 THF and methanol (200 mL) and cooled to 0 °C. Sodium borohydride (557 mg, 2 eq) was added slowly. After 10 min, the mixture was warmed up to rt slowly. The mixture was stirred 2 hr at rt. The mixture was concentrated, redissolved in EtOAc (300 mL), washed with 1% HCl solution (100 mL), brine (60 mL), and dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (40 g column, 10-65% EtOAc in Hexanes gradient, check TLC with Ninhydrin stain) to afford 2.86 g of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate as a white solid. MS ESI +m/v 410 (M+Na).

Step 8. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (244 mg, 0.63 mmol) in anhydrous DCM (6 mL) was added pyridine (2 mL) and catalytic amount of DMAP, the solution was chilled to 0 °C. Tosic chloride (360 mg, 1.88 mmol) was added and stirred at rt overnight. The reaction mixture was diluted with EtOAc (40 mL) and washed with 1 N HCl (2x, 50 ml + 20 ml), followed by H_2O, aq. $NaHCO_3$, brine, dried over Na_2SO_4, and filtered. After evaporation of solvent, the residue was purified on silica gel column, eluted with 0-20% EtOAc in hexane to afford (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (317 mg, yield 93%).

Step 9. (*S*)-*tert*-butyl 4-((*R*)-5-hydroxy-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (317 mg, 0.58 mmol) in anhydrous DCM (8 mL) at -78 °C under N_2 was added DiBAlH (1 M in hexane, 1.75 mL, 1.75 mmol) dropwise. After the addition, the reaction mixture was stirred for another 30 min. The reaction was quenched with MeOH (2 mL), followed by 50% Rochelle's salt aq solution and stirred 2 hr. The resulting solution was extracted with DCM (3 × 20 mL), the combined organic phases were concentrated and dissolved in THF/MeOH (10 mL, 4/1, v/v), and chilled to 0 °C, $NaBH_4$ (11 mg, 0.29 mmol) was added and stirred at this temperature for 30 min. The reaction was quenched by aqueous NH_4Cl, then extracted with EtOAc (3 × 20 mL), the combined organic phases were washed with H_2O, brine, and dried over Na_2SO_4, and filtered, and concentrated to give crude product (*S*)-*tert*-butyl 4-((*R*)-5-hydroxy-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (255 mg, 92%). It was used without further purification.

Step 10. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-hydroxy-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (254 mg, 0.54 mmol) in anhydrous DMF (8 mL) at 0 °C under N_2 was added NaH (43 mg, 1.08 mmol). After stirring at this temperature for 1 hr, the reaction was quenched with aq. NH_4Cl and then evaporated to dryness. The residue was dissolved in EtOAc and H_2O, the separated aqueous phase was extracted with EtOAc. The combined organic phases were washed with H_2O, brine, and dried over Na_2SO_4, filtered, and evaporated. The residue was purified on silica gel column to afford (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate (136 mg, 84%).

The following compounds were prepared using procedures analogous to those described above:

1) (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-5-oxo-2-((*R*)-2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate using (*R*)-4-phenyl-2-oxalozolidinone in Step 5 and cyclohexyl acrylate in Step 6.

2) (*S*)-*tert*-butyl 4-((*R*)-5-ethoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate using (*R*)-4-phenyl-2-oxalozolidinone in Step 5 and using ethyl acrylate in step 6.

PREPARATION L1

2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine



Step 1. (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate

To a solution of HMDS in anhydrous THF (200 mL) was added dropwise 2.5 M *n*-BuLi in hexane (130 mL) and the mixture was stirred at -78 °C for 1 hr. To a solution of (*S*)-1-*tert*-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate (80 g, 0.311 mol) in anhydrous THF (1600 mL) stirred at -78 °C was added lithium hexamethyldisilazide in THF. After the reaction mixture was stirred at -78 °C for 1 hr, 3-bromopropene (38.47 g, 0.318 mol) in THF (200 mL) was added and stirring was continued for 2 hr. The reaction mixture was quenched with saturated ammonium chloride solution (600 mL) at -78 °C and extracted with EtOAc (3×500 mL) . The combined organic layers were dried over Na_2SO_4, filtered and evaporated to dryness. The crude product was

separated by column chromatography to afford (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate (15 g, 16%).

Step 2. *tert*-butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate

To a solution of (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate (30 g, 0.1 mol) in MeOH/H_2O (700/70 mL) was added $NaBH_4$ (25 g, 0.66 mol), the result mixture was stirred 1 hr at rt and quenched with sat. aq. NH_4Cl (300 mL). The organic solvent was removed under vacuum and extracted with EtOAc (3×250 mL). The combined organic phases were washed with brine (250 mL) and dried over anhydrous Na_2SO_4, filtered and evaporated to afford crude *tert* -butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate (22 g, 85%). It was used in the next step without further purification.

Step 3. (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of *tert* -butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate (6.8 g, 26.2 mmol) in acetone (150 mL), PTSA (0.45 g, 2.62 mmol) was added. The reaction mixture was cooled to -20 °C followed by the addition of 2,2-dimethoxypropane (4.1 g, 39.4 mmol). The resulting mixture was stirred and allowed to warm to rt for 1 hr. TEA (0.5 mL) was then added and stirred for another 5 min. The solvent was removed under reduced pressure. The residue was dissolved in Et_2O (300 mL), washed with 1 N HCl (80 mL), sat. aq. $NaHCO_3$ (80 mL), brine (80 mL) successively, and dried, filtered, and concentrated under vacuum to give crude (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (7.5 g, 96%). It was used without further purification.

Step 4. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (11.5 g, 38.4 mmol), imidazole (7.84 g, 115.2 mmol) and DMAP (234 mg, 1.92 mmol) in CH_2Cl_2 (200 mL) was added a solution of TBSCl (8.68 g, 57.6 mmol) in CH_2Cl_2 (100 mL) dropwise. The reaction mixture was

stirred at rt for overnight. The reaction was washed with water (100 mL) and the aqueous layer was extracted with CH_2Cl_2 (3×100 mL), the combined organic layers was washed with brine (70 mL), then dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (9 g, 57%).

Step 5. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate

A solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (26 g, 63 mmol) in THF (200 mL) was cooled in an ice-bath, followed by dropwise addition of 10 M $BH_3.SMe_2$ (6.3 mL). After stirring for 5 hr, 10% NaOH solution (32 mL) followed by 30% H_2O_2 (32 mL) were added carefully. The reaction mixture was stirred at rt for 16 hr. The reaction mixture was diluted with diethyl ether (500 mL) and the aqueous layer was extracted with diethyl ether (3×250 mL). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate (19.6 g, 72%).

Step 6. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate (32 g, 74.2 mmol) and Et_3N (22.5 g, 226 mmol) in CH_2Cl_2 (400 mL) was added a solution of MsCl (10.1 g, 89 mmol) in CH_2Cl_2 (50 mL) at 0-5 °C. After addition, the reaction mixture was allowed to warm to rt and stir for 1 hr. The reaction was washed with water (200 mL) and the aqueous layer was extracted with CH_2Cl_2 (3×150 mL). The combined organic layers was washed with 10% citric acid (60 mL), sat. $NaHCO_3$ (60 mL) and brine (100 mL), then dried over Na_2SO_4, filtered and concentrated to give (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-

butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (37.7 g, 100%), which was used in the next step without purification.

Step 7. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (37.7 g, 74.2 mmol) in THF (1000 mL) was added tetraethylammonium fluoride hydrate (41 g, 185.5 mmol) in portions. The reaction mixture was stirred under reflux overnight. The mixture was diluted with EtOAc (1000 mL), washed with water (300 mL) and brine (500 mL). The organic phase was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate (12.0 g, 54%).

PREPARATION M1

tert-butyl (*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate



Step 1. tetrahydro-2*H*-pyran-3-ol

To the solution of 3,4-dihydro-2*H*-pyran (126 g, 1.5 mol) in dry THF (1350 mL) was added a solution of B_2H_6 in Me_2S (10 M, 75mL, 0.75 mol) under nitrogen atmosphere at 0 °C. The mixture was stirred at this temperature for 3 hr, and then was stirred at 25 °C for another 2 hr. The mixture was warmed to 40-45 °C, and was added aq. NaOH (3 N, 390 mL) and H_2O_2 (30%, 270mL). After stirring for 2 hr, the reaction was quenched by sat. brine. The mixture was filtered, and the filtrate was extracted with EtOAc (3×300 mL). The organic phase was washed with aq. $Na_2S_2O_3$ (3×100 mL), dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product, which was purified through column chromatography to give tetrahydro-2*H*-pyran-3-ol (72.8 g, 48%). ^{1}H NMR (CD_3OD) δ 3.7-3.6 (m, 4H), 3.6-3.5 (m, 1H), 3.4-3.3 (m, 1H), 1.9-1.7 (m, 2H), 1.6-1.5 (m, 2H),

Step 2. dihydro-2*H*-pyran-3(4H)-one

To the solution of tetrahydro-2*H*-pyran-3-ol (30 g, 0.29 mol) in dry CH_2Cl_2 (900 mL) was added 3Å molecule series (30g) and PCC (94.9g, 0.44mol). The mixture was stirred at rt overnight. When the reaction was over, the mixture was filtered through celite, dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product, which was purified through column chromatography to give dihydro-2*H*-pyran-3(4*H*)-one (23 g, 76%). ^{1}H NMR (CD_3OD) δ 3.9 (s, 2H), 3.8-3.7 (t, 2H), 3.7-3.6 (m, 4H), 2.5-2.4 (m, 2H), 2.0-1.9 (m, 2H).

Step 3. 3-(dihydro-2*H*-pyran-3(4*H*)-ylidene)propan-1-ol

To a suspension of the phosphonium salt (69 g, 1.5 eg) in dry THF (1100 mL) at 0 °C under nitrogen atmosphere was added *n*-BuLi (2.5 M, 111 mL, 0.413 mol). The solution was stirred for 1 hr, followed by addition of dihydro-2*H*-pyran-3(4*H*)-one (11.5 g, 0.115 mol). Stirring was continued at rt overnight. The mixture was quenched by sat. aq. NH_4Cl, and then filtered. The filtrate was dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product, which was purified through column chromatography to give 3-(dihydro-2*H*-pyran-3(4*H*)-ylidene)propan-1-ol (11.2 g, 69%). ^{1}H NMR (CD_3OD) δ 4.2-3.9 (d, 2H),), 3.8-3.5 (m, 4H), 2.4-2.2 (m, 4H), 5.3-5.2 (d, 1H), 2.1-1.8 (s, 1H), 1.8-1.6 (m, 2H).

Step 4. 3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol

To the solution of compound 3-(dihydro-2*H*-pyran-3(4*H*)-ylidene)propan-1-ol (11.2 g, 0.0789 mol) in methanol (200 mL) was added $Pd(OH)_2/C$ (1.12g). The reaction flask was degassed and filled with H_2. When the reaction was over, the mixture was filtered through celite, and the filter cake was washed with MeOH (2×10 mL). The combined organic layers were dried over Na_2SO_4, and concentrated *in vacuo* to give 3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (10.35g, yield 91 %), which was used for the next step without further purification. ^1H NMR (CD_3OD) δ 3.9-3.8 (m, 1H), 3.7-3.6 (m, 2H), 3.5-3.4 (m, 1H), 3.3 (m, 1H), 3.1-2.9 (t, 1H), 2.6-2.4 (m, 1H), 2.3-1.8 (m, 3H), 1.6-1.4 (m, 4H), 1.3-1.0 (m, 2H).

Step 5. 3-(tetrahydro-2*H*-pyran-3-yl)propanal

To the solution of 3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (10.35 g, 0.0719 mol) in CH_2Cl_2 (200 mL) was added Dess-Martin periodinane (61.24 g, 0.1438 mol). The mixture was stirred at rt. When the reaction was over, the solution was poured into Et_2O (300 mL) and anhydrous K_2CO_3 (19.84 g, 0.1438 mol) was added. The mixture was filtered and the filtrate was dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product, which was purified through column chromatography to give 3-(tetrahydro-2*H*-pyran-3-yl)propanal (8.25 g, 80%).

Step 6. dibenzyl 1-((2*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-yl)hydrazine-1,2-dicarboxylate

To a stirred solution of 3-(tetrahydro-2*H*-pyran-3-yl)propanal (8.25 g, 0.058 mol) and dibenzyl azodicarboxylate (94%, 12.3 g, 0.041 mol) in MeCN (250 mL) at 0 °C was added (*R*-proline) (0.47 g, 0.0041 mol). After stirring the mixture at 0 °C for 15 hr, ethanol (100 mL) and $NaBH_4$ (1.56 g, 0.041 mol) was added, and the mixture was stirred at 0 °C for 40 min. The reaction was quenched by slow addition of 10% aqueous citric acid (15 ml), and the whole solution was concentrated *in vacuo*. This residue was diluted with EtOAc (200 ml), washed with saturated brine(1×50 mL), dried over Na_2SO_4, and concentrated *in vacuo* to give the crude product, which was purified

through column chromatography to give dibenzyl 1-((2*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-yl)hydrazine-1,2-dicarboxylate (14.68 g, 81%).

Step7. (2*S*)-2-hydrazinyl-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol

To the solution of 1-((2*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-yl)hydrazine-1,2-dicarboxylate (14.68 g, 0.0332 mol) in methanol (250 mL) was added $Pd(OH)_2/C$ (1.47 g). The reaction flask was degassed and filled wirh H_2. When the reaction was over, the mixture was filtered through celite, and the filter cake was washed with MeOH (2×20 mL). The combined organic solvent was dried over Na_2SO_4, and concentrated *in vacuo* to give (2*S*)-2-hydrazinyl-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (5.79 g, 94 %), which was used for the next step without purification.

Step 8. (2*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol

To the solution of (2*S*)-2-hydrazinyl-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (5.79 g, 0.033 mol) in MeOH (100 mL) was added Raney Ni. The flask was degassed and equipped with a hydrogen inflated balloon. The flask was dipped into an ultrasound bath filled with water and sonicated for 4 hr at rt until the starting material was completely consumed. The mixture was then filtered through celite, and the filter cake was washed with MeOH (2×30 mL). Removal under reduced pressure gave (2*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (5.4 g, 90%).

Step 9. *tert*-butyl (*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

To a solution of 2-amino-3-(tetrahydro-pyran-3-yl)-propan-1-ol (5.4 g, 0.034 mol) and Et_3N (10.23 g, 0.101 mol) in CH_2Cl_2 (54 mL) at 0 °C was added Boc_2O (8.829 g, 0.041 mol). After stirring at rt for 2 h, the mixture was concentrated to give *tert*-butyl (*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate 9.7 g), which was used for the next reaction without further purification. ^{1}H NMR (CD_3OD) δ 1.2-1.3 (m, 3H), 1.3-1.5 (m, 10H), 1.6-1.7 (m, 3H), 1.8-1.9 (m, 1H), 2.6-2.7 (s, 1H), 3.0-3.1 (m, 1H), 3.3-3.4 (m, 1H), 3.5-3.7 (m, 3H), 3.8-3.9 (m, 2H), 4.6-4.8 (d, 1H).

The following compound was prepared following procedures analogous to those descried above:

1) *tert*-butyl (*S*)-1-hydroxy-3-(tetrahydrofuran-3-yl)propan-2-ylcarbamate using 2,3-dihydrofuran in Step 1 and Dess-Martin Periodiane oxidation in Step 2.

2) (*S*)-*tert*-butyl 1-hydroxy-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamate following Steps 3-9, using tetrahydropyran-4-one in Step 3.

Preparation N1

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate



Step 1. *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

(*S*)-*tert*-Butyl-2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate (9 g, 30.1 mmol) was dissolved in 80% CH_3CO_2H (90ml). The solution was stirred at 50 °C during 1.5 hr and evaporated to dryness at reduced pressure. The residue was dissolved in Et_2O (150ml) and washed with saturated $NaHCO_3$ (4×100 mL) . The organic layer was dried over Na_2SO_4, filtered, and the solvent removed under reduced pressure to give *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (6.2 g, 79.5%) as an oil ,which was used in the next step without further purification.

Step 2. (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl methanesulfonate

To a solution of *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (6.2 g, 23.9 mmol) and triethylamine (7.25 g, 71.8 mmol) in CH_2Cl_2 at 0 °C was added mesyl chloride (5.5 g, 47.8 mmol) dropwise. The reaction mixture was stirred at rt until the starting material disappeared. The reaction was quenched with ice-cold water and extracted with CH_2Cl_2 (3×100 ml). The combined organic layers were washed with water (3×50 ml), dried over Na_2SO_4, and concentrated under *vacuo* to give the (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl methanesulfonate (9 g), which was used for the next step without purification.

Step 3. *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

To an ethanol solution of $MeNH_2$ (100 mL) was added *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (9 g, 26.7 mmol). The mixture was stirred at 30-40 °C overnight. When the reaction was complete, the solution was concentrated to afford *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (10 g), which was used for the further reaction without purification.

Step 4. (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate

Solid 1-[2-Trimethylsilyl)ethxoycarbonyloxy]pyrrolidin-2,5-dione (9.5 g, 36.7 mmol) was added to a vigorously stirred biphasic solution of the *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (10 g, 36.7 mmol), K_2CO_3 (15.1 g, 110.1mmol), H_2O (50 mL) and CH_2Cl_2 (100 mL). After the reaction was stirred for 2 hr at rt, the reaction was taken up into 65mL of CH_2Cl_2. The solution was washed with aq. $NaHCO_3$ (3×50 mL) and brine (3×50 mL), then dried over Na_2SO_4. The organic layer was concentrated under vacuum to give the crude product, which was purified through column chromatography to give (*S*)-*tert*-butyl 1-

(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate (6 g, 46.2%).

Step 5. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate

To a solution of (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate (6 g, 14.4 mmol) in Et_2O (100 mL) was added a solution of tosic acid (2.8 g, 14.4 mmol) in 13.0 mL of absolute EtOH. This solution was placed on a rotary evaporator and the Et_2O was removed at ambient temp. The flask was then lowered into a 60 °C water bath and the remainder of the solvent was evaporated over 2 hr to afford a white solid. The solid was cooled to rt and dissolved into 80 mL of a mixture of 1:1 EtOH:H_2O. This was washed with 5:1 Hexanes:EA (3×10mL), basified with 1N NaOH (pH>10), and extracted with Et_2O (3×50 mL). The combined Et_2O extracts were washed with brine (3×5mL), dried over Na_2SO_4, concentrated under vacuum to give 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate 3.3 g (72%).

The following compound was prepared following procedures analogous to those descried above:

1) 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate following Steps 2-5, using *tert*-butyl (*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate in Step 2.
2) 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(tetrahydrofuran-3-yl)propyl(methyl)carbamate following Steps 2-5, using *tert*-butyl (*S*)-1-hydroxy-3-(tetrahydrofuran-3-yl)propan-2-ylcarbamate in Step 2.
3) (*S*)-2-(trimethylsilyl)ethyl 2-amino-3-(tetrahydro-2*H*-pyran-4-yl)propyl(methyl)carbamate following Steps 2-5, using (*S*)-*tert*-butyl 1-hydroxy-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamate in Step 2.
4) 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-oxepan-3-yl)propyl(methyl)carbamate following Steps 2-5, using *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamate in Step 2.

PREPARATION O1

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propyl(methyl)carbamate



Step 1. (2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-carboxylic acid

A 500 mL round-bottomed equipped with a thermocouple was charged with (2*S*,6*R*)-2,6-dimethyl-tetrahydropyran-4-one (10.2 g, 0.08 mol, 1.0 equiv), *p*-tolylsulphonylmethyl isocyanide (20.2 g, 0.103 mol, 1.3 equiv), ^{t}BuOH (10.0 g, 0.135 mol, 1.7 equiv) and DME (300 mL). The mixture was cooled in an ice/brine bath so that the internal temperature was below 0 °C, and KO^{t}Bu (22.3 g, 0.199 mol, 2.5 equiv) was added in portions at a rate which maintained the reaction temperature below 10 °C. The mixture was heated to 35 °C and allowed to stir for 16h. After this time the mixture was cooled to ambient and ca 100 mL of Et_2O was added. The mixture was filtered through a bed of Celite and the cake washed with additional Et_2O. The resulting orange solution was evaporated. The tacky residue was taken up in Et_2O and the resulting solution filtered through Celite and evaporated, yielding 10.0 g of the crude nitrile. This material was placed in a flask containing 200 mL of 2.25 M KOH. The mixture was heated to reflux for 17 h. The mixture was then cooled to ambient temperature and transferred to a separatory funnel. The aqueous layer was extracted with 3 x 50 mL of CH_2Cl_2 and placed in a flask and cooled to 0 °C. The pH was lowered to <2 by addition of concentrated HCl. The resulting slurry was transferred to a separatory funnel and

extracted with 4 x 50 mL of EtOAc. The combined organic fractions were washed with brine, then added to a flask containing ~1 g of activated carbon and the mixture stirred for 1h. After this time it was filtered through a pad of Celite and evaporated to yield (2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-carboxylic acid as a tan solid.

Step 2. ((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)methanol

The (2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-carboxylic acid above acid (2.10 g, 13.3 mmol, 1.0 equiv) was dissolved in THF and the solution cooled to 0 °C. To this was added a solution of BH_3 (1.0 M in THF, 20 mL, 20 mmol, 1.5 equiv). The mixture was stirred for 1.5 h at 0 °C. The excess BH_3 was quenched by the dropwise addition of saturated NH_4Cl. The mixture was transferred to a separatory funnel and the layers separated. The aqueous layer was extracted with 3 x 20 mL of EtOAc, and the combined organic extracts washed with brine, dried over Na_2SO_4, filtered, and evaporated. The crude alcohol was purified by flash chromatography on silica, eluting with 0 – 49% EtOAc. This afforded 1.67 g (87% yield) of ((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)methanol.

Step 3. (2*S*,4*r*,6*R*)-4-(iodomethyl)-2,6-dimethyl-tetrahydro-2*H*-pyran

The ((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)methanol (1.67 g, 11.6 mmol, 1.0 equiv), PPh_3 (3.64 g, 13.9 mmol, 1.2 equiv) and imidazole (2.36 g, 34.7 mmol, 3.0 equiv) were dissolved in 67 mL of THF and the solution cooled to 0 °C. Iodine (3.67 g, 14.5 mmol, 1.25 equiv) was added in ca 0.5 g portions over a 0.5 h period. After stirring for 1h an additional 1.62 g of PPh_3 and 1.83 g of I_2 were added and the mixture stirred for 1h. The solvent was removed and the mixture filtered through a pad of silica, eluting with Et_2O. The filtrate was evaporated and the iodide purified by flash chromatography on silica, eluting with 0-7% EtOAc in hexanes. This afforded 1.69 g (57% yield) of (2*S*,4*r*,6*R*)-4-(iodomethyl)-2,6-dimethyl-tetrahydro-2*H*-pyran.

Step 4. (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propanoate

The (*R*)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (3.20 g, 17.4 mmol, 2.6 equiv) was dissolved in 70 mL of THF and the solution cooled to -78 °C. A 2.5 M solution of ^{n}BuLi (10.8 mL, 17.4 mmol, 2.6 equiv) was added over a 15 min period and the resulting solution stirred for 0.5 h. A solution of (2*S*,4*r*,6*R*)-4-(iodomethyl)-2,6-dimethyl-tetrahydro-2*H*-pyran (1.69 g, 6.56 mmol, 1.0 equiv) was added. The mixture was stirred at -78 °C for 2h, then warmed to -20 °C and allowed to stir overnight at that temperature. The mixture was quenched with water and the organic layer washed with brine, dried over Na_2SO_4, filtered, and evaporated. The resulting mixture was dissolved in 300 mL of 1:1 CH_3CN:2.0 M HCl. After stirring for 2 h at ambient temperature the mixture was evaporated and re-dissolved in 100 mL of CH_3CN. To this was added 200 mL of 10% K_2CO_3, followed by 8.5 g (35 mmol, 5.2 equiv) of CBzOSu and the mixture rapidly stirred for 1h. After the time the solution was evaporated. The yellow residue was dissolved in EtOAc and washed with 10% K_2CO_3, 0.5 M HCl, brine, then dried over Na_2SO_4, filtered, and evaporated. The desired protected amino acid was purified by flash chromatography on silica, eluting with 0-29% EtOAc. The (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propanoate isolated from this procedure (2.57 g) was contaminated with ca 20% $CBzNHCH_2CO_2Me$ and was used in subsequent steps.

Step 5. benzyl (*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-hydroxypropan-2-ylcarbamate

The (*S*)-methyl 2-(benzyloxycarbonylamino)-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propanoate (2.57 g, 7.4 mmol, 1.0 equiv) and MeOH (0.5 mL) were added to THF (50 mL) and the mixture cooled to 0 °C. Solid $LiBH_4$ (481 mg, 22 mmol, 3.0 equiv) was added and the mixture stirred for 2h. The mixture was allowed to stir at 0 °C until the starting material was consumed by LC/MS analysis. After this time the excess $LiBH_4$ was quenched by addition of saturated NH_4Cl and the contents transferred to a separatory funnel. The layers were separated, the aqueous layer was extracted with EtOAc, and the combined organic layers washed with brine, dried over Na_2SO_4, filtered and evaporated. The benzyl (*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-

tetrahydro-2*H*-pyran-4-yl)-3-hydroxypropan-2-ylcarbamate was used in the next step with no further purification.

Step 6. (*S*)-2-(benzyloxycarbonylamino)-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propyl 4-bromobenzenesulfonate

The benzyl (*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-hydroxypropan-2-ylcarbamate, DMAP (1.12 g, 9.2 mmol) and NEt^iPr_2 (2.1 g, 14.7 mmol) were dissolved in 40 mL of CH_2Cl_2 and the mixture cooled to 0 °C. Brosylchloride (2.35 g, 9.2 mmol) was added the mixture stirred for 2.5 h with warming to ambient temperature. The mixture was quenched by addition of saturated NH_4Cl and the mixture transferred to a separatory funnel, and the organic layer was washed with brine, then dried over Na_2SO_4, filtered, and evaporated. The (*S*)-2-(benzyloxycarbonylamino)-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propyl 4-bromobenzenesulfonate was purified by flash chromatography on silica, eluting with 0-27% EtOAc in hexanes.

Step 7-8. benzyl (*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)propan-2-ylcarbamate

Benzyl (*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)propan-2-ylcarbamate was obtained following procedures analogous to Preparation U, Steps 6-7, using (*S*)-2-(benzyloxycarbonylamino)-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propyl 4-bromobenzenesulfonate in Step 6.

Step 9. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propyl(methyl)carbamate

Benzyl (*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)propan-2-ylcarbamate (540 mg, 1.13 mmol) and 10% Pd/C (200 mg) were shaken under 45 psi of H_2 for 3h. After this time LC/MS showed clean removal of the CBz group. The mixture was filtered and evaporated to yield 388 mg of 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)propyl(methyl)carbamate.

PREPARATION P1

(*S*)-2-(trimethylsilyl)ethyl 2-amino-4-(1-methoxycyclopentyl)butyl(methyl)carbamate



Step 1. (*S*)-*tert*-butyl 4-(2-(1-hydroxycyclopentyl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (1.02 g, 3.55 mmol, 1.0 equiv) was dissolved in 50 mL of THF and cooled to -10 °C. A 1.0 M solution of $BrMg(CH_2)_4MgBr$ (7.1 mL, 2.0 equiv) was added and the mixture stirred for 2h. After this time a second portion of $BrMg(CH_2)_4MgBr$ was added and the mixture stirred for 1h. The mixture was quenched by addition of saturated NH_4Cl and the mixture transferred to a separatory funnel, and the organic layer was washed with brine, then dried over Na_2SO_4, filtered, and evaporated to provide crude (*S*)-*tert*-butyl 4-(2-(1-hydroxycyclopentyl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate.

Step 2. (*S*)-*tert*-butyl 4-(2-(1-methoxycyclopentyl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 4-(2-(1-hydroxycyclopentyl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate was added to a suspension of NaH (568 mg, 14.2 mmol, 4.0 equiv) and the mixture stirred for 0.5 h. Methyl iodide (2.106 g, 14.2 mmol, 4.0 equiv) was added and the mixture stirred for 48 h at ambient temperature. The excess NaH was quenched by careful addition of water. The mixture was evaporated, and then taken up in EtOAc. The solution was washed with water, then brine and evaporated. The ether was purified

by flash chromatography on silica, eluting with 0- 41% EtOAc in hexanes. This afforded 1170 mg (3.4 mmol, 95% yield for two steps) of the desired (*S*)-*tert*-butyl 4-(2-(1-methoxycyclopentyl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate.

Step 3. (*S*)-*tert*-butyl 1-hydroxy-4-(1-methoxycyclopentyl)butan-2-ylcarbamate

The above (*S*)-*tert*-butyl 4-(2-(1-methoxycyclopentyl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate (1170 mg, 3.5 mmol, 1.0 equiv) was dissolved in 40 mL of methanol. Camphorsulphonic acid (417 mg, 1.8 mmol, 0.5 equiv) was added and the mixture stirred for 4h at ambient temperature. The mixture was quenched by addition of ca. 1 mL of NEt_3 and the reaction evaporated. The residue was taken up in EtOAc, washed with brine, then dried over $MgSO_4$, filtered through a pad of silica gel, and evaporated. This afforded 1.03 g (3.5 mmol, 100% yield) of the desired (*S*)-*tert*-butyl 1-hydroxy-4-(1-methoxycyclopentyl)butan-2-ylcarbamate .

Step 2-5. (*S*)-2-(trimethylsilyl)ethyl 2-amino-4-(1-methoxycyclopentyl)butyl(methyl)carbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-4-(1-methoxycyclopentyl)butyl(methyl)-carbamate was obtained using procedures analogous to Preparation S, Steps 3-6, using (*S*)-*tert*-butyl 1-hydroxy-4-(1-methoxycyclopentyl)butan-2-ylcarbamate in Step 3.

PREPARATION Q1

(*S*)-benzyl 2-amino-3-(4-oxocyclohexyl)propyl(methyl)carbamate



Step 1. (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)propanoate

To a solution of the (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-hydroxycyclohexyl)propanoate (96.56 g, 0.32 mol) in CH_2Cl_2 (500 mL) was added imidazole (43.52 g, 0.64 mol), followed by TBSCl (72 g, 0.48 mol) at 0 °C. After addition, the mixture was allowed to stir at rt overnight. The reaction mixture was treated with water and extracted with CH_2Cl_2. The organic layer was dried over Na_2SO_4, filtered, and evaporated to give (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)propanoate (133 g, yield 100%). ^{1}H NMR: ($CDCl_3$, 400 MHz) δ 0.08 (d, 6 H), 0.89 (d, 9 H), 1.45 (s, 9 H), 1.51 (m, 4 H), 1.58 (m, 1 H), 1.68 (t, 4 H), 1.85 (d, 1 H) 3.71 (d, 3 H), 3.91 (m, 1 H), 4.34 (m, 1 H), 4.86 (m,1 H).

Step 2. (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-hydroxypropan-2-ylcarbamate

To a solution of (*S*)-methyl 2-(*tert*-butoxycarbonylamino)-3-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)propanoate (133 g, 0.32 mol) in 1500 mL methanol was added $NaBH_4$ (73 g, 1.92 mol) at rt. After stirring at rt for 4 h, the solution was evaporated to remove methanol. The remaining solution was treated with water (800 mL), extracted with EtOAc (500 mL x 3). The combined organic layers were washed with water (300 mL), dried, filtered, and evaporated to give the desired (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-hydroxypropan-2-ylcarbamate (102 g, yield 82%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.08 (d, 6 H), 0.89 (d, 9 H), 1.30 (m, 4 H), 1.40 (t, 2 H), 1.45 (s, 9 H), 1.61 (m, 1 H), 1.58 (m, 1 H), 1.68 (t, 4 H), 1.85 (d, 1 H), 3.50 (m, 1 H), 3.65 (m, 1 H), 3.73 (m, 1 H), 3.91 (s, 1 H), 4.53 (s, 1 H).

Step 3. (*S*)-2-(*tert*-butoxycarbonylamino)-3-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)propyl methanesulfonate

To a solution of (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-hydroxypropan-2-ylcarbamate (101.6 g, 0.263 mol) and Et_3N (66.3 g, 0.656 mol) in CH_2Cl_2 (500 mL) was added MsCl (66.1 g, 0.577 mol) at –20 °C, which was allowed stir for 1 h at rt. The reaction mixture was treated with water (300 mL) and extracted with CH_2Cl_2 (3×100 mL). The organic layers dried over Na_2SO_4 and evaporated give (*S*)-2-(*tert*-butoxycarbonylamino)-3-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)propyl methanesulfonate (121 g, 99%).

Step 4. (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(methylamino)propan-2-ylcarbamate

(*S*)-2-(*tert*-butoxycarbonylamino)-3-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)propyl methanesulfonate (121 g, 0.26 mol) was dissolved in methylamine alcohol solution (1000 mL), which was heated to 50-60 °C overnight. The solvent was removed and the residue was purified by silica column to give a crude (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(methylamino)propan-2-ylcarbamate (57 g, 55%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.08 (d, 6 H), 0.89 (d, 9 H), 1.25 (t, 3 H), 1.45 (s, 9 H), 1.61 (m, 2 H), 1.82 (t, 2 H), 2.01 (d,

1 H), 2.56 (d, 2 H), 2.80 (d, 2 H), 2.95 (t, 2 H), 3.49 (m, 1 H), 3.61 (m, 1 H), 3.90 (s, 1 H), 5.35 (d, 1 H), 7.15 (m, 1 H).

Step 5. (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(methylamino)propan-2-ylcarbamate (57 g, 0.142 mol) and Et_3N (28.8 g, 0.285 mol) in CH_2Cl_2 (600 mL) was added CbzCl (26.6 g, 0.156 mol) at –20 °C, which was allowed to stir for 1 h at rt. The reaction mixture was treated with water (200 mL) and extracted with CH_2Cl_2 (3×100 mL). The organic layer was dried over Na_2SO_4 and evaporated. The residue was separated on a silica column to give the pure isomer (*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamate (5.5 g) and a fraction with a mixture isomers (33 g, total yield 51%). Mixture isomer: ^1H NMR ($CDCl_3$, 400 MHz) δ 0.02 (d, 6 H), 0.88 (s, 9 H), 1.16-1.29 (m, 5 H), 1.41 (d, 9 H), 1.60 (m, *5* H), 1.83 (m, 1 H), 2.95 (t, 3 H), 3.00-3.40 (m, 1 H), 3.49 (m, 1 H), 3.89 (m, 2 H), 5.11 (s, 2 H), 7.34 (m, 5 H).

Step 6. (*S*)-benzyl 2-amino-3-(4-hydroxycyclohexyl)propyl(methyl)carbamate

(*S*)-*tert*-butyl 1-(4-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamate (1.2 g, 2.25 mmol) was dissolved in 2 M HCl MeOH (10 mL) and stirred at 30 °C for 1 hr. The solvent was removed to give the crude (*S*)-benzyl 2-amino-3-(4-hydroxycyclohexyl)propyl(methyl)carbamate which was used for next step directly.

Step 7. (*S*)-*tert*-butyl 1-(4-hydroxycyclohexyl)-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamate

(*S*)-benzyl 2-amino-3-(4-hydroxycyclohexyl)propyl(methyl)carbamate (1.25 g, 3.9 mmol) was dissolved in 10 mL CH_2Cl_2, Et_3N was added, the mixture was cooled to 0 °C and Boc_2O in 5 mL of CH_2Cl_2 was added dropwise. The reaction mixture was stirred at rt for two hr. The mixture was added 50 mL of CH_2Cl_2 washed with 10% citric acid solution (20 mL) then with saturated $NaHCO_3$, brine, and dried over Na_2SO_4.

After filtration, solvent removal gave (*S*)-*tert*-butyl 1-(4-hydroxycyclohexyl)-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamate (1.1 g, 2.62 mmol).

Step 8. (*S*)-*tert*-butyl 1-(N-methyl-N-(benzyloxycarbonyl)amino)-3-(4-oxocyclohexyl)propan-2-ylcarbamate

A solution of DMSO (0.82 g, 10.47 mmol) in 10 mL of dry CH_2Cl_2, under protection of N_2, was cooled to -78 °C, followed by the slow, dropwise addition of oxalyl chloride (0.664 g, 5.23 mmol). After addition the mixture was stirred 2 hr at -65 °C, then the solution of (*S*)-*tert*-butyl 1-(4-hydroxycyclohexyl)-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamate (1.1 g, 2.62 mmol) was added dropwise. After addition, the mixture was stirred 3 hr at -30 °C. The reaction was quenched with Et_3N (4 mL) and stirred 10 min, then saturated $NaHCO_3$ (10 mL) was added. The aqueous layer was extracted 3 times with CH_2Cl_2 (3×20 mL). The CH_2Cl_2 layer was washed with 10% citric acid solution (20 mL), followed by saturated $NaHCO_3$, brine, then dried over Na_2SO_4. After filtration, solvent removal gave crude product (1 g), which was purified by preparative TLC to give (*S*)-*tert*-butyl 1-(N-methyl-N-(benzyloxycarbonyl)amino)-3-(4-oxocyclohexyl)propan-2-ylcarbamate (500 mg, 1.2 mmol).

Step 9. (*S*)-benzyl 2-amino-3-(4-oxocyclohexyl)propyl(methyl)carbamate

(*S*)-*tert*-butyl 1-(N-methyl-N-(benzyloxycarbonyl)amino)-3-(4-oxocyclohexyl)propan-2-ylcarbamate (300 mg, 0.72 mmol) was dissolved in 5 mL of 20% TFA/ CH_2Cl_2 and stirred 1 hr at rt. The solvent was removed to give the crude (*S*)-benzyl 2-amino-3-(4-oxocyclohexyl)propyl(methyl)carbamate, which was used directly for the next step without further purification.

The following compounds were made analogously to those described above: (*S*)-benzyl 2-amino-3-(4-hydroxycyclohexyl)propyl(methyl)carbamate, Step 1 - Step 6.

PREPARATION R1

(*S*)-*tert*-butyl 1-amino-5-methoxy-4,4-dimethylpentan-2-ylcarbamate



Step 1. (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid

To a solution of (*S*)-2-amino-5-methoxy-5-oxopentanoic acid (100 g, 621 mmol) and $NaHCO_3$ (133.5 g, 1.55 mol) in water (1.6 L) was added a solution of Boc_2O (162.5 g, 745 mmol) in 1,4-dioxane (1.6 L). The mixture was stirred for 32 h at rt and then was filtered and washed with Et_2O (500 mL). The aqueous layer was acidified with 1 N aqueous HCl to pH=2 and was extracted with methylene chloride and propan-2-ol (1:3, 1Lx2). The extract was washed with brine (500mL), dried over $MgSO_4$, filtered and concentrated *in vacuo* to give (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid (112 g, yield 84%) as an oil that was used in the next step without further purification. ^1H NMR ($CDCl_3$, 400 MHz) δ 3.69 (s, 3 H), 4.33 (m, 1 H), 2.475 (m, 2 H), 2.23 (m, 1 H), 2.05 (m, 1 H), 1.445 (s, 9 H).

Step 2. (*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate

To a solution (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid (26.1 g, 0.1 mol) in THF (500 mL), BH_3•Me_2S (80 mL, 0.8 mmol) was added dropwise at –78 °C, then stirred at rt for 3 hrs. The reaction was stopped by careful addition of methanol. After evaporation and three distillations of methanol, the residue was

dissolved in EtOAc, washed with 1 M $NaHCO_3$, and brine. (*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate (12 g, yield 49%) was obtained as an oil that was used in the next step without further purification.

Step 3. (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate (12 g, 48.6 mmol) and isopropenyl methyl ether (44.4 g, 427.3 mmol) was dissolved in acetone (200 mL) and $BF_3 \cdot Et_2O$ (0.41 mL, 2.92 mmol) was added at rt and stirred for 1 hour. The reaction was stopped by addition of Et_3N (5.8 mL). The reaction solution was washed with 100 mL of saturated $NaHCO_3$ and evaporated, and (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (10 g, yield 72%) was obtained as an oil that was used in the next step without further purification.

Step 4. (*S*)-*tert*-butyl 4-(3-methoxy-2,2-dimethyl-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate

To a –78 °C solution LiHMDS (139.3 mmol) in THF (100 mL) was added a solution of (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (10 g, 34.82 mmol) in THF (50 mL) over 30 min. The mixture was stirred at –78 °C for 1 h, and methyl iodide (24.7 g, 174.1 mmol) was added. Stirring was continued at –78 °C for another 1 h, then the reaction was stirred overnight at rt. The reaction was stopped by addition of saturated NH_4Cl. (*S*)-*tert*-butyl 4-(3-methoxy-2,2-dimethyl-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate was obtained by extraction with EtOAc and the residue was purified by column chromatography on silica gel eluting with EtOAc/Petroether (1:50→1:10) to provide the yellow oil (7 g, 63%).

Step 5. (*S*)-*tert*-butyl 4-(3-hydroxy-2,2-dimethylpropyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-(3-methoxy-2,2-dimethyl-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (7 g, 22.21 mol) in THF was added with $LiAlH_4$ (1.27 g, 33.31 mol). The reaction mixture was stirred overnight at rt. Water was added

and extracted with EtOAc, dried over Na_2SO_4 and concentrated *in vacuo* to give the crude product (*S*)-*tert*-butyl 4-(3-hydroxy-2,2-dimethylpropyl)-2,2-dimethyloxazolidine-3-carboxylate (6.6 g, 100%) as an oil that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 3.69 (m, 4 H), 3.32 (m, 1 H), 1.82 (m, 1 H), 1.54 (s, 3 H), 1.48 (s, 9 H), 1.42 (s, 3 H), 1.22 (m, 1 H), 0.91 (m, 3 H), 0.72 (s, 2 H).

Step 6. (*S*)-*tert*-butyl 4-(3-methoxy-2,2-dimethylpropyl)-2,2-dimethyloxazolidine-3-carboxylate

To a suspension of NaH (2.76 g, 69 mmol) in DMF (100 mL) was added dropwise a solution of (*S*)-*tert*-butyl 4-(3-hydroxy-2,2-dimethylpropyl)-2,2-dimethyloxazolidine-3-carboxylate (6.6 g, 23 mmol) in DMF (150 mL). After the reaction mixture was stirring for 2 h, MeI (6.53 g, 46 mmol) was added dropwise. The mixture was quenched with NH_4Cl (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. (*S*)-*tert*-butyl 4-(3-methoxy-2,2-dimethylpropyl)-2,2-dimethyloxazolidine-3-carboxylate (6.4 g, 93%) was obtained as an oil that was used in the next step without further purification.

Step 7. (*S*)-*tert*-butyl 1-hydroxy-5-methoxy-4,4-dimethylpentan-2-ylcarbamate

(*S*)-*tert*-butyl 4-(3-methoxy-2,2-dimethylpropyl)-2,2-dimethyloxazolidine-3-carboxylate (6.4 g, 21.3 mmol) was dissolved in 70% CH_3COOH. The solution was heated to 50-60 °C and stirred for 2 h. The reaction solution was evaporated to give (*S*)-*tert*-butyl 1-hydroxy-5-methoxy-4,4-dimethylpentan-2-ylcarbamate (7.8 g, 100%) as an oil that was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 3.69 (m, 3 H), 3.32 (s, 3 H), 3.01 (m, 2 H), 2.11 (s, 7 H), 1.48 (m, 10 H), 1.23 (m, 22 H), 0.91 (m, 18 H).

Step 8. (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-4,4-dimethylpentyl methanesulfonate

A solution of (*S*)-*tert*-butyl 1-hydroxy-5-methoxy-4,4-dimethylpentan-2-ylcarbamate (7.8 g, 30 mmol) in methylene chloride (150 mL) and Et_3N (10.4 mL, 75

mmol) was cooled to -20 °C, MsCl (6.9 g,60 mmol) was added with fast dropwise addition maintaining the internal temperature at -20 °C. The reaction mixture was stirred for 1 h in rt. The reaction was quenched with water (100mL), extracted with CH_2Cl_2 (3 x 100 mL), washed with water and brine, dried over Na_2SO_4 and concentrated *in vacuo* to give (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-4,4-dimethylpentyl methanesulfonate (10.1 g, 100%) as an oil that was used in the next step without further purification.

Step 9-10. (*S*)-*tert*-butyl 1-amino-5-methoxy-4,4-dimethylpentan-2-ylcarbamate

(*S*)-*tert*-butyl 1-amino-5-methoxy-4,4-dimethylpentan-2-ylcarbamate was obtained following procedures analogous to Preparation H1, Steps 2-3, using (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-4,4-dimethylpentyl methanesulfonate in Step 2. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 3.69 (m, 1 H), 3.48 (s, 1 H), 3.32 (m, 3 H), 3.11 (m, 2 H), 2.61 (m, 2 H), 1.62 (s, 3 H), 1.48 (s, 9 H), 1.42 (m, 2 H), 0.91 (d, 6 H).

PREPARATION S1

(*S*)-2-(trimethylsilyl)ethyl 2-amino-5-methoxypentyl(methyl)carbamate

(*S*)-2-(trimethylsilyl)ethyl 2-amino-5-methoxypentyl(methyl)carbamate was obtained using procedures analogous to Preparation R1, Steps 5-7, and Preparation S, Steps 3-6 starting with (S)-tert-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate in Preparation R1, Step 5.

PREPARATION T1

(*R*)-*tert*-butyl 1-amino-3-phenoxypropan-2-ylcarbamate



Step 1. (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-phenoxypropan-2-ylcarbamate

(*S*)-*tert*-butyl 2-((*tert*-butyldimethylsilyloxy)methyl)aziridine-1-carboxylate (5.0 g, 17.4 mmol), phenol (4.92 g, 52.3 mmol), K_2CO_3 (24 g, 174 mmol) and 150 mL of acetonenitrile were mixed, and heated to reflux for 48 h. The mixture was filtrated, and

the filtrate was concentrated *in vacuo*. The residue was dissolved in 100 mL of EA, which was washed with water (50 mL × 2), brine (50 mL) and dried with Na_2SO_4. The solution was concentrated *in vacuo* to give crude product, which was purified with flash column to give (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-phenoxypropan-2-ylcarbamate (2.0 g, 5.2 mmol, yield 30%) ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.0 (s, 6 H), 0.87 (s, 9 H), 1.45 (s, 9 H), 3.71 (dd, 1 H), 3.85 (dd, 1 H), 3.98 (d, 2 H), 4.05 (s, 1 H), 6.93 (m, 3 H), 7.28 (m, 2 H). MS ESI +ve m/z 382 (M+1).

Step 2-3. (*S*)-2-(*tert*-butoxycarbonylamino)-3-phenoxypropyl methanesulfonate

(*S*)-2-(*tert*-butoxycarbonylamino)-3-phenoxypropyl methanesulfonate was obtained following procedures analogous to Preparation R, Steps 2-3, using (*S*)-*tert*-butyl 1-(*tert*-butyldimethylsilyloxy)-3-phenoxypropan-2-ylcarbamate in Step 2. MS ESI +ve m/z 345 (M+1).

Steps 4-5. (*R*)-*tert*-butyl 1-amino-3-phenoxypropan-2-

(*R*)-*tert*-butyl 1-amino-3-phenoxypropan-2-ylcarbamate was obtained following procedures analogous to Preparation H1, Steps 2-3, using (*S*)-2-(*tert*-butoxycarbonylamino)-3-phenoxypropyl methanesulfonate in Step 2. MS ESI +ve m/z 267 (M+1).

PREPARATION U1



Step 1. (1*R**,2*R**)-2-bromocyclohexanol

To a solution of cyclohexene (10 g, 0.122 mol) in THF (100 mL) and H_2O (100 mL) was added NBS (31 g, 0.134 mol), the reaction mixture was stirred for 2-3 hours. 20% aqueous solution of $KHSO_4$ (20 mL) was added and the solution was stirred for 20

minutes. EtOAc was added and the organic layer was separated, which was washed by aqueous $Na_2S_2O_3$ solution until the solution turned from red to colorless. The organic phase was dried, filtered, and the solvent removed by distillation. The residue (1*R**,2*R**)-2-bromocyclohexanol (22 g, 85 %) was used in the next step without further purification. ^{1}H NMR ($CDCl_3$, 400MHz) δ 1.25-1.40 (m, 3H), 1.60-1.85 (m, 3H), 2.08-2.16 (m, 1H), 2.28-2.48 (m, 1H), 3.53-3.63 (m, 1H), 3.82-3.94 (m, 1H).

Step 2. ((1*R**,2*R**)-2-bromocyclohexyloxy)(*tert*-butyl)dimethylsilane

To a solution (1*R**,2*R**)-2-bromocyclohexanol (27 g, 0.151 mol) of and imidazole (24.9 g, 0.366 mol) in DMF (500 mL) was added TBSCl (24.9 g, 0.166 mol), the reaction mixture was stirred overnight at rt. Water was added and extracted by EtOAc three times. The combined organic layers were dried, filtered, and concentrated to give ((1*R**,2*R**)-2-bromocyclohexyloxy)(*tert*-butyl)dimethylsilane (32 g, 72 %). ^{1}H NMR ($CDCl_3$, 400MHz) δ 0.05-1.05 (d, 6H), 0.90 (s, 9H), 1.20-1.40 (m, 3H), 1.60-1.85 (m, 3H), 1.98-2.10 (m, 1H), 2.25-2.40 (m, 1H), 3.63-3.73 (m, 1H), 3.85-3.97 (m, 1H).

Step 3. methyl 2-(benzyloxycarbonylamino)-3-((1*S**,2*R**)-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)propanoate

A benzene solution of ((1*R**,2*R**)-2-bromocyclohexyloxy)(*tert*-butyl)dimethylsilane (17.8 g, 0.061 mol), 2-benzyloxycarbonylamino-acrylic acid methyl ester (8 g, 0.037 mol), AIBN (1.22 g, 0.019 mol) was heated to reflux. After 5 minutes, n-Bu_3SnH (19.8 mL, 0.074 mol) was added. The resulting mixture was then stirred at reflux for 14 hours. Solvent was removed under reduced pressure, the residue was purified by column chromatography to give methyl 2-(benzyloxycarbonylamino)-3-((1*S**,2*R**)-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)propanoate (6.5 g, 24 %).

Step 4-7. benzyl 1-((1*S**,2*R**)-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(N-methyl-(N-tert-butoxycarbonyl)amino)propan-2-ylcarbamate

Benzyl 1-((1*S**,2*R**)-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(N-methyl-(N-tert-butoxycarbonyl)amino)propan-2-ylcarbamate was prepared according to procedures analogous to Preparation W, Steps 4-7, using methyl 2-

(benzyloxycarbonylamino)-3-(trans-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)propanoate in Step 4. MS ESI +ve m/z 535 (M+1).

Step 8. *tert*-butyl 2-amino-3-((1*S**,2*R**)-2-(tert-butyldimethylsilyloxy)cyclohexyl)propyl(methyl)carbamate

To the solution of benzyl 1-((1*S**,2*R**)-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)-3-(N-methyl-(N-tert-butoxycarbonyl)amino)propan-2-ylcarbamate (420 mg) in MeOH (8 mL) was added $Pd(OH)_2$ (1 g) under stream of N_2. The solution was hydrogenated at 0 °C for 1 hour. $Pd(OH)_2$ was filtered and the filtrate was concentrated to afford the product *tert*-butyl 2-amino-3-((1*S**,2*R**)-2-(tert-butyldimethylsilyloxy)cyclohexyl)propyl(methyl)carbamate (300 mg, 95 %). ^{1}H NMR (CD_3OD, 400 MHz) δ 0.05 (s, 6H), 0.88 (d, 9H), 1.10-1.50 (m, 4H), 1.44 (s, 9H), 1.50-1.78 (m, 4H), 1.80-1.98 (m, 1H), 2.80 (s, 3H), 3.10-3.40 (m, 2H), 3.55-3.90 (m, 3H), 5.10 (s, 2H), 7.30-7.40 (m, 5H). MS ESI +ve m/z 401 (M+1).

PREPARATION V1

tert-butyl (2*R*,3*S*)-2-amino-3-cyclopentyl-3-(trimethylsilyloxy)propyl(methyl)-carbamate

tert-butyl (2*R*,3*S*)-2-amino-3-cyclopentyl-3-(trimethylsilyloxy)propyl(methyl)carbamate was obtained following procedures analogous to Preparation I, Steps 1-8 above, using cyclopentanecarbaldehyde in Step 4.

PREPARATION D2

(*S*)-*tert*-butyl 4-(((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate



Step 1. (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-5-oxo-2-((*R*)-2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (8.12g, 13.9 mmol, 1.0 equiv) was dissolved in a 4:1 mixture of THF:MeOH (150 mL) and the solution cooled to 0 °C. Solid $NaBH_4$ (1.05 g, 27.8 mmol, 2.0 equiv) was added in ca 200 mg portions over a 20 min period. The solution was stirred at 0 °C for 4h. During this time two additional 500 mg portions of $NaBH_4$ were added. After this time LC/MS analysis showed consumption of the starting material. The excess hydride reagent was quenched by the addition of 10% citric acid. The mixture was diluted with ca 100 mL of EtOAc and the organic layer separated. The aqueous layer was extracted with additional EtOAc. The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and evaporated. The alcohol was purified by flash chromatography on silica, (120 g), eluting with 0-41% EtOAc in hexanes. This afforded 5.2 g (90% yield) of (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate as a clear syrup. MS ESI +ve m/z 436 (M+Na).

Step 2. (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (4.97 g, 12.0 mmol, 1.0 equiv), DMAP (1.47 mg, 12.0 mmol, 1.0 equiv) and tosyl chloride (9.2 g, 48.2 mmol, 4.0 equiv) were dissolved in pyridine (100 mL) and the solution stirred for 18 hr. The pyridine was removed in *vacuo* and the residue taken up in EtOAc/0.5 M HCl. The layers were separated, and the organic layer washed with 10 % K_2CO_3, brine, dried over Na_2SO_4, filtered and evaporated. The tosylate was purified by flash chromatography on silica, (12 g), eluting with 0-29% EtOAc in hexanes. This afforded 6.66 g (98% yield) of (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate as a white solid. MS ESI +ve m/z 590 (M+Na).

Step 3. (*S*)-*tert*-butyl 4-(((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (309 mg, 0.545 mmol, 1.0 equiv) was dissolved in 17 mL of THF and the solution cooled to 0 °C. Methylmagnesiumbromide (3.0 M in THF, 1.64 mL, 3.0 equiv) was added via syringe. LC/MS analysis showed ca 15% conversion to the mono–tosylate. An additional 0.55 mL of MeMgBr solution was added and the mixture warmed to ambient and stirred overnight. LC/MS analysis showed complete conversion to the mono-tosylate. The mixture was heated to reflux for 24 hr. After this time, complete conversion to the cyclised product was observed. The mixture was cooled to ambient and quenched with water. The layers were separated and the organic layer washed with brine, dried over Na_2SO_4, filtered and evaporated. The pyran derivative was purified by flash chromatography on silica, (12 g), eluting with 0-41% EtOAc in hexanes. This afforded 138 g (78% yield) of (*S*)-*tert*-butyl 4-(((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate as a clear syrup. MS ESI +ve m/z 350 (M+Na).

PREPARATION E2

(*S*)-*tert*-butyl 4-(((*R*)-4-oxaspiro[2.5]oct-6-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate



Step 1. (*S*)-*tert*-butyl 4-((*R*)-4-(1-hydroxycyclopropyl)-2-(tosyloxymethyl)butyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-*tert*-Butyl 4-((*R*)-5-ethoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (1.82 g, 3.55 mmol) and Ti(O*i*-Pr)$_4$ were dissolved in THF (30 mL) and allowed to stir at ambient temperature. A solution of EtMgBr (3.0 M, 5.91 mL, 17.8 mmol, 5.0 equiv) was added over a 6 hr period via syringe pump and the resulting mixture stirred overnight. The mixture was treated with a 50% solution of Rochelle's salt and diluted with EtOAc. The layers were separated and the aqueous layer extracted with additional EtOAc. The combined organic layers were washed with

brine, dried over Na_2SO_4, filtered and evaporated. The resulting crude (*S*)-*tert*-butyl 4-((*R*)-4-(1-hydroxycyclopropyl)-2-(tosyloxymethyl)butyl)-2,2-dimethyloxazolidine-3-carboxylate was used in the next step with no further purification.

Step 2. (*S*)-*tert*-butyl 4-(((*R*)-4-oxaspiro[2.5]oct-6-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate

The (*S*)-*tert*-butyl 4-((*R*)-4-(1-hydroxycyclopropyl)-2-(tosyloxymethyl)butyl)-2,2-dimethyloxazolidine-3-carboxylate was dissolved in 30 mL of THF and MeMgBr (7.0 mL of a 3.0 M solution, 2.0 equiv) was added and the mixture heated to reflux for 56 hr. After cooling to ambient the mixture was quenched by addition of water and the mixture transferred to a separatory funnel. The layers were separated and the organic layer were washed with brine, dried over Na_2SO_4, filtered and evaporated. The pyran derivative was purified by flash chromatography on silica (40 g) eluting with 0-29% EtOAc in hexanes. This afforded 1.05 g (91% yield) of (*S*)-*tert*-butyl 4-(((*R*)-4-oxaspiro[2.5]oct-6-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate. MS ESI +ve m/z 348 (M+Na).

PREPARATION F2

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate



Step 1. *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-hydroxypropan-2-ylcarbamate

The (*S*)-*tert*-butyl 4-(((*R*)-4-oxaspiro[2.5]oct-6-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate (3.0 g, 9.17 mmol) and camphor sulphonic acid (2.2 g, 9.17 mmol, 1.0 equiv) were dissolved in 200 mL of MeOH and allowed to react at ambient temperature for 3 hr. The mixture was quenched with saturated $NaHCO_3$ solution, the methanol removed in *vacuo*, and the mixture diluted with EtOAc. The layers were separated and the organic layer washed with brine, dried over Na_2SO_4, filtered and evaporated. This yielded 1.70 g (65%) of *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-hydroxypropan-2-ylcarbamate which was used in the next step with no further purification. MS ESI +ve m/z 310 (M+Na).

Step 2. (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propyl 4-methylbenzenesulfonate

The *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-hydroxypropan-2-ylcarbamate (1.70 g, 5.92 mmol) and tosyl chloride (4.5 g, 23.7 mmol, 4.0 equiv) were dissolved in pyridine (30 mL) and the mixture stirred at room temperature for 17 hr. The pyridine was removed in *vacuo* and the residue partitioned between EtOAc and 1.0 M HCl. The layers were separated and the organic layer washed with brine, dried over Na_2SO_4, filtered and evaporated. The (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propyl 4-methylbenzenesulfonate was purified by flash chromatography on silica eluting with 0-29% EtOAc in hexanes. The fractions were evaporated and used directly in the next step. MS ESI +ve m/z 464 (M+Na).

Step 3. *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-(methylamino)propan-2-ylcarbamate

The (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propyl 4-methylbenzenesulfonate was dissolved in 100 mL of 33% NH_2Me in ethanol. The mixture was heated to 50 °C for 3 hr. After this time LC/MS analysis shows formation of the desired amine. The solution was evaporated and the residue taken up in EtOAc, washed with 10% K_2CO_3, brine, dried over Na_2SO_4, filtered and evaporated. The *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-(methylamino)propan-2-ylcarbamate was used directly in the next step with no further purification. MS ESI +ve m/z 301 (M+1).

Step 4. (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propylcarbamate

The *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-(methylamino)propan-2-ylcarbamate was dissolved in 25 mL of acetonitrile and 10% K_2CO_3 (25 mL) and Teoc-OSu (1.54 g, 5.92 mmol) were subsequently added. The mixture was stirred for 1 hr at ambient temperature. The acetonitrile was removed in *vacuo* and the mixture diluted with EtOAc. The layers were separated and the organic layer washed with brine, dried over Na_2SO_4, filtered and evaporated. The *tert*-butyl (*S*)-1-((*R*)-4-oxaspiro[2.5]oct-6-yl)-3-(methylamino)propan-2-ylcarbamate was purified by flash chromatography on silica, eluting with 0-41% EtOAc in hexanes. The fractions staining with ninhydrin were evaporated to yield 1.5 g (60% yield for 3 steps) of (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propylcarbamate as a clear syrup. MS ESI +ve m/z 467 (M+Na).

Step 5. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propyl(methyl)carbamate

The (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propylcarbamate (250 mg, 0.565 mmol) and tosic acid hydrate (132 mg, 0.694 mmol, 1.22 equiv) were heated to reflux in methanol for 7h. The solution was then cooled and evaporated. The residue was taken up in EtOAc/10% K_2CO_3. The layers were separated and the organic layer washed with brine, dried over Na_2SO_4, filtered and evaporated. The resulting 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-4-oxaspiro[2.5]oct-6-yl)propyl(methyl)carbamate was used directly in the next step with no further purification. MS ESI +ve m/z 343 (M+1).

The following compounds were prepared using procedures analogous to those described above:

1) 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate using (*S*)-*tert*-butyl 4-(((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate as in Step 1.

EXAMPLE 1

(3R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide (I-58A)



Step 1. *tert*-Butyl (2S)-2-((3R)-3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A solution of (S)-tert-butyl 2-amino-3-cyclohexylpropyl(methyl)carbamate (34.7 mg, 0.129mmol) in CH_2Cl_2 (2 mL) was cooled in an ice-bath and CDI (25 mg, 1.2 mmol) and DIEA (83.2 mg, 0.11 mL, 0.645 mmol) were added. The mixture was stirred at rt for 0.5 h and 2-((3-chlorophenyl)((R)-piperidin-3-yl)methoxy)-N-ethylacetamide (40 mg, 0.129 mmol) was added. The reaction mixture was stirred overnight, washed with brine, dried over Na_2SO_4 and concentrated to give crude *tert*-butyl (2S)-2-((3R)-3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (60 mg, yield: 75.6 %). MS (E/Z): 607 ($M+H^+$).

Step 2. (R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

To a solution of TFA in CH_2Cl_2 (20%, v/v, 5 mL) under stirring was *tert*-butyl (2S)-2-((3R)-3-((3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (60.3 mg, 0.099 mmol). The reaction was followed by tlc (eluting solvent 5:1 petroleum ether/EtOAc). When the reaction was complete, the mixture was washed sequentially with satd aq $NaHCO_3$ and

water, dried over Na_2SO_4 and concentrated to give the product, which was purified by preparative HPLC to give 3R-[R-(3-chloro-phenyl)-ethylcarbamoylmethoxy-methyl]-piperidine-1-carboxylic acid (1S-cyclo hexylmethyl-2-methylamino-ethyl)-amide (14 mg). ^{1}H NMR (400MHz, MeOD): 1.30-1.65 (m, 14H), 1.77-1.89 (m, 7H), 2.68 (s, 3H), 2.89-2.97 (m, 2H), 3.03-3.12 (m, 2H), 3.23-3.34(m, 4H), 3.69-3.84 (m, 3H), 4.08-4.23 (m, 3H), 7.22-7.26 (m, 1H), 7.33-7.41 (m, 3H). MS (E/Z): 507 ($M+H^+$).

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-56a	(3R)-3-((R)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-56b	(3R)-3-((S)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-57a	(R)-3-((S)-(2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-58b	(3R)-3-((S)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-59a	(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-60a	(R)-3-((R)-(3-chlorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-61a	(R)-3-((R)-(3-chlorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-62a	(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)piperidine-1-carboxamide
I-63a	(R)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide
I-65a	(R)-3-((R)-(3-chlorophenyl)(2-(2-methoxyethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-66a	(3R)-3-((R)-(3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

I-67a	(3R)-3-((R)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-67b	(3R)-3-((S)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-68a	(3R)-3-((R)-(3-chlorophenyl)(3-oxo-3-(propylamino)propoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-69a	(R)-3-((R)-(3-chlorophenyl)(3-(isopropylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-70a	(R)-3-((R)-(3-chloro-2-fluorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-71a	(3R)-3-((S)-5-amino-1-(3-chlorophenyl)-1-hydroxy-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-72a	(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-73a	(3R)-3-((S)-1-(3-chlorophenyl)-5-(ethylamino)-1-hydroxy-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

The following compounds were prepared using procedures analogous to those described in Example 1 except $Et_4N^+F^-$ was used to deprotect a Teoc protecting group in Step 2:

1) (*R*)-3-((*R*)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl)piperidine-1-carboxamide I*-30a

2) (*R*)-3-((*R*)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-yl)piperidine-1-carboxamide I*-31a

3) (*R*)-3-((*R*)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-yl)piperidine-1-carboxamide I*-61a

4) methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate I*-154a

5) methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-155a**

6) methyl 2-((*R*)-((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate I*156a

7) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate I*-157a

8) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((*R*)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate I*-158a

9) methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-((*R*)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate I*-159a

10) methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-((*R*)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate I*-160a

The following compounds were prepared using procedures analogous to those described in Example 1 except 4 M HCl/dioxane was used to deprotect a Boc protecting group in Step 2:

1) (*R*)-3-((*R*)-(3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide I*-126(a)

EXAMPLE 2

Methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate



Step 1. Methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(t-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

To a solution of tert-butyl (2R,3S)-2-amino-3-cyclohexyl-3-(trimethylsilyloxy)propyl(methyl)carbamate (79.8 mg, 0.223 mmol) in anhydrous CH_2Cl_2 (2 mL) were added DIEA (190 μL, 1.12 mmol) and CDI (36.2 mg, 0.223 mmol). The mixture was stirred at 0 °C for 45 min, and methyl (S)-4-(2-chloro-3-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate (80.0 mg, 0.223 mmol) was added in one portion and the mixture was allowed to warm to rt and stirred overnight. The reaction was quenched with water and extracted with CH_2Cl_2 (3 x 20 mL). The organic extracts were washed with brine and concentrated to give crude product, which was purified by preparative HPLC to afford methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(t-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (70 mg, 46.8%). MS (E/Z): 671 ($M+H^+$).

Step 2. Methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

(S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(t-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (70 mg, 0.104 mmol) was cooled to 0 °C and a 20% solution of TFA in CH_2Cl_2 (5mL) was added. The mixture was stirred at 0 °C for about 20 min and quenched with satd aq $NaHCO_3$. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3 x). The combined organic layers were washed with brine, then concentrated in vacuo to give crude product, which was purified by preparative HPLC to afford methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (50 mg, yield 84%). ^1H NMR (400MHz, MeOD): 0.90-1.87 (m, 18H), 1.87-2.08 (m, 2H), 2.10-2.22 (s, 1H), 2.60-2.72 (t, 1H), 2.72 (s, 3H), 2.75-2.85 (t, 1H), 2.90-3.10 (m, 3H), 3.40-3.47 (m, 1H), 3.60 (s, 3H), 3.90-4.05 (d, 1H), 4.05-4.15 (m, 1H), 4.25-4.40 (d, 1H), 7.10-7.20 (s, 1H), 7.32-7.41 (t, 1H), 7.50-7.60 (t, 1H). MS (E/Z): 571.35 ($M+H^+$).

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-15a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-20a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

The following compounds were prepared using procedures analogous to those described above except that the acidic conditions used to remove a Boc group in step 2 were replaced with hydrogenation in the presence of $PdCl_2$ to remove a Cbz protecting group:

Cpd. No.	Cpd Name
I-17a	methyl (S)-4-(2,3-difluorophenyl)-4-((R)-1-((S)-1-((1r,4S)-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-22a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-((1r,4S)-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 2:

Cpd. No.	Cpd Name
I*-27a	methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-48a	methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-53a	methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-67a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((1*S*,2*R*)-1-cyclopentyl-1-hydroxy-3-(methylamino) propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-72a	methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I*-100a	methyl 2-((R)-(3-chlorophenyl)((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino) propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-107a	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((1*S*,2*R*)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-112a	methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate I*-112a

I*-138a	methyl 2-((*R*)-(3-chloro-2-fluorophenyl)((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 2 except $Et_4N^+F^-$ was used to deprotect a Teoc protecting group in Step 2:

1) methyl (*S*)-4-(3-fluorophenyl)-4-hydroxy-4-((3*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate I*-54a

2) methyl (*S*)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((3*R*)-1-((S)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate I*-139a

3) methyl (*S*)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate I*-142a

EXAMPLE 3

Methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate



Step 1. Methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(N-methyl-N-(t-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

To a solution of tert-butyl (S)-2-amino-3-cyclohexylpropylmethylcarbamate (65 mg, 0.24 mmol) and CDI (40 mg, 0.24 mmol) in anhydrous CH_2Cl_2 (5 mL) cooled in an

ice bath was added DIEA (104 mg, 0.81 mmol). After addition, the mixture was stirred for 1 h at 0 °C, a solution of methyl 2-((R)-(3-fluorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate (50 mg, 0.16 mmol) in anhydrous CH_2Cl_2 (5 mL) was added dropwise. The reaction mixture was allowed to warm to rt and stirred overnight. After the reaction was complete, the solvent was removed in vacuo. The product was purified by preparative tlc to afford the desired isomer of methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(N-methyl-N-(t-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate (50 mg, 52 % yield). MS (E/Z): 607 ($M+H^+$).

Step 2. Methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

A mixture of methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(N-methyl-N-(t-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate (20 mg, 0.03 mmol) and a 20% solution of TFA in CH_2Cl_2 (2 mL) were stirred for about 1h at rt until the reaction was complete. The solvent was removed by evaporation and the crude product was purified by preparative HPLC to afford methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate (7.5 mg, 44% yield). ^{1}H-NMR (400MHz, CD_3OD): 0.90 (m, 1H), 1.04 (m, 1H), 1.11-1.45 (m, 8H), 1.51 (m, 1H), 1.71 (m, 7H), 2.71 (s, 3H), 2.91 (m, 2H), 3.06 (m, 1H), 3.23 (m, 3H), 3.61 (s, 3H), 3.81 (m, 1H), 4.07 (m, 2H), 7.03 (m, 2H), 7.09 (m, 1H), 7.36 (m, 1H). MS (E/Z): 507 ($M+H^+$).

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-1a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluorophenyl)-4-hydroxybutylcarbamate
I-2a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-3a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-dimethylphenyl)-4-hydroxybutylcarbamate
I-4a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-5a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate
I-6a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-7a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-7b	methyl (R)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-8a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-difluorophenyl)-4-hydroxybutylcarbamate
I-11a	ethyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-12a	methyl (S)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate
I-13a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-14a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate
I-16a	methyl (S)-4-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-35a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-37a	methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate
I-41a	ethyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-43b	methyl 2-((3-chloro-2-fluorophenyl)(1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-44a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-45a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-46b	methyl 2-((1R)-(3-chlorophenyl)((3R)-1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-48a	methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate
I-49a	ethyl 2-((R)-(3-chloro-2-fluorophenyl)((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-50a	methyl 2-((1R)-(3-chloro-2-fluorophenyl)((3R)-1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-51a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-75a	(R)-3-((R)-(3-chlorophenyl)(4-oxohexyloxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

The following compounds were prepared using procedures analogous to those described in Example 3:

Cpd. No.	Cpd Name
I*-4a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-fluoro phenyl)methoxy)ethylcarbamate I*-4a

I*-18a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate I*-18a
I*-40a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate **I*-40a**
I*-63a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate **I*-63a**
I*-64a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate **I*-64a**
I*-65a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4-difluorophenyl)methoxy)ethylcarbamate **I*-65a**
I*-66a	methyl 2-((*S*)-(3-chlorophenyl)((*R*)-4-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate **I*-66a**
I*-85a	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-85a**
I*-91a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate **I*-91a**
I*-92a	methyl 2-((*S*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate **I*-92a**
I*-96a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate **I*-96a**
I*-97a	methyl 2-((*R*)-((*S*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate **I*-97a**
I*-115a	methyl 2-((*R*)-(2,3-difluoro-6-methylphenyl)(1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-115a**
I*-116a	methyl 2-((5-chloro-2-fluorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-116a**
I*-117a	methyl 2-((*R*)-(5-chloro-2-fluorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-117a**
I*-118a	methyl 2-((*R*)-(3-chloro-4-fluorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-118a**
I*-119a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4,5-trifluorophenyl)methoxy)ethylcarbamate **I*-119a**

I*-128a	(*R*)-3-((*R*)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)-N-((*S*)-1-cyclohexyl-3-(methyl amino)propan-2-yl)piperidine-1-carboxamide **I*-128a**
I*-129a	methyl 2-((*R*)-((3*R*)-1-(1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate **I*-129a**
I*-136a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl) (3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate **I*-136a**

The following compounds were prepared using procedures analogous to those described in Example 3 except $Et_4N^+F^-$ was used to deprotect a Teoc protecting group in Step 2:

Cpd. No.	Cpd Name
I*-6a	methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydrofuran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-7a	methyl 2-((*R*)-((*R*)-1-((*S*)-4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-20a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate
I*-26a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-34a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-36a	methyl 2-((*R*)-(3,5-dimethylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-37a	methyl 2-((*R*)-(2,5-dimethylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-39a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

I*-46a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-47a	methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-49a	methyl 2-((*R*)-(2-fluoro-5-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-50a	methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-52a	methyl 2-((*R*)-(3-fluoro-5-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-56a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl) propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-60a	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-62a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(2-oxopyrrolidin-1-yl)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-69a	methyl 2-((*R*)-(2,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-70a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-71a	methyl 2-((*R*)-(2,3-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-75a	methyl 2-((*S*)-(3-chlorophenyl)((*R*)-4-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate

I*-77a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-78a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-yl-carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-84a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)methoxy)ethylcarbamate
I*-93a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-yl-carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-98a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-4-yl)propan-2-yl-carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-99a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-101a	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-108a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate
I*-121a	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-123a	methyl 2-((*R*)-((3*R*)-1-((*S*)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-125a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((1*s*,3*R*,4*S*)-3,4-difluorocyclopentyl)-3-(methyl amino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
ethylcarbamate **I*-132a**	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((2*S*,4*r*,6*R*)-2,6-dimethyl-tetrahydro-2*H*-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)

I*-134a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-4-(1-methoxycyclopentyl)-1-(methylamino) butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-135a	methyl 2-((*R*)-(3-chloro-2-fluorophenyl)((*R*)-1-((*S*)-1-cycloheptyl-3-(methylamino)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-137a	methyl 2-((*R*)-(3-chloro-2-fluorophenyl)((3*R*)-1-((*S*)-1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-144a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate
I*-145a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-148a	methyl 2-((*R*)-(3-chloro-2,4-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-149a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate
I*-150a	methyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl carbamoyl)piperidin-3-yl)butoxy)ethylcarbamate
I*-152a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 3 except H_2 and Pd/C or $Pd(OH)_2$ was used to deprotect a Cbz protecting group in Step 2:

1) methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate **I*-5a**

2) methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate **I*-24a**

3) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-29a**

4) methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-51a**

5) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(4-oxocyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-80a**

6) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate **I*-102a**

The following compounds were prepared using procedures analogous to those described in Example 3 except 20% TFA/CH_2Cl_2 (V/V) was used to deprotect a Teoc protecting group in Step 2:

Cpd. No.	Cpd Name
I*-9a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate
I*-12a	methyl 2-((*S*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl)methoxy)ethylcarbamate
I*-13a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl)methoxy)ethylcarbamate
I*-15a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate
I*-16a	methyl 2-((*S*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate
I*-32a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate
I*-33a	methyl 2-((*S*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate

EXAMPLE 4

Methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate (I-9A)



Step 1. Methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate

To a stirred suspension of the HCl salt of methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate (31.6 mg, 0.08 mmol) and (S)-4-nitrophenyl 2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamate (45 mg, 0.105 mmol) in MeCN (1 mL) and CH_2Cl_2 (1 mL) was added DIEA (80 μL, 0.45 mmol). The mixture was stirred at rt for 3 d, diluted with ether (90 mL), washed with 5% aq HCl (20 mL), 1M aq NaOH (20 mL) and brine (20 mL), and dried over $MgSO_4$. Removal of the solvent left a white solid (61 mg) which was applied to a 2-g silica SPE cartridge. The cartridge was eluted sequentially with 0, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each) to afford five fractions. Fractions 4 and 5 were pooled and concentrated to afford methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate (35 mg) as an oil.

Step 2. Methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate

Methyl (S)-4-((R)-1-((S)-2-(t-butoxycarbonylamino)-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate (35 mg, 0.055 mmol) was dissolved in MeCN (5 mL) and 5% aq HCl (5 mL) was added. The mixture was stirred at rt for 2 d. Solid K_2CO_3 was added and, after stirring for 1 h, MeCN was recovered on the rotary evaporator. The aqueous residue was extracted with CH_2Cl_2 (2 x 50 mL) and the combined organic extracts were washed with brine and dried over Na_2SO_4. Removal of the solvent left a white solid which was purified by preparative HPLC to afford methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate as its TFA salt (28 mg).

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-10a	methyl (4S)-4-((3R)-1-((2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate
I-19a	methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxybutylcarbamate
I-39a	methyl 2-((R)-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)(3-chloro-2-fluorophenyl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 4 except 20% TFA/CH_2Cl_2 (V/V) was used to deprotect a Boc protecting group in Step 2:

Cpd. No.	Cpd Name
I*-28a	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate
I*-58a	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate
I*-68a	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-73a	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-109a	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)ethylcarbamate
I*-122a	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 4 except 20% TFA/CH_2Cl_2 (V/V) was used to deprotect Teoc protecting group in Step 2:

Cpd. No.	Cpd Name
I*-110a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-133a	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-143a	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

The following compound was prepared using procedures analogous to those described in Example 4:

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((1*r*,3*S*,4*R*)-3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

EXAMPLE 5

Methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (I-23a)



Step 1. Methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

To a stirred solution of methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxy-4-((R)-piperidin-3-yl)butylcarbamate (25 mg, 0.066 mmol) and 4-nitrophenyl (S)-3-cyclohexyl-1-((2-(trimethylsilyl)ethylcarbamate)methylamino)propan-2-yl)carbamate (42 mg, 0.088 mmol) in MeCN (1 mL) and CH_2Cl_2 (1 mL) was added DIEA (0.06 mL, 0.34 mmol). The mixture was stirred at rt for 3 d, diluted with ether (90 mL), washed with 5% aq HCl (20 mL), 1M aq NaOH (20 mL) and brine (20 mL), and dried over $MgSO_4$. Removal of the solvent left a white solid (61 mg) which was applied to a 2-g silica SPE cartridge. The cartridge was eluted sequentially with 0, 25, 50, 75 and 100% EtOAc in hexanes (15 mL of each) to afford five fractions. Fractions 3, 4 and 5 were pooled and concentrated to afford methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (48 mg, quant) as an oil.

Step 2. Methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate

To a stirred solution of methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (48 mg, 0.066 mmol) in MeCN

(2 mL) was added $Et_4N^+F^-$ (200 mg, 1.3 mmol). The resulting solution was stirred at rt for 2 d and submitted directly to preparative HPLC to afford the TFA salt of methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (34 mg, 74%) as a syrup.

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-18A	methyl (4S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((3R)-1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate
I-30A	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-32A	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-34A	methyl 2-((1R)-((3R)-1-((2S)-1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I-38A	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-38B	methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-42A	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I-46A	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47A	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-47B	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I-52A	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I-64A	(3R)-3-((R)-(3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-64B	(3R)-3-((3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-74A	(R)-3-((S)-1-(3-chlorophenyl)-4-formamido-1-hydroxybutyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide
I-76A	(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-6-oxoheptyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

The following compounds were prepared using procedures analogous to those described above except that the $Et4N^+F^-$ used to remove a Teoc group in step 2 were replaced with hydrogenation in the presence of PdCl2 to remove a Cbz protecting group:

Cpd. No.	Cpd Name
I-36A	methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 5:

Cpd. No.	Cpd Name
I*-81a	methyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-82a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-103a	methyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate
I*-151a	methyl 2-((*R*)-1-(3-chlorophenyl)-1-((3*R*)-1-((*S*)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 5 except 20% TFA/CH_2Cl_2 (V/V) was used to deprotect Boc protecting group in Step 2:

I*-120a-methyl 2-((*R*)-((*R*)-1-((*S*)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 5 except H_2 and $PdCl_2$ was used to deprotect Cbz protecting group in Step 2:

I*-11a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((3*R**,4*S**)-4-isobutylpyrrolidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-44a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((3*S**,4*R**)-4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

The following compounds were prepared using procedures analogous to those described in Example 5 except 20% TFA/CH_2Cl_2 (V/V) was used to deprotect Teoc protecting group in Step 2:

Cpd. No.	Cpd Name
I*-1a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl) piperidin-3-yl)methoxy)ethylcarbamate
I*-17a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl) piperidin-3-yl)methoxy)ethylcarbamate
I*-22a	methyl (*S*)-4-((*S*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate
I*-23a	methyl (*R*)-4-((*S*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate
I*-41a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl) (3-fluorophenyl)methoxy)ethylcarbamate
I*-42a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-43a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-55a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-59a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-amino-3-cyclohexyl-2-methylpropan-2-ylcarbamoyl)piperidin-3-yl) (3-chlorophenyl)methoxy)ethylcarbamate
I*-76a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-((*R*)-1-methyl-6-oxopiperidin-3-yl)-3-(methylamino) propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-79a	methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-83a	methyl 2-((*R*)-((*R*)-1-((2*S*,3*R*)-3-amino-1-cyclohexylpentan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate
I*-86a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(4-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-88a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl) piperidin-3-yl)methoxy)ethylcarbamate
I*-89a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-90a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-94a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-95a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-106a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-113a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-yl carbamoyl)piperidin-3-yl)methoxy)ethylcarbamate 1
I*-131a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((*R*)-1-methyl-6-oxopiperidin-3-yl)-3-(methylamino) propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-140a	methyl 2-((*R*)-(3-chloro-2-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-141a	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-146a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
I*-147a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl) piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate
I*-153a	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(4,4-difluorocyclohexyl)-3-(methylamino) propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

EXAMPLE 6

2-((R)-(3-Chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate (I-53A)



Step 1. 2-(trimethylsilyl)ethyl (S)-2-((R)-3-((R)-(3-chlorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A mixture of the HCl salt of 2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethanol, (S)-4-nitrophenyl 1-cyclohexyl-3-(2-(trimethylsilyl)ethoxycarbonylmethylamino)propan-2-ylcarbamate (0.3724 g, 0.78 mmol, 1.3 equiv), and DIEA (2 mL, 12 mmol, 20 equiv) in CH_2Cl_2 was stirred at rt for 17 h. After the solvents were removed in vacuo, the residue was purified by reversed-

phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 70% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 8 min and then 90% CH_3CN/H_2O, 0.1% CF_3COOH over 7 min, flow rate 25 mL/min) to give 0.1880 g (51% in 3 steps) of 2-(trimethylsilyl)ethyl (S)-2-((R)-3-((R)-(3-chlorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate. LC-MS (3 min) t_R = 2.52 min, m/z 612, 610 (MH^+).

Step 2. 2-(trimethylsilyl)ethyl (S)-2-((R)-3-((R)-(3-chlorophenyl)(2-((4-nitrophenoxy)carbonyloxy)ethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A mixture of 2-(trimethylsilyl)ethyl (S)-2-((R)-3-((R)-(3-chlorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (0.1880 g, 0.3 mmol, 1.0 equiv), DMAP (0.150 g, 1.2 mmol, 4 equiv), DIEA (1 mL, 6 mmol, 20 equiv), and 4-nitrophenyl chloroformate (0.1346 g, 0.67 mmol, 2.2 equiv) in CH_2Cl_2 (6 mL) was stirred at rt for 24 h. The reaction mixture was directly used in the next step without further purification. LC-MS (3 min) t_R = 2.68 min, m/z 777, 775 (MH^+).

Step 3. 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(2-(trimethylsilyl)ethoxycarbonylmethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate

A solution of 2-(trimethylsilyl)ethyl (S)-2-((R)-3-((R)-(3-chlorophenyl)(2-((4-nitrophenoxy)carbonyloxy)ethoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate in CH_2Cl_2 (1 mL, ca. 0.044 mmol), obtained as described above, and 2.0 M NH_3 in EtOH (4 mL) was stirred at rt for 19 h. After the solvents were removed in vacuo, the residue was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 70% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 8 min and then 90% CH_3CN/H_2O, 0.1% CF_3COOH over 6 min, flow rate 25 mL/min) to give of 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(2-(trimethylsilyl)ethoxycarbonylmethylamino)propan-2-

ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate (0.0250 g, 87%). LC-MS (3 min) t_R = 2.36 min, m/z 655, 653 (MH^+).

Step 4. 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate

A mixture of 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(2-(trimethylsilyl)ethoxycarbonylmethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate (0.0250 g, 0.038 mmol) and trifluoroacetic acid (1 mL) in CH_2Cl_2 (5 mL) was stirred at rt for 3 h. After the solvents were removed in vacuo, the residue was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 10% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 13 min, flow rate 25 mL/min) to give 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate as its TFA salt (0.0205 g, 86%). LC-MS (3 min) t_R = 1.49 min, m/z 511, 509 (MH^+); ^1H NMR (400 MHz, CD_3OD) δ 7.28-7.12 (m, 4H), 4.20 (d, J = 13.2 Hz, 1H), 4.11-3.99 (m, 3H), 3.95 (d, J = 8.8 Hz, 1H), 3.87 (d, J = 13.2 Hz, 1H), 3.40-3.28 (m, 2H), 2.96 (dd, J = 12.6, 3.2 Hz, 1H), 2.84 (dd, J = 12.6, 10.2 Hz, 1H), 2.73-2.63 (m, 2H), 2.61 (s, 3H), 1.71-0.75 (m, 18H).

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-54a	2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl methylcarbamate
I-55a	2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl ethylcarbamate

The following compounds were prepared using procedures analogous to those described above except that (R)-(3-chlorophenyl)((R)-piperidin-3-yl)methanol was used in Step 1:

Cpd. No.	Cpd Name
I-26a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl carbamate
I-27a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl methylcarbamate
I-28a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate
I-28b	(S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate
I-29b	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate
I-29b	(S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate

EXAMPLE 7

Methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate (I-24A)



A mixture of the fumarate salt of methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate (0.0658 g), acetonitrile (8 mL), and conc H_2SO_4 (20 drops) was stirred at rt for 4 d. The mixture was neutralized with DIEA and the solvent was removed in vacuo. The crude product was purified by reversed-phase HPLC (phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 10% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 13 min, flow rate 25 mL/min) to give the TFA salt

of methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate (0.0062 g) and the TFA salt of methyl (R)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate (0.0192 g).

Data for the TFA salt of methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate: LC-MS (3 min) t_R = 1.40 min, m/z 578, 580 (MH^+); ^1H NMR (400 MHz, CD_3OD) δ 7.88 (s, 1H), 7.26-7.14 (m, 4H), 4.11 (d, J = 12.0 Hz, 1H), 4.04-3.97 (m, 1H), 3.78 (d, J = 12.3 Hz, 1H), 3.52 (s, 3H), 3.03-2.96 (m, 3H), 2.89 (dd, J = 12.6, 10.2 Hz, 1H), 2.62 (s, 3H), 1.98 (s, 3H), 2.39-0.73 (m, 24H).

Data for TFA salt of methyl (R)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate: LC-MS (3 min) t_R = 1.36 min, m/z 578, 580 (MH^+); ^1H NMR (400 MHz, CD_3OD) δ 7.79 (s, 1H), 7.24-7.12 (m, 4H), 4.05-3.99 (m, 2H), 3.83 (d, J = 12.6 Hz, 1H), 3.51 (s, 3H), 3.07-2.94 (m, 3H), 2.83 (dd, J = 12.6, 10.0 Hz, 1H), 2.60 (s, 3H), 1.93 (s, 3H), 2.37-0.74 (m, 24H).

The following compounds were prepared using procedures analogous to those described above:

Cpd. No.	Cpd Name
I-25a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate
I-25b	methyl (R)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate

EXAMPLE 8

I*-19a-methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate was obtained using procedures analogous to Example 2, Step 1, using methyl 2-((*R*)-phenyl((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 1.

Step 2. methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

A solution of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (5 mg, .008 mmol) in EtOH (2 mL) was stirred with 10% Pd/C (5 mg) under H_2 overnight. The mixture was filtered thru Celite. After removal of solvent *in vacuo*, the residue was used directly in the next step.

Step 3. methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

A solution of methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate in 20% (V/V) CH_2Cl_2 (1 mL) was stirred for 1 h. The solution was evaporated under reduced pressure and the residue purified via prep HPLC to afford methyl 2-((*R*)-((*R*)-1-((1*S*,2*R*)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate (1.01 mg).

EXAMPLE 9

I*-38a-methyl 2-((*R*)-((*R*)-1-((*R*)-2-amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-((*R*)-1-((*R*)-2-(N-*tert*butoxycarbonyl)amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

DIEA (66 mg, 0.52 mmol) was added to a solution of (*R*)-*tert*-butyl 1-amino-3-phenoxypropan-2-ylcarbamate (68.7 mg, 0.26 mmol) in 2 mL of anhydrous dichloromethane at 0 °C. After the mixture stirred for 1.5 h, a solution of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate (84 mg, 0.26 mol) in 2 mL of anhydrous dichloromethane was added. The reaction mixture was stirred overnight. The reaction mixture concentrated *in vacuo* to remove the solvent, and the

residue was purified by preparative TLC to get crude methyl 2-((*R*)-((*R*)-1-((*R*)-2-(N-*tert*butoxycarbonyl)amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate (152 mg), which was used in the next step without further purification.

Step 2. methyl 2-((*R*)-((*R*)-1-((*R*)-2-amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

20% TFA solution in CH_2Cl_2 (2 mL) was added to methyl 2-((*R*)-((*R*)-1-((*R*)-2-(N-*tert*butoxycarbonyl)amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate (150 mg, 0.24 mmol) at 0 °C. The reaction was stirred for 1 h and concentrated *in vacuo*. The residue was purified by preparative HPLC to get methyl 2-((*R*)-((*R*)-1-((*R*)-2-amino-3-phenoxypropylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate (70 mg, 56%).

The following compounds were prepared using procedures analogous to those described above except hydrogen gas was used.

I*-35A-methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

I*-14a-methyl 2-((*R*)-((*R*)-1-((S)-2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate

EXAMPLE 10

I*-8a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5,5-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. (*S*)-prop-1-en-2-yl 5,5-dimethyl-1-(N-methyl-N-(trimethylsilylethoxycarbonyl)amino)hexan-2-ylcarbamate

(S)-2-(trimethylsilyl)ethyl 2-amino-5,5-dimethylhexyl(methyl)carbamate (34 mg, 0.113 mmol, 1.0 equiv) and K_2CO_3 (50 mg, 0.362 mmol, 3.0 equiv) were added CH_2Cl_2 and the solution cooled to 0 °C. Isopropenylchloroformate (41 mg, 0.339 mmol, 3.0 equiv) was added and the mixture warmed to ambient temperature and stirred for 3h. The solution was filtered, evaporated and residual solvent removed *in vacuo* to afford (*S*)-prop-1-en-2-yl 5,5-dimethyl-1-(N-methyl-N-(trimethylsilylethoxycarbonyl)amino)hexan-2-ylcarbamate and used without further purification.

Step 2. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5,5-dimethyl-1-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

The resulting (*S*)-prop-1-en-2-yl 5,5-dimethyl-1-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)hexan-2-ylcarbamate was dissolved in THF (5 mL) and methyl 2-((R)-(3-chlorophenyl)((R)-piperidin-3-yl)methoxy)ethylcarbamate (40 mg, 0.1227 mmol, 1.1 equiv) added and the mixture heated to 50 °C overnight. After completion of the reaction, the solution was washed with 0.5 M HCl, brine, then dried

over Na_2SO_4, filtered, and evaporated to afford crude methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5,5-dimethyl-1-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate which was taken directly to the next step.

Step 3. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5,5-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5,5-dimethyl-1-(N-methyl-N-(2-trimethylsilylethoxycarbonyl)amino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate was dissolved in CH_3CN and treated with 75 mg (0. 504 mmol, 4.5 equiv) of TEAF and the mixture heated to 55 °C for 3h. The solution was evaporated and purified by prep HPLC to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-5,5-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate.

Example 11

I*-130a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

To a solution of 4-nitrophenolchloroformate (14 mg, 0.068 mmol) and 2-(trimethylsilyl)ethyl (2*S*,3*R*)-2-amino-1-cyclohexylpentan-3-yl(methyl)carbamate (23 mg, 0.068 mmol) in anhydrous DCM was added TEA (12 μL, 0.88 mmol). The resulting solution was stirred at room temperature for 5 min. A solution of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate (26 mg, 0.82 mmol) in DCM (2 mL) was added, followed by TEA (0.5 mL), then stirred for another 30 min. The solvent was removed *in vacuo*, the slurry was purified through preparative HPLC to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (17 mg). MS ESI +ve m/z 695 (M+H).

Step 2. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (17 mg) was dissolved in DCM/TFA (4/1 mL) and stirred for 30 min. After concentrated, the slurry was purified through preparative HPLC to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((2*S*,3*R*)-1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate TFA salt (11.9 mg).

EXAMPLE 12

I*-114a-methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate

Methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate was obtained following procedures analogous to Example 3, Step 1, using methyl 2-((*R*)-(2-(benzyloxy)-3,5-difluorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate and (*S*)-benzyl 2-amino-3-cyclohexylpropyl(methyl)carbamate in Step 1.

Step 2. methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate

methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate (100 mg, 0.131 mmol) was dissolved in MeOH (1 mL) and Pd/C (20 mg) was added to it. The reaction mixture was stirred in 30 psi at room temperature for 2 h. The suspension was filtered and the filtrate was concentrated *in vacuo*. The residue was purified by preparative HPLC to afford methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate (20 mg, 28%).

EXAMPLE 13

I*-2a-methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate was obtained by using procedures analogous to Example 3, Step 1, methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate and (*S*)-benzyl 2-amino-3-cyclohexylpropyl(methyl)carbamate in Step 1.

Step 2. methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

A 100 mL flask was charged with methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(benzyloxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate (230 mg, 0.35 mmol) and $Pd(OH)_2$ (45 mg) dissolved in MeOH (35 mL) under H_2 and stirred for 1hr. After completion of the

reaction, the mixture was filtered. The solution was evaporated to give the crude product (120 mg), which was purified by preparative HPLC to obtain the target molecule (50.2mg, 29%).

EXAMPLE 14

I*-105a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((1*R*,2*S*)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(1-((1*R**,2*S**)-2-hydroxycyclohexyl)-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

Methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(1-((1*R**,2*S**)-2-hydroxycyclohexyl)-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate was obtained following procedures analogous to Example 3, Step 1, using methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate and *tert*-butyl 2-amino-3-((1*R*,2*S*)-2-(*tert*-butyldimethylsilyloxy)cyclohexyl)propyl(methyl)carbamate in Step 1.

Step 2. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((1*R**,2*S**)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(1-((1*R**,2*S**)-2-hydroxycyclohexyl)-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-

yl)methoxy)ethylcarbamate (30 mg, 0.04 mmol) was dissolved in a solution of HCL/CH_3OH (3 mL,2 M). The reaction mixture was stirred at room temperature for 1 h. After the reaction was completed the product was concentrated *in vacuo* and purified via preparative HPLC to afford the desired product methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((1*R**,2*S**)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (3 mg, 14%) and side product **I*-104a**-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*R*)-1-((1*R**,2*S**)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (4.5 mg, 21%).

Example 15

I*-127a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(N'-cyano-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. Potassium cyanocarbonimidodithioate

To a mixture of amine cyanamide (21g, 0.5 mol) and carbon disulfide (58.5 g, 46 mL, 0.77 mol) in anhydrous EtOH (62.5 mL) was added dropwise a solution of potassium hydroxide (56.2 g, 1 mol) in EtOH (210 mL)at -2-0 °C. The mixture was kept at the same temperature for 3 hours. The precipitate was then filtered, washed with cold EtOH, and dried to afford potassium cyanocarbonimidodithioate (68 g, 70%).

Step 2. dimethyl cyanocarbonimidodithioate

To a mixture of potassium cyanocarbonimidodithioate (19.4 g, 0.1 mmol) in 100 mL of methanol and 150 mL of water was added dropwise dimethyl sulfate (15.1 g, 0.12 mol). The mixture was left to stand overnight at rt. The precipitate was separated and recrystallized from IPA-isopropyether to give dimethyl cyanocarbonimidodithioate (11 g, 75%).

Step 3. (*S*)-*tert*-butyl 2-((cyanoimino)(methylthio)methylamino)-3-cyclohexylpropyl(methyl)carbamate

To a solution of (*S*)-*tert*-butyl 2-amino-3-cyclohexylpropyl(methyl)carbamate (1.08 g, 4 mmol) in CH_3CN (15 mL) and Et_3N (3 mL) was added dimethyl cyanocarbonimidodithioate (642 mg, 4.4 mmol). The mixture was heated to reflux for 4 h. The reaction mixture was concentrated to give the residue, which was purified by column to give (*S*)-*tert*-butyl 2-((cyanoimino)(methylthio)methylamino)-3-cyclohexylpropyl(methyl)carbamate (450 mg, 31%).

Step 4. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(N'-cyano-N-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate

To a solution of (*S*)-*tert*-butyl 2-((cyanoimino)(methylthio)methylamino)-3-cyclohexylpropyl(methyl)carbamate (200 mg, 0.543 mmol) in DMF (8 mL) and Et_3N (0.5 mL) was added methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate (178 mg, 0.543 mmol). The mixture was heated at 100-110 °C for 48 h. The reaction mixture was diluted with ethyl acetate (100 mL), washed with water (30 mL x 4), dried over Na_2SO_4 and concentrated to give the residue, which was purified by column to give methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(N'-cyano-N-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate (8 mg, 2%).

Step 5. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(N'-cyano-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate

The methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-(N'-cyano-N-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate (8 mg, 0.0124 mmol) was dissolved in a solution of 4 N HCl/dioxane (5 mL). The reaction mixture was stirred at rt for 1 h and then concentrated *in vacuo*. The residue was purified by preparative HPLC to afford the product (4 mg, 59%).

EXAMPLE 16

I*-11a-methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate

To a solution of (*S*)-*tert*-butyl 2-amino-3-cyclohexylpropyl(methyl)carbamate (326 mg, 1 mmol), DIEA (258 mg, 2 mmol) and methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate (270 mg, 1 mmol) in ethyl acetate (6 mL) was added dropwise a solution of di-imidazol-1-yl-methanethione (194 mg, 1 mmol) in ethyl acetate (4 mL) at 0-5 °C. After addition, the mixture was allowed to warm to room temperature for 3-4 h, the mixture was washed with water (20 mL) and brine (20

ml), the organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to give the residue, which was purified by preparative TLC to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate. MS ESI +ve m/z 638 (M+H).

Step 2. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(N-methyl-N-(*tert*-butoxycarbonyl)amino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate (640 mg, 0.1 mmol) was dissolved in a solution of 20% (V/V) TFA/CH_2Cl_2 (5 mL). The reaction mixture was stirred at room temperature for 1 h, a solution of saturated sodium bicarbonate was added dropwise to adjust the pH to 7-8. The resulting mixture was extracted with CH_2Cl_2 (3×15 mL), washed with brine, dried over Na_2SO_4, concentrated *in vacuo*. The residue was purified by preparative HPLC to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate (10 mg, 19%).

EXAMPLE 17

I*-10a-methyl 2-((*S*)-cyclohexyl((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

A mixture of fumarate salt (0.120 g) of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate, HCO_2NH_4 (1.200 g), and 10% Pd/C (0.150 g) in MeOH was stirred at rt for 3 d. The mixture was filtered off precipitates through Celite® 545 and washed with MeOH. After the solvent was evaporated under reduced pressure, the crude methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate was directly used in the next step without further purification. MS ESI +ve m/z 489 (M+H).

Step 2. methyl 2-((*S*)-cyclohexyl((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

A 250 mL Parr shaker vessel was charged with methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate, 0.1595 g of 5% Rh/Al_2O_3, and MeOH. The vessel was placed in a Parr hydrogenation shaker and pressurized to 60 psi. After the reaction vessel was shook for 27 h, the contents were filtered through HPLC filter and washed with MeOH. The filtrate was evaporated under reduced pressure and the residue was

purified by reversed-phase to give the TFA salt of methyl 2-((*S*)-cyclohexyl((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate. MS ESI +ve m/z 495 (M+H). ^{1}H NMR (CD_3OD, 400 MHz) δ 4.04-3.89 (m, 3H), 3.53 (s, 3H), 3.58-2.64 (m, 9H), 2.60 (s, 3H), 1.72-0.77 (m, 29H).

EXAMPLE 18

I*-57a-methyl 2-((1*R*)-(2-fluorophenyl)((3*R*)-1-(1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((1*R*)-(2-fluorophenyl)((3*R*)-1-(1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

To a solution of methyl 2-((1*R*)-(3-chloro-2-fluorophenyl)((3*R*)-1-(1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate TFA salt (12 mg, 0.018 mmol) in MeOH (5 mL) was added HCO_2NH_4 (1.2 g) and 10% Pd/C (50 mg). The mixture was stirred for 1 h at rt. The catalyst was filtered off and concentrated, the residue was purified on preparative HPLC to give methyl 2-((1*R*)-(2-fluorophenyl)((3*R*)-1-(1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate as a TFA salt (1.84 mg, 16%).

The following compounds were prepared using procedures analogous to those described above except hydrogen gas was used:

I*-21a-Methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate following Example 18, Step 1, using methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

I*-74a-methyl 2-((*R*)-((3*R*)-1-((*S*)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate following Example 18, Step 1, using methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate.

EXAMPLE 19

I*-3a-methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-((*R*)-1-((*S*)-1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

A 50mL flask was charged with methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (100 mg, 0.15 mmol) and $Pd(OH)_2$ (20 mg) dissolved in MeOH (5 mL) under H_2. After stirring for 0.5 hr, the mixture was filtered, evaporated to give crude methyl 2-((*R*)-((*R*)-1-((*S*)-1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate (20 mg, 21%), which was used without further purification.

Step 2. methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

In a round bottom flask methyl 2-((*R*)-((*R*)-1-((*S*)-1-(N-methyl-N-(2-(trimethylsilyl)ethoxycarbonyl)amino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate (20 mg, 0.03 mmol) and TEAF (15 mg, 0.07 mmol) was dissolved in a 15 mL of in MeCN. The solution was allowed to stir at reflux for 1 h. The mixture was concentrated *in vacuo* and purified by preparative HPLC to give methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate (6.24 mg, 42%).

EXAMPLE 20

I*-45a-(*R*)-3-((*R*)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide



Step 1. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(3-cyanopropoxy)methyl)piperidine-1-carboxylate

To a suspension of NaH (763 mg, 19.1 mmol) and (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (1.55 g, 4.77 mmol) in CH_3CN (20 mL) at 0-5 °C was added dropwise a solution of 4-bromobutyronitrile (3.17 g, 21.5

mmol) in CH_3CN (5 mL), the reaction mixture was stirred for overnight at rt. The reaction mixture was poured into saturated aqueous NH_4Cl, ethyl acetate (50 mL) was added. The organic layer was washed with water (3×20 mL) and brine, dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(3-cyanopropoxy)methyl)piperidine-1-carboxylate (0.44 g, 21% yield). ^{1}H NMR (CD_3OD, 400 MHz) δ 7.38-7.28 (m, 3H), 7.22 (m, 1H), 4.22 (m, 1H), 4.02 (d, 1H), 3.86 (d, 1H), 3.34 (m, 2H), 2.77 (q, 2H), 2.56 (t, 2H), 1.62 (m, 1H), 1.59 (m, 1H), 1.43 (s, 9H), 1.35-1.25 (m, 3H), 1.12 (d, 1H).

Step 2. methyl 4-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)butanoate

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(3-cyanopropoxy)methyl)piperidine-1-carboxylate (200 mg, 0.51 mmol) was dissolved in 20 mL of CH_3OH, and HCl was bubbled into the mixture over 30 min at –78 °C. The mixture was stirred at rt overnight, then under reflux for another 6 hr. The solvent was removed and the residue was treated with sat. $NaHCO_3$, the mixture was extracted with ethyl acetate (20 mL). The organic layers was dried over $NaSO_4$ and evaporated to give the crude methyl 4-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)butanoate, which was used in the next step without further purification (75 mg, 46% yield). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 7.35 (m, 3H), 7.25 (m, 1H), 3.56 (m, 3H), 3.31-3.25 (m, 5H), 2.96 (m, 2H), 2.41 (m, 2H), 2.02 (m, 1H), 1.84 (m, 2H), 1.60 (m, 1H), 1.38-1.19 (m, 2H), 0.95 (d, 1H).

Step 3. methyl 4-((*R*)-((*R*)-1-((*S*)-1-(*tert*-butoxycarbonyl(methyl)amino)-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)butanoate

To a solution of (*S*)-*tert*-butyl 2-amino-3-cyclohexylpropyl(methyl)carbamate (165 mg, 0.61 mmol) and DIEA (3 mL) in anhydrous CH_2Cl_2 (10 mL) was added CDI (98 mg, 0.61 mmol) with ice bath. After addition, the mixture was stirred for 1 h at 0 °C, followed by the addition of methyl 4-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)butanoate (165 mg, 0.51 mmol) in anhydrous CH_2Cl_2 (2 mL). The reaction mixture was allowed to warm to rt and stirred overnight. The reaction mixture was washed with water (10 mL) and the aqueous layer extracted with CH_2Cl_2 (15 mL x 2), the combined organic layers was washed with saturated brine, dried over Na_2SO_4, filtered, then evaporated to give a residue, which was purified via preparative TLC to

afford methyl 4-((*R*)-((*R*)-1-((*S*)-1-(*tert*-butoxycarbonyl(methyl)amino)-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)butanoate (70 mg, 22% yield). ^{1}H NMR (CD_3OD, 400 MHz) δ 7.34-7.28 (m, 3H), 7.19 (t, 1H), 4.25 (d, 1H), 4.11 (d, 1H), 3.95 (m, 2H), 3.64 (t, 3H), 3.27 (m, 1H), 3.10 (m, 1H), 2.87 (s, 2H), 2.69 (m, 2H), 2.43 (t, 1H), 1.84 (t, 2H), 1.72-1.52 (m, 6H), 1.45 (d, 9H), 1.39-1.22 (m, 10H), 1.14 (d, 1H), 0.97 (d, 2H), 0.85 (t, 1H).

Step 4. *tert*-butyl (*S*)-2-((*R*)-3-((*R*)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

methyl 4-((*R*)-((*R*)-1-((*S*)-1-(*tert*-butoxycarbonyl(methyl)amino)-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)butanoate (70 mg, 0.11 mmol) was dissolved in the CH_3NH_2/C_2H_5OH (20 mL), which was stirred at rt overnight. After the reaction was completed, the solvent was removed *in vacuo*. The product was purified via preparative TLC to afford *tert*-butyl (*S*)-2-((*R*)-3-((*R*)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (50 mg, 71% yield), which was used immediately in the next step.

Step 5. (*R*)-3-((*R*)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

tert-butyl (*S*)-2-((*R*)-3-((*R*)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (50 mg, 0.08 mmol) was dissolved in a solution of 20% (V/V) TFA/CH_2Cl_2 (10 mL). The reaction mixture was stirred at rt for 1 h, a solution of saturated sodium bicarbonate was added dropwise to adjust pH=7-8. The resulting mixture was extracted with CH_2Cl_2 (3×15 mL), washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. The residue was purified by preparative HPLC to afford (*R*)-3-((*R*)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide (3.30 mg, yield 8%). ^{1}H NMR (CD_3OD, 400 MHz) δ 7.30-7.34 (m, 3H), 7.20 (d, 1H), 4.30 (d, 1H), 4.05 (m, 1H), 3.97 (m, 2H), 2.76 (m, 3H), 2.69 (s, 3H), 2.53 (s, 3H), 2.27 (m, 3H), 1.83 (m, 3H), 1.71 (m, 5 H), 1.13-1.28 (m, 10H), 0.89 (m, 4 H).

EXAMPLE 21

I*-25a-(*R*)-3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide



Step 1. (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-ethoxy-2-oxoethoxy)ethyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-hydroxyethyl)piperidine-1-carboxylate (0.4395 g, 1.29 mmol), 60% NaH (1.320 g, 33 mmol), and ethyl iodoacetate (5.237 g, 24.5 mmol) in THF (20 mL) was heated at 90 °C for 18 h and then cooled to rt. The reaction mixture was then quenched with saturated brine and extracted with ethyl acetate (3×), dried over Na_2SO_4. After the solvent was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 0.0775 g (14%) of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-ethoxy-2-oxoethoxy)ethyl)piperidine-1-carboxylate. MS ESI +ve m/z 450 (M+Na).

Step 2. ethyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-piperidin-3-yl)ethoxy)acetate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-1-(3-chlorophenyl)-1-(2-ethoxy-2-oxoethoxy)ethyl)piperidine-1-carboxylate (0.0580g, 0.136 mmol), 2 *N* HCl (50 mL), and CH_3CN (50 mL) was vigorously stirred at rt for 24 h. After the reaction mixture was evaporated under reduced pressure, the crude product ethyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-piperidin-3-yl)ethoxy)acetate was directly used in the next step without further purification. MS ESI +ve m/z 328 (M+H).

Step 3. ethyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-1-((*S*)-1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)acetate

A mixture of ethyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-piperidin-3-yl)ethoxy)acetate, (*S*)-4-nitrophenyl 1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)propan-2-ylcarbamate (0.096 g, 0.20 mmol), and DIPEA (1 mL) in CH_2Cl_2 was stirred at rt for 24 h. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 0.0425 g (47% in two steps) of ethyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-1-((*S*)-1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)acetate. MS ESI +ve m/z 668 (M+H).

Step 4. 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A mixture of ethyl 2-((*R*)-1-(3-chlorophenyl)-1-((*R*)-1-((*S*)-1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)acetate (0.0185 g) and 33% wt. methylamine in ethyl alcohol (10 mL) was stirred at rt for 3 d. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 0.0035 g of 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate. MS ESI +ve m/z 653 (M+H).

Step 5. (*R*)-3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)-N-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide

A mixture of 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (0.0035 g) and 0.5 *M* Et_4NF in CH_3CN (6 mL) was heated at 80 °C for 1.5 h and then stirred at rt overnight. After the solvent was removed *in vacuo*, the residue was purified by reversed-phase HPLC to give TFA salt of (*R*)-3-((*R*)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)-N-((*S*)-1-cyclohexyl-

3-(methylamino)propan-2-yl)piperidine-1-carboxamide. MS ESI +ve m/z 509 (M+H). ^{1}H NMR (CD_3OD, 400 MHz) δ 7.31-7.14 (m, 4H), 4.17 (s, 2H), 4.20-3.98 (m, 3H), 3.02 (dd, J = 12.6, 3.2 Hz, 1H), 2.89 (dd, J = 12.3, 10.5 Hz, 1H), 2.65 (s, 3H), 2.38 (s, 3H), 1.41 (s, 3H), 2.69-0.83 (m, 20H).

EXAMPLE 22

I*-87a-methyl 1-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)propan-2-ylcarbamate



Step 1. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2,2-dimethoxypropoxy)methyl)piperidine-1-carboxylate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (0.2234 g, 0.68 mmol), 60% NaH (1.460 g, 36.5 mmol), and 1-bromo-2,2-dimethoxypropane (7.760 g, 42.4 mmol) in THF (20 mL) was heated at 80 °C for 3 d and then cooled to rt. The reaction mixture was then quenched with water, extracted with ethyl acetate (3×), and dried over Na_2SO_4. After the solvent was evaporated under

reduced pressure, the crude product (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2,2-dimethoxypropoxy)methyl)piperidine-1-carboxylate was directly used in the next step without further purification.

Step 2. 1-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)propan-2-one

A mixture of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2,2-dimethoxypropoxy)methyl)piperidine-1-carboxylate, obtained as described above, 2 *N* HCl (100 mL) and CH_3CN (100 mL) was vigorously stirred at rt for 22 h. After the reaction mixture was evaporated under reduced pressure, the crude 1-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)propan-2-one was directly used in the next step without further purification. MS ESI +ve m/z 284 (M+H).

Step 3. 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-(3-chlorophenyl)(2-oxopropoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A mixture of 1-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)propan-2-one, obtained as described above, (*S*)-4-nitrophenyl 1-cyclohexyl-3-(methyl((2-(trimethylsilyl)ethoxy)carbonyl)amino)propan-2-ylcarbamate (0.390 g, 0.81 mmol), and DIPEA (2.5 mL) in CH_2Cl_2 was stirred at rt for 16 h. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to afford 0.0487 g (11.4% in three steps) of 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-(3-chlorophenyl)(2-oxopropoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate. MS ESI +ve m/z 624 (M+H).

Step 4. 2-(trimethylsilyl)ethyl (2*S*)-2-((3*R*)-3-((1*R*)-(2-aminopropoxy)(3-chlorophenyl)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A mixture of 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-(3-chlorophenyl)(2-oxopropoxy)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (0.0487 g, 0.078 mmol, 1.0 equiv), $NaBH_3CN$ (0.0296 g, 0.471 mmol, 6.0 equiv), NH_4OAc (0.2550 g, 3.31 mmol, 42 equiv), and 4A molecular sieves (0.0555 g) in MeOH (1 mL) was stirred at rt for 22 h. The reaction mixture was diluted with MeOH and filtered through filter agent, Celite® 545. The filtrate was evaporated under reduced pressure to afford 0.2405 g of crude 2-(trimethylsilyl)ethyl (2*S*)-2-((3*R*)-3-((1*R*)-(2-

aminopropoxy)(3-chlorophenyl)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate, which was used in the next step without further purification. MS ESI +ve m/z 625 (M+H).

Step 5. 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-(2-(methoxycarbonylamino)propoxy)(3-chlorophenyl)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate

A mixture of crude 2-(trimethylsilyl)ethyl (2*S*)-2-((3*R*)-3-((1*R*)-(2-aminopropoxy)(3-chlorophenyl)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate (0.1340 g), obtained as described above, DMAP (0.151 g), DIPEA (2 mL), and methyl chloroformate (0.483 g) in CH_2Cl_2 was stirred at rt for 2 d. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to give 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-(2-(methoxycarbonylamino)propoxy)(3-chlorophenyl)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate. MS ESI +ve m/z 705 (M+Na).

Step 6. methyl 1-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)propan-2-ylcarbamate

A mixture of 2-(trimethylsilyl)ethyl (*S*)-2-((*R*)-3-((*R*)-(2-(methoxycarbonylamino)propoxy)(3-chlorophenyl)methyl)piperidine-1-carboxamido)-3-cyclohexylpropyl(methyl)carbamate and TFA (2 mL) in CH_2Cl_2 (5 mL) was stirred at rt for 3 h. After the reaction mixture was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC to give TFA salt of methyl 1-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)propan-2-ylcarbamate. MS ESI +ve m/z 539 (M+H).

GENERAL SYNTHETIC SCHEMES FOR COMPOUNDS OF FORMULA (XL)

The compounds of Formula (XL) of present invention can be synthesized by coupling a pyran intermediate represented by the following structure:



with a piperidine intermediate represented by the following structure:



,

described in the following scheme:



Preparation of the Pyran Intermediate from Glutamic Ester

The pyran intermediate can be prepared from glutamic ester using the following synthetic scheme:



Preparation of the Pyran Intermediate from Pyroglutamic Ester

The pyran intermediate can also be prepared from pyroglutamic ester using the following synthetic scheme:



Preparation of the Piperidine Intermediate

The piperidine intermediate can be prepared by using the following synthetic scheme.



Alternatively, the piperidine intermediate can be prepared using the following synthetic scheme:



Specific conditions for synthesizing the disclosed aspartic protease inhibitors according to the above schemes are provided in the following 0preparations/examples.

5

PREPARATION 28

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate

(*R*)-1-(*tert*-Butoxycarbonyl)piperidine-3-carboxylic acid (25 g, 0.11 mol, 1.0 equiv), N,O-dimethylhydroxylamine hydrochloride, (10.5 g, 0.14 mol, 1.25 equiv) and EDCI•HCl (26.3 g, 0.14 mol, 1.25 equiv) and diisopropylethylamine (48 mL, 0.28 mol, 2.5 equiv) were dissolved in solvent (400 mL) and stirred overnight at rt. The reaction mixture was diluted with EtOAc, washed with 5% aq HCl (2 X 150mL), satd aq $NaHCO_3$ (150 mL), brine (100 mL), and dried over Na_2SO_4. Concentration afforded (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (24.42 g, 82%) as a clear oil. The crude product was used for next step without further purification. MS ESI +ve m/z 295 (M+Na). ^1H NMR ($CDCl_3$) δ 4.19-4.00 (m, 2H), 3.77 (m, 3H), 3.12 (s, 3H), 2.79 (m, 2H), 2.64 (m, 1H), 1.89 (m, 1H), 1.71-1.52 (m, 2H), 1.51-1.33 (m, 10H).

Step 2. (*R*)-*tert*-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate

To a solution of 1-bromo-3-chlorobenzene (100 g, 0.52 mol) in anhydrous THF (550 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in

hexane (210 mL, 0.52 mol). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (120 g, 0.44 mol) in anhydrous THF (500 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with EtOAc (3×400 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give the crude (*R*)-*tert*-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (178 g), which was used immediately for next step without purification.

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (178 g, 0.55 mol) in anhydrous THF (600 mL) at –15 °C under nitrogen was added dropwise a solution of 1 M *R*-CBS-oxazaborolidine in toluene (82 mL, 82 mmol, 0.15 eq). After stirring for 1 hr at –15 °C, a solution of 10 M BH_3 in THF (60 mL, 0.60 mol, 1.1 eq) was added dropwise. After addition, the reaction mixture was stirred for 2 hr at –15 °C. Methanol (400 mL) was added dropwise carefully at –15 °C. The solvent was removed under reduced pressure, the residue was purified by column chromatography on silica gel eluting with AcOEt/hexane (1:30→1:15) to provide the light yellow oil (95 g, HPLC purity≥70%, isomer ratio≥3:1). The mixture was dissolved in EtOAc till the alcohol was just dissolved (about 5mL/1g), the solvent was removed on the rotary evaporator until a few crystals appeared. The solution was cooled to rt slowly and stood for 1-2 hr. To the above solution was added hexane (about 300 mL) and then filtered, the crystals were washed with cool hexane and re-crystallized from AcOEt-hexane twice to afford the pure isomer (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (20 g, ee≥99%).

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a suspension of NaH (7.44 g, 161 mmol) in anhydrous DMF (50 mL) at 0-5°C was added dropwise a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (17.45 g, 54 mmol) in anhydrous DMF (100 mL), the reaction mixture was stirred for 1 hr at rt. A solution of

ethyl bromoacetate (17.82 g, 11.87 mL, 107 mmol) in anhydrous DMF (100 mL) was added dropwise to the above mixture at 0-5 °C. After addition, the reaction mixture was stirred for 2-3 hr at rt. The reaction mixture was poured into saturated aqueous NH_4Cl and EtOAc (1000 mL) was added. The organic layer was washed with water (3×200 mL) and brine, dried over Na_2SO_4, filtered and concentrated in *vacuo*. The residue was purified on silica gel chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (14 g, 64% yield).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (14 g, 34 mmol) in MeOH (200 mL) was added $NaBH_4$ (10.35 g, 272 mmol) in portions while the temperature was lower than 40 °C. After addition, the mixture was stirred at rt for 2-3 hr. The solvent was removed in *vacuo* to provide a residue which was partitioned between water and EtOAc. The organic layer was washed with H_2O and brine, dried over Na_2SO_4 and evaporated to give the crude (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (12.50g), which was used in the next step without purification.

Step 6. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (12.50 g, 34 mmol) in dry CH_2Cl_2 (150 mL) was added Et_3N (13.74 g, 18.3 mL, 136 mmol, 4 eq) at -5-0 °C. Then a solution of MsCl (7.75 g, 5.16 mL, 68 mmol, 2 eq) in dry CH_2Cl_2 (50 mL) was added dropwise at the same temperature. After addition, it was allowed to warm to rt gradually. Upon reaction completion water (100 mL) was added. The aqueous layer was extracted with CH_2Cl_2 (3×80 mL), the combined organic layers was washed with 10% citric acid, sat. $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give (*R*)-*tert*-

butyl 3-((*R*)-(3-chlorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (15g), which was used in the next step without purification.

Step 7. (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (15 g, 34 mmol) was dissolved into anhydrous DMF (150 mL), solid NaN_3 (6.7 g, 102 mmol, 3 eq) was added and the reaction mixture was heated to 80 °C for overnight. The reaction mixture was cooled to rt and then was added with EtOAc (500 mL), the organic phase was washed with water (3×100 mL) and brine (2×80 mL), dried over Na_2SO_4 and concentrated in *vacuo* to provide crude (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (13.3 g), which was used for next step without purification.

Step 8. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (13.3 g, 33.8 mmol) was dissolved in THF/H_2O (20:1, 180 mL / 9 mL), triphenylphosphine (36.0 g, 135 mmol) was added in portions. The reaction mixture was stirred overnight at rt. The solvent was removed under reduced pressure to the residue, which was purified on silica gel chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (10.4 g, purity: HPLC=75%).

Step 9. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (7.7 g, 21 mmol, HPLC=75%) and DMAP (1.27 g, 10 mmol, 0.5 eq) in dry CH_2Cl_2 (120 mL), Et_3N (6.38 g, 8.45 mL, 63 mmol) was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate (8.1 mL, 104.5 mmol, 5 eq) in dry CH_2Cl_2 (50 mL)

was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. The reaction was quenched with water (80 mL). The aqueous layer was extracted with CH_2Cl_2 (3×50 mL), the combined organic layers were washed with 10% citric acid (2×80 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (4.4 g, HPLC≥98%, the total yield for five steps is 41%).

The following compounds were prepared following procedures analogous to those described above:

1) (*R*)-*tert*-butyl 3-((*R*)-(3,5-difluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3,5-difluorophenyl)lithium in Step 2.

Alternatively, (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate can be prepared by the following procedures:



Step 1: Preparation of (*R*)-*tert*-butyl 3-((*R*)-(2-amino-2-oxoethoxy)(3-chlorophenyl)methyl)-piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(2-ethoxy-2-oxoethoxy)methyl)-piperidine-1-carboxylate (0.971 g, 2.36 mmol) was dissolved in 7 M NH_3/MeOH (20 mL), and stirred overnight at room temperature. The solvent was removed under reduced pressure to give (*R*)-*tert*-butyl 3-((*R*)-(2-amino-2-oxoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (902 mg, 100%), which was used for the next step without further purification. MS ESI +ve m/z 383 $(M+H)^+$.

Step 2: Preparation of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)-piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-amino-2-oxoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (902 mg, 2.36 mmol) in anhydrous toluene (30 mL) at 0°C was added Red-Al® (65% solution in toluene, 1.4 mL, 7.07 mmol) slowly over 10 min. After the addition, the solution was stirred overnight at room temperature. The reaction was cooled to 0°C and quenched with $Na_2SO_4 \cdot 10\ H_2O$. The resulting mixture was stirred for 2-3 h, filtered through Celite®, and washed with THF (200 mL). The filtrate was dried and concentrated to give crude product (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (776 mg, 89%). MS ESI +ve m/z 369 $(M+H)^+$.

PREPARATION 29

(*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(5-fluoro-2-methylbenzoyl)piperidine-1-carboxylate

To a solution of 2-bromo-4-fluoro-1-methylbenzene (10.6 g, 0.056 mol) in anhydrous THF (150 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in hexane (22 mL, 0.056 mol). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (10 g, 0.037 mol) in anhydrous THF (120 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl (100 mL) solution and extracted with EtOAc (3×80

mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to provide crude (*R*)-*tert*-butyl 3-(5-fluoro-2-methylbenzoyl)piperidine-1-carboxylate (10.5 g, yield 88%), which was used in the next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(5-fluoro-2-methylbenzoyl)piperidine-1-carboxylate (10.5 g, 0.0336 mol) in anhydrous THF (150 mL) at –15 °C under nitrogen was added dropwise a solution of 1 M *R*-CBS-oxazaborolidine in toluene (3 mL, 3 mmol, 0.09 eq). After stirring for 1 hr at –15 °C, a solution of 10 M BH_3 in THF (17 mL, 0.0336 mol, 1 eq) was added dropwise. After addition, the reaction mixture was stirred for 2 hr at –15 °C. Methanol (80 mL) was added dropwise carefully at –15 °C. The solvent was removed under reduced pressure, the residue was purified by column chromatography on silica gel eluting with AcOEt/hexane (1:30→1:15) to provide the light yellow oil (95 g, HPLC≥70%, ratio≥3 : 1). The mixture was dissolved in a minimum volume of EtOAc, the solvent was removed on the rotary evaporator until crystals appeared. The solution was cooled to rt and stood for 1-2 h. To the solution was added hexane and then filtered , the crystals were washed with cool hexane and re-crystallized an additional two times to afford the pure isomer (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate (3.2 g, ee≥99%). ^1H NMR ($CDCl_3$) δ 7.1 (m, 2H), 6.85 (m, 1H), 4.7 (m, 1H), 2.3 (s, 3H), 1.45 (s, 9H), 1.25 (m, 4H).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(5-fluoro-2-methylphenyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate (1.2 g ,0.0037 mol) in MeCN (20 mL), NaH (0.27 g, 0.011 mol) was added at 0 °C. The mixture was stirred for 1 hr followed by cooling to –40 °C and adding bromoacetonitrile (1.3 g, 0.011 mol) in portions. The mixture was stirred for 0.5 hour at –20 °C. The reaction was quenched with H_2O. The mixture was extracted with CH_2Cl_2. The organic layer was dried by

Na_2SO_4, concentrate to get the target molecule (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(5-fluoro-2-methylphenyl)methyl)piperidine-1-carboxylate (1.2 g, 90%).

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(5-fluoro-2-methylphenyl)methyl)piperidine-1-carboxylate

A solution of (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(5-fluoro-2-methylphenyl)methyl)piperidine-1-carboxylate (1.8 g, 0.005 mol) in anhydrous THF (20 ml) was heated to reflux under nitrogen. A solution of $BH_3.Me_2S$ in THF was added dropwise and stirring was continued under reflux overnight. When the resulting solution was cooled to rt, MeOH was added dropwise to quench the reaction. After evaporation of the solution, the crude product was purified by column chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(5-fluoro-2-methylphenyl)methyl)piperidine-1-carboxylate (1.2g, yield 66%).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(5-fluoro-2-methylphenyl)methyl)piperidine-1-carboxylate (3.1 g, 8.5 mmol) and DMAP (0.54 g) in dry CH_2Cl_2 (45 mL), Et_3N (2.58 g,3.6 mL) was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate (4.0 g, 43 mmol, 5 eq) in dry CH_2Cl_2 (50 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 h at 0-5 °C. The reaction was quenched with water (50 mL). The aqueous layer was extracted with CH_2Cl_2 (3×30 mL), the combined organic layers were washed with 10% citric acid (2×50 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (400 mg, HPLC≥98%). ^1H NMR ($CDCl_3$) δ 7.2 (m, 1H), 7.1 (m, 1H), 6.9 (m, 1H), 4.4 (m, 1H), 4.1 (m, 1H), 3.7 (m, 1H), 3.6 (s, 3H), 3.2 (m, 2H), 2.9 (m, 2H), 2.3 (s, 3H), 1.75 (m, 1H), 1.6 (m, 1H), 1.4 (s, 9H), 1.25 (m, 2H).

PREPARATION 30

(*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-chloro-5-fluorobenzoyl)piperidine-1-carboxylate

In a 2 L three-necked bottle flushed with N_2, Mg (26.5 g , 1.1 mol) was warmed to 50 °C, 1-bromo-3-chloro-5-fluorobenzene (157 g, 0.75 mol) solution in anhydrous THF (1 L) was added dropwise, then the mixture was stirred at r.t. for 2 hr. To a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (120 g, 0. 441 mol) in anhydrous THF (1.1 L) at –78 °C under nitrogen was added dropwise the above Grignard reagent. The reaction mixture was allowed to warm to rt and stirred for 2 h. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with EtOAc (3×400 mL). The combined organic layer was washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give (*R*)-*tert*-butyl 3-(3-chloro-5-fluorobenzoyl)piperidine-1-carboxylate (163 g), which was used immediately without further purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

A mixture of 10 M $H_3B.S_2Me$ in THF (47.7 mL, 0.477 mol) and 1 M *R*-CBS-oxazaborolidine in toluene (72 mL, 0.072 mol) were dissolved in 100 mL anhydrous THF and cooled to –15 °C. (*R*)-*tert*-butyl 3-(3-chloro-5-fluorobenzoyl)piperidine-1-carboxylate in 400 mL anhydrous THF was added dropwise to the above solution and stirred at –15 °C for 2 hr. The reaction was quenched with methanol (500 mL). The solvent was removed under reduced pressure and the residue was purified by column

chromatography. The product was re-crystallized three times with EtOAc/Hexanes to give (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (55 g, 0.156 mol). ^{1}H NMR ($CDCl_3$, 400MHz) δ 7.10 (s, 1H), 7.04-6.90 (dd, 2H), 4.46-4.30 (d, 1H), 4.05-2.40 (m, 5H), 1.74 (s, 1H), 1.60 (s, 1H), 1.53-1.31(m, 11H), 1.30-1.14 (m, 1H).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate

A solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (55 g , 0.156 mol) in acetonitrile (1.2 L) was cooled to 0 °C, NaH (19.2 g, 0.48 mol, 60% in oil) was added in portions, then the mixture was stirred at rt for 1 hr. The mixture was cooled to -20 °C and bromoacetonitrile (57.7 g, 0.48 mol) was added dropwise. After 0.5 hr, additional NaH (19.2 g, 0.48 mol, 60% in oil) and bromoacetonitrile (57.7 g, 0.48 mol) was added. TLC showed 80% of the starting material was reacted. The reaction was quenched with saturated NH_4Cl solution (200 mL), water (1 L) was added. Acetonitrile was removed by reduced pressure, CH_2Cl_2 (1 L) was added, the aqueous layer was back extracted with CH_2Cl_2 (3×500 mL), dried over Na_2SO_4 and concentrated in *vacuo* to give the crude (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (90 g), which was used for the next step without further purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-5-fluorophenyl)methyl)piperidine-1-carboxylate

A solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (90 g) in anhydrous THF(1.3 L), under protection of N_2, was heated to reflux followed by the dropwise addition of 10 M $H_3B.SMe_2$ in THF (70 mL, 0.7 mol). The mixture was stirred at reflux overnight. The reaction was quenched with MeOH (500 mL) and the solvent removed in *vacuo*, the residue was purified by column chromatography to give (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-5-fluorophenyl)methyl)piperidine-1-carboxylate (24 g, 0.062 mol).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

A solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-5-fluorophenyl)methyl)piperidine-1-carboxylate (24 g, 0.062 mol) in dry CH_2Cl_2 (300 mL) and Et_3N (31.4 g, 43 mL) was cooled to 0 °C in ice-water bath, a solution of methyl chloroformate (11.8 g, 0.124 mol) in dry CH_2Cl_2 (100 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 h at 0-5 °C. Water (200 mL) was added to quench the reaction. The aqueous layer was extracted with CH_2Cl_2 (3×100 mL), the combined organic layers were washed with 10% citric acid (2×80 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by column chromatography to give (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (19 g, 0.043 mol). ^{1}H NMR (CD_3OD) δ 7.17(s, 1H), 7.16-7.08 (m, 1H), 7.07-7.00 (m, 1H), 4.20-4.00 (m, 2H), 3.90-3.78 (d, 1H), 3.61 (s, 3H), 3.28-3.20 (m, 2H), 2.92-2.68 (dd, 2H), 1.52-1.74 (m, 2H), 1.42 (s, 9H), 1.35-1.10 (m, 3H).

PREPARATION 31

(*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-fluorobenzoyl)piperidine-1-carboxylate

A solution of 1-bromo-3-fluoro-benzene (57.7 g, 0.33 mol) in anhydrous THF (480 mL) was added dropwise to Mg (10.6 g, 0.44 mol) at rt under nitrogen. The mixture was stirred at 50-60 °C for 1 hr. The resulting Grignard reagent was used for the next step. The Grignard reagent was added dropwise to a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (60g, 0.22 mol) in anhydrous THF (600 mL) at -78 °C under nitrogen. After addition, the mixture was allowed to stir at rt for 1.5 hr. The mixture was quenched with saturated NH_4Cl solution (300 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-(3-fluorobenzoyl)piperidine-1-carboxylate (67.5 g, 100%), which was used immediately in the next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of 1 M *R*-CBS-oxazaborolidine in toluene (33 mL, 33 mmol, 0.15 eq) and 10 M BH_3 in THF (22 mL, 0.22 mol, 1.0 eq) at –15 °C under nitrogen was added dropwise a solution of (*R*)-*tert*-butyl 3-(3-fluorobenzoyl)piperidine-1-carboxylate (67.5 g, 0.22 mol) in anhydrous THF (300 mL). After addition, the reaction mixture was stirred for 1 hr at rt. Methanol (200 mL) was added dropwise carefully at 0 °C. The solvent was removed under reduced pressure to provide the crude product. The crude product was dissolved in EtOAc until the alcohol was just dissolved (about 5mL/1g), the solvent was removed on the rotary evaporator until a few crystals appeared. To the above solution was added petroleum ether (about 300 mL) under stirring, which was allowed to stir at rt for 2 hr and then filtered, the crystals were washed with petroleum ether and re-crystallized to afford the pure *R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (26 g, 39%).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate

To a suspension of NaH (4.8 g, 120 mmol) in THF (400 mL) at 0-5 °C was added dropwise a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-

fluorophenyl)methyl)piperidine-1-carboxylate (30.9 g, 100 mmol) in anhydrous THF (100 mL), the reaction mixture was stirred for 1 hr at rt. A solution of ethyl bromoacetate (20.04 g, 13.40 mL, 120 mmol) in anhydrous THF (100 mL) was added dropwise to the above mixture, and the reaction was heated to reflux for 3-5 hr. The reaction mixture was poured into saturated aqueous NH_4Cl, then extracted with EtOAc (3×100 mL). The organic layer was washed with water (3×100 mL) and brine, dried over Na_2SO_4, filtered and concentrated in *vacuo* to afford crude (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (29.88g 76 %), which was used for next step without purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-ethoxy-2-oxoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (29.88 g, 75.9 mmol) in MeOH (300 mL) was added $NaBH_4$ (23 g, 605.2 mmol) in portions while the temperature was lower than 40 °C. After addition, the mixture was stirred at rt for 2-3 hr. The solvent was removed in *vacuo* to give a residue which was partitioned between water and EtOAc. The organic layer was washed with H_2O and brine, dried over Na_2SO_4, filtered and concentrated in *vacuo*. The residue was purified on silica gel chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (11 g, 41%).

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (11 g, 31.16 mmol) in dry CH_2Cl_2 (140 mL) was added Et_3N (12.60 g, 16.68 mL, 124.65 mmol, 4 eq) at -5-0 °C. Then a solution of MsCl (7.1 g, 4.72 mL, 62.32 mmol, 2 eq) in dry CH_2Cl_2 (40 mL) was added dropwise at the same temperature. After addition, it was allowed to warm to rt gradually. Water (100 mL) was added. The aqueous layer was extracted with CH_2Cl_2 (3×80 mL), the combined organic layers was washed with 10% citric acid, sat. $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give (*R*)-*tert*-butyl 3-

((*R*)-(3-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (13.8 g), which was used in the next step without purification.

Step 6. (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-fluorophenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (13.8 g, 32 mmol) was dissolved into anhydrous DMF (150 mL), solid NaN_3 (6.1 g, 96 mmol, 3 eq) was added and the reaction mixture was heated to 80 ° for overnight. The reaction mixture was cooled to rt and then was added with EtOAc (500 mL), the organic phase was washed with water (3×100 mL) and brine (2×80 mL), dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (12 g), which was used in the next step without further purification.

Step 7. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate

A suspension of (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (12 g, 31.75 mmol) and $Pd(OH)_2/C$ (1.2 g) in MeOH (240 ml) was stirred under H_2 for 1 hr. The mixture was filtered and evaporated under reduced pressure to give desired (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (10 g).

Step 8. (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-fluorophenyl)methyl)piperidine-1-carboxylate (10 g, 28.41 mmol) and DMAP (1.8 g, 14.21 mmol, 0.5 eq) in dry CH_2Cl_2 (150 mL), Et_3N (8.62 g, 11.42 mL, 85.23 mmol) was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate (10.95 mL, 142.05 mmol, 5 eq) in dry CH_2Cl_2 (60 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. Water (80 mL) was added to quench the reaction. The aqueous layer was extracted

with CH_2Cl_2 (3×50 mL), the combined organic layers were washed with 10% citric acid (2×80 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by silica gel to afford (*R*)-*tert*-butyl 3-((*R*)-(3-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (11.3 g, 97%).

PREPARATION 32

(*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. 5-chloro-2-methylbenzenamine

A 2 L flask was charged the solution of 4-chloro-1-methyl-2-nitrobenzene (60 g, 0.35 mol) in MeOH (1 L), Raney Ni was added, the air in flask was replaced three times with H_2, the mixture was stirred for 3 hr at rt. The solution was filtered and concentrated. The residue was dissolved in CH_2Cl_2 (500 mL), and the solution was washed with brine, dried over Na_2SO_4. Solvent removal gave 5-chloro-2-methylbenzenamine (50 g, 0.35 mol). ^1H NMR ($CDCl_3$, 400MHz) δ 7.02-6.93 (d, 2H), 6.70-6.60 (d, 2H), 3.67 (s, 2H), 2.14 (s, 3H).

Step 2. 2-bromo-4-chloro-1-methylbenzene

5-chloro-2-methylbenzenamine (50 g, 0.355 mol) was dissolved in HBr solution (1.5 M, 100 mL) and cooled to 0 °C, a solution of $NaNO_2$ (27.6 g, 0.4 mol) in water (200 mL) was added dropwise. After addition, the mixture was stirred for 1 hr. In another flask CuBr (30 g, 0.21 mol) was added to HBr solution (1.5 M, 30 mL) and heated to 60 °C, then the mixture was added to the above solution. The mixture was heated to reflux for 1 hr then cooled to rt. The reaction was quenched with water (500 mL), the aqueous layer was extracted 3 times with CH_2Cl_2, dried over Na_2SO_4, solvent removal and purification by column chromatography afforded 2-bromo-4-chloro-1-methylbenzene (53 g, 0.26 mol). ^1H NMR ($CDCl_3$, 400MHz) δ 7.53 (s, 1H), 7.20-7.10 (m, 2H), 2.36 (s, 3H).

Step 3. (*R*)-*tert*-butyl 3-(5-chloro-2-methylbenzoyl)piperidine-1-carboxylate

To a solution of 2-bromo-4-chloro-1-methylbenzene (53 g, 0.26mol) in anhydrous THF (600 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in hexane (103 mL, 0.26 mol). After stirring for 1 hr at –78 °C, a solution of the (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (67 g, 0.246 mol) in anhydrous THF (300 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with EtOAc (3×400 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-(5-chloro-2-methylbenzoyl)piperidine-1-carboxylate (86 g), which was used immediately in the next step without purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate

A mixture of 10 M $BH_3.Me_2S$ in THF (25.4 mL, 0.254 mol) and 1 M *R*-CBS-oxazaborolidine in toluene (38 mL, 0.038 mol) were dissolved in 100 mL anhydrous THF and cooled to –15 °C. (*R*)-*tert*-butyl 3-(5-chloro-2-methylbenzoyl)piperidine-1-carboxylate in 200 mL anhydrous THF was added dropwise to the above solution and

stirred at –15 °C for 2 hr. The reaction was quenched with methanol (300 mL). The solvent was removed under reduced pressure, and the residue was purified by column chromatography to give (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate (32 g), which contained 30% isomer.

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate

To a suspension of NaH (5.64 g, 0.141 mol) in the mixed solvent of DMF (70 mL) and THF (70 mL) at -25 °C was added dropwise a solution of (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(hydroxy)methyl)piperidine-1-carboxylate (16 g, 47 mmol) in anhydrous THF (100 mL), the reaction mixture was stirred for 1 hr at rt. A solution of ethyl bromoacetate (15.6 g, 94 mmol) in anhydrous THF (70 mL) was added dropwise to the above mixture at -10- -5 °C. After addition, the reaction mixture was stirred for 2-3 hr at rt. The reaction was quenched with saturated NH_4Cl solution (100 mL) and EtOAc (500 mL) was added. The organic layer was washed with water (5×50 mL) and brine, dried over Na_2SO_4, filtered and concentrated in *vacuo*. The residue was purified by column chromatography to afford (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (8 g, 18.8 mmol).

Step 6. (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (8g, 18.8mmol) in MeOH (300 mL) was added $NaBH_4$ (5.6 g, 0.15 mol) in portions while the temperature was lower than 40 °C. After addition, the mixture was stirred overnight. The solvent was removed in *vacuo* to the residue, which was partitioned between water and EtOAc. The organic layer was washed with H_2O and brine, dried over Na_2SO_4 and evaporated to give crude (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (7 g), which was used in the next step without purification.

Step 7. (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-hydroxyethoxy)methyl)piperidine-1-carboxylate (7 g, 18.3 mmol) in dry CH_2Cl_2 (100 mL) was added Et_3N (54 g, 10 mL, 0.73 mmol) at -5-0 °C. Then a solution of MsCl (4.2 g, 36.5 mmol) in dry CH_2Cl_2 (50 mL) was added dropwise at the same temperature. After addition, it was allowed to warm to rt gradually. The reaction mixture was washed with 10% citric acid solution (30 mL), $NaHCO_3$ and brine, then dried over Na_2SO_4, filtered and concentrated to give (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (8.4 g), which was used in the next step without purification.

Step 8. (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(5-chloro-2-methylphenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methylsulfonyloxy)ethoxy)methyl)piperidine-1-carboxylate (8.4 g, 18.3 mmol) was dissolved in anhydrous DMF (150 mL), solid NaN_3 (3.56 g, 54.8 mmoL) was added and the reaction mixture was heated to 60 °C for overnight. The reaction mixture was cooled to rt and diluted with EtOAc (500 mL), the organic phase was washed with water (5×50 mL) and brine (100 mL), dried over Na_2SO_4 and concentrated in *vacuo* to give (*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(5-chloro-2-methylphenyl)methyl)piperidine-1-carboxylate (7 g).

Step 9. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(5-chloro-2-methylphenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-butyl 3-((*R*)-(2-azidoethoxy)(5-chloro-2-methylphenyl)methyl)piperidine-1-carboxylate (7 g, 17.1 mmoL) was dissolved in EtOAc (300 mL), 0.8 g of $Pd(OH)_2$ was added and the air in bottle was replaced 3 times with H_2, the reaction was stirred at rt for 3 hr. The solution was filtered and concentrated to give (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(5-chloro-2-methylphenyl)methyl)piperidine-1-carboxylate (6.2 g), which was used in the next step without further purification.

Step 10. (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(5-chloro-2-methylphenyl)methyl)piperidine-1-carboxylate (6.2 g, 16.2 mmol) and DMAP (0.2 g, 1.62 mmol) in dry CH_2Cl_2 (70 mL), Et_3N (8 g, 81 mmol) was added. The resulting mixture was cooled to 0-5 °C in ice-water bath, a solution of methyl chloroformate (3.1 g, 32.4 mmol) in dry CH_2Cl_2 (30mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. The reaction was quenched with water. The aqueous layer was extracted with CH_2Cl_2 (3×30 mL), the combined organic layers were washed with brine, then dried over Na_2SO_4, filtered and concentrated to give the crude product, which was firstly purified by column chromatography and then by preparative HPLC to give (*R*)-*tert*-butyl 3-((*R*)-(5-chloro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (1.5g). ^1H NMR (CD_3OD, 400MHz) δ 7.30 (s, 1H), 7.20-7.10 (d, 2H), 4.81 (s, 1H), 4.46-4.30 (d, 1H), 4.29-4.15 (d, 1H), 3.95-3.83 (d, 1H), 3.62 (s, 3H), 3.30 (s, 4H), 2.90-2.65 (dd, 2H), 2.30 (s, 3H), 1.70 (s, 1H), 1.59 (s, 1H), 1.41 (s, 9H), 1.35-1.20 (m, 3H).

PREPARATION W1

2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine



Step 1. (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid

To a round bottom flask, Et_3N (303g, 3mol) was added dropwise to a stirred solution of Boc_2O (261.6 g, 1.2 mol) and 2-amino-pentanedioic acid 5-methyl ester (161 g, 1 mol) in water (800 ml) and dioxane (800 ml). After 18 hr the solution was extracted with petroleum ether (2 ×1000ml) and the aqueous phase was cooled on ice and carefully acidified to pH 3 by slow addition of 10% citric acid solution. The urethane was then extracted into EtOAc (3 ×1000ml) and the combined extracts were washed with brine, then dried (Na_2SO_4), filtered and concentrated under reduced pressure to give (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid (238g, 91.2%), which was used without further purification.

Step 2. (*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate

To a stirred solution of (*S*)-2-(*tert*-butoxycarbonylamino)-5-methoxy-5-oxopentanoic acid (35.2 g,0.135 mol) in THF (500 mL) at -10 °C was added N-methylmorpholine (15 mL, 0.135 mol) followed by ethyl chloroformate (14.72 g, 0.135 mol). After 10 min, $NaBH_4$ (15.37 g, 0.405 mol) was added in one portion. MeOH (1200 mL) was then added dropwise to the mixture over a period of 20 min at 0 °C. The solution was stirred for an additional 20 min and then neutralized with 1M $KHSO_4$. The organic solvent was removed and the aqueous layer was extracted with EtOAc (3 ×500 ml). The combined organic phases were washed consecutively with 1M $KHSO_4$ (300 mL), H_2O (300 mL), 5% aqueous $NaHCO_3$ (300 mL), and dried (Na_2SO_4). The solvent was evaporated to give a residue, which was purified by column chromatography to give the desired (*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate (24 g, 72%)

Step 3. (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-methyl 4-(*tert*-butoxycarbonylamino)-5-hydroxypentanoate (24 g, 97.2 mmol) and isopropenyl methyl ether (88.8 g, 854.6 mmol) was dissolved in acetone (2000 mL) and BF_3•Et_2O (0.82 mL, 5.84 mmol) was added at rt. The mixture was stirred for 1 hr at rt. The reaction was quenched by addition of Et_3N (11.6 mL). The reaction solution was washed with aqueous saturated $NaHCO_3$ (200 mL) and evaporated, and (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (25.1 g, 90 %) was obtained as an oil , which was used in the next step without further purification.

Step 4. (*S*)-3-(3-(*tert*-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)propanoic acid

An aqueous solution of sodium hydroxide (195 mL, 4.0 M in H_2O, 0.261mol, 3.0 eq) was added to a solution of (*S*)-*tert*-butyl 4-(3-methoxy-3-oxopropyl)-2,2-dimethyloxazolidine-3-carboxylate (25.1 g, 0.087 mol), and the resulting cloudy reaction mixture was stirred at 23 °C for 3.5 hr. The mixture was concentrated under reduced pressure to ~50 mL volume and then was partitioned between 0.5 M HCl (360 ml) and EtOAc (2 ×360ml). The combined organic layers were dried over Na_2SO_4 and

were filtered. The filtrate was concentrated under reduced pressure to give (*S*)-3-(3-(*tert*-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)propanoic acid (21.6 g, 91%), which was used without further purification.

Step 5. (*S*)-*tert*-butyl 2,2-dimethyl-4-(3-((*R*)-4-methyl-2-oxooxazolidin-3-yl)-3-oxopropyl)oxazolidine-3-carboxylate

A 2000 mL flask was charged with (*S*)-3-(3-(*tert*-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)propanoic acid (21.6 g, 79 mmol) and 750 mL of dry THF. The solution was cooled to 0 °C, then triethylamine (23.94 g, 237 mmol, 3.0 equiv) and pivaloyl chloride (9.76 mL, 79 mmol, 1.0 equiv) were sequentially added. The solution was stirred for 4 hr at 0 °C. After this time (*R*)-4-benzyl-2-oxalozolidinone (13.26g, 75.2 mmol, 0.95 equiv) and dried LiCl (3.68 g, 86.4 mmol, 1.1 equiv) were added and the reaction was allowed to stir for 13 hr with concomitant warming to ambient temperature. After this time 560 mL of 0.5 M HCl was added, the mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with EtOAc (3×370 mL), and the combined organic layers washed with 10% K_2CO_3 (2×370 mL), and brine (2×370 mL), then dried over Na_2SO_4, and evaporated. The crude material was purified by flash chromatography, eluting with 0-29% EtOAc in hexanes. This afforded 26.3g (81%) of (*S*)-*tert*-butyl 2,2-dimethyl-4-(3-((*R*)-4-methyl-2-oxooxazolidin-3-yl)-3-oxopropyl)oxazolidine-3-carboxylate as a clear syrup.

Step 6. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((*R*)-4-methyl-2-oxooxazolidine-3-carbonyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate

At 0 °C, 1.0M $TiCl_4$ in CH_2Cl_2 solution (8.55 mL, 0.7 eq) was added to CH_2Cl_2 (100 mL) followed by the addition of 1.0M $TiCl(O\textit{i}\text{-}Pr)_3$ in hexanes solution (4.28 mL, 0.35 eq) and stirred 5 min DIPEA (2.87 mL, 1.35 eq) was added and stirred 15 min. A solution of (*S*)-*tert*-butyl 2,2-dimethyl-4-(3-((*R*)-4-methyl-2-oxooxazolidin-3-yl)-3-oxopropyl)oxazolidine-3-carboxylate (5.28 g, 12.22 mmol) in CH_2Cl_2 (50 mL) was added. The reaction mixture was stirred 1 hr at 0 °C. To the solution, t-butylacrylate (2.22 mL, 1.25 eq) was added and the mixture was left stirred over 48 hr with concomitant warming to rt. The mixture was concentrated, partitioned between EtOAc (300 mL) and 1% HCl solution (100 mL). The organic layer was washed with sat.

$NaHCO_3$ solution (60 mL), brine (60 mL), dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (120 g column, 0~35% EtOAc in Hexanes gradient) to afford 4.12 g (60%) (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((*R*)-4-methyl-2-oxooxazolidine-3-carbonyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate as a yellowish solid. MS ESI +ve m/z 583 (M+Na).

Step 7. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate

(*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-((*R*)-4-methyl-2-oxooxazolidine-3-carbonyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (4.12 g, 7.36 mmol) was dissolved in 4:1 THF and methanol (200 mL) and cooled to 0 °C. Sodium borohydride (557 mg, 2 eq) was added slowly. After 10 min., the mixture was warmed up to rt slowly. The mixture was stirred 2 hr at rt. The mixture was concentrated, redissolved in EtOAc (300 mL), washed with 1% HCl solution (100 mL), brine (60 mL), and dried over Na_2SO_4. After filtration and concentration, the residue was purified by ISCO (40 g column, 10-65% EtOAc in Hexanes gradient, check TLC with Ninhydrin stain) to afford 2.86 g of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate as a white solid. MS ESI +m/v 410 (M+Na).

Step 8. (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-2-(hydroxymethyl)-5-oxopentyl)-2,2-dimethyloxazolidine-3-carboxylate (244 mg, 0.63 mmol) in anhydrous DCM (6 mL) was added pyridine (2 mL) and catalytic amount of DMAP, the solution was chilled to 0 °C. Tosic chloride (360 mg, 1.88 mmol) was added and stirred at rt overnight. The reaction mixture was diluted with EtOAc (40 mL) and washed with 1 N HCl (2x, 50 ml + 20 ml), followed by H_2O, aq. $NaHCO_3$, brine, dried over Na_2SO_4, and filtered. After evaporation of solvent, the residue was purified on silica gel column, eluted with 0-20% EtOAc in hexane to afford (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (317 mg, yield 93%).

Step 9. (*S*)-*tert*-butyl 4-((*R*)-5-hydroxy-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-*tert*-butoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (317 mg, 0.58 mmol) in anhydrous DCM (8 mL) at -78 °C under N_2 was added DiBAlH (1 M in hexane, 1.75 mL, 1.75 mmol) dropwise. After the addition, the reaction mixture was stirred for another 30 min. The reaction was quenched with MeOH (2 mL), followed by 50% Rochelle's salt aq·solution and stirred 2 hr. The resulting solution was extracted with DCM (3 × 20 mL), the combined organic phases were concentrated and dissolved in THF/MeOH (10 mL, 4/1, v/v), and chilled to 0 °C, $NaBH_4$ (11 mg, 0.29 mmol) was added and stirred at this temperature for 30 min. The reaction was quenched by aqueous NH_4Cl, then extracted with EtOAc (3 × 20 mL), the combined organic phases were washed with H_2O, brine, and dried over Na_2SO_4, and filtered, and concentrated to give crude product (*S*)-*tert*-butyl 4-((*R*)-5-hydroxy-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (255 mg, 92%). It was used without further purification.

Step 10. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-5-hydroxy-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (254 mg, 0.54 mmol) in anhydrous DMF (8 mL) at 0 °C under N_2 was added NaH (43 mg, 1.08 mmol). After stirred at this temperature for 1 hr, the reaction was quenched with aq. NH_4Cl and then evaporated to dryness. The residue was dissolved in EtOAc and H_2O, the separated aqueous phase was extracted with EtOAc. The combined organic phases were washed with H_2O, brine, and dried over Na_2SO_4, filtered, and evaporated. The residue was purified on silica gel column to afford (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate (136 mg, 84%).

PREPARATION X1

2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine



Step 1. (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate

To a solution of HMDS in anhydrous THF (200 mL) was added dropwise 2.5 M *n*-BuLi in hexane (130 mL) and the mixture was stirred at -78 °C for 1 hr. To a solution of (*S*)-1-*tert*-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate (80 g, 0.311 mol) in anhydrous THF (1600 mL) stirred at -78 °C was added lithium hexamethyldisilazide in THF. After the reaction mixture was stirred at -78 °C for 1 hr, 3-bromopropene (38.47 g, 0.318 mol) in THF (200 mL) was added and stirring was continued for 2 hr. The reaction mixture was quenched with saturated ammonium chloride solution (600 mL) at -78 °C and extracted with EtOAc (3×500 mL) . The combined organic layers were dried over Na_2SO_4, filtered and evaporated to dryness. The crude product was separated by column chromatography to afford (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate (15 g, 16%).

Step 2. *tert*-butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate

To a solution of (2*S*,4*R*)-1-*tert*-butyl 2-ethyl 4-allyl-5-oxopyrrolidine-1,2-dicarboxylate (30 g, 0.1 mol) in MeOH/H_2O (700/70 mL) was added $NaBH_4$ (25 g, 0.66 mol), the result mixture was stirred 1 hr at rt and quenched with sat. aq. NH_4Cl (300 mL). The organic solvent was removed under vacuum and extracted with EtOAc (3×250 mL). The combined organic phases were washed with brine (250 mL) and

dried over anhydrous Na_2SO_4, filtered and evaporated to afford crude *tert* -butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate (22 g, 85%). It was used in the next step without further purification.

Step 3. (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of *tert* -butyl (2*S*,4*R*)-1-hydroxy-4-(hydroxymethyl)hept-6-en-2-ylcarbamate (6.8 g, 26.2 mmol) in acetone (150 mL), PTSA (0.45 g, 2.62 mmol) was added. The reaction mixture was cooled to -20 °C followed by the addition of 2,2-dimethoxypropane (4.1 g, 39.4 mmol). The resulting mixture was stirred and allowed to warm to rt for 1 hr. TEA (0.5 mL) was then added and stirred for another 5 min. The solvent was removed under reduced pressure. The residue was dissolved in Et_2O (300 mL), washed with 1 N HCl (80 mL), sat. aq. $NaHCO_3$ (80 mL), brine (80 mL) successively, and dried, filtered, and concentrated under vacuum to give crude (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (7.5 g, 96%). It was used without further purification.

Step 4. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-(hydroxymethyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (11.5 g, 38.4 mmol), imidazole (7.84 g, 115.2 mmol) and DMAP (234 mg, 1.92 mmol) in CH_2Cl_2 (200 mL) was added a solution of TBSCl (8.68 g, 57.6 mmol) in CH_2Cl_2 (100 mL) dropwise. The reaction mixture was stirred at rt for overnight. The reaction was washed with water (100 mL) and the aqueous layer was extracted with CH_2Cl_2 (3×100 mL), the combined organic layers was washed with brine (70 mL), then dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (9 g, 57%).

Step 5. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate

A solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)pent-4-enyl)-2,2-dimethyloxazolidine-3-carboxylate (26 g, 63 mmol) in THF (200 mL) was cooled in an ice-bath, followed by dropwise addition of 10 M $BH_3.SMe_2$ (6.3 mL). After stirring for 5 hr, 10% NaOH solution (32 mL) followed by 30% H_2O_2 (32 mL) were added carefully. The reaction mixture was stirred at rt for 16 hr. The reaction mixture was diluted with diethyl ether (500 mL) and the aqueous layer was extracted with diethyl ether (3×250 mL). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate (19.6 g, 72%).

Step 6. (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-hydroxypentyl)-2,2-dimethyloxazolidine-3-carboxylate (32 g, 74.2 mmol) and Et_3N (22.5 g, 226 mmol) in CH_2Cl_2 (400 mL) was added a solution of MsCl (10.1 g, 89 mmol) in CH_2Cl_2 (50 mL) at 0-5 °C. After addition, the reaction mixture was allowed to warm to rt and stir for 1 hr. The reaction was washed with water (200 mL) and the aqueous layer was extracted with CH_2Cl_2 (3×150 mL). The combined organic layers was washed with 10% citric acid (60 mL), sat. $NaHCO_3$ (60 mL) and brine (100 mL), then dried over Na_2SO_4, filtered and concentrated to give (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (37.7 g, 100%), which was used in the next step without purification.

Step 7. (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate

To a solution of (*S*)-*tert*-butyl 4-((*R*)-2-((*tert*-butyldimethylsilyloxy)methyl)-5-(methylsulfonyloxy)pentyl)-2,2-dimethyloxazolidine-3-carboxylate (37.7 g, 74.2 mmol) in THF (1000 mL) was added tetraethylammonium fluoride hydrate (41 g, 185.5 mmol)

in portions. The reaction mixture was stirred under reflux overnight. The mixture was diluted with EtOAc (1000 mL), washed with water (300 mL) and brine (500 mL). The organic phase was dried over Na_2SO_4, filtered and concentrated in *vacuo* to give the crude product, which was purified by column chromatography to afford (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate (12.0 g, 54%).

PREPARATION Y1

tert-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate



Step 1. Preparation of *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

To a solution of (*S*)-*tert*-butyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate (643 mg, 2.15 mmol) in MeOH (10 mL) was added p-TSA (37 mg, 0.22 mmol), then the solution was stirred at rt for 12 hr. TEA (2 mL) was added, followed by Boc_2O (46 mg, 0.21 mmol). After the addition the reaction solution was stirred for another 30 min. The organic solvent was removed under reduced pressure to give the crude product *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate. It was used in the next step without further purification. MS ESI +ve m/z 260 (M+1).

Step 2. Preparation of (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl 4-methylbenzenesulfonate

The above crude product *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate was dissolved in anhydrous DCM (22 mL). To this solution was added pyridine (2 mL) and TsCl (1.230 g, 6.45 mmol). After stirred at rt for 4 hr, another batch of pyridine (3 mL) and TsCl (0.700 g, 3.67 mmol) was added and stirred

for another 12 hr. The reaction mixture was diluted with EtOAc (80 mL), washed with 1 N HCl (75 mL), followed by H_2O (2 × 30 mL), saturated aq. $NaHCO_3$, brine, and dried over anhydrous Na_2SO_4, and filtered, and concentrated under reduced pressure. The resulted slurry was purified through flash chromatography on silica gel (eluted with gradient system: 0-35% EtOAc in hexane) to afford (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl 4-methylbenzenesulfonate, 670 mg, yield 75% for two steps. MS ESI +ve m/z 436 (M+Na).

Step 3. *tert*-butyl (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

The solution of (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl 4-methylbenzenesulfonate (132 mg, 0.32 mmol) and NaN_3 (62 mg, 0.95 mmol) in anhydrous DMF was heated to 80 °C under N_2 atmosphere for 1.5 hr, cooled to rt and diluted with EtOAc, and washed with H_2O (3 × 20 mL), followed by brine, and dried over anhydrous Na_2SO_4, and filtered, and concentrated under reduced pressure. The resulted slurry was purified through flash chromatography on silica gel (eluted with gradient system: 0-30% EtOAc in hexane) to afford *tert*-butyl (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate 58 mg, yield 64%. MS ESI +ve m/z 307 (M+Na).

Step 4: *tert*-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

Hydrogenation of *tert*-butyl (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (146 mg, 0.51 mmol) was carried out in MeOH (10 mL), 10% Pd/C (25 mg) under 40 psi of H_2 for 2 h. After filtration 114 mg of *tert*-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate was obtained, yield 86%. MS ESI +ve m/z 259 (M+H).

PREPARATION Z1

tert-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate



Step 1. *tert*-butyl (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate

To a solution of *tert*-butyl (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (30 mg, 0.11 mmol) in anhydrous THF (4 mL) at -78 °C was added 1.0 M LHMDS solution in THF (253 μL, 0.25 mmol), then stirred at this temperature for 30 min. To this mixture was added MeI (125 μL, 0.22 mmol), then the temperature was allowed to warm to 0 °C, and stand for 12 hr in the refrigerator. The reaction mixture was quenched with saturated aq. NH_4Cl, extracted with EtOAc (30 mL), the separated organic phase was washed with H_2O (2 × 10 mL), brine, and dried (Na_2SO_4), and filtered. The filtrate was concentrated, the resulting slurry was purified through flash chromatography on silica gel (eluted with gradient system, 0-30% EtOAc in hexane) to afford *tert*-butyl (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate 31 mg, yield 100%. MS ESI +ve m/z 321 (M+Na).

Step 2. *tert*-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate

Hydrogenation of (*S*)-1-azido-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate (62 mg, 0.51 mmol) was carried out in EtOAc (20 mL), 10% Pd/C (15 mg) under 40 psi of H_2 for 2 h. After filtration 52 mg of *tert*-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate was obtained, yield 91%. MS ESI +ve m/z 273 (M+H).

EXAMPLE 28

methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate.TFA salt

The solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (2.247 g, 5.26 mmol) in mixed solvent of DCM/TFA (24 mL, 3:1, v/v) was stirred at rt for 30 min. The solvents were removed in *vacuo* to produce 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate TFA salt in quantitative yield. MS ESI +ve m/z 327 (M+H).

Step 2. (4-nitrophenyl) (*S*)-2-(N-(*tert*-butoxycarbonyl)amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate

To a solution of *tert*-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (20.8 mg, 0.081 mmol) in anhydrous DCM (9 mL) was added 4-nitrophenyl chloroformate (17.1 mg, 0.085 mmol), followed by TEA (12.2 mg, 17 μL, 0.12 mmol). The resulting solution was stirred at rt for 5 min (monitored by LC-MS) and diluted to 12 mL. An aliquot of the carbamate mixture solution (2 mL) was used for the next step without purification.

Step 3. 2-((*R*)-((*R*)-1-((*S*)-2-(Boc-amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate

To (4-nitrophenyl) (*S*)-2-(N-(*tert*-butoxycarbonyl)amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate solution (2 mL, 0.013 mmol) was added 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate TFA salt (7.0 mg, 0.016 mmol), followed by excess TEA (0.3 mL). The mixture was stirred for 30 min, then the solvent was removed in *vacuo*. The resulting oil was purified on preparative HPLC to give methyl 2-((*R*)-((*R*)-1-((*S*)-2-(Boc-amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate 5mg, yield 63%. MS ESI +ve m/z 611 (M+H).

Step 4. methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate TFA salt

The 2-((*R*)-((*R*)-1-((*S*)-2-(Boc-amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate (5mg, 0.008 mmol) was dissolved in DCM/TFA (3/1 mL). The solution was stirred for 30 min and concentrated. The crude mixture was purified on preparative HPLC to afford 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate TFA salt 2.8 mg, yield 54%. . ^{1}H NMR (CD_3OD) δ 7.36-7.32 (m, 3H), 7.23 (d, J = 7.6 Hz, 1H), 4.20 (br d, J = 13.6 Hz, 1H), 4.04 (d, J = 8.8 Hz, 1H), 3.89-3.78 (m, 3H), 3.64 (s, 3H), 3.48-3.42 (m, 2H), 3.37 (m, 1H), 3.28-3.24 (m, 5H), 3.15 (dd, J = 10.8, 9.2 Hz, 1 H), 2.92 (m, 2H), 1.97 (m, 1H), 1.78 (m, 2H), 1.68-1.54 (m, 4H), 1.45-1.07 (m, 5H). MS ESI +ve m/z 511 (M+H).

The following compounds of Formula (XL) were prepared following procedures analogous to those described above:

1) methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate using trifluoroacetic acid salt of methyl 2-((*R*)-(3-fluorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 2.

2) methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)ethylcarbamate using trifluoroacetic acid salt of methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 2.

3) methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate using trifluoroacetic acid salt of methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 2.

4) methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)ethylcarbamate using trifluoroacetic acid salt of methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 2.

5) methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate using trifluoroacetic acid salt of methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 2.

6) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate using tert-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate in Step 1.

7) methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate using tert-butyl (*S*)-1-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-yl(methyl)carbamate in Step 1 and trifluoroacetic acid salt of methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate in Step 2.

GENERAL SYNTHETIC SCHEMES FOR COMPOUNDS OF FORMULA (L)

The compounds of present invention can be synthesized by coupling a pyran intermediate represented by the following structure:



with a piperidine intermediate represented by the following structure:



described in the following scheme:



Preparation of the Pyran Intermediate from Glutamic Ester

The pyran intermediate can be prepared from glutamic ester using the following synthetic scheme:



Preparation of the Pyran Intermediate from Pyroglutamic Ester

The pyran intermediate can also be prepared from pyroglutamic ester using the following synthetic scheme:



Preparation of the Piperidine Intermediate

The piperidine intermediate can be prepared by using the following synthetic scheme.



Alternatively, the piperidine intermediate can be prepared using the following synthetic scheme:



Specific conditions for synthesizing the disclosed aspartic protease inhibitors according to the above schemes are provided in the examples below.

PREPARATION 33

(*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(m-tolyl)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate

To a solution of 1-bromo-3-methylbenzene (88.4 g, 0.52 mol) in anhydrous THF (550 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in hexane (210 mL, 0.52 mol). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(m-tolyl)methyl)piperidine-1-carboxylate (120 g, 0.44 mol) in anhydrous THF (500 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with EtOAc (3×400 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate (168 g), which was used immediately for next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*S*)-hydroxy(m-tolyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(3-methylbenzoyl)piperidine-1-carboxylate (168 g, 0.55 mol) in anhydrous THF (600 mL) at –15 °C under nitrogen was added dropwise a solution of 1 M *R*-CBS-oxazaborolidine in toluene (82 mL, 82 mmol, 0.15 eq). After stirring for 1 hr at –15 °C, a solution of 10 M BH_3 in THF (60 mL, 0.60 mol, 1.1 eq) was added dropwise. After addition, the reaction mixture was stirred for 2 hr at –15 °C. TLC indicated the starting material was disappeared. Methanol (400 mL) was added dropwise carefully at –15 °C. The solvent was removed under reduced pressure, the residue was purified by column chromatography on silica gel eluting with EtOAc/hexane (1:30→1:15) to provide the light yellow oil (95 g, HPLC ≥ 70%, ratio ≥ 3:1). The mixture was dissolved in EtOAc until the alcohol was just dissolved (about 5 mL/1 g), the solvent was removed on the rotary evaporator until a few crystals appeared. The solution was cooled to rt slowly and stood for 1-2 hr. To the above solution was added hexane (about 300 mL) and then filtered , the crystals were washed with cool hexane and re-crystallized two more times to afford the pure isomer (*R*)-*tert*-butyl 3-((*S*)-hydroxy(m-tolyl)methyl)piperidine-1-carboxylate (20 g, ee≥99%).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(m-tolyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*S*)-hydroxy(*m*-tolyl)methyl)piperidine-1-carboxylate (30.5 g, 0.1 mol) in MeCN (300 mL), NaH (12 g, 0.3 mol) was added at 0

°C. The mixture was stirred for 1 hr at rt. The mixture was cooled to –40 °C, then bromoacetonitrile (35.7 g, 0.3 mol) was added in portions. The mixture was stirred for 0.5 hr at –20 °C continually. The reaction was quenched with sat. NH_4Cl. The mixture was extracted with CH_2Cl_2. The organic layer was dried over Na_2SO_4, concentrated. Crude (*R*)-*tert*-butyl 3-((*R*)-(cyanomethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate was used for the next step without purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(m-tolyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(cyanomethoxy)(m-tolyl)methyl)piperidine-1-carboxylate (20 g, 0.04 mol) was dissolved in anhydrous THF (300 mL), and the solution was heated to reflux under nitrogen. A solution of $BH_3.Me_2S$ (12 mL, 0.12 mol) in THF was added dropwise, and stirring was continued under reflux overnight. The resulting solution was cooled to rt and MeOH was added dropwise to quench the excess borane. After evaporation of the solution, the crude (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate was obtained and used without further purification.

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(m-tolyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate and DMAP in anhydrous CH_2Cl_2, Et_3N was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate in anhydrous CH_2Cl_2 was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. Water was added to quench the reaction. The aqueous layer was extracted with CH_2Cl_2, the combined organic layers were washed with 10% citric acid and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by preparative TLC to afford (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(*m*-tolyl)methyl)piperidine-1-carboxylate.

PREPARATION 34

(*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-chloro-4-fluorobenzoyl)piperidine-1-carboxylate

A solution of 4-bromo-2-chloro-1-fluoro-benzene (31.3 g, 0.15 mol) in anhydrous THF (150 mL) was added dropwise to Mg (4.8 g, 0.2 mol) in THF (50 mL) at rt under nitrogen. The mixture was stirred at 50-60 °C for 1 hr at which time most of the magnesium was consumed. The resulting Grignard reagent was used for the next step. The Grignard reagent was added dropwise to a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (27.2 g, 0.1 mol) in anhydrous THF (300 mL) at -78 °C under nitrogen. After addition, the mixture was allowed to stir at rt for 1.5 hr. The mixture was quenched with saturated NH_4Cl solution (300 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-(3-chloro-4-fluorobenzoyl)piperidine-1-carboxylate (31.5 g, 92%), which was used immediately for next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of 1 M *R*-CBS-oxazaborolidine in toluene (13.8 mL, 13.8 mmol, 0.15 eq) and 10 M BH_3 in THF (9.2 mL, 92.4 mmol, 1.0 eq) at –15 °C under nitrogen was added dropwise a solution of (*R*)-*tert*-butyl 3-(3-chloro-4-fluorobenzoyl)piperidine-1-carboxylate (31.5 g, 92.4 mmol) in anhydrous THF (300 mL). After addition, the reaction mixture was stirred for 1 hr at rt. Methanol (200 mL) was added dropwise carefully at 0 °C. The solvent was removed under reduced pressure to provide the crude product. The crude product was dissolved in EtOAc till the alcohol was just dissolved (about 5 mL/1 g), the solvent was removed on the rotary evaporator until a few crystals appeared. To the above solution was added petroleum ether (about 300 mL) under stirring, which was allowed to stir at rt for 2 hr and then filtered, the crystals were washed with petroleum ether and re-crystallized 6 times to afford the (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (10 g, 32%, 93%e.e.). ^{1}HNMR (CD_3OD, 400 MHZ) δ 7.44 (d, 1 H), 7.25 (d, 1 H), 7.20 (t, 1 H), 4.34 (d, 1 H), 4.20 (s, 1 H), 3.93 (d, 1 H), 2.68 (m, 2 H), 1.62 (m, 2 H),), 1.41 (s, 9H), 1.32 (m, 2H), 1.21 (m, 1 H).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (5.1 g, 15 mmol) in CH_3CN (150 mL), NaH (1.8 g, 45 mmol) was added at 0 °C. The mixture was stirring for 1 hour. Then the mixture was cooled to –40 °C, the bromoacetonitrile (5.4 g, 45 mmol) was added dropwise. The mixture was allowed to warm to 0 °C gradually. The addition of NaH and bromoacetonitrile was repeated three times. The mixture was quenched with H_2O and exacted with CH_2Cl_2. The organic layer was dried over Na_2SO_4 and concentrate to get the crude (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (6.5g, 100%).

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-4-fluorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (2.28 g, 6 mmol) was dissolved in anhydrous THF (50 mL), and the solution was heated to reflux under nitrogen. A solution of 10 M of $BH_3.Me_2S$ (1.8 mL, 18 mmol) in THF was added dropwise and stirring was continued under reflux overnight. The resulting solution was cooled to 0 °C, CH_3OH was added dropwise to quench the reaction. Evaporation of the solvent led to crude (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-4-fluorophenyl)methyl)piperidine-1-carboxylate (2 g, yield 87%), which was used in the next step without further purification.

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-4-fluorophenyl)methyl)piperidine-1-carboxylate (1 g, 2.6 mmol) and DMAP (79 mg, 0.62 mmol) in dry CH_2Cl_2 (20 mL), Et_3N (657 mg, 6.5 mmol) was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate (1.22 g, 13 mmol, 5 eq) was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at rt. Water (20 mL) was added to quench the reaction. The aqueous layer was extracted with CH_2Cl_2 (3×20 mL), the combined organic layers were dried over Na_2SO_4, filtered and concentrated to give the crude product, which was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-4-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (50 mg, yield 4.3%). ^1H NMR ($CDCl_3$, 400 MHz) δ 7.27 (m, 1 H), 7.12 (m, 2 H), 4.30 (s, 1 H), 3.91 (d, 2 H), 3.66 (s, 3 H), 3.10-3.40 (m, 5 H), 2.90 (m, 1 H), 1.75 (s, 1 H), 1.55 (d, 1 H), 1.46 (s, 9 H), 1.33 (m, 2 H), 1.04 (m, 1 H).

The following compounds were prepared following procedures analogous to those described above:

1) (*R*)-*tert*-butyl 3-((*R*)-(5-fluoro-2-methylphenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (5-fluoro-2-methylphenyl)magnesium bromide in Step 1.

2) (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate using (3-chloro-5-fluorophenyl)magnesium bromide in Step 1.

PREPARATION 35

(*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(ethoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-chloro-5-fluorobenzoyl)piperidine-1-carboxylate

A solution of 1-bromo-3-chloro-5-fluoro-benzene (31.5 g, 0.15 mol) in anhydrous THF (120 mL) was added dropwise to the Mg (5.4 g, 0.22 mol) at rt under nitrogen. The mixture was stirred at 50-60 °C for 1 hr until most of the magnesium was consumed. The resulting Grignard reagent was used for the next step. The Grignard reagent was added dropwise to a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (20.4 g, 0.075 mol) in anhydrous THF (200 mL) at -78 °C under nitrogen. After addition, the mixture was allowed to stir at rt for 1.5 hr. The mixture was quenched with saturated NH_4Cl solution (300 mL) and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-(3-chloro-5-fluorobenzoyl)piperidine-1-carboxylate (25 g, 98%), which was used in the next step without further purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of 1 M *R*-CBS-oxazaborolidine in toluene (11 mL, 11 mmol, 0.15 eq) and 10 M BH_3 in THF (7.3 mL, 73 mmol, 1.0 eq) at –15 °C under nitrogen was added dropwise a solution of (*R*)-*tert*-butyl 3-(3-chloro-5-fluorobenzoyl)piperidine-1-carboxylate (25 g, 73 mmol) in anhydrous THF (50 mL). After addition, the reaction mixture was stirred for 1 hr at rt. Methanol (100 mL) was added dropwise carefully at 0 °C. The solvent was removed under reduced pressure to provide the crude product. The crude product was dissolved in EtOAc until the alcohol was just dissolved (about 5 mL/1 g), the solvent was removed on the rotary evaporator until a few crystals appeared. To the above solution was added petroleum ether (about 300 mL) under stirring, which was allowed to stir at rt for 2 hr and then filtered, the crystals were washed with petroleum ether and re-crystallized a few more times to afford pure (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (9.2 g, 37%). ^{1}H NMR (DMSO, 400 MHz): δ 7.44 (d, 1 H), 7.38 (s, 1 H), 7.30 (d, 1 H), 4.48 (t, 1 H), 4.20 (brs, 1 H), 3.98 (d, 1 H), 2.73 (s, 2 H), 1.70 (s, 2 H), 1.48 (s, 10H), 1.36-1.39 (m, 2 H).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (3.5 g, 10.2 mmol) in CH_3CN (140 mL), NaH (1.2 g, 30.6 mmol) was added at 0 °C. The mixture was stirred for 1 hr. Then the mixture was cooled to –20 °C, bromoacetonitrile (3.6 g, 30.6 mmol) was added dropwise. The mixture was allowed warm to 0 °C gradually. Another batch of NaH and bromoacetonitrile was added in the same manner. The mixture was quenched with H_2O and extracted with CH_2Cl_2. The organic layer was dried over Na_2SO_4 and concentrate to give the crude (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (4.4, 100%).

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-5-fluorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (4.4 g, 10.2 mmol, crude) was dissolved in anhydrous THF (60 mL), and the solution was heated to reflux under nitrogen. A solution of 10 M of $BH_3.Me_2S$ (3 mL, 30.6 mmol) in THF was added dropwise and stirring was continued under reflux overnight. The resulting solution was cooled to 0 °C, CH_3OH was added dropwise to quench the reaction. Evaporation of the solvent to give the crude product, which was purified by silica column to give (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-5-fluorophenyl)methyl)piperidine-1-carboxylate (1.1 g, yield 28%), which was used in the next step without further purification.

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(ethoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chloro-5-fluorophenyl)methyl)piperidine-1-carboxylate (1.1 g, 2.85 mmol) in dry CH_2Cl_2 (20 mL), Et_3N (2 mL) was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of ethyl chloroformate (615 mg, 5.7 mmol) in dry CH_2Cl_2 (2 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at rt. Water (20 mL) was added to quench the reaction. The aqueous layer was extracted with CH_2Cl_2 (3×20 mL), the combined organic layers were dried over Na_2SO_4, filtered and concentrated to give the crude (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(ethoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (1.3 mg, 100%). ^1H NMR (CD_3OD, 400 MHz) δ 7.01 (d, 2 H), 6.87 (d, 1 H), 4.32 (m, 2 H), 4.09 (m, 2 H), 3.92 (m, 2 H), 3.33 (m, 5 H), 1.75 (s, 1 H), 1.55 (m, 1 H), 1.43 (s, 9 H), 1.34 (m, 2 H), 1.23 (t, 3 H), 1.09 (t, 1 H).

PREPARATION 36

(*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(phenyl)methyl)piperidine-1-carboxylate



Step 1. (*R*)-*tert*-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate

To a solution of 1-bromo-3-chlorobenzene (100 g, 0.52 mol) in anhydrous THF (550 mL) at –78 °C under nitrogen was added dropwise a solution of 2.5 M *n*-BuLi in hexane (210 mL, 0.52 mol). After stirring for 1 hr at –78 °C, a solution of (*R*)-*tert*-butyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (120 g, 0.44 mol) in anhydrous THF (500 mL) was added dropwise. After addition, the reaction mixture was allowed to warm to rt and stirred for 2 hr. The mixture was quenched with saturated NH_4Cl solution (500 mL) and extracted with EtOAc (3×400 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated in *vacuo* to give crude (*R*)-*tert*-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (178 g), which was used immediately for next step without purification.

Step 2. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate (178 g, 0.55 mol) in anhydrous THF (600 mL) at –15 °C under nitrogen was added dropwise a solution of 1 M *R*-CBS-oxazaborolidine in toluene (82 mL, 82 mmol, 0.15 eq). After stirring for 1 hr at –15 °C, a solution of 10 M BH_3 in THF (60 mL, 0.60 mol, 1.1 eq) was added dropwise. After addition, the reaction mixture was stirred for 2 hr at –15 °C.

Methanol (400 mL) was added dropwise carefully at –15 °C. The solvent was removed under reduced pressure, the residue was purified by column chromatography on silica gel eluting with EtOAc/hexane (1:30→1:15) to provide the light yellow oil (95 g, HPLC≥70%, ratio≥3:1). The mixture was dissolved in EtOAc until the alcohol was just dissolved (about 5mL/1g), the solvent was removed on the rotary evaporator until a few crystals appeared. The solution was cooled to rt slowly and stood for 1-2 hr. To the above solution was added hexane (about 300 mL) and then filtered , the crystals were washed with cool hexane and re-crystallized an additional two times to afford the pure (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (20 g, ee≥99%).

Step 3. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (32.5 g, 0.1 mol) in MeCN (325 mL), NaH (12 g, 0.3 mol) was added at 0 °C. The mixture was stirred for 1 hr at rt. The mixture was cooled to –40 °C, then bromoacetonitrile (35.7 g, 0.3 mol) was added in portions. The mixture was stirred for 0.5 hr at –20 °C. After the reaction was complete it was quenched with sat. NH_4Cl. The mixture was extracted with CH_2Cl_2. The organic layer was dried over Na_2SO_4, concentrated. Crude (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate was used for the next step without further purification.

Step 4. (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate

(*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(cyanomethoxy)methyl)piperidine-1-carboxylate (23 g, 0.04 mol) was dissolved in anhydrous THF (300 mL), and the solution was heated to reflux under nitrogen. A solution of $BH_3.Me_2S$ (12 mL, 0.12 mol) in THF was added dropwise, and stirring was continued at reflux overnight. The resulting solution was cooled to rt and MeOH was added dropwise to quench the reaction. After evaporation of the solution, the crude (*R*)-*tert*-butyl 3-((*R*)-(2-

aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate was obtained which was used for the next step without purification.

Step 5. (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(2-aminoethoxy)(3-chlorophenyl)methyl)piperidine-1-carboxylate (7.7 g, 21 mmol) and DMAP (1.27 g, 10 mmol, 0.5 eq) in dry CH_2Cl_2 (120 mL), Et_3N (6.38 g, 8.45 mL, 63 mmol) was added. The resulting mixture was cooled to 0-5 °C under ice-water bath, a solution of methyl chloroformate (9.88 g, 8.1 mL, 104.5 mmol, 5 eq) in dry CH_2Cl_2 (50 mL) was added dropwise. After addition, the reaction mixture was stirred for 1-2 hr at 0-5 °C. The reaction was quenched with water (80 mL). The aqueous layer was extracted with CH_2Cl_2 (3×50 mL), the combined organic layers were washed with 10% citric acid (2×80 mL) and brine, then dried over Na_2SO_4, filtered and concentrated to the crude product, which was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (4.4 g, the total yield for five steps is 41%).

Step 6. (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(phenyl)methyl)piperidine-1-carboxylate

To a solution of (*R*)-*tert*-butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (3 g, 7.04 mmol) in MeOH (60 mL) was added wet $Pd(OH)_2/C$ (300 mg). The reaction mixture was stirred under 50 of hydrogen psi at 50 °C for 3 hr. The suspension was filtered and the filtrate was concentrated hydrogen in *vacuo*. The crude product was purified by preparative HPLC to afford (*R*)-*tert*-butyl 3-((*R*)-(2-(methoxycarbonylamino)ethoxy)(phenyl)methyl)piperidine-1-carboxylate (1.4 g, 51%). ^1H NMR (CD_3OD) δ 7.40-7.22 (m, 5H), 4.20 (m, 1H), 4.01 (m, 1H), 3.81 (m, 1H), 3.6 (s, 3H), 3.27 (m, 3H), 2.84 (m, 2H), 1.8-1.5 (m, 2H), 1.45 (s, 9H). MS ESI +ve m/z 393 (M+1).

PREPARATION A2

The following compounds were prepared using procedures analogous to those described above in PREPARATION W1:

1) (*S*)-*tert*-butyl 4-((*R*)-5-(cyclohexyloxy)-5-oxo-2-((*R*)-2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate using (*R*)-4-phenyl-2-oxalozolidinone in Step 5 and cyclohexyl acrylate in Step 6.

2) (*S*)-*tert*-butyl 4-((*R*)-5-ethoxy-5-oxo-2-(tosyloxymethyl)pentyl)-2,2-dimethyloxazolidine-3-carboxylate using (*R*)-4-phenyl-2-oxalozolidinone in Step 5 and using ethyl acrylate in step 6.

3) (*S*)-benzyl 2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine-3-carboxylate using benzyl chloroformate in Step 1.

PREPARATION B2

tert-butyl (*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate



Step 1. tetrahydro-2*H*-pyran-3-ol

To the solution of 3,4-dihydro-2*H*-pyran (126 g, 1.5 mol) in dry THF (1350 mL) was added a solution of B_2H_6 in Me_2S (10 M, 75mL, 0.75 mol) under nitrogen atmosphere at 0 °C. The mixture was stirred at this temperature for 3 hr, and then was stirred at 25 °C for another 2 hr. The mixture was warmed to 40-45 °C, and was added aq. NaOH (3 N, 390 mL) and H_2O_2 (30%, 270mL). After stirring for 2 hr, the reaction was quenched by sat. brine. The mixture was filtered, and the filtrate was extracted

with EtOAc (3×300 mL). The organic phase was washed with aq. $Na_2S_2O_3$ (3×100 mL), dried over Na_2SO_4, and concentrated in *vacuo* to give the crude product, which was purified through column chromatography to give tetrahydro-2*H*-pyran-3-ol (72.8 g, 48%). ^{1}H NMR (CD_3OD) δ 3.7-3.6 (m, 4H), 3.6-3.5 (m, 1H), 3.4-3.3 (m, 1H), 1.9-1.7 (m, 2H), 1.6-1.5 (m, 2H),

Step 2. dihydro-2*H*-pyran-3(4H)-one

To the solution of tetrahydro-2*H*-pyran-3-ol (30 g, 0.29 mol) in dry CH_2Cl_2 (900 mL) was added 3Å molecule series (30g) and PCC (94.9g, 0.44mol). The mixture was stirred at rt overnight. When the reaction was over, the mixture was filtered through celite, dried over Na_2SO_4, and concentrated in *vacuo* to give the crude product, which was purified through column chromatography to give dihydro-2*H*-pyran-3(4H)-one (23 g, 76%). ^{1}H NMR (CD_3OD) δ 3.9 (s, 2H), 3.8-3.7 (t, 2H), 3.7-3.6 (m, 4H), 2.5-2.4 (m, 2H), 2.0-1.9 (m, 2H).

Step 3. 3-(dihydro-2*H*-pyran-3(4H)-ylidene)propan-1-ol

To a suspension of the phosphonium salt (69 g, 1.5 eg) in dry THF (1100 mL) at 0 °C under nitrogen atmosphere was added *n*-BuLi (2.5 M, 111 mL, 0.413 mol). The solution was stirred for 1 hr, followed by addition of dihydro-2*H*-pyran-3(4H)-one (11.5 g, 0.115 mol). Stirring was continued at rt overnight. The mixture was quenched by sat. aq. NH_4Cl, and then filtered. The filtrate was dried over Na_2SO_4, and concentrated in *vacuo* to give the crude product, which was purified through column chromatography to give 3-(dihydro-2*H*-pyran-3(4H)-ylidene)propan-1-ol (11.2 g, 69%). ^{1}H NMR (CD_3OD): δ 4.2-3.9 (d, 2H),), 3.8-3.5 (m, 4H), 2.4-2.2 (m, 4H), 5.3-5.2 (d, 1H), 2.1-1.8 (s, 1H), 1.8-1.6 (m, 2H).

Step 4. 3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol

To the solution of compound 3-(dihydro-2*H*-pyran-3(4H)-ylidene)propan-1-ol (11.2 g, 0.0789 mol) in methanol (200 mL) was added $Pd(OH)_2/C$ (1.12g). The reaction flask was degassed and filled into H_2. Stirring was continued until the starting material disappeared. When the reaction was over, the mixture was filtered through celite, and the filter cake was washed with MeOH (2×10 mL). The combined organic

layers were dried over Na_2SO_4, and concentrated in *vacuo* to give 3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (10.35g, yield 91 %), which was used for the next step without purification. ^1H NMR (CD_3OD) δ 3.9-3.8 (m, 1H), 3.7-3.6 (m, 2H), 3.5-3.4 (m, 1H), 3.3 (m, 1H), 3.1-2.9 (t, 1H), 2.6-2.4 (m, 1H), 2.3-1.8 (m, 3H), 1.6-1.4 (m, 4H), 1.3-1.0 (m, 2H).

Step 5. 3-(tetrahydro-2*H*-pyran-3-yl)propanal

To the solution of 3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (10.35 g, 0.0719 mol) in CH_2Cl_2 (200 mL) was added Dess-Martin periodinane (61.24 g, 0.1438 mol). The mixture was stirred at rt. When the reaction was over, the solution was poured into Et_2O (300 mL) and anhydrous K_2CO_3 (19.84 g, 0.1438 mol) was added. The mixture was filtered. The filtrate was dried over Na_2SO_4, and concentrated in *vacuo* to give the crude product, which was purified through column chromatography to give 3-(tetrahydro-2*H*-pyran-3-yl)propanal (8.25 g, 80%).

Step 6. dibenzyl 1-((2*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-yl)hydrazine-1,2-dicarboxylate

To a stirred solution of 3-(tetrahydro-2*H*-pyran-3-yl)propanal (8.25 g, 0.058 mol) and dibenzyl azodicarboxylate (94%, 12.3 g, 0.041 mol) in MeCN (250 mL) at 0 °C was added (*R*-proline) (0.47 g, 0.0041 mol). After stirring the mixture at 0 °C for 15 hr, ethanol (100 mL) and $NaBH_4$ (1.56 g, 0.041 mol) was added, and the mixture was stirred at 0 °C for 40 min. The reaction was quenched by slow addition of 10% aqueous citric acid (15 ml), and the whole solution was concentrated in *vacuo*. This residue was diluted with EtOAc (200 ml), washed with saturated brine(1×50 mL), dried over Na_2SO_4, and concentrated in *vacuo* to give the crude product, which was purified through column chromatography to give dibenzyl 1-((2*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-yl)hydrazine-1,2-dicarboxylate (14.68 g, 81%).

Step 7. (2*S*)-2-hydrazinyl-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol

To the solution of 1-((2*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-yl)hydrazine-1,2-dicarboxylate (14.68 g, 0.0332 mol) in methanol (250 mL) was added $Pd(OH)_2/C$ (1.47 g). The reaction flask was degassed and filled into H_2. Stirring was

continued until the starting material disappeared. When the reaction was over, the mixture was filtered through celite, and the filter cake was washed with MeOH (2×20 mL). The combined organic solvent was dried over Na_2SO_4, and concentrated in *vacuo* to give (2*S*)-2-hydrazinyl-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (5.79 g, 94 %), which was used for the next step without purification.

Step 8. (2*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol

To the solution of (2*S*)-2-hydrazinyl-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (5.79 g, 0.033 mol) in MeOH (100 mL) was added Raney Ni. The flask was degassed and equipped with a hydrogen-inflated balloon. The flask was dipped into an ultrasound bath filled with water and sonicated for 4 hr at rt until the starting material was completely consumed. The mixture was then filtered through celite, and the filter cake was washed with MeOH (2×30 mL). Removal under reduced pressure gave (2*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propan-1-ol (5.4 g, 90%).

PREPARATION C2

2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate



Step 1. *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

(*S*)-*tert*-Butyl-2,2-dimethyl-4-(((*R*)-tetrahydro-2*H*-pyran-3-yl)methyl)oxazolidine- 3-carboxylate (9 g, 30.1 mmol) was dissolved in 80% aq

CH_3CO_2H (90ml). The solution was stirred at 50 °C during 1.5 hr and evaporated to dryness at reduced pressure. The residue was dissolved in Et_2O (150ml) and washed with saturated $NaHCO_3$ (4×100 mL) . The organic layer was dried over Na_2SO_4, filtered, and the solvent removed under reduced pressure to give *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (6.2 g, 79.5%) as an oil ,which was used in the next step without further purification.

Step 2. (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl methanesulfonate

To a solution of *tert*-butyl (*S*)-1-hydroxy-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (6.2 g, 23.9 mmol) and triethylamine (7.25 g, 71.8 mmol) in CH_2Cl_2 at 0 °C was added mesyl chloride (5.5 g, 47.8 mmol) dropwise. The reaction mixture was stirred at rt until the starting material disappeared. The reaction was quenched with ice-cold water and extracted with CH_2Cl_2 (3×100 ml). The combined organic layers were washed with water (3×50 ml), dried over Na_2SO_4, and concentrated under *vacuo* to give the (*S*)-2-(*tert*-butoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl methanesulfonate (9 g), which was used for the next step without purification.

Step 3. *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

To an ethanol solution of $MeNH_2$ (100 mL) was added *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (9 g, 26.7 mmol). The mixture was stirred at 30-40 °C overnight. When the reaction was complete, the solution was concentrated to afford *tert*-butyl (*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (10 g), which was used for the further reaction without purification.

Step 4. (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate

Solid 1-[2-Trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione (9.5 g, 36.7 mmol) was added to a vigorously stirred biphasic solution of the *tert*-butyl (*S*)-1-

(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (10 g, 36.7 mmol), K_2CO_3 (15.1 g, 110.1mmol), H_2O (50 mL) and CH_2Cl_2 (100 mL). After the reaction was stirred for 2 hr at rt, the reaction was taken up into 65mL of CH_2Cl_2. The solution was washed with aq. $NaHCO_3$ (3×50 mL) and brine (3×50 mL), then dried over Na_2SO_4. The organic layer was concentrated under vacuum to give the crude product, which was purified through column chromatography to give (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate (6 g, 46.2%).

Step 5. 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate

To a solution of (*S*)-*tert*-butyl 1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamate (6 g, 14.4 mmol) in Et_2O (100 mL) was added a solution of tosic acid (2.8 g, 14.4 mmol) in 13.0 mL of absolute EtOH. This solution was placed on a rotary evaporator and the Et_2O was removed at ambient temp. The flask was then lowered into a 60 °C water bath and the remainder of the solvent was evaporated over 2 hr to afford a white solid. The solid was cooled to rt and dissolved into 80 mL of a mixture of 1:1 EtOH:H_2O. This was washed with 5:1 Hexanes:EA (3×10mL), basified with 1N NaOH (pH>10), and extracted with Et_2O (3×50 mL). The combined Et_2O extracts were washed with brine (3×5mL), dried over Na_2SO_4, concentrated under vacuum to give 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate 3.3 g (72%).

The following compound was prepared following procedures analogous to those descried above:

1) 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate using *tert*-butyl (*S*)-1-hydroxy-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate in Step 2.

EXAMPLE 29

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate

(*R*)-*tert*-Butyl 3-((*R*)-(3-chlorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (4.86 g, 11.4 mmol) was dissolved in a solution of 20% (V/V) TFA/ CH_2Cl_2 (10 mL). The reaction mixture was stirred at rt for 1 hr. The solvent was removed in *vacuo* to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate as TFA salt (4.8 g, 100%), which was used for the next step directly without purification.

Step 2. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

At 0 °C, to a solution of 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate (1.9 g, 6 mmol) and DIPEA (3.87 g, 30 mmol) in anhydrous CH_2Cl_2 (20 mL) was added CDI (1.26 g, 7.8 mmol). After addition, the mixture was stirred for 1 hr at 0 °C, followed by addition of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate as TFA salt (2.8 g, 6.6 mmol) in anhydrous CH_2Cl_2 (20 mL). The reaction mixture was allowed to warm to rt and stirred overnight. After the reaction was completed, the solvent was removed in *vacuo*. The product was purified by column chromatography on silica gel eluting with

petroleum ether/EtOAc (5:1→2:1) to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (3.0 g, 75% yield).

Step 3. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate.trifluoroacetic acid salt

Methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (2.9 g, 4.34 mmol) and TEAF (1.42 g, 9.6 mmol) was dissolved in CH_3CN (40 mL). The reaction mixture was heated under reflux for 20 min. Then the mixture was concentrated in *vacuo*. The residue was purified by preparative HPLC to afford methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate as TFA salt (2.23 g, 83%).

The following compounds were prepared using procedures analogous to those described above:

1) methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(*m*-tolyl)methoxy)ethylcarbamate

2) methyl 2-((*R*)-(3-chloro-4-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

3) ethyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

4) methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

EXAMPLE 30

methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. (4-nitrophenyl) (*S*)-1-(N-methyl-N-(trimethylsilylethoxycarbonyl)amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate

A solution of 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate (0.7350 g, 2.32 mmol, 1.0 equiv, ~7% diastereomeric impurities) in CH_3CN (50 mL) was treated with 4-nitrophenyl chloroformate (0.4950 g, 2.45 mmol, 1.05 equiv) and 0.600 g (7.14 mmol, 3 equiv) of $NaHCO_3$. The reaction was stirred at rt for 3 hr. The mixture was filtered using Celite® 545. The filtrate was evaporated under reduced pressure to afford 1.1647 g (100%) of (4-nitrophenyl) (*S*)-1-(N-methyl-N-(trimethylsilylethoxycarbonyl)amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate, which was used in the next step without further purification. MS ESI +ve m/z 504 (M+Na).

Step 2. methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

A mixture of (*R*)-*tert*-butyl 3-((*R*)-(3-chloro-5-fluorophenyl)(2-(methoxycarbonylamino)ethoxy)methyl)piperidine-1-carboxylate (0.1915 g, 0.43 mmol) in TFA (4 mL) and CH_2Cl_2 (6 mL) was stirred at rt for 2 hr. After the solvents were removed in *vacuo*, the TFA salt of methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate was directly used in the next step without further purification. MS ESI +ve m/z 345, 347 (M+1).

A mixture of TFA salt of methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-piperidin-3-yl)methoxy)ethylcarbamate (0.43 mmol, 1.0 equiv), (4-nitrophenyl) (*S*)-1-(N-methyl-N-(trimethylsilylethoxycarbonyl)amino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamate (0.2710 g, 0.56 mmol, 1.3 equiv), and DIEA (4 mL) in CH_2Cl_2 was stirred at rt for 19 hr. After the solvents were removed in *vacuo*, the crude product was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 70% →90% CH_3CN/H_2O, 0.1% CF_3CO_2H over 8 min and then 90% CH_3CN/H_2O, 0.1% CF_3CO_2H over 2 min, flow rate 25 mL/min) to afford 0.2840 g (96%) the product as a mixture of diastereoisomers. MS ESI +ve m/z 687, 689 (M+1). The mixture was further separated by chiral HPLC (CHIRALPAK AD-H, 1 cm ø x 25 cm, 10% IPA in hexane with 0.025% diethylamine, flow rate 4 mL/min) to give four fractions in the ratio of 49.8 (t_R = 11.00 min): 4.8 (t_R = 12.77 min): 43.3 (t_R = 13.97 min): 2.1 (t_R = 16.23 min). Among them, the two major fractions [methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (11 min) and methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (13.97 min) , were assigned *S* configurations at the amine chiral center and other two minor fractions [methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((3*R*)-1-((*R*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Isomer 1(12.77 min) and methyl

2-((*R*)-(3-chloro-5-fluorophenyl)((3*R*)-1-((*R*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Isomer 2 (16.23 min), were assigned *R* configurations at the amine chiral center based on stereoselective synthesis of this diamine. The chiral center at 3-pyran portion was finally determined by asymmetric synthesis of the third fraction. For the two minor fractions, however, the chiral centers at 3-pyran portion were not confirmed by asymmetric synthesis.

Step 3. methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

A solution of methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (0.0948 g) in TFA (5 mL) and CH_2Cl_2 (10 mL) was stirred at rt for 2.5 hr. After the solvents were removed in *vacuo*, the crude product was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 10% →90% CH_3CN/H_2O, 0.1% CF_3CO_2H over 13 min, flow rate 25 mL/min) to give 0.0928 g of TFA salt of methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate.

The methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate, methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((3*R*)-1-((*R*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Isomer 1, and methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((3*R*)-1-((*R*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Isomer 2 was prepared as above.

The following compounds were prepared using procedures analogous to those described above:

1) methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

2) methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

3) methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

4) methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

5) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

EXAMPLE 31

methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate and methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

To a solution of 2-(trimethylsilyl)ethyl (*S*)-2-amino-3-(tetrahydro-2*H*-pyran-3-yl)propyl(methyl)carbamate (300 mg, 0.95 mmol) and CDI (154 mg, 0.95 mmol) in anhydrous CH_2Cl_2 (20 mL), DIEA (612 mg, 4.7 mmol) was added with ice bath. After addition, the mixture was stirred for 1 h at 0 °C, then was added to a solution of {2-[(3-fluoro-phenyl)-piperidin-3-yl-methoxy]-ethyl}-carbamic acid methyl ester (245 mg, 0.79 mmol) in anhydrous CH_2Cl_2 (25 mL). The reaction mixture was allowed to warm to rt and stirred overnight. After the reaction was completed, the solvent was removed in *vacuo*. The product was purified by preparative TLC to afford methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (258 mg, 50 % yield).

Step 2. methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

A solution of methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(N-Methyl-2-(trimethylsilyl)ethoxycarbonylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (258 mg, 0.40 mmol) in MeCN (25 mL) was treated with TEAF (192 mg, 0.87 mmol) and allowed to stir under reflux for 1 h. The mixture was concentrated in *vacuo* and purified by preparative HPLC to give methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate as trifluoroacetic acid salt. (162 mg, 81 % yield).

Step 3. methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate and methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

A solution of methyl 2-((*R*)-(3-fluorophenyl)((3*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-

yl)methoxy)ethylcarbamate as trifluoroacetic acid salt in CH_2Cl_2 (5 mL) was washed with 1 M NaOH (2 mL, 2x). The aqueous layer was extracted with CH_2Cl_2 (1 mL, 3x) and the combined organic fractions were washed with water, brine, and dried over sodium sulfate. The filtrate was evaporated to afford the free base. The crude product was separated via chiral HPLC (CHIRALPAK AD-H, 1 cm ø x 25 cm, 10% IPA in hexane with 0.025% diethylamine, flow rate 4 mL/min) to afford two isomers, methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (78.57 mg, t_R=20.70 min) and methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (90.9 mg, t_R= 29.63 min).

Step 4. methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate fumaric acid salt

An ethanol solution of methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (71.2 mg, 0.14 mmol) was treated with fumaric acid (16.3 mg, 0.14 mmol). The solvent was removed in *vacuo* and the residue re-dissolved in water. The solution was frozen using a dry ice-acetone bath and placed on a lyopholizer to afford methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate fumaric acid salt (87.46 mg) as a white solid.

Step 5. methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate fumaric acid salt

An ethanol solution of methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (87.2 mg, 0.17 mmol) was treated with fumaric acid (19.8 mg, 0.17 mmol). The solvent was removed in *vacuo* and the residue re-dissolved in water. The solution was frozen using a dry ice-acetone bath and placed on a

lyopholizer to afford methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate fumaric acid salt (106.8 mg) as a white solid.

EXAMPLE 32

methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate



Step 1. methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate

A mixture of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (0.0027 g), HCO_2NH_4 (0.7350 g), and 10% Pd/C (0.0545 g) in MeOH was stirred at rt for 3 hr. The mixture was filtered off precipitates through filter agent, Celite® 545 and washed with MeOH. After the solvent was evaporated under reduced pressure, the crude product was purified by reversed-phase HPLC (Phenomenex® Luna 5μ C18(2) 100A, 250 × 21.20 mm, 5 micron, 10% →90% CH_3CN/H_2O, 0.1% CF_3COOH over 13 min, flow rate 25 mL/min) to give TFA salt of methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate. MS ESI +ve m/z 491 (M+1).

EXAMPLE 33

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate fumaric acid salt



Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate

The TFA salt of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (2.2300 g, 3.49 mmol) was treated with 10 mL of 1 N NaOH. The mixture was extracted with CH_2Cl_2 (4 ×) and dried over K_2CO_3. After the solvent was removed in *vacuo*, the residue was dissolved into Et_2O and filtered through HPLC filter. The filtrate was evaporated under reduced pressure and the residue was dried in *vacuo* to give 1.6806 g (3.20 mmol, 92%) methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate as free base. ^{1}H NMR (CD_3OD, 400 MHz) δ 7.27-7.13 (m, 4H), 4.05 (br d, J = 13.5 Hz, 1H), 3.92 (d, J = 9.1 Hz, 1H), 3.89-3.83 (m, 2H), 3.79-3.70 (m, 2H), 3.53 (s, 3H), 3.32-3.26 (m, 1H), 3.18-3.13 (m, 4H), 3.01 (dd, J = 10.8, 10.0 Hz, 1H), 2.88-2.75 (m, 2H), 2.53-2.44 (m, 2H), 2.29 (s, 3H), 1.78-1.47 (m, 6H), 1.30-1.03 (m, 6H).

Step 2. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate fumaric acid salt

The free base of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (1.6806 g, 3.20 mmol) and fumaric acid (0.3713 g, 3.20 mmol) were dissolved into EtOH and the solution was evaporated under reduced

pressure. The residue was dissolved into H_2O, frozen in a dry ice—acetone bath, and dried by lyophilization to provide fumarate salt of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate as a white powder. ^{1}H NMR (CD_3OD, 400 MHz) δ 7.27-7.13 (m, 4H), 6.59 (s, 1.76H), 4.04 (br d, *J* = 12.0 Hz, 1H), 3.99-3.96 (m, 1H), 3.92 (d, J = 9.1 Hz, 1H), 3.82-3.73 (m, 3H), 3.53 (s, 3H), 3.35-3.28 (m, 1H), 3.18-3.12 (m, 4H), 3.03 (dd, *J* = 10.8, 10.0 Hz, 1H), 2.97 (dd, *J* = 12.6, 3.5 Hz, 1H), 2.93-2.78 (m, 3H), 2.62 (s, 3H), 1.79-1.48 (m, 6H), 1.45-1.02 (m, 6H).

EXAMPLE 34

methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate *L*-tartaric acid salt

Step 1. methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate *L*-tartaric acid salt

The free base of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (0.28 g, 0.53 mmol) and *L*-tartaric acid (84.4 mg, 0.56 mmol, 99.5%) were dissolved in ethanol (5 mL) to give a clear solution. The solvent was removed in *vacuo* to dryness, and the residue was redissolved in 95% ethanol: MeCN (3:97 v/v) (10.5 mL) at 35 °C. A seed crystal was added and the resulting solution was stirred at 35 °C for 2 hr, then cooled to rt slowly, and stirred for 48 hr. The resulting white crystal was filtered and washed with MeCN (2 x 5 mL) to give 1:1 *L*-tartrate of methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate (0.31 g, 84%). Selected ^{1}H NMR (CD_3OD, 400 MHz,) δ: 7.36 (m, 3 H), 7.22 (d, 1 H), 4.40 (s, 2 H), 4.18-4.00 (m, 3 H), 3.86 (m, 3 H), 3.62 (s, 3 H), 3.40 (m, 1 H), 3.24 (m, 3 H), 3.18-2.84 (m, 5 H), 2.72 (s, 3 H), 1.90-1.08 (m, 12 H); mp = 122-127 °C. MS ESI +ve m/z 525 (M+1).

X-ray powder diffraction of two batches of 1:1 methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate *L*-tartaric acid salt is shown in Figure 1.

The following are aspartic protease inhibitors of the invention. Compound names were generated with the assistance of ChemDraw® versions 8.0 and 9.0 (CambridgeSoft Corporation, 100 CambridgePark Drive, Cambridge, MA 02140 USA). When the stereochemistry at a chiral center is not defined in the compound name this indicates that the sample prepared contained a mixture of isomers at this center.

Table of Compound of Formula (I*)

I*-1a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate			
I*-2a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	2.21	489 (M+1)	0.89 (m, 1H), 1.04 (m, 1H), 2.70 (s, 3H), 3.62 (s, 3H), 3.85 (m, 1H), 4.00 (m, 1H), 4.15 (m, 2H), 7.31 (m, 5H)
I*-3a	methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	1.77	491 (M+1)	2.65 (s, 3H), 3.06 (m, 1H), 3.61 (s, 3H), 4.16 (m, 2H), 7.32 (m, 5H)
I*-4a	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	2.18	493 (M+1)	0.95 (m, 2H), 3.60 (s, 3H), 3.85 (m, 1H), 6.91 (m, 3H), 7.35 (m, 1H)

I*-5a	methyl 2-((R)-((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	2.15	493 (M+1)	1.17 (m, 3H), 1.84 (m, 3H), 2.71 (s, 3H), 2.92 (m, 3H), 3.10 (m, 1H), 3.61 (s, 3H), 3.85 (m, 1H), 4.05 (m, 2H), 4.17 (m, 1H), 7.06 (m, 3H), 7.35 (m, 1H)
I*-6a	methyl 2-((R)-(3-fluorophenyl)((3R)-1-((S)-1-(methylamino)-3-(tetrahydrofuran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.65	495 (M+1)	0.89 (m, 1H), 2.10 (m, 1H), 2.30 (m, 1H), 2.72 (s, 3H), 3.11 (m, 1H), 3.61 (s, 3H), 4.19 (m, 1H), 7.06 (m, 3H), 7.46 (m, 1H)
I*-7a	methyl 2-((R)-((R)-1-((S)-4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	2.00	495 (M+1)	0.86 (t, 3H), 0.92 (s, 6H), 2.70 (s, 3H), 3.60 (s, 3H), 3.85 (m, 1H), 4.10 (m, 2H), 7.03 (m, 3H), 7.35 (m, 1H)
I*-8a	methyl 2-((R)-((R)-1-((S)-5,5-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.51	495 (M+1)	7.36 (m, 1H), 7.09 (d, 1H), 7.04 (m, 2H), 4.05 (d, 1H), 3.62 (s, 3H), 2.72 (s, 3H), 0.93 (s, 9H),
I*-9a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate	2.17	495 (M+1)	1.81-1.86 (m, 6H), 2.80 (s, 3H), 3.7 (s, 3H), 4.23 (m, 2H), 4.40 (d, 1H), 7.10 (m, 2H), 7.50 (d, 1H)
I*-10a	methyl 2-((S)-cyclohexyl((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.71	495 (M+1)	4.04-3.89 (m, 3H), 3.53 (s, 3H), 3.58-2.64 (m, 9H), 2.60 (s, 3H), 1.72-0.77 (m, 29H).
I*-11a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3R*,4S*)-4-isobutylpyrrolidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.48	495(M+)	7.36-7.15(m, 3H), 4,19(d, 1H), 3.79(t, 1H), 3.62(s, 3H), 2.88(m, 3H), 2.44(m, 2H), 1.18(t, 1H), 0.94(m, 6H).

I*-12a	methyl 2-((S)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl)methoxy)ethylcarbamate	1.87	496 (M+1)	1.58 (m, 25H), 2.71 (s, 3H), 3.01 (m, 4H), 3.47 (m, 2H), 3.62 (s, 3H), 3.78 (m, 1H), 4.11 (m, 2H), 4.47 (d, 1H), 7.65 (d, 1H), 7.79(d, 1H),
I*-13a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(thiazol-2-yl)methoxy)ethylcarbamate	1.84	496 (M+1)	1.48 (m, 30H), 2.71 (s, 3H), 3.01 (m, 5H), 3.52 (m, 2H), 3.62 (s, 3H), 3.74 (m, 2H), 4.11 (m, 1H), 4.60 (d, 1H), 7.65 (d, 1H), 7.79 (d, 1H),
I*-14a	methyl 2-((R)-((R)-1-((S)-2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl) piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.95	497 (M+1)	0.97 (d, 6H), 1.15 (m, 1H), 1.54 (m, 1H), 1.75 (b, 1H), 2.81-2.98 (m, 2H), 3.62 (s, 3H), 3.75 (d, 2H), 4.06 (d, 1H), 4.19 (d, 1H), 6.97-7.11 (m, 3H), 7.45 (m, 1H)
I*-15a	methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate	1.68	497 (M+1)	2.72 (s, 3H), 3.07 (m, 1H), 3.62 (s, 3H), 3.91 (m, 4H), 4.32 (m, 1H), 7.00 (m, 2H), 7.41 (m, 1H)
I*-16a	methyl 2-((S)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(thiophen-2-yl)methoxy)ethylcarbamate	1.57	497 (M+1)	1.10-1.49 (m , 7H), 1.55-1.90 (m, 7H), 2.60-2.73 (d, 4H), 3.65 (s, 2H), 7.01 (m, 2H), 7.40 (m, 1H)
I*-17a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-5-methoxy-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate			

I*-18a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate	2.15	503 (M+1)	2.31 (s, 3H), 2.70 (s, 3H), 3.05 (m, 1H), 3.60 (s, 3H), 3.85 (m, 1H), 3.95 (m, 1H), 4.14 (m, 2H), 7.05 (m, 3H), 7.20 (m, 1H)
I*-19a	methyl 2-((R)-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	1.47	505 (M+1)	7.37-7.25 (m), 7.17 (m), 3.62 (s), 2.73 (s)
I*-20a	methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(m-tolyl)methoxy)ethylcarbamate	1.47	505 (M+1)	2.34 (s, 3H), 2.72 (s, 3H), 3.09 (m, 1H), 3.62 (s, 3H), 3.94 (m, 4H), 4.18 (m, 2H), 7.07 (m, 3H), 7.24 (m, 1H)
I*-21a	methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	1.32	505(M+H)	7.37-7.27 (m, 5H),4.18-4.00 (m, 3H), 3.85 (brd, J = 12.4 Hz, 1H), 3.77-3.67 (m, 3H), 3.62 (s, 3H), 3.44 (dd, J = 12.4, 7.6 Hz, 1H), 3.28-3.21 (m, 4H), 3.08 (dd, J = 12.8, 3.2 Hz, 1H), 3.00-2.85 (m, 3H), 2.71 (s, 3H), 1.88-1.28 (m, 13H), 1.15 (m, 1H).

I*-22a	methyl (S)-4-((S)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate	1.63	505 (M+1)	7.24-7.19 (m, 1H), 6.91-6.82 (m, 3H), 3.95-3.89 (m, 1H), 3.81 (d, J = 12.9 Hz, 1H), 3.54 (d, J = 12.9 Hz, 1H), 3.49 (s, 3H), 2.93-2.88 (m, 3H), 2.74 (dd, J = 12.6, 10.3 Hz, 1H), 2.64-2.57 (m, 1H), 2.56 (s, 3H), 2.36-2.30 (m, 2H), 2.02-0.74 (m, 22H).
I*-23a	methyl (R)-4-((S)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluorophenyl)butylcarbamate	1.67	505 (M+1)	7.24-7.18 (m, 1H), 6.87-6.78 (m, 3H), 4.07-3.98 (m, 2H), 3.77 (d, J = 13.5 Hz, 1H), 3.49 (s, 3H), 2.61 (s, 3H), 2.99-2.33 (m, 7H), 1.84-0.79 (m, 22H).
I*-24a	methyl 2-((R)-((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate	2.21	507 (M+1)	1.00-1.50 (m, 7H), 1.51-1.95 (m, 10H), 2.30 (s, 3H), 2.70 (s, 3H), 3.63 (s, 3H), 3.92 (d, 1H), 4.25 (d, 1H), 4.35 (d, 1H), 6.91 (m, 1H), 7.08 (m, 1H), 7.18 (t, 1H)
I*-25a	R)-3-((R)-1-(3-chlorophenyl)-1-(2-(methylamino)-2-oxoethoxy)ethyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.53	507 (M+)	7.31-7.14 (m, 4H), 4.17 (s, 2H), 4.20-3.98 (m, 3H), 3.02 (dd, J = 12.6, 3.2 Hz, 1H), 2.89 (dd, J = 12.3, 10.5 Hz, 1H), 2.65 (s, 3H), 2.38 (s, 3H), 1.41 (s, 3H), 2.69-0.83 (m, 20H).
I*-26a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.72	509 (M+1)	2.70 (s, 3H), 3.07 (m, 1H), 3.61 (s, 3H), 3.91 (m, 3H), 4.05 (m, 1H), 4.15 (m, 2H), 7.05 (m, 3H), 7.35 (m, 1H)

I*-27a	methyl 2-((R)-((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.37	509 (M+1)	7.39-7.34, (m), 7.10-7.02 (m), 4.16 (d), 3.62 (s), 3.54 (t), 2.72 (s)
I*-28a	methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.26	509(M+H)	7.36 (m, 1H), 7.11-7.00 (m, 3H), 4.18 (brd, J = 13.6 Hz, 1H), 4.04 (d, J = 8.8 Hz, 1H), 3.79-3.65 (m, 5H), 3.62 (s, 3H), 3.44 (m, 2H), 3.33-3.22 (m, 5H), 2.91 (m, 2H), 1.89-1.29 (m, 13H), 1.15 (m, 1H).
I*-29a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.25	509 (M+)	2.71 (s, 3H), 2.90 (m, 3H), 3.10 (m, 1H), 3.62 (s, 3H), 3.85 (m, 1H), 4.03 (m, 2H), 4.15 (m, 1H), 7.20 (m, 1H), 7.33 (m, 3H)
I*-30a	(R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-yl)piperidine-1-carboxamide	1.76	509 (M+)	1.48(m, 17H) 2.71(s, 3H) 3.01(m, 7H) 3.42(m, 1H) 3.62(s, 3H) 3.84(m, 8H) 7.32(m, 4H)
I*-31a	(R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-yl)piperidine-1-carboxamide	1.83	509 (M+)	1.48(m, 15H) 2.73(s, 3H) 3.28(m, 9H) 3.98(m, 8H) 7.37(m, 4H)

I*-32a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate	1.88	510 (M+1)	1.48(m, 19H) 2.41(m, 7H) 2.98(m, 2H) 3.47(m, 5H) 3.62(s, 3H) 3.78(m, 1H) 4.11(m, 2H) 4.47(d, 1H) 7.18(s, 1H)
I*-33a	methyl 2-((S)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(4-methylthiazol-2-yl)methoxy)ethylcarbamate	1.84	510 (M+1)	1.48(m, 20H) 2.47(m, 9H) 2.82(m, 2H) 3.47(m, 8H) 3.49(d, 1H) 7.11(m, 1H)
I*-34a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-4,4-dimethyl-1-(methylamino)hexan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.15	511 (M+)	0.85 (t, 3H), 0.92 (s, 6H), 2.70 (s, 3H), 3.61 (s, 3H), 3.85 (m, 1H), 7.17 (m, 1H), 7.30 (m, 3H)
I*-35a	methyl 2-((R)-((R)-1-((S)-2-amino-5-methoxy-4,4-dimethylpentylcarbamoyl) piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	2.05	513 (M+)	0.91 (d, 6H), 2.80 (m, 2H), 3.55 (s, 3H), 3.75 (d, 1H), 3.95 (d, 1H), 4.15 (d, 1H), 7.15 (d, 1H), 7.20-7.30 (m, 3H)
I*-36a	methyl 2-((R)-(3,5-dimethylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.97	519 (M+1)	1.57-1.80 (m, 6H), 2.30 (s, 6H), 2.70 (s, 3H),3.75-4.00 (m, 4H), 6.87 (s, 2H), 6.95 (s, 1H)
I*-37a	methyl 2-((R)-(2,5-dimethylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.95	519 (M+1)	1.31 (m, 7H), 1.65 (m, 6H), 2.29 (s, 6H), 2.72 (s, 3H), 3.07 (m, 4H), 3.26 (m, 4H), 3.42 (m, 3H), 3.62 (s, 3H), 3.95 (m, 3H), 4.30 (m, 3H), 7.02 (m, 3H),

I*-38a	methyl 2-((R)-((R)-1-((R)-2-amino-3-phenoxypropylcarbamoyl) piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	1.92	519 (M+)	1.15 (m, 1H), 1.30 (m, 2H), 1.61 (m, 1H), 1.75 (m, 1H), 2.90 (m, 2H), 3.24 (m, 3H), 3.54 (m, 2H), 3.60 (s, 3H), 3.74 (m, 2H), 4.00 (d, 1H), 4.20 (m, 3H), 7.00 (m, 3H), 7.20 (m, 1H), 7.31 (m 5H)
I*-39a	methyl 2-((R)-((R)-1-((S)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	2.14	521 (M+1)	2.71 (s, 3H), 3.07 (m, 1H), 3.25 (m, 3H), 3.62 (s, 3H), 3.89 (m, 1H), 4.11 (m, 3H), 7.05 (m, 3H), 7.35 (m, 1H)
I*-40a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate	2.31	521 (M+1)	0.95 (m, 2H), 2.30 (s, 3H), 2.70 (s, 3H), 3.61 (s, 3H), 3.95 (m, 1H), 4.10 (m, 1H), 4.25 (m, 1H), 4.35 (m, 1H), 6.90 (m, 1H), 7.03 (m, 1H), 7.17 (m, 1H)
I*-41a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.71	521 (M+1)	7.37(m, 1H), 7.11-7.01 (m, 3H)), 4.18-4.08 (m, 2H), 4.04 (d, J = 8.4 Hz, 1H), 3.88 (brd, J = 13.2 Hz, 1H), 3.62 (s, 3H), 3.34-2.83 (m, 14H),1.83-0.88 (m 21H)

I*-42a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.55	521 (M+1)	7.30-7.24 (m, 1H), 7.01-6.91 (m, 3H), 4.33 (d, J = 13.2 Hz, 1H), 4.14-4.10 (m, 1H), 3.93 (d, J = 8.8 Hz, 1H), 3.70 (d, J = 13.2 Hz, 1H), 3.52 (s, 3H), 2.61 (s, 3H), 3.20-2.53 (m, 8H), 1.62-1.03 (m, 17H), 0.87 (s, 3H).
I*-43a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.55	521 (M+1)	7.30-7.25 (m, 1H), 6.99-6.91 (m, 3H), 4.13 (m, 1H), 4.00 (d, J = 12.6 Hz, 1H), 3.95 (d, J = 8.2 Hz, 1H), 3.77 (d, J = 10.8 Hz, 1H), 3.53 (s, 3H), 3.23-2.74 (m, 8H), 2.61 (s, 3H), 1.62-1.07 (m, 17H), 0.87 (s, 3H).
I*-44a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((3S*,4R*)-4-(cyclobutylmethyl)piperidin-3-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.56	521 (M+)	7.31(m, 3H), 7.21(m, 1H), 4.24(dd, 1H), 4.02(d, 1H), 3.83(dd, 1H), 3.68(t, 1H), 3.62(s, 3H), 2.88(t, 2H), 2.41(m, 1H), 1.42(q, 1H), 1.20(q, 1H).
I*-45a	R)-3-((3R)-(3-chlorophenyl)(4-(methylamino)-4-oxobutoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	2.24	521 (M+)	2.30 (m, 3H), 2.53 (s, 3H), 2.70 (s, 3H), 2.75 (m, 3H), 3.95 (m, 2H), 4.28 (m, 1H), 5.48 (s, 1H), 7.20 (m, 1H), 7.30 (m, 3H)
I*-46a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.24	522 (M+1)	7.64 (m, 1H), 7.07 (m, 3H), 4.33 (m, 1H), 4.22 (m, 1H), 3.62 (s, 3H), 2.73 (s, 3H), 2.43 (m, 2H)

I*-47a	methyl 2-((R)-(3-fluorophenyl)((3R)-1-((S)-1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.72	523 (M+1)	2.71 (s, 3H), 3.08 (m, 1H), 3.22 (m, 3H), 3.60 (s, 3H), 3.90 (m, 1H), 7.05 (m, 3H), 7.48 (m, 1H)
I*-48a	methyl 2-((R)-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	2.01	523 (M+1)	2.72 (s, 3H), 3.46 (m, 1H), 3.61 (s, 3H), 3.86 (m, 1H), 7.06 (m, 3H), 7.35 (m, 1H)
I*-49a	methyl 2-((R)-(2-fluoro-5-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.94	523 (M+1)	2.32 (s, 3H), 2.72 (s, 3H), 2.93 (m, 2H), 3.08 (m, 2H), 3.60 (s, 3H), 3.80 (m, 1H), 3.93 (s, 2H), 4.40 (m, 1H), 6.95 (m, 1H), 7.11 (m, 2H)
I*-50a	methyl 2-((R)-(5-fluoro-2-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.87	523 (M+1)	2.31 (s, 3H), 2.67 (s, 3H), 3.08 (m, 1H), 3.62 (s, 3H), 3.93 (m, 3H), 6.90 (m, 1H), 7.04 (m, 1H), 7.17 (m, 1H)
I*-51a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.66	523 (M+1)	0.95 (m, 1H), 2.71 (s, 3H), 2.91 (m, 3H), 3.07 (m, 1H), 3.49 (m, 1H), 3.62 (s, 3H), 3.86 (m, 1H), 4.03 (m, 1H), 4.14 (m, 2H), 7.02 (m, 2H), 7.10 (m, 1H), 7.37 (m, 1H)
I*-52a	methyl 2-((R)-(3-fluoro-5-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.89	523 (M+1)	1.55-1.80 (m, 6H), 2.37 (s, 3H), 2.72 (s, 3H), 3.65 (s, 3H), 6.78-6.94 (m, 3H)

I*-53a	methyl 2-((R)-((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate	2.05	523 (M+1)	1.92 (m, 16H), 2.31 (s, 3H), 2.73 (s, 3H), 3.24 (m, 8H), 3.58 (m, 1H), 3.65 (s, 3H), 3.79 (m, 1H), 4.09 (m, 2H), 4.44 (d, 1H), 7.13 (m, 3H),
I*-54a	methyl (S)-4-(3-fluorophenyl)-4-hydroxy-4-((3R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate	1.33	523 (M+1)	1.92 (m, 17H), 2.55 (m, 2H), 2.71 (s, 3H), 3.08 (m, 5H), 3.41 (m, 1H), 3.58 (s, 3H), 4.06 (m, 5H), 6.94 (m, 1H), 7.17 (d, 1H), 7.13 (m, 1H),
I*-55a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.32	523 (M+1)	7.36 (m, 1H), 7.11-7.01(m, 3H), 4.13-4.03 (m, 3H), 3.85 (brd, J = 13.2 Hz, 1H), 3.87-3.71 (m, 3H), 3.62 (s, 3H), 3.43 (dd, J = 12.4, 7.6 Hz, 1H), 3.28-3.20 (m, 4H), 3.08 (dd, J = 13.2, 3.2 Hz, 1H), 3.00-2.85 (m, 3H), 2.71 (s, 3H), 1.88-1.29 (m, 13H), 1.17 (m, 1H).
I*-56a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate	1.841	523 (M+1)	1.10 (m, 1H), 2.75 (s, 3H), 3.64 (s, 3H), 3.90 (m, 1H), 4.01 (m, 1H), 4.14 (m, 2H), 7.10 (m, 3H), 7.38 (m, 1H)

I*-57a	methyl 2-((R)-(2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.32	523 (M+1)	7.40 (m, 1H), 7.33 (m, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 4.45 (d, J = 8.8 Hz, 1H), 4.08 (m, 2H), 3.79-3.66 (m, 4H), 3.62 (s, 3H), 3.45 (dd, J = 12.4, 7.2 Hz, 1H), 3.31-3.25 (m, 4H), 3.10-3.06 (m, 2H), 3.00-2.89 (m, 2H), 2.71 (s, 3H), 2.32 (s, 3H), 1.83-1.39 (m, 13H), 1.25 (m, 1H)
I*-58a	methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate	1.35	523 (M+1)	7.18 (d, J = 6.8 Hz, 1H), 7.10 (m, 1H), 6.95 (dd, J = 10.0, 8.4, 1H), 4.39 (d, J = 8.8 Hz, 1H), 4.14 (brd, J = 12.4 Hz, 1H), 3.79-3.65 (m, 5H), 3.62 (s, 3H), 3.44 (m, 2H), 3.34-3.24 (m, 5H), 3.01-2.92 (m, 2H), 2.32 (s, 3H), 1.88-1.56 (m, 9H), 1.50-1.34 (m, 4H), 1.20 (m, 1H)

I*-59a	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexyl-2-methylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	1.72	524 (M+H)	7.37-7.29 (m, 3H), 7.21 (dd, J = 7.2, 1.2 Hz, 1H), 4.27 (brd, J = 14.0 Hz, 1H), 4.01 (d, J = 8.8 Hz, 1H), 3.81 (brd, J = 12.4 Hz, 1H), 3.62 (s, 3H), 3.33-3.24 (m, 4H), 2.94 (d, J = 12.8 Hz, 1H), 2.86 (m, 1H),1.99 (dd, J = 14.4, 6.4 Hz, 1H), 1.76-1.62 (m, H), 1.46 (m, 1H), 1.32 (s, 3H), 1.36-1.00 (m, 8H)
I*-60a	methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-1-cyclopentyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.30	523 (M+)	1.92 (m, 17H), 2.31 (s, 3H), 2.71 (s, 3H), 3.09 (m, 8H), 3.62 (s, 3H), 4.30 (m, 4H), 7.16 (m, 2H), 7.27 (m, 1H),
I*-61a	R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-yl)piperidine-1-carboxamide	1.88	523 (M+)	1.48(m, 18H) 2.71(s, 3H) 3.01(m, 6H) 3.48(m, 1H) 3.62(m, 6H) 4.11(m, 3H) 7.31(m, 4H)
I*-62a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(2-oxopyrrolidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.82	546 (M+Na-1)	1.05-1.20 (m, 1H), 1.27-1.40 (m, 2H), 2.05-2.17 (m, 2H), 2.71 (s, 3H), 3.62 (s, 3H), 1.14 (d, 1H), 7.22 (d, 1H), 7.30-7.40 (m, 3H)

I*-63a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate	2.08	525 (M+1)	0.98 (m, 2H), 2.71 (s, 3H), 2.92 (m, 2H), 3.07 (m, 2H), 3.61 (s, 3H), 3.81 (m, 1H), 4.10 (m, 2H), 4.45 (d, 1H), 7.10 (m, 3H)
I*-64a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate	2.24	525 (M+1)	0.98 (m, 2H), 2.70 (s, 3H), 3.06 (m, 1H), 3.61 (s, 3H), 3.87 (m, 1H), 4.10 (m, 3H), 6.90 (m, 3H)
I*-65a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4-difluorophenyl)methoxy)ethylcarbamate	2.08	525 (M+1)	2.70 (s, 3H), 3.08 (m, 1H), 3.23 (m, 3H), 3.60 (s, 3H), 3.85 (m, 1H), 4.01 (m, 1H), 4.15 (m, 2H), 7.06 (m, 1H), 7.21 (m, 2H)
I*-66a	methyl 2-((S)-(3-chlorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate	2.16	525 (M+)	1.6-1.8 (m, 5H), 2.65 (s, 3H), 2.8-2.9 (m, 2H), 3.6 (m, 3H), 4.0-4.1 (m, 2H), 4.25 (d, 1H), 7.2-7.35 (m, 4H)
I*-67a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.05	525 (M+)	2.67 (s, 3H), 3.60 (s, 3H), 3.68 (d, 1H), 7.15 (d, 1H), 7.20-7.35 (m, 3H)

I*-68a	methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	1.35	526 (M+H)	7.36-7.29 (m, 3H), 7.21 (d, J = 7.2 Hz, 1H), 4.18 (brd, J = 12.4 Hz, 1H), 4.02 (d, J = 8.8 Hz, 1H), 3.79-3.65 (m, 5H), 3.62 (s, 3H), 3.45 (m, 2H), 3.33-3.22 (m, 5H), 2.90 (m, 2H), 1.87-1.31 (m, 13H), 1.17 (m, 1H).
I*-69a	methyl 2-((R)-(2,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.78	527 (M+1)	2.70 (s, 3H), 2.94 (m, 2H), 3.07 (m, 2H), 3.61 (s, 3H), 4.11 (m, 1H), 4.46 (d, 1H), 7.10 (m, 3H)
I*-70a	methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.76	527 (M+1)	2.70 (s, 3H), 3.07 (m, 1H), 3.61 (s, 3H), 3.94 (m, 3H), 6.90 (m, 3H)
I*-71a	methyl 2-((R)-(2,3-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate			1.79 (m, 1H), 2.72 (s, 3H), 3.08 (m, 2H), 3.62 (s, 3H), 3.80 (m, 1H), 3.93 (m, 2H), 4.14 (m, 2H), 4.45 (d, 1H), 7.21 (m, 3H)
I*-72a	methyl 2-((R)-((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate	1.94	527 (M+1)	2.02 (m, 1H), 2.72 (s, 3H), 3.55 (t, 1H), 3.62 (s, 3H), 4.47 (d, 1H), 7.15-7.26 (m, 3H)

I*-73a	methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate	1.30	527 (M+H)	6.93-6.86 (m, 3H), 4.16 (brd, J = 12.4 Hz, 1H), 4.05 (d, J = 8.8 Hz, 1H), 3.78-3.65 (m, 5H), 3.62 (s, 3H), 3.44 (m, 2H), 3.34-3.26 (m, 5H), 2.94-2.84 (m, 2H), 2.32 (s, 3H), 1.87-1.57 (m, 9H), 1.49-1.34 (m, 4H), 1.19 (m, 1H)
I*-74a	methyl 2-((R)-((3R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	1.62	527 (M+1)	7.36-7.24 (m, 5H), 4.24 (m, 1H), 3.62 (s, 3H), 2.72 (s, 3H), 2.21 (m, 2H)
I*-75a	methyl 2-((S)-(3-chlorophenyl)((R)-4-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate	1.70	527 (M+)	1.52-176 (m, 4H), 2.70 (s, 3H), 3.65 (s, 3H), 4.33 (m, 1H), 7.20-7.40 (m, 4H)
I*-76a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-1-((R)-1-methyl-6-oxopiperidin-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.10	536 (M+H)	7.37 (m, 1H), 7.07-7.02 (m, 3H), 4.23 (d, J = 13.2 Hz, 1H), 4.11 (m, 1H), 4.02 (d, J = 8.4 Hz, 1H), 3.90 (d, J = 13.2 Hz, 1H), 3.62 (s, 3H), 3.39 (m, 1H), 3.33-3.21 (m, 4H), 3.13-2.95 (m, 3H), 2.92 (s, 3H), 2.88-2.81 (m, 2H), 2.73 (s, 3H), 2.45-2.36 (m, 2H), 2.02 (m, 1H), 1.88 (m, 1H), 1.68-1.50 (m, 5H), 1.38-1.13 (m, 3H).

I*-77a	methyl 2-((R)-((R)-1-((S)-1-((2S,4r,6R)-2,6-dimethyl-tetrahydro-2H-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.36	537 (M+H)	7.37 (m, 1H), 7.09 (d, 1H), 7.04 (m, 2H), 3.62 (s, 3H), 3.49 (m, 2H), 2.72 (s, 3H), 1.17 (m, 7H)
I*-78a	methyl 2-((R)-(3-fluorophenyl)((R)-1-((S)-4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.38	536 (M+H)	7.37 (m, 1H), 7.06 (m, 3H), 4.28 (d, 1H), 3.62 (s, 3H), 2.72 (s, 3H),
I*-79a	methyl 2-((R)-(5-fluoro-2-methylphenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.38	537(M+H)	7.19 (m, 1H), 7.11 (m, 1H), 6.95 (m, 1H), 4.39 (d, J = 9.6 Hz, 1H), 4.08 (m, 2H), 3.83-3.66 (m, 4H), 3.62 (s, 3H), 3.45 (dd, J = 12.4, 7.2 Hz, 1H), 3.34-3.25 (m, 4H), 3.10-3.13 (m, 2H), 2.96-2.89 (m, 2H), 2.71 (s, 3H), 2.32 (s, 3H), 1.83-1.20 (m, 14H)
I*-80a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(4-oxocyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.90	559 (M+Na)	1.00-1.50 (m, 9H), 1.51-1.80 (m, 5H), 2.15 (m, 2H), 2.72 (s, 3H), 3.10 (m, 1H), 3.65 (s, 3H), 3.90 (m, 1H), 7.21 (d, 1H), 7.30-7.40 (m, 3H)

I*-81a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate	1.66	537(M+)	7.30-7.18 (m, 4H), 4.16 (d, J = 13.2 Hz, 1H), 4.10-4.04 (m, 1H), 3.99 (d, J = 12.9 Hz, 1H), 3.57 (s, 3H), 3.35-2.53 (m, 8H), 2.63 (s, 3H), 1.45 (s, 3H), 1.76-0.79 (m, 18H).
I*-82a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((2S,3R)-1-cyclohexyl-3-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.68	538 (M+H)	7.37-7.30 (m, 3H), 7.21 (dd, J = 7.2, 1.6 Hz, 1H), 4.20-4.17 (m, 2H), 4.01 (d, J = 8.8 Hz, 1H), 3.89 (brd, J = 10.8 Hz, 1H), 3.62 (s, 3H), 3.36-3.13 (m, 5H), 2.99 (dd, J = 13.2, 10 Hz, 1H), 2.89 (m, 1H), 2.73 (s, 3H),1.81-0.88 (m 21H)
I*-83a	methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylpentan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	1.69	538 (M+H)	7.37-7.31 (m, 3H), 7.21 (d, J = 7.2, Hz, 1H)), 4.18 (d, J = 12.8 Hz, 1H), 4.07 (d, J = 10.8 Hz 1H), 4.01 (d, J = 9.2 Hz, 1H), 3.87 (brd, J = 12.0 Hz, 1H), 3.62 (s, 3H), 3.50-3.20 (m, 5H),3.09 (m, 1H) 2.99-2.85 (m, 2H), 1.81-0.88 (m 24H)
I*-84a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.25	537 (M+)	2.71 (s, 3H), 3.06 (m, 1H), 3.62 (s, 3H), 7.20 (m, 1H), 7.32 (m, 3H)

I*-85a	methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.35	537 (M+)	2.32 (s, 3H), 2.70 (s, 3H), 3.07 (m, 1H), 3.63 (s, 3H), 3.95 (m, 1H), 4.12 (m, 1H), 4.31 (m, 2H), 7.16 (m, 2H), 7.31 (m, 1H)
I*-86a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(4-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.69	537 (M+)	7.29-7.12 (m, 4H), 4.09-4.00 (m, 2H), 3.94 (d, J = 8.8 Hz, 1H), 3.80-3.77 (m, 1H), 3.54 (s, 3H), 3.17-2.75 (m, 8H), 2.63 (s, 3H), 1.73-0.93 (m, 17H), 0.86, 0.83 (d, J = 6.6 Hz, 3H).
I*-87a	methyl 1-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)propan-2-ylcarbamate	1.67	537(M+)	
I*-88a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(ethylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.78	538 (M+H)	7.37-7.30 (m, 3H), 7.21 (d, J = 7.2 Hz, 1H), 4.18-4.08 (m, 2H), 4.02 (d, J = 8.8 Hz, 1H), 3.89 (brd, J = 12.4 Hz, 1H), 3.62 (s, 3H), 3.34-2.82 (m, 10H),1.81-0.88 (m 21H)
I*-89a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.57	537(M+)	7.27-7.11 (m, 4H), 4.33 (d, J = 12.9 Hz, 1H), 4.15-4.11 (m, 1H), 3.92 (d, J = 8.8 Hz, 1H), 3.71 (d, J = 12.9 Hz, 1H), 3.53 (s, 3H), 2.61 (s, 3H), 3.20-2.53 (m, 8H), 1.63-1.03 (m, 17H), 0.87 (s, 3H).

I*-90a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.57	537(M)	7.28-7.10 (m, 4H), 4.14 (m, 1H), 4.02 (d, J = 13.8 Hz, 1H), 3.94 (d, J = 8.5 Hz, 1H), 3.78 (d, J = 11.4 Hz, 1H), 3.54 (s, 3H), 3.16-2.74 (m, 8H), 2.62 (s, 3H), 1.63-1.08 (m, 17H), 0.88 (s, 3H).
I*-91a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate	1.636	537 (M+)	2.73 (s, 3H), 3.04 (m, 4H), 3.62 (s, 3H), 4.09 (m, 1H), 4.21 (m, 1H), 7.21 (m, 1H), 7.33 (m, 3H)
I*-92a	methyl 2-((S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate	1.588	537 (M+)	2.03 (m, 1H), 2.70 (s, 3H), 3.02 (m, 3H), 3.63 (s, 3H), 4.17 (m, 1H), 4.31 (m, 1H), 7.30 (m, 4H)
I*-93a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(2-oxopiperidin-1-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.91	538 (M+)	2.71 (S, 3H), 3.65 (s, 3H), 4.00 (d, 1H), 4.21 (d, 1H), 7.23 (m, 1H), 7.31 (m, 3H)
I*-94a	methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((R)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.57	539 (M+1)	6.83-6.76 (m, 3H), 4.30 (d, J = 12.9 Hz, 1H), 4.14-4.10 (m, 1H), 3.96 (d, J = 8.2 Hz, 1H), 3.71 (d, J = 14.3 Hz, 1H), 3.52 (s, 3H), 2.60 (s, 3H), 3.23-2.51 (m, 8H), 1.62-1.05 (m, 17H), 0.86 (s, 3H).

I*-95a	methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(1-methylcyclohexyl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.57	539 (M+1)	6.81-6.77 (m, 3H), 4.14-4.09 (m, 1H), 4.00-3.96 (m, 2H), 3.78 (d, J = 12.0 Hz, 1H), 3.53 (s, 3H), 3.25-2.71 (m, 8H), 2.61 (s, 3H), 1.60-1.11 (m, 17H), 0.86 (s, 3H).
I*-96a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate	2.23	539 (M+1)	1.58 (m, 22H), 2.19 (m, 1H), 2.41 (s, 3H), 2.71 (s, 3H), 3.01 (m,4H), 3.62(s, 3H), 3.78 (m, 1H), 4.18 (m, 2H), 4.59 (m, 1H), 7.02 (m, 2H),
I*-97a	methyl 2-((R)-((S)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluoro-6-methylphenyl)methoxy)ethylcarbamate	2.23	539 (M+1)	1.58 (m, 20H), 2.19 (m, 1H), 2.41 (s, 3H), 2.71 (s, 3H), 3.01 (m,4H), 3.16 (s, 3H), 3.33 (m, 1H), 4.18 (m, 1H), 4.51 (m, 2H), 7.02 (m, 2H),
I*-98a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate			7.36-7.29 (m), 7.21 (d), 4.20 (d), 3.86 (d), 3.62 (s), 2.83 (q), 2.68 (d), 2.45 (s)
I*-99a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((S)-oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate			7.36-7.29 (m), 7.21 (d), 3.62 (s), 2.88-2.79 (m), 2.65 (m), 2.43 (s)
I*-100a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.49	539 (M+)	7.37-7.31 (m), 7.21-7.20 (d), 4.17 (d), 4.09 (m), 4.02 (d), 3.62 (s), 2.72 (s)

I*-101a	methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.52	539 (M+)	2.34 (s, 3H), 2.70 (s, 3H), 3.10 (m, 2H), 3.62 (s, 3H), 3.95 (m, 3H)
I*-102a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(4-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.78	539 (M+)	1.0-1.5 (m, 10H), 1.59 (m, 2H), 1.74 (m, 3H), 1.98 (m, 2H), 2.7 (s, 3H), 3.6 (s, 3H), 4.0 (d, 1H), 7.2 (m, 1H), 7.3-7.35 (m, 3H),
I*-103a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate	1.30	539(M+)	7.27-7.16 (m, 4H), 4.15 (d, J = 13.2 Hz, 1H), 4.09-4.04 (m, 1H), 3.94 (d, J = 12.0 Hz, 1H), 3.89-3.83 (m, 2H), 3.55 (s, 3H), 2.62 (s, 3H), 3.40-2.86 (m, 8H), 2.61-2.52 (m, 2H), 1.43 (s, 3H), 1.63-1.12 (m, 12H).
I*-104a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-((1R*,2S*)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.02	539 (M+)	2.70 (s, 3H), 3.65 (s, 3H), 3.75-3.90 (m, 2H), 7.20 (m, 1H), 7.35 (m, 3H)
I*-105a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((1R*,2S*)-2-hydroxycyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.06	539 (M+)	2.72 (s, 3H), 3.65 (s, 3H), 4.15 (d, 1H), 7.21 (m, 1H), 7.30-7.40 (m, 3H)

I*-106a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.39	540 (M+1)	7.36-7.23 (m, 3H), 7.22 (d, J = 7.8 Hz, 1H), 4.16-4.01 (m, 3H), 3.85 (brd, J = 12.8 Hz, 1H), 3.78-3.71 (m, 3H), 3.62 (s, 3H), 3.43 (dd, J = 12.4, 7.6 Hz, 1H), 3.28-3.22 (m, 4H), 3.08 (dd, J = 12.8, 3.2 Hz, 1H), 3.00-2.85 (m, 3H), 2.71 (s, 3H), 1.88-1.30 (m, 13H), 1.17 (m, 1H).
I*-107a	methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((1S,2R)-1-cyclopentyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.16	539 (M+)	1.58 (m, 15H), 2.31 (s, 3H), 2.71 (s, 3H), 2.84 (m, 2H), 3.17 (m, 5H), 3.56 (m, 1H), 3.62 (s, 3H), 3.99 (m, 2H), 4.29 (m, 2H), 7.17 (m, 2H), 7.31 (d, 1H),
I*-108a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)azepan-3-yl)methoxy)ethylcarbamate	1.94	539 (M+)	2.73 (s, 3H), 3.07 (m, 2H), 3.63 (s, 3H), 3.94 (m, 2H), 4.10 (m, 1H), 4.23 (m, 1H)
I*-109a	methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)ethylcarbamate	1.38	540 (M+1)	7.30 (d, J = 3.2 Hz, 1H), 7.19-7.13 (m, 2H), 4.33-4.26 (m, 2H), 3.86-3.65 (m, 5H), 3.62 (s, 3H), 3.47-3.42 (m, 2H), 3.34-3.20 (m, 5H), 2.90-2.80 (m, 2H), 2.32 (s, 3H), 1.89-1.56 (m, 9H), 1.49-1.20 (m, 5H).

I*-110a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.36	540 (M+1)	7.37-7.30 (m, 3H), 7.21 (d, J= 7.2 Hz, 1H), 4.20 (brd, J = 13.2 Hz, 1H), 4.02 (d, J = 8.8 Hz, 1H), 3.81-3.67 (m, 5H), 3.62 (s, 3H), 3.58 (m, 1H), 3.44 (dd J = 12.4, 7.2 Hz, 1H), 3.34-3.22 (m, 5H), 2.94-2.85 (m, 2H), 2.75 (s, 3H), 1.88-1.52 (m, 10H), 1.39-1.29 (m, 3H), 1.16 (m, 1H)
I*-111a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamothioyl)piperidin-3-yl)methoxy)ethylcarbamate	2.52	539 (M+1)	0.90 (m, 1H), 1.05 (m, 1H), 2.72 (s, 3H), 3.05 (m, 2H), 3.62 (s, 3H), 4.02 (d, 1H), 4.70 (m, 2H), 5.13 (m, 1H), 7.20 (m, 1H), 7.32 (m, 3H)
I*-112a	methyl 2-((R)-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate	2.09	541 (M+)	2.66 (s, 3H), 2.90 (m, 2H), 3.05 (m, 1H), 3.44 (m, 1H), 3.62 (s, 3H), 3.87 (m, 1H), 6.90 (m, 3H)

I*-113a	methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.39	541 (M+1)	6.95-6.86 (m, 3H), 4.12-4.05 (m, 3H), 3.85 (brd, J = 12.0 Hz, 1H), 3.78-3.71 (m, 3H), 3.62 (s, 3H), 3.41 (dd, J = 12.4, 7.6 Hz, 1H), 3.34-3.20 (m, 4H), 3.07 (dd, J = 12.8, 3.2 Hz, 1H), 2.99-2.85 (m, 3H), 2.71 (s, 3H), 1.84-1.34 (m, 13H), 1.22 (m, 1H).
I*-114a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluoro-2-hydroxyphenyl)methoxy)ethylcarbamate	1.93	541 (M+1)	1.58 (m, 19H), 2.19 (d, 2H), 2.71 (s, 3H), 3.13 (m, 7H), 3.42 (m, 2H), 3.62 (s, 3H), 3.78 (m, 1H), 4.26 (m, 2H), 4.59 (m, 1H) 6.88 (m, 2H),
I*-115a	methyl 2-((R)-(2,3-difluoro-6-methylphenyl)(1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.75	541 (M+1)	1.48(m, 11H) 2.17(m, 1H) 2.40(s, 3H) 2.71(s, 3H) 3.01(m, 6H) 3.48(m, 2H) 3.62(s, 3H) 3.89(m, 3H) 4.19(m, 2H) 4.60(m, 2H) 7.03(m, 2H)
I*-116a	methyl 2-((5-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.16	541 (M+)	2.70 (s, 3H), 2.79 (m, 1H), 2.91 (m, 2H), 3.07 (m, 1H), 3.23 (m, 2H), 3.62 (s, 3H), 3.80 (m, 1H), 4.12 (m, 1H), 4.42 (d, 1H), 7.10 (m, 1H), 7.32 (m, 1H), 7.40 (m, 1H)

I*-117a	methyl 2-((R)-(5-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.30	541 (M+)	2.71 (s, 3H), 2.90 (m, 2H), 3.05 (m, 2H), 3.61 (s, 3H), 3.80 (m, 1H), 4.10 (m, 2H), 4.41 (m, 1H), 7.10 (m, 1H), 7.35 (m, 2H)
I*-118a	methyl 2-((R)-(3-chloro-4-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.44	541 (M+)	1.66-1.84 (m, 6H), 2.70 (s, 3H), 3.65 (s, 3H), 3.87 (d, 1H), 7.25 (d, 2H), 7.40 (d, 1H)
I*-119a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,4,5-trifluorophenyl)methoxy)ethylcarbamate	2.14	543 (M+1)	2.70 (s, 3H), 3.05 (d, 1H), 3.62 (s, 3H), 3.89 (m, 1H), 4.10 (m, 3H), 7.08 (m, 2H)
I*-120a	methyl 2-((R)-((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.42	543 (M+1)	7.34-7.28 (m, 1H), 7.04-6.95 (m, 3H), 4.15 (d, J = 12.9 Hz, 1H), 4.09-4.03 (m, 1H), 3.99 (d, J = 8.5 Hz, 1H), 3.83 (d, J = 12.3 Hz, 1H), 3.56 (s, 3H), 3.29-2.74 (m, 8H), 2.66 (s, 3H), 1.99-1.11 (m, 16H).
I*-121a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.80	543 (M+)	2.70 (s, 3H), 3.08 (m, 1H), 3.61 (s, 3H), 7.01 (m, 1H), 7.16 (m, 2H)

I*-122a	methyl 2-((R)-((R)-1-((S)-2-amino-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)ethylcarbamate	1.36	544 (M+1)	7.16-7.13 (m, 2H), 7.03(d, J = 7.6 Hz, 1H), 4.17 (brd, J = 11.2 Hz, 1H), 4.05 (d, J = 8.8 Hz, 1H), 3.78-3.65 (m, 5H), 3.62 (s, 3H), 3.44 (d, J = 12.4, 6.8 Hz, 2H), 3.34-3.26 (m, 5H), 2.94-2.84 (m, 2H), 1.87-1.56 (m, 9H), 1.49-1.34 (m, 4H), 1.19 (m, 1H).
I*-123a	methyl 2-((R)-((3R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.63	545 (M+1)	7.36 (q, 1H), 7.05 (m, 3H0, 4.25 (m, 1H0, 3.63 (s, 3H), 2.72 (s, 3H), 2.21 (m, 1H).
I*-124a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((1r,3S,4R)-3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.38	545 (M+)	7.33(m, 3H), 7.21(d, 1H), 4.93(m, 1H), 4.81(m, 1H), 4.20(d, 1H), 3.87(d, 1H), 3.62(s, 3H), 3.23(s, 3H), 3.10(dd, 1H), 2.71(s, 3H), 2.19(m, 2H), 2.04(m, 1H), 1.18(q, 1H).
I*-125a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((1s,3R,4S)-3,4-difluorocyclopentyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.38	546 (M+1)	7.36 (m, 3H), 7.25 (d, 1H), 5.04 (d of m, 2H), 3.63 (s, 3H), 2.76 (s, 3H)

I*-126a	(R)-3-((R)-(3-chlorophenyl)(2-(2-cyano-3-methylguanidino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	2.24	546 (M+)	0.95 (m, 2H), 1.55 (m, 2H), 2.67 (s, 3H), 2.79 (s, 3H), 2.94 (m, 2H), 3.85 (m, 1H), 4.05 (m, 2H), 4.16 (m, 1H), 7.21 (m, 1H), 7.35 (m, 3H)
I*-127a	methyl 2-((R)-(3-chlorophenyl)((R)-1-(N'-cyano-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)carbamimidoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.27	547 (M+)	0.95 (m, 4H), 2.70 (s, 3H), 2.95 (m, 3H), 3.61 (d, 3H), 4.06 (m, 2H), 4.30 (m, 2H), 7.20 (m, 1H), 7.33 (m, 2H)
I*-128a	(R)-3-((R)-(3-chlorophenyl)(2-(thiazol-2-ylamino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.95	548 (M+)	0.95 (m, 2H), 2.72 (s, 3H), 2.91 (m, 1H), 3.07 (m, 2H), 3.50 (m, 3H), 3.96 (m, 1H), 4.15 (m, 2H), 6.79 (d, 1H), 7.19 (m, 2H), 7.32 (m, 3H)
I*-129a	methyl 2-((R)-((3R)-1-(1-(bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	2.39	549 (M+)	1.30-1.50 (m, 10H), 1.52-1.80 (m, 10H), 2.70 (s, 3H), 3.65 (s, 3H), 4.05 (d, 1H), 4.41 (d, 1H), 7.22 (m, 1H), 7.30-7.40 (m, 3H)
I*-130a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((2S,3R)-1-cyclohexyl-3-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.75	552 (M+1)	7.37-7.31 (m, 3H), 7.21 (m, 1H)), 4.20-4.13 (m, 2H), 4.02 (d, J = 8.8 Hz 1H), 3.88 (brd, J = 12.0 Hz, 1H), 3.63 (s, 3H), 3.36-3.21 (m, 5H),3.01 (m, 3H), 2.80 (s, 3H), 1.83-0.88 (m 24H)

I*-131a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((R)-1-methyl-6-oxopiperidin-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.18	553 (M+1)	7.37-7.29 (m, 3H), 7.17 (d, J = 7.2 Hz, 1H), 4.23 (d, J = 12.4 Hz, 1H), 4.11 (m, 1H), 4.01 (d, J = 8.8 Hz, 1H), 3.91 (d, J = 12.8 Hz, 1H), 3.62 (s, 3H), 3.39 (dd, J = 12.0, 4.0 Hz, 1H), 3.26-3.21 (m, 4H), 3.13-2.95 (m, 3H), 2.92 (s, 3H), 2.90-2.81 (m, 2H), 2.73 (s, 3H), 2.45-2.32 (m, 2H), 2.01 (m, 1H), 1.88 (m, 1H), 1.71-1.49 (m, 5H), 1.38-1.12 (m, 3H).
I*-132a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-((2S,4r,6R)-2,6-dimethyl-tetrahydro-2H-pyran-4-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.43	554 (M+1)	7.33 (m, 3H), 7.20 (d, 1H), 3.38 (m, 2H), 3.62 (s, 3H), 2.71 (s, 3H), 1.17 (m, 7H), 0.84 (d of q, 2H)
I*-133a	methyl 2-((R)-(5-chloro-2-methylphenyl)((R)-1-((S)-2-(methylamino)-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.41	554 (M+1)	7.30 (d, J= 1.6 Hz, 1H), 7.19-7.13 (m, 2H), 4.33-4.27 (m, 2H), 3.88-3.68 (m, 5H), 3.62 (s, 3H), 3.58 (m, 1H), 3.44 (m, 1H), 3.33-3.20 (m, 5H), 2.89-2.80 (m, 2H), 2.75 (s, 3H), 2.32 (s, 3H), 1.88-1.51 (m, 10H), 1.37-1.23 (m, 4H)

I*-134a	methyl 2-((R)-(3,5-difluorophenyl)((R)-1-((S)-4-(1-methoxycyclopentyl)-1-(methylamino)butan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.41	555 (M+1)	6.96 (m, 3H), 4.18 (d, 1H), 4.04 (d, 1H), 3.62 (s, 3H), 3.15 (s, 3H), 2.72 (s, 3H)
I*-135a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cycloheptyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	2.24	555 (M+)	2.71 (s, 3H), 2.92 (m, 2H), 3.06 (m, 2H), 3.62 (s, 3H), 3.81 (m, 1H), 4.09 (m, 2H), 4.47 (d, 1H), 7.20 (m, 1H), 7.32 (m, 1H), 7.44 (m, 1H)
I*-136a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate	1.69	556 (M+)	1.48(m, 20H) 2.71(s, 3H) 2.97(m, 8H) 3.62(s, 3H) 3.71(m, 1H) 3.87(m, 1H) 4.16(m, 3H) 7.59(m, 4H)
I*-137a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((3R)-1-((S)-1-(methylamino)-3-(oxepan-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.84	557 (M+)	2.71 (s, 3H), 3.61 (s, 2H), 4.12 (m, 2H), 4.45 (d, 1H), 7.21 (m, 1H), 7.41 (m, 2H)
I*-138a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.49	558 (M+1)	7.42 (t), 7.33 (t), 7.19 (t), 4.45 (d), 3.61 (s), 2.71 (s)
I*-139a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((3R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate	1.85	557 (M+)	1.92 (m, 17H), 2.64 (m, 1H), 2.29 (s, 3H), 3.09 (m, 6H), 3.41 (m, 1H), 3.58 (s, 3H), 4.15 (m, 5H), 7.34 (t, 1H), 7.49 (t, 1H), 7.54 (m, 1H),

I*-140a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.41	558 (M+1)	7.43 (td, J = 8.8, 1.6 Hz, 1H), 7.36 (td, J = 6.0, 1.6 Hz, 1H), 7.21-7.01(t, J = 7.6 Hz, 1H), 4.45 (d, J = 8.8 Hz, 1H), 4.08 (m, 2H), 3.81 (m, 1H), 3.76-3.65 (m, 3H), 3.62 (s, 3H), 3.45 (dd, J = 12.4, 7.6 Hz, 1H), 3.33-3.26 (m, 4H), 3.10-3.06 (m, 2H), 3.95-2.85 (m, 2H), 2.71 (s, 3H), 1.85-1.39 (m, 13H), 1.27 (m, 1H)
I*-141a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-oxepan-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.42	556 (M+1)	7.18-7.13 (m, 2H), 7.05 (d, J =9.2 Hz, 1H), 4.12-4.04 (m, 3H), 3.85 (brd, J = 13.2 Hz, 1H), 3.78-3.71 (m, 3H), 3.62 (s, 3H), 3.41 (dd, J = 12.8, 7.6 Hz, 1H), 3.34-3.23 (m, 4H), 3.07 (dd, J = 13.2, 3.2 Hz, 1H), 2.97-2.89 (m, 3H), 2.71 (s, 3H), 1.88-1.19 (m, 14H)
I*-142a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((R)-1-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate	1.78	557 (M+)	1.00 (m, 1H), 1.95 (m, 3H), 2.72 (s, 3H), 2.80 (m, 1H), 3.44 (m, 1H), 3.60 (s, 3H), 4.36 (m, 1H), 7.15 (m, 1H), 7.38 (m, 1H), 7.52 (m, 1H)

I*-143a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-oxepan-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.40	558 (M+H)	7.17-7.13 (m, 2H), 7.03 (d, J = 8.8 Hz, 1H), 4.18 (d, J = 11.2 Hz, 1H), 4.05 (d, J = 8.4 Hz, 1H) 3.80-3.68 (m, 5H), 3.62 (s, 3H), 3.56 (d, J = 14.4 Hz, 1H), 3.44 (d, J = 12.4, 7.2 Hz, 1H), 3.34-3.21 (m, 5H), 2.94-2.83 (m, 2H), 2.74 (s, 3H), 2.32 (s, 3H), 1.88-1.53 (m, 10H), 1.37-1.33 (m, 3H), 1.19 (m, 1H)
I*-144a	methyl 2-((R)-((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-(trifluoromethyl)phenyl)methoxy)ethylcarbamate	1.94	559 (M+1)	1.12-1.47 (m, 6H), 1.52-1.70 (m, 6H), 2.70 (s, 3H), 3.62 (s, 3H), 3.82-3.96 (m, 3H), 7.50-7.69 (m, 4H)
I*-145a	methyl 2-((R)-((R)-1-((S)-1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	1.68	559 (M+1)	7.36 (q, 1H), 7.04 (m, 3H), 4.21 (m, 1H), 3.63 (s, 3H), 2.70 (2, 3H)
I*-146a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.45	559 (M+)	7.31-7.14 (m, 4H), 4.16 (d, J = 13.5 Hz, 1H), 4.08-4.03 (m, 1H), 3.96 (d, J = 8.5 Hz, 1H), 3.83 (d, J = 12.0 Hz, 1H), 3.56 (s, 3H), 3.27-2.74 (m, 8H), 2.66 (s, 3H), 2.00-1.10 (m, 16H).

I*-147a	methyl 2-((R)-((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate	1.47	561 (M+1)	6.87-6.80 (m, 3H), 4.13 (d, J = 12.0 Hz, 1H), 4.08-4.03 (m, 1H), 4.01 (d, J = 8.2 Hz, 1H), 3.83 (d, J = 13.2 Hz, 1H), 3.56 (s, 3H), 3.31-2.74 (m, 8H), 2.65 (s, 3H), 1.99-1.12 (m, 16H).
I*-148a	methyl 2-((R)-(3-chloro-2,4-difluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.98	561 (M+)	1.62 (m, 12H), 2.71 (s, 6H), 3.01 (m, 4H), 3.39 (m, 3H), 3.81 (m, 3H), 4.12 (m, 2H), 4.42 (d, 1H), 7.18 (t, 1H), 7.38 (m, 1H),
I*-149a	methyl 2-((R)-((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate	1.64	563 (M+1)	7.10 (m, 3H), 4.24 (m, 1H0, 3.63 (s, 3H), 2.72 (s, 3H).
I*-150a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butoxy)ethylcarbamate	2.48	565 (M+)	0.80-0.98 (m, 6H), 1.17-1.58 (m, 10H), 1.60-1.85 (m, 7H), 1.90-2.34 (m, 5H), 2.37-2.49 (m, 1H), 2.70 (s, 3H), 3.65 (s, 3H), 3.95 (d, 1H), 4.11 (d, 2H), 7.20-7.30 (m, 3H), 7.40 (s, 1H)
I*-151a	methyl 2-((R)-1-(3-chlorophenyl)-1-((3R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate	1.73	575 (M+)	7.27-7.14 (m, 4H), 4.18-4.15 (m, 2H), 4.03 (d, J = 12.6 Hz, 1H), 3.55 (s, 3H), 2.62 (s, 3H), 3.30-2.48 (m, 8H), 1.42 (s, 3H), 2.18-1.15 (m, 20H).

I*-152a	methyl 2-((R)-((R)-1-((S)-1-(1-adamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,5-difluorophenyl)methoxy)ethylcarbamate	1.68	577 (M+1)	7.10 (m, 3H), 4.45 (d, 1H), 4.22 (m, 1H0, 3.96 (d, 1H), 3.63 (s, 3H), 2.70 (s, 3H), 1.96 (bs, 3H)
I*-153a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-(4,4-difluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.52	577 (M+)	7.10-7.07 (m, 2H), 6.97-6.95 (m, 1H), 4.14 (d, J = 13.2 Hz, 1H), 4.09-4.03 (m, 1H), 4.00 (d, J = 8.2 Hz, 1H), 3.83 (d, J = 12.3 Hz, 1H), 3.57 (s, 3H), 3.31-2.75 (m, 8H), 2.66 (s, 3H), 1.99-1.14 (m, 16H).
I*-154a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.36	536 (M+)	7.38-7.34, m, 1H; 7.12-7.01, m, 3H; 3.62, s, 3H; 2.71, s, 3H; 1.21, s, 6H
I*-155a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.35	555 (M+)	6.90 (m, 3H), 3.62 (s, 3H), 2.71 (s, 3H), 1.20 (s, 6H)
I*-156a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	1.35	518(M+)	7.37-7.28, m, 5H; 3.62, s, 3H; 2.72, s, 3H; 1.21, s, 6H
I*-157a	methyl 2-((*R*)-((*R*)-1-((*S*)-1-((*R*)-6,6-dimethyl-tetrahydro-2*H*-pyran-3-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(phenyl)methoxy)ethylcarbamate	1.41	553 (M+)	7.35-7.30 m, 3H 7.23, ap d, 1H; 3.63 s, 3H; 2.71, s, 3H; 1.21, s, 6H
I*-158a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-((*R*)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.44	551 (M+)	7.36-7.26, m, 4H; 3.64, s, 3H; 2.73, s, 3H; 0.80 m, 1H; 0.63, m, 1H; 0.52, m, 1H; 0.41, m, 1H

I*-159a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-((*R*)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.35	535 (M+)	7.36, m, 1H; 7.15-7.0, m, 3H; 3.62, s, 3H; 2.72, s, 3H; 0.79, m, 1H; 0.62, m, 1H; 0.51, m, 1H; 0.40, m, 1H
I*-160a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-((*R*)-4-oxaspiro[2.5]octan-6-yl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	1.41	553 (M+)	6.98, m, 2H; 6.88, m, 1H; 3.63, s, 3H; 2.72, s, 3H; 0.80, m, 1H; 0.61, m, 1H; 0.51, m, 1H; 0.40, m, 1H

Table of Compounds Formula (I)

Cpd. No.	Cpd Name	Example	LC-MS (3 min) t_R (min)	Mass observed	Selected 1H NMR
I-1a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluorophenyl)-4-hydroxybutylcarbamate	3.1		521	0.90 (m, 1H), 1.96 (m, 2H), 2.15 (m, 1H), 2.62 (m, 1H), 2.70 (s, 3H), 2.87 (m, 2H), 3.01 (m, 3H), 3.56 (s, 3H), 3.98 (d, 1H), 4.14 (m, 1H), 4.32 (d, 1H), 7.00 (m, 1H), 7.14 (m, 1H), 7.26 (m, 1H), 7.58 (m, 1H)
I-2a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	3.1		529	0.99 (s, 9H), 2.14 (m, 1H), 2.62 (m, 1H), 2.71 (s, 3H), 3.59 (s, 3H), 4.02 (d, 1H), 4.24 (m, 1H), 4.34 (d, 1H), 7.14 (m, 1H), 7.36 (m, 1H), 7.52 (m, 1H)
I-3a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-dimethylphenyl)-4-hydroxybutylcarbamate	3.1		531	0.92 (m, 1H), 1.02 (m, 1H), 2.28 (s, 6H), 2.54 (m, 2H), 2.71 (s, 3H), 3.60 (s, 3H), 3.98 (d, 1H), 4.14 (m, 1H), 4.23 (d, 1H), 6.86 (s, 1H), 6.97 (s, 2H)

I-4a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate	3.1		535	0.88 (m, 1H), 1.06 (m, 1H), 2.34 (s, 3H), 2.54 (m, 2H), 2.70 (s, 3H), 3.59 (s, 3H), 3.96 (d, 1H), 4.12 (m, 1H), 4.26 (d, 1H), 6.76 (d, 1H), 6.94 (d, 1H), 6.97 (s, 1H)
I-5a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2-fluoro-5-methylphenyl)-4-hydroxybutylcarbamate	3.1		535	1.02 (m, 1H), 1.15 (m, 2H), 2.24 (m, 1H), 2.44 (s, 3H), 2.74 (m, 1H), 2.82 (s, 3H), 2.92 (m, 2H), 3.71 (s, 3H), 4.12 (d, 1H), 4.14 (m, 1H), 4.43 (d, 1H), 6.98 (m, 1H), 7.16 (m, 1H), 7.50 (m, 1H)
I-6a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	3.1	1.43	538, 540	7.34-7.33 (m, 1H), 7.24-7.12 (m, 3H), 4.19 (d, J = 12.9 Hz, 1H), 4.07-4.00 (m, 1H), 3.88 (d, J = 11.7 Hz, 1H), 3.50 (s, 3H), 2.99-2.93 (m, 3H), 2.83 (dd, J = 12.6, 10.2 Hz, 1H), 2.61 (s, 3H), 2.48-2.39 (m, 2H), 1.92-0.76 (m, 22H).
I-7a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate	3.1		539	0.88 (m, 1H), 2.14 (m, 1H), 2.69 (s, 3H), 3.58 (s, 3H), 3.96 (m, 1H), 4.14 (m, 1H), 4.38 (m, 1H), 7.13 (m, 2H), 7.46 (m, 1H)
I-7b	methyl (R)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate	3.1		539	0.88 (m, 1H), 2.18 (m, 1H), 2.69 (s, 3H), 3.58 (s, 3H), 3.86 (d, 1H), 4.16 (m, 1H), 4.95 (d, 1H), 7.12 (m, 2H), 7.35 (m, 1H)

I-8a	methyl (S)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(3,5-difluorophenyl)-4-hydroxybutylcarbamate	3.1		539	0.92 (m, 2H), 2.54 (m, 2H), 2.70 (s, 3H), 2.92 (m, 1H), 3.60 (s, 3H), 3.94 (d, 1H), 4.14 (m, 1H), 4.28 (d, 1H), 6.80 (m, 1H), 6.99 (m, 2H)
I-9a	methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate	4	1.41	541	2.18 (m, 1H), 2.67 (m, 2H), 3.55 (s, 3H), 3.87 (d, 1H), 4.39 (d, 1H), 7.11 (m, 1H), 7.36 (m, 1H), 7.51 (m, 1H)
I-10a	methyl (4S)-4-((3R)-1-((2S)-2-amino-3-(tetrahydro-2H-pyran-2-yl)propylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate	4.1	1.36	543	7.51 (m), 7.36 (m), 7.13 (m), 6.81 (br s), 4.39 (d), 3.97 (br m), 3.85 (br m), 3.25 (ap d), 2.68 (br m)
I-11a	ethyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	3.1	1.48	551, 553	7.35-7.34 (m, 1H), 7.24-7.12 (m, 3H), 4.20 (d, J = 13.2 Hz, 1H), 4.08-4.01 (m, 1H), 3.94 (q, J = 7.1 Hz, 2H), 3.88 (d, J = 14.4 Hz, 1H), 2.99-2.92 (m, 3H), 2.84 (dd, J = 12.6, 10 Hz, 1H), 2.61 (s, 3H), 2.49-2.39 (m, 2H), 1.11 (t, J = 7.0 Hz, 3H), 1.92-0.76 (m, 22H).
I-12a	methyl (S)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-(2,3-difluorophenyl)-4-hydroxybutylcarbamate	3.1		555	1.98 (m, 2H), 2.16 (m, 1H), 2.66 (m, 1H), 2.73 (s, 3H), 3.05 (m, 3H), 3.46 (m, 1H), 3.64 (s, 3H), 3.96 (m, 1H), 4.13 (m, 1H), 4.42 (m, 1H), 7.15 (m, 2H), 7.36 (m, 1H)

I-13a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	3.1		555	2.16 (m, 1H), 2.71 (s, 3H), 3.59 (s, 3H), 3.98 (d, 1H), 4.16 (m, 1H), 4.34 (d, 1H), 7.14 (m, 1H), 7.37 (m, 1H), 7.53 (m, 1H)
I-14a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	3.1		555	0.92 (m, 1H), 2.48 (m, 1H), 2.70 (s, 3H), 3.58 (s, 3H), 3.98 (d, 1H), 4.14 (m, 1H), 4.42 (d, 1H), 7.14 (m, 1H), 7.31 (m, 1H), 7.60 (m, 1H)
I-15a	methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	2.1		555	0.88 (m, 1H), 1.03 (m, 1H), 2.54 (m, 2H), 2.70 (s, 3H), 2.94 (m, 1H), 3.05 (m, 3H), 3.60 (s, 3H), 3.96 (d, 1H), 4.13 (m, 1H), 4.28 (d, 1H), 7.08 (m, 2H), 7.23 (m, 1H)
I-16a	methyl (S)-4-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2-fluorophenyl)-4-hydroxybutylcarbamate	3.1			
I-17a	methyl (S)-4-(2,3-difluorophenyl)-4-((R)-1-((S)-1-((1r,4S)-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	2.2		557	1.78 (m, 1H), 2.72 (s, 3H), 3.58 (s, 3H), 3.90 (m, 1H), 4.13 (m, 1H), 4.42 (m, 2H), 7.13 (m, 2H), 7.35 (m, 1H)
I-18a	methyl (4S)-4-(3-chloro-2-fluorophenyl)-4-hydroxy-4-((3R)-1-(1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate	5.1	1.27	557, 559	2.70 (s, 3H), 3.58 (s, 3H), 7.15 (m, 1H), 7.38 (m, 1H), 7.53 (m, 1H)

I-19a	methyl (S)-4-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)-4-(3-chloro-2,4-difluorophenyl)-4-hydroxybutylcarbamate	4.1	1.48	559	2.18 (m, 1H), 2.65 (m, 2H), 3.56 (s, 3H), 3.87 (d, 1H), 4.39 (d, 1H), 7.09 (m, 1H), 7.56 (m, 1H)
I-20a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	2.1		571	2.15 (m, 1H), 2.64 (m, 1H), 2.72 (s, 3H), 3.04 (m, 3H), 3.44 (m, 1H), 3.58 (s, 3H), 3.96 (d, 1H), 4.12 (m, 1H), 4.32 (d, 1H), 7.15 (m, 1H), 7.37 (m, 1H), 7.54 (m, 1H)
I-21a	methyl (S)-4-(2-chloro-3-fluorophenyl)-4-((R)-1-((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	2		571	2.48 (m, 1H), 2.64 (m, 2H), 2.72 (s, 3H), 3.05 (m, 3H), 3.43 (m, 1H), 3.58 (s, 3H), 3.96 (d, 1H), 4.12 (m, 1H), 4.34 (d, 1H), 7.15 (m, 1H), 7.28 (m, 1H), 7.58 (m, 1H)
I-22a	methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-((1r,4S)-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	2.2		573	1.79 (m, 1H), 2.65 (m, 1H), 2.70 (s, 3H), 2.82 (m, 1H), 3.59 (s, 3H), 3.97 (m, 1H), 4.14 (m, 1H), 4.35 (m, 1H), 4.46 (m, 1H), 7.12 (m, 1H), 7.37 (m, 1H), 7.52 (m, 1H)
I-23a	methyl (S)-4-(3-chloro-2,4-difluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate	5	1.53	573	2.13 (m, 1H), 2.62 (m, 1H), 2.70 (s, 3H), 3.59 (s, 3H), 3.99 (d, 1H), 4.15 (m, 1H), 4.32 (d, 1H), 7.09 (m, 1H), 7.58 (m, 1H)

I-24a	methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate	7	1.4	578, 580	7.88 (s, 1H), 7.26-7.14 (m, 4H), 4.11 (d, J = 12.0 Hz, 1H), 4.04-3.97 (m, 1H), 3.78 (d, J = 12.3 Hz, 1H), 3.52 (s, 3H), 3.03-2.96 (m, 3H), 2.89 (dd, J = 12.6, 10.2 Hz, 1H), 2.62 (s, 3H), 1.98 (s, 3H), 2.39-0.73 (m, 24H).
I-25a	methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate	7.1	1.42	592, 594	7.78 (s, 1H), 7.31-7.18 (m, 4H), 4.13 (d, J = 13.2 Hz, 1H), 4.08-4.02 (m, 1H), 3.84 (d, J = 14.0 Hz, 1H), 3.56 (s, 3H), 3.07-2.89 (m, 4H), 2.67 (s, 3H), 2.31 (q, J = 7.5 Hz, 2H), 1.11 (t, J = 7.6 Hz, 3H), 2.43-0.74 (m, 24H).
I-25b	methyl (R)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate	7.1	1.41	592, 594	7.69 (s, 1H), 7.24-7.12 (m, 4H), 4.10-3.98 (m, 2H), 3.83 (d, J = 12.0 Hz, 1H), 3.50 (s, 3H), 3.07-2.81 (m, 4H), 2.60 (s, 3H), 2.21 (q, J = 7.6 Hz, 2H), 1.03 (t, J = 7.6 Hz, 3H), 2.37-0.75 (m, 24H).

I-26a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl carbamate	6.2	1.42	465, 467	7.29-7.16 (m, 4H), 5.32 (d, J = 8.5 Hz, 1H), 4.05-4.00 (m, 1H), 3.89 (d, J = 13.5 Hz, 1H), 3.62 (d, J = 13.2 Hz, 1H), 3.00-2.79 (m, 4H), 2.62 (s, 3H), 1.90-0.78 (m, 18H).
I-27a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl methylcarbamate	6.2	1.49	479, 481	7.28-7.14 (m, 4H), 5.32 (d, J = 7.9 Hz, 1H), 4.04-3.99 (m, 1H), 3.95 (d, J = 12.3 Hz, 1H), 3.69 (d, J = 13.5 Hz, 1H), 2.98-2.74 (m, 4H), 2.61 (s, 3H), 2.58 (s, 3H), 1.85-0.78 (m, 18H).
I-28a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate	6.2		493	0.90 (m, 2H), 1.07 (t, 3H), 2.70 (s, 3H), 3.77 (m, 1H), 4.05 (m, 2H), 5.40 (d, 1H), 7.25 (m, 1H), 7.33 (m, 3H)
I-28b	(S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl ethylcarbamate	6.2		493	0.91 (m, 2H), 1.08 (t, 3H), 2.70 (s, 3H), 3.08 (m, 3H), 3.78 (m, 1H), 4.05 (m, 2H), 5.40 (d, 1H), 7.25 (m, 1H), 7.33 (m, 3H)
I-29a	(R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate	6.2		521	0.89 (m, 4H), 2.70 (s, 3H), 2.90 (m, 3H), 3.05 (m, 3H), 3.79 (m, 1H), 4.06 (m, 2H), 5.39 (d, 1H), 7.32 (m, 1H), 7.33 (m, 3H)

I-29b	(S)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methyl butylcarbamate	6.2		521	0.92 (m, 5H), 2.70 (s, 3H), 2.89 (m, 3H), 3.79 (m, 1H), 4.04 (m, 2H), 5.39 (d, 1H), 7.21 (m, 1H), 7.33 (m, 3H)
I-30a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-4,4-dimethyl-1-(methylamino)pentan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1			
I-31a	methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	3		507	0.95 (m, 2H), 2.71 (s, 3H), 3.04 (m, 1H), 3.25 (m, 3H), 3.60 (s, 3H), 3.88 (m, 1H), 4.12 (m, 3H), 7.03 (m, 3H), 7.37 (m, 1H)
I-32a	methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	5.1			
I-34a	methyl 2-((1R)-((3R)-1-((2S)-1-amino-3-(tetrahydro-2H-pyran-2-yl)propan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	5.1			

I-35a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1		523	0.95 (m, 2H), 2.71 (s, 3H), 3.24 (m, 3H), 3.62 (s, 3H), 3.87 (m, 1H), 4.01 (m, 1H), 4.13 (m, 2H), 7.20 (m, 1H), 7.32 (m, 3H)
I-36a	methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	5.2			
I-37a	methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate	3.1		525	0.90 (m, 1H), 1.03 (m, 1H), 1.53 (m, 1H), 2.71 (s, 3H), 3.62 (s, 3H), 3.81 (m, 1H), 4.11 (m, 2H), 4.48 (m, 1H), 7.19 (m, 3H)
I-38a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1			
I-38b	methyl 2-((R)-(3-chlorophenyl)((R)-1-((R)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1			

I-39a	methyl 2-((R)-((R)-1-((S)-2-amino-3-cyclohexylpropylcarbamoyl)piperidin-3-yl)(3-chloro-2-fluorophenyl)methoxy)ethylcarbamate	4.1	1.53	527	2.97 (m, 12H), 3.61(s, 3H), 4.12 (d, 1H), 4.43 (d, 1H), 7.10(m, 1H), 7.35 (m, 1H), 7.42 (m, 1H)
I-41a	ethyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1		537	0.90 (m, 1H), 1.03 (m, 1H), 1.21 (t, 3H), 2.71 (s, 3H), 2.91 (m, 3H), 3.06 (m, 1H), 3.89 (m, 1H), 7.21 (m, 1H), 7.32 (m, 3H)
I-42a	methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate	5.1			
I-43a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1	1.59	541	7.42 (t), 7.35 (t), 7.20 (t), 4.46 (d), 4.07 (m), 4.45 (d), 4.07 (m), 3.79 (d), 3.61 (s), 3.25 (s), 3.02 (t), 2.91 (t), 2.62 (d), 2.42 (s).
I-43b	methyl 2-((3-chloro-2-fluorophenyl)(1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1	1.62	541	7.42 (t), 7.35 (m), 7.19 (t), 4.45 (d), 4.22 (d), 4.06 (br s), 3.75 (d), 3.60 (s), 3.24 (m), 2.88 (m), 2.61 (m), 2.40 (s).

I-44a	methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1		541	0.98 (m, 2H), 2.71 (s, 3H), 2.90 (m, 2H), 3.06 (m, 1H), 3.26 (m, 3H), 3.62 (s, 3H), 3.87 (m, 1H), 4.10 (m, 3H), 7.01 (m, 1H), 7.14 (m, 2H)
I-45a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1			
I-46a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1	1.55	540	7.32 (m, 3H), 7.20 ("d", 1H), 3.62 (s, 3H), 2.72 (s, 3H)
I-46b	methyl 2-((1R)-(3-chlorophenyl)((3R)-1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1		541	1.14 (m, 1H), 2.71 (s, 3H), 3.27 (m, 3H), 3.62 (s, 3H), 3.79 (m, 1H), 4.12 (d, 1H), 4.30 (m, 2H), 7.21 (m, 1H), 7.32 (m, 3H)

I-47a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1	1.32	543	7.45 (q), 7.35 (q), 7.23 (q), 4.47 (m), 4.13 (m), 3.94 (d), 3.82 (d), 3.64 (s), 3.27 (s), 3.08 (m), 2.96 (m), 2.73 (m)
I-47b	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((R)-1-(methylamino)-3-(tetrahydro-2H-pyran-4-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1	1.33	543	7.44 (q), 7.36 (q), 7.22, 4.48 (m), 4.33 (d), 4.17 (br m), 3.93 (m), 3.79 (m), 3.63 (s), 3.10 (m), 2.97 (m), 2.80 (m), 2.72 (d)
I-48a	methyl 2-((S)-(3-chloro-2-fluorophenyl)((R)-4-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)morpholin-2-yl)methoxy)ethylcarbamate	3.1			
I-49a	ethyl 2-((R)-(3-chloro-2-fluorophenyl)((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1		555	0.98 (m, 2H), 1.21 (t, 3H), 2.71 (s, 3H), 2.95 (m, 2H), 3.04 (m, 2H), 3.24 (m, 2H), 3.82 (m, 1H), 4.48 (m, 1H), 7.21 (m, 1H), 7.35 (m, 1H), 7.43 (m, 1H)

I-50a	methyl 2-((1R)-(3-chloro-2-fluorophenyl)((3R)-1-(1-(1-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1		559	2.64 (s, 3H), 3.53 (s, 3H), 3.69 (m, 1H), 4.23 (m, 2H), 4.48 (m, 1H),
I-51a	methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	3.1	1.41	559	7.42 (m), 7.33 (m), 7.21 (m), 4.46 (m), 4.35 (m), 4.16 (m), 3.82 (m), 3.62 (s), 3.05 (m), 2.91 (m), 2.70 (d)
I-52a	methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	5.1	1.65	561	7.31 (m, 3H), 7.19 ("d", 1H), 4.12 (m, 2H), 4.02 ("d", 1H), 3.87 ("d", 1H), 3.62 (s, 3H), 2.37 (s, 3H)
I-53a	2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl carbamate	6	1.49	509, 511	7.28-7.12 (m, 4H), 4.20 (d, J = 13.2 Hz, 1H), 4.11-3.99 (m, 3H), 3.95 (d, J = 8.8 Hz, 1H), 3.87 (d, J = 13.2 Hz, 1H), 3.40-3.28 (m, 2H), 2.96 (dd, J = 12.6, 3.2 Hz, 1H), 2.84 (dd, J = 12.6, 10.2 Hz, 1H), 2.73-2.63 (m, 2H), 2.61 (s, 3H), 1.71-0.75 (m, 18H).

I-54a	2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl methylcarbamate	6.1	1.48	523, 525	7.30-7.14 (m, 4H), 4.22 (d, J = 11.7 Hz, 1H), 4.09-4.00 (m, 3H), 3.98 (d, J = 8.5 Hz, 1H), 3.88 (d, J = 13.5 Hz, 1H), 3.43-3.33 (m, 2H), 2.99 (dd, J = 12.6, 3.2 Hz, 1H), 2.85 (dd, J = 12.6, 10.2 Hz, 1H), 2.75-2.66 (m, 2H), 2.634 (s, 3H), 2.628 (s, 3H), 1.73-0.79 (m, 18H).
I-55a	2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethyl ethylcarbamate	6.1	1.55	537, 539	7.29-7.13 (m, 4H), 4.21 (d, J = 12.9 Hz, 1H), 4.07-4.00 (m, 3H), 3.97 (d, J = 8.5 Hz, 1H), 3.86 (d, J = 13.5 Hz, 1H), 3.41-3.32 (m, 2H), 3.04 (q, J = 7.0 Hz, 2H), 2.98 (dd, J = 12.7, 2.8 Hz, 1H), 2.85 (dd, J = 12.0, 10.5 Hz, 1H), 2.74-2.65 (m, 2H), 2.62 (s, 3H), 1.03 (t, J = 7.0 Hz, 3H), 1.72-0.78 (m, 18H).
I-56a	(3R)-3-((R)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		493	0.95 (m, 2H), 2.70 (s, 3H), 2.78 (s, 3H), 2.96 (m, 2H), 3.05 (m, 2H), 3.70 (m, 3H), 4.12 (m, 3H), 7.26 (m, 1H), 7.37 (m, 3H)
I-56b	(3R)-3-((S)-(3-chlorophenyl)(2-(methylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		493	0.90 (m, 2H), 2.66 (s, 3H), 2.78 (s, 3H), 2.89 (m, 1H), 3.01 (m, 1H), 3.77 (m, 3H), 3.86 (m, 1H), 4.07 (m, 1H), 4.24 (m, 1H), 7.26 (m, 1H), 7.37 (m, 3H)

I-57a	(R)-3-((S)-(2-amino-2-oxoethoxy)(3-chloro-2-fluorophenyl)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		497	1.83 (m, 1H), 2.71 (s, 3H), 2.96 (m, 1H), 3.06 (m, 1H), 3.21 (m, 1H), 4.12 (m, 2H), 4.58 (d, 2H), 7.25 (m, 1H), 7.48 (m, 1H), 7.50 (m, 1H)
I-58a	(3R)-3-((R)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1		507	1.12 (t, 3H), 2.70 (s, 3H), 2.95 (m, 2H), 3.06 (m, 2H), 3.75 (m, 3H), 4.15 (m, 3H), 7.25 (m, 1H), 7.38 (m, 3H)
I-58b	(3R)-3-((S)-(3-chlorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		507	1.11 (t, 3H), 2.66 (s, 3H), 3.00 (m, 1H), 3.76 (m, 3H), 3.88 (m, 1H), 4.06 (m, 1H), 4.24 (m, 1H), 7.27 (m, 1H), 7.37 (m, 3H)
I-59a	(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide	1.1		509	0.92 (m, 2H), 1.07 (t, 3H), 1.92 (m, 1H), 2.65 (s, 3H), 3.19 (m, 3H), 3.68 (m, 3H), 4.08 (m, 2H), 4.50 (m, 1H), 7.18 (m, 3H)
I-60a	(R)-3-((R)-(3-chlorophenyl)(2-oxo-2-(propylamino)ethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		521	2.71 (t, 3H), 2.71 (s, 3H), 2.94 (m, 2H), 3.06 (m, 2H), 3.17 (m, 2H), 7.23 (m, 1H), 7.36 (m, 3H)

I-61a	(R)-3-((R)-(3-chlorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1			
I-62a	(3R)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-oxo-2-(propylamino)ethoxy) methyl)piperidine-1-carboxamide	1.1		523	0.92 (m, 3H), 1.52 (m, 3H), 2.00 (m, 1H), 2.71 (s, 3H), 3.01 (m, 3H), 3.19 (m, 3H0, 3.76 (m, 3H), 4.15 (m, 2H), 4.55 (m, 1H), 7.24 (m, 3H)
I-63a	(R)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)-3-((R)-(2,3-difluorophenyl)(2-(isopropylamino)-2-oxoethoxy)methyl)piperidine-1-carboxamide	1.1		523	0.97 (m, 2H), 1.13 (m, 6H), 2.70 (s, 3H), 3.98 (m, 1H), 4.15 (m, 2H), 4.52 (d, 1H), 7.20 (m, 3H)
I-64a	(3R)-3-((R)-(3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	5.1		525	7.47 (m), 7.37 (m), 7.23 (m), 7.55 (m), 4.11 (m), 3.75 (m), 3.24 (m), 3.05 (m), 2.92 (s), 2.70 (s)
I-64b	(3R)-3-((3-chloro-2-fluorophenyl)(2-(ethylamino)-2-oxoethoxy)methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	5.1		525	7.47 (m), 7.37 (m), 7.23 (m), 7.55 (m), 4.11 (m), 3.75 (m), 3.24 (m), 3.05 (m), 2.92 (s), 2.70 (s)

I-65a	(R)-3-((R)-(3-chlorophenyl)(2-(2-methoxyethylamino)-2-oxoethoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		537	0.95 (m, 2H), 2.71 (s, 3H), 2.93 (m, 2H), 3.05 (m, 2H), 3.36 (s, 3H), 3.40 (m, 2H), 3.45 (m, 2H), 4.15 (m, 3H), 7.24 (m, 1H), 7.36 (m, 3H)
I-66a	(3R)-3-((R)-(3-chlorophenyl)(3-(methylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		507	0.89 (m, 1H), 0.98 (m, 1H), 2.40 (m, 2H), 2.52 (s, 3H), 2.72 (s, 3H), 3.50 (m, 2H), 3.84 (m, 1H), 4.10 (m, 3H), 4.20 (m, 1H), 7.32 (m, 3H)
I-67a	(3R)-3-((R)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		521	0.89 (m, 1H), 0.96 (m, 1H), 1.11 (m, 3H), 2.40 (m, 2H), 2.70 (s, 3H), 2.85 (m, 2H), 3.00 (m, 2H), 3.20 (m, 2H), 3.50 (m, 2H), 3.83 (m, 1H), 4.05 (m, 1H), 4.16 (m, 2H), 7.20 (m, 1H), 7.31 (m, 3H)
I-67b	(3R)-3-((S)-(3-chlorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		521	0.86 (m, 1H), 0.94 (m, 1H), 1.12 (m, 5H), 1.72 (m, 7H), 1.89 (m, 1H), 2.39 (m, 2H), 2.66 (s, 3H), 2.87 (m, 1H), 3.02 (m, 1H), 3.20 (m, 2H), 3.53 (m, 2H), 3.70 (m, 1H), 3.90 (m, 1H), 4.07 (m, 1H), 4.16 (m, 2H), 7.20 (m, 1H), 7.30 (m, 3H)
I-68a	(3R)-3-((R)-(3-chlorophenyl)(3-oxo-3-(propylamino)propoxy) methyl)-N-((2S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		535	0.93 (t, 3H), 1.51 (m, 3H), 2.41 (m, 2H), 2.70 (s, 3H), 3.14 (m, 2H), 3.51 (m, 2H), 3.82 (m, 1H), 4.05 (m, 1H), 4.14 (m, 2H), 7.19 (m, 1H), 7.31 (m, 3H)

I-69a	(R)-3-((R)-(3-chlorophenyl)(3-(isopropylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		535	1.13 (d, 6H), 2.38 (m, 2H), 3.78 (m, 3H), 3.80 (m, 2H), 4.10 (m, 4H), 7.20 (m, 1H), 7.32 (m, 3H)
I-70a	(R)-3-((R)-(3-chloro-2-fluorophenyl)(3-(ethylamino)-3-oxopropoxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		539	0.97 (m, 3H), 1.13 (t, 3H), 2.39 (m, 2H), 2.70 (s, 3H), 3.18 (m, 2H), 3.51 (m, 2H), 3.72 (m, 1H), 4.15 (m, 2H), 4.46 (d, 1H), 7.20 (m, 1H), 7.32 (m, 1H), 7.42 (m, 1H)
I-71a	(3R)-3-((S)-5-amino-1-(3-chlorophenyl)-1-hydroxy-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		507	0.99 (m, 2H), 2.18 (m, 2H), 2.55 (m, 2H), 2.71 (s, 3H), 2.96 (m, 1H), 3.06 (m, 2H), 4.07 (m, 1H), 4.25 (m, 2H), 7.27 (m, 3H), 7.44 (m, 1H)
I-72a	(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-5-(methylamino)-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		521	0.98 (m, 2H), 2.13 (m, 2H), 2.69 (s, 3H), 2.71 (s, 3H), 2.96 (m, 1H), 3.05 (m, 1H), 4.06 (m, 1H), 4.21 (m, 2H), 7.26 (m, 3H), 7.45 (m, 1H)
I-73a	(3R)-3-((S)-1-(3-chlorophenyl)-5-(ethylamino)-1-hydroxy-5-oxopentyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	1.1		535	0.89 (m, 2H), 1.08 (t, 3H), 2.12 (m, 2H), 2.60 (m, 2H), 2.70 (s, 3H), 2.96 (m, 1H), 3.06 (m, 1H), 3.16 (m, 2H), 4.08 (m, 1H), 4.24 (m, 2H), 7.26 (m, 3H), 7.43 (m, 1H)

I-74a	(R)-3-((S)-1-(3-chlorophenyl)-4-formamido-1-hydroxybutyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	5.1	1.32	507, 509	7.90 (s, 1H), 7.35-7.34 (m, 1H), 7.25-7.13 (m, 3H), 4.21 (d, J = 13.2 Hz, 1H), 4.08-4.01 (m, 1H), 3.88 (d, J = 12.9 Hz, 1H), 3.08 (t, J = 7.0 Hz, 2H), 2.98 (dd, J = 12.7, 3.4 Hz, 1H), 2.86 (dd, J = 12.6, 10 Hz, 1H), 2.62 (s, 3H), 2.50-2.42 (m, 2H), 1.93-0.76 (m, 22H).
I-75a	(R)-3-((R)-(3-chlorophenyl)(4-oxohexyloxy)methyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	3.1		520	0.89 (m, 1H), 1.00 (t, 3H), 2.48 (m, 4H), 2.70 (s, 3H), 2.92 (m, 1H), 3.06 (m, 1H), 3.23 (m, 2H), 3.96 (m, 2H), 4.10 (m, 1H), 4.21 (m 1H), 7.19 (m, 1H), 7.31 (m, 3H)
I-76a	(3R)-3-((S)-1-(3-chlorophenyl)-1-hydroxy-6-oxoheptyl)-N-((S)-1-cyclohexyl-3-(methylamino)propan-2-yl)piperidine-1-carboxamide	5.1	1.53	520, 522	7.34 (t, J = 1.76 Hz, 1H), 7.24-7.12 (m, 3H), 4.21 (d, J = 13.2 Hz, 1H), 4.08-4.01 (m, 1H), 3.88 (d, J = 12.6 Hz, 1H), 2.98 (dd, J = 12.7, 3.4 Hz, 1H), 2.87 (dd, J = 12.6, 10.0 Hz, 1H), 2.63 (s, 3H), 2.50-2.42 (m, 2H), 2.33 (t, J = 7.2 Hz, 2H), 1.99 (s, 3H), 1.94-0.77 (m, 24H).

The following are examples of aspartic protease inhibitors of the invention. When the stereochemistry at a chiral center is not defined in the compound name, this indicates that the sample prepared contained a mixture of isomers at this center.

Table of Compounds of Formula (XL)

Cpd. No.	Cpd Name	Example	LC-MS[a] (3min) t_R (min)	Mass Observed	Selected ^{1}H NMR[b]
XL-1	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate	11	1.29	511 (M^+)	7.36-7.32 (m, 3H), 7.23 (d, J = 7.6 Hz, 1H), 4.20 (br d, J = 13.6 Hz, 1H), 4.04 (d, J = 8.8 Hz, 1H), 3.89-3.78 (m, 3H), 3.64 (s, 3H), 3.48-3.42 (m, 2H), 3.37 (m, 1H), 3.28-3.24 (m, 5H), 3.15 (dd, J = 10.8, 9.2 Hz, 1 H), 2.92 (m, 2H), 1.97 (m, 1H), 1.78 (m, 2H), 1.68-1.54 (m, 4H), 1.45-1.07 (m, 5H)
XL-2	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate	11.1	1.22	495 (M+1)	7.39 (m, 1H), 7.12 (d, J = 7.6 Hz, 1H), 7.09-7.04 (m, 2H), 7.23 (d, J = 7.6 Hz, 1H), 4.21 (br d, J = 14.0 Hz, 1H), 4.07 (d, J = 8.8 Hz, 1H), 3.90-3.79 (m, 3H), 3.65 (s, 3H), 3.49-3.43 (m, 2H), 3.39-3.37 (m, 2H), 3.28-3.25 (m, 4H), 3.16 (dd, J = 10.8, 10.0 Hz, 1 H), 2.94 (m, 2H), 1.98 (m, 1H), 1.79 (m, 2H), 1.68-1.53 (m, 4H), 1.46-1.07 (m, 5H)

XL-3	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3-chloro-5-fluorophenyl)methoxy)ethylcarbamate	11.2	1.32	529 (M^+)	7.19 (s, 1H), 7.16 (m, 1H), 7.23 (d, J = 8.8 Hz, 1H), 4.19 (br d, J = 14.4 Hz, 1H), 4.07 (d, J = 8.8 Hz, 1H), 3.89-3.79 (m, 3H), 3.64 (s, 3H), 3.48-3.42 (m, 2H), 3.40-3.34 (m, 2H), 3.30-3.24 (m, 4H), 3.19 (dd, J = 11.2, 9.2 Hz, 1 H), 2.91 (m, 2H), 1.97 (m, 1H), 1.75 (m, 2H), 1.70-1.52 (m, 4H), 1.45-1.17 (m, 5H)
XL-4	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(3,5-difluorophenyl)methoxy)ethylcarbamate	11.3	1.25	513(M+1)	6.96-6.91 (m, 3H), 4.19 (br d, J = 13.6 Hz, 1H), 4.09 (d, J = 8.8 Hz, 1H), 3.89-3.79 (m, 3H), 3.65 (s, 3H), 3.49-3.43 (m, 2H), 3.39-3.37 (m, 2H), 3.30-3.25 (m, 4H), 3.16 (dd, J = 10.8, 10.0 Hz, 1 H), 2.92 (m, 2H), 1.97 (m, 1H), 1.77 (m, 2H), 1.68-1.53 (m, 4H), 1.45-1.09 (m, 5H)

XL-5	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(5-chloro-2-methylphenyl)methoxy)ethylcarbamate	11.4	1.34	525 (M^+)	7.32 (s, 1H), 7.21-7.15 (m, 2H), 4.34 (d, J = 8.8 Hz, 1H), 4.29 (br d, J = 14.4 Hz, 1H), 3.87 (m, 3H), 3.64 (s, 3H), 3.48-3.42 (m, 2H), 3.38-3.34 (m, 2H), 3.30-3.24 (m, 4H), 3.19 (dd, J = 10.8, 9.6 Hz, 1 H), 2.87 (m, 2H), 2.34 (s, 3H), 1.98 (m, 1H), 1.79 (m, 2H), 1.71-1.53 (m, 4H), 1.45-1.24 (m, 5H)
XL-6	methyl 2-((*R*)-((*R*)-1-((*S*)-2-amino-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)(5-fluoro-2-methylphenyl)methoxy)ethylcarbamate	11.5	1.28	509(M+1)	7.20 (dd, J = 6.8, 2.4 Hz, 1H), 7.14 (m, 1H), 6.97 (dd, J = 10.0, 8.4Hz, 1H), 4.41 (d, J = 8.8 Hz, 1H), 4.16 (br d, J = 12.4 Hz, 1H), 3.87 (m, 2H), 3.77 (br d, J = 12.8 Hz, 1 H), 3.45 (m, 2H), 3.35 (m, 1H), 3.48-3.42 (m, 2H), 3.38-3.34 (m, 2H), 3.29-3.26 (m, 4H), 3.16 (dd, J = 11.2, 9.6 Hz, 1 H), 3.00 (m, 2H), 2.34 (s, 3H), 1.97 (m, 1H), 1.86 (m, 1H), 1.71 (m, 1H), 1.66 (m, 3H), 1.56 (m, 1H), 1.45-1.21 (m, 5H)

XL-7	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	11.6	1.3	525 (M^+)	7.37-7.29 (m, 3H), 7.21 (d, J= 6.8 Hz, 1 H), 4.20 (br d, J = 12.4 Hz, 1 H), 4.02 (d, J = 9.2 Hz, 1H), 3.87-3.78 (m, 3H), 3.62 (s, 3H), 3.57 (d, J = 15.2 Hz, 1H), 3.44 (dd, J = 11.2, 3.6 Hz, 1H), 3.28-3.22 (m, 6H), 3.15 (td, J = 10.8, 9.6 Hz, 1 H), 2.89 (m, 2H), 2.75 (s, 3H), 1.97 (m, 1H), 1.77 (m, 2H), 1.65-1.17 (m, 9H)
XL-8	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-2-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	11.7	1.34	539 (M^+)	7.30 (d, J = 2.4 Hz, 1H), 7.19-7.13 (m, 2H), 4.33-4.27 (m, 2H), 3.87-3.84 (m, 3H), 3.62 (s, 3H), 3.57 (d, J = 13.2 Hz, 1H), 3.44 (td, J = 10.8, 3.2 Hz, 1H), 3.29-3.21 (m, 6H), 3.15 (dd, J = 11.2, 9.6 Hz, 1 H), 2.85 (m, 2H), 2.74 (s, 3H), 2.32 (s, 3H), 1.98 (m, 1H), 1.76 (m, 2H), 1.65-1.21 (m, 9H)

Table of Compounds of Formula (L)

Cpd. No.	Cpd Name	Example	LC-MS[a] (3min) t_R (min)	Mass Observed	Selected ^{1}H NMR[b]
L-1	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)(*m*-tolyl)methoxy)ethyl carbamate	13.1	1.942	505 (M+1)	7.21 (m, 1H), 7.11 (m, 3H), 4.12 (m, 2H), 3.87 (m, 4H), 3.61 (s, 3H), 3.41 (m, 1H), 2.95 (m, 3H), 2.72 (s, 3H), 2.34 (s, 3H)
L-2b	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	15			7.26 (q, 1), 7.01-6.83 (m, 3), 3.51 (s, 3), 2.61 (s, 3)
L-2a	methyl 2-((*R*)-(3-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	15			7.25 (q, 1), 7.01-6.89 (m, 3), 3.50 (s, 3), 2.59 (s, 3)

L-3a	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	14	1.34	543, 545 (M+1)	7.12 (m, 1H), 7.08-7.06 (m, 1H), 7.00-6.98 (m, 1H), 4.03-3.95 (m, 2H), 3.97 (d, J = 9.1 Hz, 1H), 3.83-3.74 (m, 3H), 3.55 (s, 3H), 3.36-2.82 (m, 10H), 2.63 (s, 3H), 1.80-1.11 (m, 12H).
L-3b	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate		1.34	543, 545 (M+1)	7.08 (m, 1H), 7.03-7.01 (m, 1H), 6.95-6.93 (m, 1H), 4.08-3.96 (m, 2H), 3.91 (d, J = 8.8 Hz, 1H), 3.82-3.73 (m, 3H), 3.49 (s, 3H), 3.32-2.67 (m, 10H), 2.59 (s, 3H), 1.81-1.02 (m, 12H).
L-4b	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	14.1	1.26	527 (M+1)	6.87-6.76 (m, 3H), 4.10-3.99 (m, 2H), 3.95 (d, J = 8.8 Hz, 1H), 3.84-3.75 (m, 3H), 3.52 (s, 3H), 3.35-2.17 (m, 10H), 2.62 (s, 3H), 1.84-1.05 (m, 12H).
L-4a	methyl 2-((*R*)-(3,5-difluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	14.2	1.29	527 (M+1)	6.87-6.76 (m, 3H), 4.02-3.98 (m, 2H), 3.96 (d, J = 9.1 Hz, 1H), 3.80-3.73 (m, 3H), 3.53 (s, 3H), 3.34-2.78 (m, 10H), 2.61 (s, 3H), 1.78-1.09 (m, 12H).

L-5b	methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	14.3	1.25	523 (M+1)	7.10-7.08 (m, 1H), 7.00-6.97 (m, 1H), 6.84-6.79 (m, 1H), 4.25 (d, J = 9.4 Hz, 1H), 4.04-3.97 (m, 2H), 3.79-3.72 (m, 3H), 3.48 (s, 3H), 3.31-2.72 (m, 10H), 2.59 (s, 3H), 2.19 (s, 3H), 1.81-1.05 (m, 12H).
L-5a	methyl 2-((*R*)-(5-fluoro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate	14.4	1.25	523 (M+1)	7.09-7.07 (m, 1H), 7.00-6.97 (m, 1H), 6.84-6.79 (m, 1H), 4.26 (d, J = 9.2 Hz, 1H), 3.98-3.95 (m, 2H), 3.77-3.66 (m, 3H), 3.49 (s, 3H), 3.31-2.77 (m, 10H), 2.58 (s, 3H), 2.19 (s, 3H), 1.75-1.07 (m, 12H).
L-6b	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*S*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	14.5	1.26	525, 527 (M+1)	7.18-7.04 (m, 4H), 4.04-3.93 (m, 2H), 3.83 (d, J = 9.1 Hz, 1H), 3.77-3.68 (m, 3H), 3.44 (s, 3H), 3.27-2.64 (m, 10H), 2.54 (s, 3H), 1.77-0.97 (m, 12H).
L-6a	methyl 2-((*R*)-(3-chlorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	13	1.26	525, 527 (M+1)	7.23-7.10 (m, 4H), 4.02-3.93 (m, 2H), 3.89 (d, J = 8.8 Hz, 1H), 3.78-3.70 (m, 3H), 3.50 (s, 3H), 3.31-2.76 (m, 10H), 2.59 (s, 3H), 1.76-1.02 (m, 12H).

L-3c	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)ethylcarbamate Isomer 1		1.33	543, 545 (M+1)	7.10-6.92 (m, 3H), 4.22 (dm, J = 11.1 Hz, 1H), 4.06-3.99 (m, 1H), 3.95 (d, J = 8.2 Hz, 1H), 3.76-3.67 (m, 3H), 3.52 (s, 3H), 3.32-2.76 (m, 10H), 2.61 (s, 3H), 1.86-1.03 (m, 12H).
L-3d	methyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*R*)-1-(methylamino)-3-(tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)ethylcarbamate Isomer 2		1.36	543, 545 (M+1)	7.10-6.93 (m, 3H), 4.23 (dm, J = 11.7 Hz, 1H), 3.99-3.93 (m, 1H), 3.95 (d, J = 8.8 Hz, 1H), 3.80-3.69 (m, 3H), 3.51 (s, 3H), 3.33-2.75 (m, 10H), 2.60 (s, 3H), 1.75-1.07 (m, 12H).
L-7	methyl 2-((*R*)-((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)-(phenyl)methoxy)-ethylcarbamate	16	1.25	491 (M+1)	
L-8	methyl 2-((*R*)-(3-chloro-4-fluorophenyl)((*R*)-1-((*S*)-1-12.2(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	13.2	1.903	543 (M+)	7.44 (m, 1H), 7.23 (m, 2H), 4.05 (m, 3H), 3.86 (m, 3H), 3.61 (s, 3H), 3.40 (m, 1H), 3.10 (m, 3H), 2.94 (m, 2H), 2.71 (s, 3H)

L-9	ethyl 2-((*R*)-(3-chloro-5-fluorophenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)ethylcarbamate	13.3	2.045	557 (M+)	7.20 (s, 1H), 7.14 (m, 1H), 7.07 (m, 1H), 4.08 (m, 5H), 3.87 (m, 3H), 3.10 (m, 3H), 2.90 (m, 2H), 2.71 (s, 3H), 1.23 (t, 3H)
L-10	methyl 2-((*R*)-(5-chloro-2-methylphenyl)((*R*)-1-((*S*)-1-(methylamino)-3-((*R*)-tetrahydro-2*H*-pyran-3-yl)propan-2-ylcarbamoyl)-piperidin-3-yl)methoxy)-ethylcarbamate	13.4	1.993	539 (M+)	7.31 (s, 1H), 7.13 (m, 2H), 4.31 (m, 1H), 4.23 (m, 1H), 3.61 (s, 3H), 3.12 (m, 1H), 2.86 (m, 2H), 2.67 (m, 2H), 2.45 (s, 3H), 2.31 (s, 3H).

For Tables containing compounds XL1-8 and X-1-10 notations "a" and "b" have the following meanings:

a. LC-MS (3 min) method

Column: Chromolith SpeedRod, RP-18e, 50 x 4.6 mm; Mobil phase: A: 0.01%TFA/water, B: 0.01%TFA/CH_3CN; Flow rate: 1 mL/min; Gradient:

Time (min)	A%	B%
0.0	90	10
2.0	10	90
2.4	10	90
2.5	90	10
3.0	90	10

b. d_4-MeOH was used as ^1H NMR solvent.

PHARMACOLOGICAL METHODS

IN VITRO ACTIVITY STUDIES

The disclosed aspartic protease inhibitors have enzyme-inhibiting properties. In particular, they inhibit the action of the natural enzyme renin. The latter passes from the kidneys into the blood where it effects the cleavage of angiotensinogen, releasing the decapeptide angiotensin I which is then cleaved in the blood, lungs, the kidneys and other organs by angiotensin converting enzyme to form the octapeptide angiotensin II. The octapeptide increases blood pressure both directly by binding to its receptor, causing arterial vasoconstriction, and indirectly by liberating from the adrenal glands the sodium-ion-retaining hormone aldosterone, accompanied by an increase in extracellular fluid volume. That increase can be attributed to the action of angiotensin II. Inhibitors of the enzymatic activity of renin bring about a reduction in the formation of angiotensin I. As a result a smaller amount of angiotensin II is produced. The reduced concentration of that active peptide hormone is the direct cause of the hypotensive effect of renin inhibitors.

Fluorescence Assay

The action of renin inhibitors *in vitro* can be demonstrated experimentally by means of a test which measures the increase in fluorescence of an internally quenched peptide substrate. The sequence of this peptide corresponds to the sequence of human angiotensinogen. The following test protocol can be used. All reactions are carried out in a flat bottom white opaque microtiter plate. A 4 μL aliquot of 400 μM renin substrate (DABCYL-γ-Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS) in 192 μL assay buffer (50 mM BES, 150 mM NaCl, 0.25 mg/mL bovine serum albumin, pH7.0) is added to 4 μL of test compound in DMSO at various concentrations ranging from 10 μM to 1 nM final concentrations. Next, 100 μL of trypsin-activated recombinant human renin (final enzyme concentration of 0.2-2 nM) in assay buffer is added, and the solution is mixed by pipetting. The increase in fluorescence at 495 nm (excitation at 340 nm) is measured for 60-360 minutes at rt using a Perkin-Elmer Fusion microplate reader. The slope of a linear portion of the plot of fluorescence-increase as a function of time is then determined, and the rate is used for calculating percent inhibition in relation to uninhibited control. The percent inhibition values are then plotted as a function of inhibitor concentration, and the IC_{50} is determined from a fit of

this data to a four parameter equation. The IC_{50} is defined as the concentration of a particular inhibitor that reduces the formation of product by 50% relative to a control sample containing no inhibitor. In the *in vitro* systems, the disclosed aspartic protease inhibitors exhibit inhibiting activities at minimum concentrations of from approximately 5 x 10^{-5} M to approximately 10^{-12} M. Specific aspartic protease inhibitors exhibit inhibiting activities at minimum concentrations of from approximately 10^{-7} M to approximately 10^{-12} M. (Wang G. T. et al. *Anal. Biochem.* **1993**, *210*, 351; Nakamura, N. et al. *J. Biochem. (Tokyo)* **1991**, *109*, 741; Murakami, K. et al. *Anal Biochem.* **1981**, *110*, 232).

Plasma Assay

The action of renin inhibitors *in vitro* in human plasma can also be demonstrated experimentally by the decrease in plasma renin activity (PRA) levels observed in the presence of the compounds. Incubations mixtures contain in the final volume of 250 μL 95.5 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, pH 7.0, 8 mM EDTA, 0.1 mM neomycin sulfate, 1 mg/mL sodium azide, 1 mM phenylmethanesulfonyl fluoride, 2% DMSO and 87.3% of pooled mixed-gender human plasma stabilized with EDTA. For plasma batches with low PRA (less than 1 ng/ml/hr) ~2 pM of recombinant human renin is added to achieve PRA of 3-4 ng/ml/hr. The cleavage of endogenous angiotensinogen in plasma is carried out at 37°C for 90 min and the product angiotensin I is measured by competitive radioimmunoassay using DiaSorin PRA kit. Uninhibited incubations containing 2% DMSO and fully inhibited controls with 2 μM of isovaleryl-Phe-Nle-Sta-Ala-Sta-OH are then used for deriving percent of inhibition for each concentration of inhibitors and fitting dose-response data into a four parametric model from which IC_{50} values, defined as concentrations of inhibitors at which 50% inhibition occurs, are determined.

RESULTS

The *in vitro* enzyme activity studies were carried out for compounds of the invention and the data is shown below:

Compounds **I-1a through I-76a** have an IC_{50} for renin (fluorescence assay) of between about 5,000 nM to about 0.001 nM. Many of these compounds have an IC_{50} between about 50 nM to about 0.001 nM; and others between about 5 nM to about 0.001 nM.

Cpd No.	IC_{50}
I*-1a	#
I*-2a	***
I*-3a	*
I*-4a	****
I*-5a	***
I*-6a	#
I*-7a	***
I*-8a	***
I*-9a	****
I*-10a	***
I*-11a	*
I*-12a	#
I*-13a	**
I*-14a	#
I*-15a	#
I*-16a	#
I*-17a	#
I*-18a	****
I*-19a	***
I*-20a	*
I*-21a	***
I*-22a	#
I*-23a	***
I*-24a	****
I*-25a	#

I*-26a	*
I*-27a	***
I*-28a	***
I*-29a	****
I*-30a	**
I*-31a	#
I*-32a	***
I*-33a	#
I*-34a	***
I*-35a	**
I*-36a	*
I*-37a	**
I*-38a	*
I*-39a	****
I*-40a	****
I*-41a	***
I*-42a	#
I*-43a	***
I*-44a	***
I*-45a	*
I*-46a	#
I*-47a	***
I*-48a	***
I*-49a	#
I*-50a	***
I*-51a	#
I*-52a	***
I*-53a	**
I*-54a	*
I*-55a	****
I*-56a	***

I*-57a	***
I*-58a	***
I*-59a	***
I*-60a	****
I*-61a	***
I*-62a	NA
I*-63a	****
I*-64a	****
I*-65a	***
I*-66a	***
I*-67a	***
I*-68a	****
I*-69a	*
I*-70a	**
I*-71a	**
I*-72a	***
I*-73a	***
I*-74a	**
I*-75a	#
I*-76a	#
I*-77a	#
I*-78a	#
I*-79a	***
I*-80a	***
I*-81a	NA
I*-82a	****
I*-83a	****
I*-84a	****
I*-85a	****
I*-86a	****
I*-87a	*

I*-88a	****
I*-89a	#
I*-90a	****
I*-91a	***
I*-92a	#
I*-93a	#
I*-94a	#
I*-95a	***
I*-96a	***
I*-97a	**
I*-98a	***
I*-99a	***
I*-100a	****
I*-101a	***
I*-102a	*
I*-103a	**
I*-104a	**
I*-105a	***
I*-106a	****
I*-107a	***
I*-108a	*
I*-109a	****
I*-110a	****
I*-111a	****
I*-112a	****
I*-113a	***
I*-114a	***
I*-115a	***
I*-116a	***
I*-117a	****
I*-118a	****

I*-119a	***
I*-120a	****
I*-121a	**
I*-122a	***
I*-123a	***
I*-124a	**
I*-125a	***
I*-126a	#
I*-127a	**
I*-128a	#
I*-129a	#
I*-130a	**
I*-131a	#
I*-132a	#
I*-133a	****
I*-134a	#
I*-135a	***
I*-136a	***
I*-137a	***
I*-138a	***
I*-139a	***
I*-140a	****
I*-141a	****
I*-142a	***
I*-143a	****
I*-144a	#
I*-145a	***
I*-146a	****
I*-147a	****
I*-148a	#
I*-149a	***

I*-150a	*
I*-151a	****
I*-152a	***
I*-153a	****
I*-154a	**
I*-155a	***
I*-156a	**
I*-157a	***
I*-158a	***
I*-159a	***
I*-160a	****

*represents less than 50 nM; ** represents less than 20 nM; *** represents less than 10 nM; **** represents less than 1 nM.; # represents greater than 50 nM; NA=Not Available

5

In vitro IC_{50} and PRA data for aspartic protease inhibitors of Formula (XL)

Cpd No.	IC_{50}	PRA
XL-1	***	***
XL-2	***	**
XL-3	***	***
XL-4	***	***
XL-5	****	****
XL-6	***	*
XL-7	****	***
XL-8	****	***

* represents less than 50 nM; ** represents less than 20 nM; *** represents less than 10 nM; **** represents less than 1 nM.

The *in vitro* enzyme activity studies were carried out for compounds **L-1, L-2a, L-2b, L-3a, L-3b, L-3c, L-3d, L-4a,L- 4b, L-5a, L-5b, L-6a, L-6b, L-7, L-8, L-9 and L-10** and the data is shown in the table below.

In vitro IC_{50} and PRA data for aspartic protease inhibitors of Formula (L)

Cpd No.	IC_{50}	PRA
1	***	***
2a	***	***
2b	***	**
3a	****	****
3b	***	***
3c	***	***
3d	**	**
4a	***	***
4b	***	*
5a	***	***
5b	**	*
6a	****	****
6b	***	***
7	**	*
8	***	***
9	***	*
10	***	****

* represents less than 50 nM; ** represents less than 20 nM; *** represents less than 10 nM; **** represents less than 1 nM.

IN VIVO ACTIVITY STUDIES

The cardiac and systemic hemodynamic efficacy of selective renin inhibitors can be evaluated *in vivo* in sodium-depleted, normotensive cynomolgus monkeys and in sodium-depleted, normotensive beagle dogs following a single oral and intravenous

administration of the test compound. Arterial blood pressure is monitored by telemetry in freely moving, conscious animals.

Cynomolgus Monkey: Six male naïve cynomolgus monkeys weighing between 2.5 and 3.5 kg can be used in the studies. At least 4 weeks before the experiment, the monkeys are anesthetized with ketamine hydrochloride (15 mg/kg, i.m.) and xylazine hydrochloride (0.7 mg/kg, i.m.), and are implanted into the abdominal cavity with a transmitter (Model #TL11M2-D70-PCT, Data Sciences, St. Paul, MN). The pressure catheter is inserted into the lower abdominal aorta *via* the femoral artery. The bipotential leads are placed in Lead II configuration. The animals are housed under constant temperature (19-25°C), humidity (>40%) and lighting conditions (12 h light and dark cycle), are fed once daily, and are allowed free access to water. The animals are sodium depleted by placing them on a low sodium diet (0.026%, Expanded Primate Diet 829552 MP-VENaCl (P), Special Diet Services, Ltd., UK) 7 days before the experiment and furosemide (3 mg/kg, intramuscularly i.m., Aventis Pharmaceuticals) is administered at -40 h and -16 h prior to administration of test compound.

For oral dosing, the renin inhibitors are formulated in 0.5% methylcellulose at dose levels of 10 and 30 mg/kg (5 mL/kg) by infant feeding tubes. For intravenous delivery, a silastic catheter is implanted into posterior vena cava *via* a femoral vein. The catheter is attached to the delivery pump *via* a tether system and a swivel joint. Test compound (dose levels of 0.1 to 10 mg/kg, formulated at 5% dextrose) is administered by continuous infusion (1.67 mL/kg/h) or by bolus injection (3.33 mL/kg in 2 min).

Arterial blood pressures (systolic, diastolic and mean) and body temperature are recorded continuously at 500 Hz and 50 Hz, respectively, using the Dataquest™ A.R.T. (Advanced Research Technology) software. Heart rate is derived from the phasic blood pressure tracing. During the recording period, the monkeys are kept in a separate room without human presence to avoid pressure changes secondary to stress. All data are expressed as mean ± SEM. Effects of the renin inhibitors on blood pressure are assessed by ANOVA, taking into account the factors dose and time compared with the vehicle group.

Beagle Dogs: Non-naive Beagle dogs (2 per sex) weighing between 9 and 11 kg can be used in the studies. Each animal is implanted subcutaneously with a telemetry transmitter (Data Sciences) and the blood pressure catheter is inserted into the left femoral artery. The electrocardiogram leads are also tunneled subcutaneously to the appropriate anatomical regions. The animals are housed under constant temperature and lighting conditions, are fed once daily, and are allowed free access to water. A sodium depleted state is produced by placing them on a low-sodium diet (<4 meq/day, a combination of canned Prescription Diet canine h/d, from Hill's Pet Products and dry pellets from Bio-Serv Inc., Frenchtown, NJ) beginning 10 days before the experiment, and furosemide (3 mg/kg i.m.; Aventis Pharmaceuticals) is administered at -40 and -16 h prior to administration of test compound.

A renin inhibitor is orally administered by orogastric gavage to all overnight fasted animals at a dose level of 30 mg/kg (4 mL/kg formulated in 0.5% methylcellulose). Food is given 4 h postdose. In some experiments, the renin inhibitor is administered by bolus *i.v.* at increasing dose levels of 1, 3 and 6 mg/kg (2, 6 and 20 mg/mL formulated in sterile saline). Cardiovascular parameters are collected continuously at least 80 min predose and 3 h postdose, followed by every 10 min for 5 h and every 30 min for 16 h postdose. The Dataquest™ ART (version 2.2) software package from DSI (Data Sciences International) is used to collect telemetered cardiovascular data.

Double Transgenic Rats: The efficacy of the renin inhibitors can also evaluated *in vivo* in double transgenic rats engineered to express human renin and human angiotensinogen (Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC, Ganten D. High human renin hypertension in transgenic rats. *Hypertension* **1997**, *29*, 428–434). *In vivo* activity for compound **7** was conducted according to the following procedures.

Experiments were conducted in 6-week-old double transgenic rats (dTGRs). The model has been described in detail earlier. Briefly, the human renin construct used to generate transgenic animals made up the entire genomic human renin gene (10 exons and 9 introns), with 3.0 kB of the 5'-promoter region and 1.2 kB of 3' additional sequences. The human angiotensinogen construct made up the entire human angiotensinogen gene (5 exons and 4 introns), with 1.3 kB of 5'-flanking and 2.4 kB of

3'-flanking sequences. The rats were purchased from RCC Ltd (Füllinsdorf, Switzerland). Radio telemetry transmitters were surgically implanted at 4 weeks of age. The telemetry system provided 24-h recordings of systolic, mean, diastolic arterial pressure (SAP, MAP, DAP, respectively) and heart rate (HR). Beginning on day 42, animals were transferred to telemetry cages. A 24 h telemetry reading was obtained. Rats were then dosed orally on the following 4 consecutive days (days 43-46). The rats were monitored continuously and allowed free access to standard 0.3%-sodium rat chow and drinking water.

RESULTS

The *in vivo* double transgenic rat activity for compound XL-7 is shown in the Figure 1. As shown in the Figure 1, compound XL-7 exhibited significant effect in lowering blood pressures of double transgenic rats at a dosage of 10 mg/kg.

The *in vivo* double transgenic rat activities for compound L-**6a** are shown in Figures 2 and 3. As shown in Figure 2, compound L-**6a** is readily available in rat's plasma following oral administration and the plasma concentration of compound L-**6a** remains relatively high over 24 h period, demonstrating its excellent oral bioavailability and metabolic stability. In addition, compound L-**6a** exhibited significant effect in lowering blood pressures of double transgenic rats at a dosage of 10 mg/kg, as shown in Figure 3.

CLAIMS

What is claimed is:

1. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

Z is –O- or -CH_2-

X_1 is a covalent bond, -O-, -S-, -S(O)-, -$S(O)_2$-;

Y_1 is a covalent bond or C_1-C_{10} alkylene, C_1-C_{10} alkenylene or C_1-C_{10} alkynylene, each optionally substituted at one or moresubstitutable carbon atoms with halogen, cyano, hydroxyl, (C_1-C_3)alkyl, (C_1-C_3)alkoxy or halo(C_1-C_3)alkoxy, provided that Y_1 is a covalent bond only when X_1 is a covalent bond;

R^1 is a) (C_3-C_7) cycloalkyl; or b) phenyl, heteroaryl, or bicyclic heteroaryl optionally substituted with 1 to 3 groups independently selected from: 1) fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl;

R^2 is –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), –SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)SR^9, -NHC(S)OR^9, -NHC(O)SR^9, -C(O)R^9, -C(S)R^9, -C(O)(NH_2), -C(S)(NH_2), -C(O)(NHR^9), -C(S)(NHR^9) or -NHC(O)H, wherein R^9 is a straight

or branched C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl, (C_3-C_4)cycloalkyl or straight or branched C_1-C_5 alkoxyalkyl;

R^3 is –H, -F, C_1-C_5 alkyl, -NHC(O)R^{10}, -OH or –OR^{10}, wherein R^{10} is C_1-C_3 alkyl, provided that when R^3 is –F or –OH, then X_1 is not -O-, -S-, -S(O)-, -$S(O)_2$- and R^1-Y_1-X_1 is not –OC(O)(NH_2), –OC(S)(NH_2), –SC(S)(NH_2), -SC(O)(NH_2), -OC(O)(NHR^9), -OC(S)(NHR^9), -SC(S)(NHR^9), -SC(O)(NHR^9), -NHC(O)OR^9, -NHC(S)OR^9, -NHC(S)SR^9, -NHC(O)SR^9 or -NHC(O)H;

Q is Q1, Q2, Q3, Q4, Q5, or Q6:



Q1 Q2 Q3 Q4 Q5 Q6

;

R^4 is H or (C_1-C_3)alkyl;

R^5 and R^6 are independently a) H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl; or b) phenyl(C_1-C_2)alkyl, phenoxymethyl or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy, provided that R^5 and R^6 are not both H;

G is OH, NH_2 or NHR^7;

R^7 is a) (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, (C_4-C_{10})cycloalkylalkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, or aminocarbonyl(C_1-C_6)alkyl or b) phenyl(C_1-C_2)alkyl optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy; or c) R^5 and R^7 together are –CH_2-, -$(CH_2)_2$-, -$(CH_2)_3$-, or –$(CH_2)_4$-, optionally substituted with 1 or 2 groups independently selected from fluorine,

$(C_1$-$C_8)$alkyl, halo$(C_1$-$C_8)$alkyl, $(C_3$-$C_6)$cycloalkyl, halo$(C_3$-$C_6)$cycloalkyl, hydroxy$(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl$(C_1$-$C_2)$alkyl, halo$(C_3$-$C_6)$cycloalkyl$(C_1$-$C_2)$alkyl, hydroxylated$(C_3$-$C_6)$cycloalkyl$(C_1$-$C_2)$alkyl, $(C_1$-$C_8)$alkoxy, halo$(C_1$-$C_8)$alkoxy, $(C_3$-$C_6)$cycloalkoxy, halo$(C_3$-$C_6)$cycloalkoxy, and heterocyclyl.

2. The compound of Claim 1 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

3. The compound of Claim 2 one of R^5 and R^6 is -H or methyl and the other is a) H, $(C_1$-$C_{10})$alkyl, $(C_4$-$C_{10})$cycloalkylalkyl, halo$(C_1$-$C_{10})$alkyl, hydroxy$(C_1$-$C_{10})$alkyl, halo$(C_4$-$C_{10})$cycloalkylalkyl, hydroxylated $(C_4$-$C_{10})$cycloalkylalkyl, $(C_1$-$C_2)$alkyl$(C_4$-$C_{10})$cycloalkylalkyl, halogenated $(C_1$-$C_2)$alkyl$(C_4$-$C_{10})$cycloalkylalkyl, di$(C_1$-$C_2)$alkyl$(C_4$-$C_{10})$cycloalkylalkyl, hydroxylated $(C_1$-$C_2)$alkyl$(C_4$-$C_{10})$cycloalkylalkyl, hydroxylated di$(C_1$-$C_2)$alkyl$(C_4$-$C_{10})$cycloalkylalkyl, $(C_4$-$C_{10})$bicycloalkyl$(C_1$-$C_3)$alkyl, $(C_8$-$C_{12})$tricycloalkyl$(C_1$-$C_3)$alkyl, $(C_1$-$C_5)$alkoxy$(C_1$-$C_5)$alkyl, halo$(C_1$-$C_5)$alkoxy$(C_1$-$C_5)$alkyl, $(C_1$-$C_5)$alkylthio$(C_1$-$C_5)$alkyl, halo$(C_1$-$C_5)$alkylthio$(C_1$-$C_5)$alkyl, or saturated heterocyclyl$(C_1$-$C_3)$alkyl; or b) phenyl$(C_1$-$C_2)$alkyl, phenoxymethyl or heteroaryl$(C_1$-$C_2)$alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, cyano, $(C_1$-$C_3)$alkyl, halo$(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$alkoxy, and halo$(C_1$-$C_3)$alkoxy.

4. The compound of Claim 3 wherein R^6 is -H or methyl.

5. The compound of Claim 3 wherein R^5 is -H or methyl.

6. The compound of Claim 2 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

7. The compound of Claim 6 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^{11} is fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-

C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl;

n is 0, 1, 2 or 3; and

m is 2 or 3.

8. The compound of Claim 7 wherein:

R^5 is (C_1-C_7)alkyl, halo(C_1-C_7)alkyl, hydroxy(C_1-C_7)alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, (C_1-C_2)alkyl cyclohexylmethyl, di(C_1-C_2)alkyl cyclohexylmethyl, hydroxylated (C_1-C_2)alkyl cyclohexylmethyl, hydroxylated di(C_1-C_2)alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3-$ optionally substituted with C_1-C_4 alkyl or cyclohexyl.

9. The compound of Claim 7 wherein:

R^6 is (C_1-C_7)alkyl, halo(C_1-C_7)alkyl, hydroxy(C_1-C_7)alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, (C_1-C_2)alkyl cyclohexylmethyl, di(C_1-C_2)alkyl cyclohexylmethyl, hydroxylated (C_1-C_2)alkyl cyclohexylmethyl, hydroxylated di(C_1-C_2)alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^5 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^6 and R^7 together are $-(CH_2)_3-$ optionally substituted with C_1-C_4 alkyl or cyclohexyl.

10. The compound of Claim 8 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

11. The compound of Claim 9 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

12. The compound of Claim 7 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^5 is $(C_1\text{-}C_7)$alkyl, halo$(C_1\text{-}C_7)$alkyl, hydroxy$(C_1\text{-}C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, di$(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1\text{-}C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3$- optionally substituted with $C_1\text{-}C_4$ alkyl or cyclohexyl.

13. The compound of Claim 12 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

14. The compound of Claim 13 wherein the compound is represented by a structural formula selected from:



;



; and



or a pharmaceutically acceptable salt thereof.

15. The compound of Claim 4 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

16. The compound of Claim 15 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^{11} is fluorine, chlorine, bromine, cyano, nitro, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_4\text{-}C_7)$cycloalkylalkyl, $(C_2\text{-}C_6)$alkenyl, $(C_5\text{-}C_7)$cycloalkylalkenyl, $(C_2\text{-}C_6)$alkynyl, $(C_3\text{-}C_6)$cycloalkyl$(C_2\text{-}C_4)$alkynyl, halo$(C_1\text{-}C_6)$alkyl, halo$(C_3\text{-}C_6)$cycloalkyl, halo$(C_4\text{-}C_7)$cycloalkylalkyl, halo$(C_2\text{-}C_6)$alkenyl, halo$(C_3\text{-}C_6)$alkynyl, halo$(C_5\text{-}C_7)$-cycloalkylalkynyl, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_6)$cycloalkoxy, $(C_4\text{-}C_7)$cycloalkylalkoxy, halo$(C_1\text{-}C_6)$alkoxy, halo$(C_3\text{-}C_6)$cycloalkoxy, halo$(C_4\text{-}C_7)$cycloalkylalkoxy and $(C_1\text{-}C_6)$alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, $(C_1\text{-}C_3)$alkyl, halo$(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$-alkoxy, and halo$(C_1\text{-}C_3)$alkoxy, and aminocarbonyl;

n is 0, 1, 2 or 3; and

m is 2 or 3.

17. The compound of Claim 16 wherein:

R^5 is $(C_1\text{-}C_7)$alkyl, halo$(C_1\text{-}C_7)$alkyl, hydroxy$(C_1\text{-}C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, di$(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1\text{-}C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3-$ optionally substituted with $C_1\text{-}C_4$ alkyl or cyclohexyl.

18. The compound of Claim 17 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

19. The compound of Claim 16 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^5 is $(C_1\text{-}C_7)$alkyl, halo$(C_1\text{-}C_7)$alkyl, hydroxy$(C_1\text{-}C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, di$(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated

di(C_1-C_2)alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3-$ optionally substituted with C_1-C_4 alkyl or cyclohexyl.

20. The compound of Claim 19 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

21. The compound of Claim 20 wherein the compound is represented by a structural formula selected from:



;



; and



or a pharmaceutically acceptable salt thereof.

22. The compound of Claim 4 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

23. The compound of Claim 22 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^{11} is fluorine, chlorine, bromine, cyano, nitro, $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_4$-$C_7)$cycloalkylalkyl, $(C_2$-$C_6)$alkenyl, $(C_5$-$C_7)$cycloalkylalkenyl, $(C_2$-$C_6)$alkynyl, $(C_3$-$C_6)$cycloalkyl$(C_2$-$C_4)$alkynyl, halo$(C_1$-$C_6)$alkyl, halo$(C_3$-$C_6)$cycloalkyl, halo$(C_4$-$C_7)$cycloalkylalkyl, halo$(C_2$-$C_6)$alkenyl, halo$(C_3$-$C_6)$alkynyl, halo$(C_5$-$C_7)$-cycloalkylalkynyl, $(C_1$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkoxy, $(C_4$-$C_7)$cycloalkylalkoxy, halo$(C_1$-$C_6)$alkoxy, halo$(C_3$-$C_6)$cycloalkoxy, halo$(C_4$-$C_7)$cycloalkylalkoxy and $(C_1$-$C_6)$alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, $(C_1$-$C_3)$alkyl, halo$(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$-alkoxy, and halo$(C_1$-$C_3)$alkoxy, and aminocarbonyl;

n is 0, 1, 2 or 3; and

m is 2, 3 or 4.

24. The compound of Claim 23 wherein:

R^5 is $(C_1$-$C_7)$alkyl, halo$(C_1$-$C_7)$alkyl, hydroxy$(C_1$-$C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1$-$C_2)$alkyl cyclohexylmethyl, di$(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1$-$C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3$- optionally substituted with C_1-C_4 alkyl or cyclohexyl.

25. The compound of Claim 24 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

26. The compound of Claim 23 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^5 is $(C_1\text{-}C_7)$alkyl, halo$(C_1\text{-}C_7)$alkyl, hydroxy$(C_1\text{-}C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, di$(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1\text{-}C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3$- optionally substituted with $C_1\text{-}C_4$ alkyl or cyclohexyl.

27. The compound of Claim 26 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

28. The compound of Claim 27 wherein the compound is represented by a structural formula selected from:



;



; and



or a pharmaceutically acceptable salt thereof.

29. The compound of Claim 4 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

30. The compound of Claim 29 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^{11} is fluorine, chlorine, bromine, cyano, nitro, $(C_1$-$C_6)$alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_4$-$C_7)$cycloalkylalkyl, $(C_2$-$C_6)$alkenyl, $(C_5$-$C_7)$cycloalkylalkenyl, $(C_2$-$C_6)$alkynyl, $(C_3$-$C_6)$cycloalkyl$(C_2$-$C_4)$alkynyl, halo$(C_1$-$C_6)$alkyl, halo$(C_3$-$C_6)$cycloalkyl, halo$(C_4$-$C_7)$cycloalkylalkyl, halo$(C_2$-$C_6)$alkenyl, halo$(C_3$-$C_6)$alkynyl, halo$(C_5$-$C_7)$-cycloalkylalkynyl, $(C_1$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkoxy, $(C_4$-$C_7)$cycloalkylalkoxy, halo$(C_1$-$C_6)$alkoxy, halo$(C_3$-$C_6)$cycloalkoxy, halo$(C_4$-$C_7)$cycloalkylalkoxy and $(C_1$-$C_6)$alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, $(C_1$-$C_3)$alkyl, halo$(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$-alkoxy, and halo$(C_1$-$C_3)$alkoxy, and aminocarbonyl;

n is 0, 1, 2 or 3; and

m is 2 or 3.

31. The compound of Claim 30 wherein:

R^5 is $(C_1$-$C_7)$alkyl, halo$(C_1$-$C_7)$alkyl, hydroxy$(C_1$-$C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1$-$C_2)$alkyl cyclohexylmethyl, di$(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1$-$C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1$-$C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3$- optionally substituted with C_1-C_4 alkyl or cyclohexyl.

32. The compound of Claim 31 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

33. The compound of Claim 30 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^5 is $(C_1$-$C_7)$alkyl, halo$(C_1$-$C_7)$alkyl, hydroxy$(C_1$-$C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-

(cyclohexyl)lethyl, (C_1-C_2)alkyl cyclohexylmethyl, di(C_1-C_2)alkyl cyclohexylmethyl, hydroxylated (C_1-C_2)alkyl cyclohexylmethyl, hydroxylated di(C_1-C_2)alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3-$ optionally substituted with C_1-C_4 alkyl or cyclohexyl.

34. The compound of Claim 33 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

35. The compound of Claim 34 wherein the compound is represented by a structural formula selected from:



;



; and



or a pharmaceutically acceptable salt thereof.

36. The compound of Claim 4 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

37. The compound of Claim 36 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^{11} is fluorine, chlorine, bromine, cyano, nitro, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; or 2) phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylemthoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl;

n is 0, 1, 2 or 3; and

m is 2, 3 or 4.

38. The compound of Claim 37 wherein:

R^5 is (C_1-C_7)alkyl, halo(C_1-C_7)alkyl, hydroxy(C_1-C_7)alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, (C_1-C_2)alkyl cyclohexylmethyl, di(C_1-C_2)alkyl cyclohexylmethyl, hydroxylated (C_1-C_2)alkyl cyclohexylmethyl, hydroxylated di(C_1-C_2)alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3-$ optionally substituted with C_1-C_4 alkyl or cyclohexyl.

39. The compound of Claim 38 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

40. The compound of Claim 37 wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

R^5 is $(C_1\text{-}C_7)$alkyl, halo$(C_1\text{-}C_7)$alkyl, hydroxy$(C_1\text{-}C_7)$alkyl, cyclohexylmethyl, halocyclohexylmethyl, hydroxylated cyclohexylmethyl, 2-(cyclohexyl)lethyl, $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, di$(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated $(C_1\text{-}C_2)$alkyl cyclohexylmethyl, hydroxylated di$(C_1\text{-}C_2)$alkylcyclohexylmethyl, (3-noradamantyl)methyl or (tetrahydropyranyl)methyl;

R^6 is –H or methyl;

G is NH_2 or NHR^7;

R^7 is methyl or R^5 and R^7 together are $-(CH_2)_3$- optionally substituted with $C_1\text{-}C_4$ alkyl or cyclohexyl.

41. The compound of Claim 40 wherein:

R^9 is methyl or ethyl; and

R^{11} is chloro, fluoro or methyl.

42. The compound of Claim 41 wherein the compound is represented by a structural formula selected from:



;



; and



or a pharmaceutically acceptable salt thereof.

43. Methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate; methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate; methyl (S)-4-(3-chloro-5-fluorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate ;

methyl (S)-4-(3-chloro-2-fluorophenyl)-4-((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-hydroxybutylcarbamate; methyl (S)-4-acetamido-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)butylcarbamate; methyl (S)-4-(3-chlorophenyl)-4-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)-4-propionamidobutylcarbamate; methyl 2-((R)-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(3-fluorophenyl)methoxy)ethylcarbamate; methyl 2-((R)-((R)-1-((S)-1-amino-3-cyclohexylpropan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate; methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate; methyl 2-((R)-((R)-1-((2S,3R)-3-amino-1-cyclohexylbutan-2-ylcarbamoyl)piperidin-3-yl)(3-chlorophenyl)methoxy)ethylcarbamate; methyl 2-((R)-((3R)-1-((2S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)(2,3-difluorophenyl)methoxy)ethylcarbamate; methyl 2-((R)-1-(3-chlorophenyl)-1-((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)ethoxy)ethylcarbamate; methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate; methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate; methyl 2-((R)-(3-chloro-5-fluorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate; methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate; methyl 2-((R)-(3-chloro-2-fluorophenyl)((R)-1-((S)-1-(trans-4-fluorocyclohexyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate; and methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(3-noradamantyl)-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate or a pharmaceutically acceptable salt of any of the foregoing.

44. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and the compound of any one of Claims 1-44 or a pharmaceutically acceptable salt thereof.

45. The pharmaceutical composition of Claim 44 further comprising a α-blocker, β-blocker, calcium channel blocker, diuretic, natriuretic, saluretic, centrally acting antiphypertensive, angiotensin converting enzyme (ACE) inhibitor, dual ACE and neutral endopeptidase (NEP) inhibitor, angiotensin-receptor blocker (ARB), aldosterone synthase inhibitor, aldosterone-receptor antagonist, or endothelin receptor antagonist.

46. A method of antagonizing one or more aspartic proteases in a subject in need thereof, comprising administering to the subject an effective amount of the compound of any of Claims 1-43 or a pharmaceutically acceptable salt thereof.

47. The method of Claim 46 wherein the aspartic protease is renin.

48. A method for treating an aspartic protease mediated disorder in a subject comprising administering to the subject an effective amount of the compound of any one of Claims 1-43 or a pharmaceutically acceptable salt thereof.

49. The method of Claim 48, wherein said disorder is hypertension, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy post-infarction, nephropathy, vasculopathy and neuropathy, a disease of the coronary vessels, post-surgical hypertension, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, an anxiety state, or a cognitive disorder.

50. The method of Claim 48 further comprising administering to the one or more additional agents selected from the group consisting of an α-blockers, a β-blocker, a calcium channel blocker, a diuretic, an angiotensin converting enzyme (ACE) inhibitor, a dual ACE and neutral endopeptidase (NEP) inhibitor, a angiotensin-receptor blocker (ARB), a aldosterone synthase inhibitor, a aldosterone-receptor antagonist, and an endothelin receptor antagonist.

51. The method of Claim 50 wherein the aspartic protease is β-secretase.

52. The method of Claim 50 wherein the aspartic protease is plasmepsin.

53. The method of Claim 50 wherein the aspartic protease is HIV protease.

54. A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein:

Z is –O- or $-(CH_2)_q-$, wherein q is 0-3;

X_1 is a covalent bond, -O-, -S-, -S(O)-, $-S(O)_2-$;

Y_1 is a covalent bond or C_1-C_{10} alkylene, C_1-C_{10} alkenylene or C_1-C_{10} alkynylene, each optionally substituted at one or more substitutable carbon atom with halogen, cyano, nitro, hydroxyl, (C_1-C_3)alkyl, (C_1-C_3)alkoxy or halo(C_1-C_3)alkoxy, provided that Y_1 is a covalent bond only when X_1 is a covalent bond;

R^1 is (C_3-C_7) cycloalkyl, phenyl, heteroaryl, or bicyclic heteroaryl each optionally substituted with 1 to 3 groups independently selected from:

fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-

C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy and (C_1-C_6)alkanesulfonyl; and phenyl, heteroaryl, phenoxy, heteroaryloxy, phenylthio, heteroarylthio, benzyl, heteroarylmethyl, benzyloxy and heteroarylmethoxy, each optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)-alkoxy, and halo(C_1-C_3)alkoxy, and aminocarbonyl;

R^2 is $-NHC(=NR_{12})(NH_2)$, $-NHC(=NR^{12})(NHR^9)$,  , $-OC(O)(NH_2)$, $-OC(S)(NH_2)$, $-SC(S)(NH_2)$, $-SC(O)(NH_2)$, $-OC(O)(NHR^9)$, $-OC(S)(NHR^9)$, $-SC(S)(NHR^9)$, $-SC(O)(NHR^9)$, $-NHC(O)OR^9$, $-NHC(S)SR^9$, $-NHC(S)OR^9$, $-NHC(O)SR^9$, $-C(O)R^9$, $-C(S)R^9$, $-C(O)(NH_2)$, $-C(S)(NH_2)$, $-C(O)(NHR^9)$, $-C(S)(NHR^9)$ or -NHC(O)H, wherein R^9 is a straight or branched C_1-C_5 alkyl, straight or branched C_1-C_5 haloalkyl, (C_3-C_4)cycloalkyl or straight or branched C_1-C_5 alkoxyalkyl and R^{12} is H, (C_1-C_6)alkyl, phenyl, heteroaryl, cyano, nitro, $-S(O)R^9$, $-S(O_2)R^9$, $-S(O_2)NHR^9$, $-S(O_2)NR^9R^9$, $-C(O)R^9$, $-C(S)R^9$, $-C(O)OR^9$, $-C(S)OR^9$, $-C(O)(NH_2)$, $-C(O)(NHR^9)$;

R^3 is –H, -F, C_1-C_5 alkyl, $-NHC(O)R^{10}$, -OH or $-OR^{10}$, wherein R^{10} is C_1-C_3 alkyl, provided that when R^3 is –F or –OH, then X_1 is not -O-, -S-, -S(O)-, $-S(O)_2$- and R^1-Y_1-X_1 is not $-OC(O)(NH_2)$, $-OC(S)(NH_2)$, $-SC(S)(NH_2)$, $-SC(O)(NH_2)$, $-OC(O)(NHR^9)$, $-OC(S)(NHR^9)$, $-SC(S)(NHR^9)$, $-SC(O)(NHR^9)$, $-NHC(O)OR^9$, $-NHC(S)OR^9$, $-NHC(S)SR^9$, $-NHC(O)SR^9$ or -NHC(O)H;

Q is Q1, Q2, Q3, Q4, Q5, or Q6:



;

R^4 is -H or (C_1-C_3)alkyl;

R^5 is a) H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-

C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl; or b) phenyl(C_1-C_2)alkyl, phenoxymethyl, or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl wherein s is 1 or 2;

R^6 is a) -H, (C_1-C_{10})alkyl, (C_4-C_{10})cycloalkylalkyl, halo(C_1-C_{10})alkyl, hydroxy(C_1-C_{10})alkyl, halo(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_4-C_{10})cycloalkylalkyl, (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, halogenated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated (C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, hydroxylated di(C_1-C_2)alkyl(C_4-C_{10})cycloalkylalkyl, (C_4-C_{10})bicycloalkyl(C_1-C_3)alkyl, (C_8-C_{12})tricycloalkyl(C_1-C_3)alkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, halo(C_1-C_5)alkoxy(C_1-C_5)alkyl, (C_1-C_5)alkylthio(C_1-C_5)alkyl, halo(C_1-C_5)alkylthio(C_1-C_5)alkyl, or saturated heterocyclyl(C_1-C_3)alkyl optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-

C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl;

or b) phenyl(C_1-C_2)alkyl, phenoxymethyl or heteroaryl(C_1-C_2)alkyl each optionally substituted with 1 to 3 groups independently selected from fluorine, chlorine, bromine, cyano, nitro, hydroxyl, (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl, (C_4-C_7)cycloalkylalkyl, (C_2-C_6)alkenyl, (C_5-C_7)cycloalkylalkenyl, (C_2-C_6)alkynyl, (C_3-C_6)cycloalkyl(C_2-C_4)alkynyl, halo(C_1-C_6)alkyl, halo(C_3-C_6)cycloalkyl, halo(C_4-C_7)cycloalkylalkyl, halo(C_2-C_6)alkenyl, halo(C_3-C_6)alkynyl, halo(C_5-C_7)-cycloalkylalkynyl, (C_1-C_6)alkoxy, (C_3-C_6)cycloalkoxy, (C_4-C_7)cycloalkylalkoxy, halo(C_1-C_6)alkoxy, halo(C_3-C_6)cycloalkoxy, halo(C_4-C_7)cycloalkylalkoxy, (C_1-C_6)alkanesulfonyl and aminocarbonyl provided that R^5 and R^6 are not both -H.;

G is OH, NH_2 or NHR^7; and

R^7 is a) (C_1-C_6)alkyl, halo(C_1-C_6)alkyl, (C_4-C_{10})cycloalkylalkyl, (C_1-C_5)alkoxy(C_1-C_5)alkyl, or aminocarbonyl(C_1-C_6)alkyl or b) phenyl(C_1-C_2)alkyl optionally substituted with 1 to 3 groups independently selected from: fluorine, chlorine, cyano, (C_1-C_3)alkyl, halo(C_1-C_3)alkyl, (C_1-C_3)alkoxy, and halo(C_1-C_3)alkoxy;

or c) R^5 and R^7 together are $-CH_2$-, -$(CH_2)_2$-, -$(CH_2)_3$-, or -$(CH_2)_4$-, optionally substituted with 1 or 2 groups independently selected from fluorine, (C_1-C_8)alkyl, halo(C_1-C_8)alkyl, (C_3-C_6)cycloalkyl, halo(C_3-C_6)cycloalkyl, hydroxy(C_3-C_6)cycloalkyl, (C_3-C_6)cycloalkyl(C_1-C_2)alkyl, halo(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, hydroxylated(C_3-C_6)cycloalkyl(C_1-C_2)alkyl, (C_1-C_8)alkoxy, halo(C_1-C_8)alkoxy, (C_3-C_6)cycloalkoxy, halo(C_3-C_6)cycloalkoxy, and heterocyclyl.


Vehicle (n=5)
Compound XL-7 at 10 mg/kg p.o. (n=5)
60.0
40.0
20.0
0.0
-20.0
-40.0
-60.0
mmHg
0
10
20
30
40
50
60
Time (hrs)

FIG. 1


Plasma Concentrations
10mg/kg p.o.
10
1
0.1
ng/mL
0
6
12
18
24
30
Time (Hours)
Compound L-6a
N=3

FIG. 2


Change in MAP
(10 mg/kg po)
50
25
0
-25
-50
-75
mmHg
0 6 12 18 24 30 36 42 48
Time (Hrs)
Vehicle
Compound L-6a

FIG. 3


Intensity (counts)
6000
5000
4000
3000
2000
1000
0
5
10
15
20
25
30
35
40
2Theta (°)

FIG. 4

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2006/043920

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D211/26 C07D211/22 C07D401/12 C07D407/12 C07D409/06
C07D417/06 A61K31/445 A61K31/453 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/002483 A (ACTELION PHARMACEUTICALS LTD [CH]; BOSS CHRISTOPH [CH]; BUR DANIEL [CH) 8 January 2004 (2004-01-08) page 8, line 1 - page 9, line 20 page 1, line 1 - page 1, line 15	1-54
A	WO 00/40558 A1 (US HEALTH [US]; RANDAD RAMNARAYAN S [US]; ERICKSON JOHN W [US]; EISSEN) 13 July 2000 (2000-07-13) page 7, line 11 - page 11, line 12	1-54
P,X	WO 2006/042150 A (VITAE PHARMACEUTICAL INC [US]; BALDWIN JOHN J [US]; CLAREMON DAVID A [) 20 April 2006 (2006-04-20) page 3, line 4 - page 3, line 10; claim 5	1-54

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
13 March 2007	20/03/2007
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Usuelli, Ambrogio

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2006/043920

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004002483 A	08-01-2004	AU 2003238046 A1	19-01-2004
WO 0040558 A1	13-07-2000	AT 322483 T	15-04-2006
		AU 2492500 A	24-07-2000
		EP 1140846 A1	10-10-2001
WO 2006042150 A	20-04-2006	NONE	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2006/043920

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 46-53 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.